Companies Investors Start
Transcription
Companies Investors Start
Companies Start-up projects Investors Rhône-Alpes’Gateway to Innovative Business in Life Sciences 70 000 jobs in Life Sciences - 600 Life Sciences companies -10 company creations per year More than e 1 billon of private investment in vaccines and diagnostics Supported by: In partnership with: Contents c o m pa n i e s PA G E > S ta r t-up projects PA G E > 157 169 investors PA G E > index PA G E > 2 11 201 Grain (Grenoble-Alpes-Incubation) is a public incubator whose aim is to convert mature research projects into innovative start-ups. These companies, closely linked to public research, integrate technology in such a way as to convert it into a significant competitive advantage both for their development and their client’s welfare. Figures GRAIN was established in 1999. By the end of 2009, more than 100 young start-ups have benne launched after being incubated at GRAIN, raising more than 75 Me frome venture capital over the years and making an approximate consolidated gross income of 63 Me for 2009 with 665 highly qualified jobs. Know-How Within 18 months, GRAIN provides a personal and team coaching and up to 300 training hours a year. The projects leaders are encouraged to optimize: - The building of a motivated and talented team; - The production of an effective business plan, - The choice between growth strategies. To doing so, a sharp focus is put on: - Questioning the applications and opportunities of the technology, - Surveying the potential market, - Consolidating the competitive positioning of the start up, - Launching its first commercial campaign. Objectives GRAIN particularly encourages the creation of the new companies with high-growth potential, helping them integrate into the regional economic system. The clear aim is that these companies will generate a sustainable economic activity resulting in a significant source of the new jobs for qualified people, and the development of new export markets. GRAIN 31, rue Gustave Eiffel - F-38000 GRENOBLE +33 (0)4 76 61 38 00 www.grain-incubation.com Companies Start-up projects Investors Companies Rhône-Alpes’Gateway to Innovative Business in Life Sciences Companies index 12 ADNucleis 13 Dextérité Surgical 57 Magnisense 110 ADOCIA 14 Drive 58 Mellitech 112 Advanced Accelerator Applications 16 Ecrins Therapeutics 59 Merial 113 17 EDAP TMS 60 Metabolys 114 Advicenne Edelris 61 115 Aguettant 18 Movea 19 Elicityl 62 Nano-H 116 Alaxia 20 ERYtech Pharma 63 NatX-ray 117 Alizé Pharma 21 ESRF 65 NETRIS Pharma 118 AltraBio Estenity R&D 66 119 Alvedia 22 Nocosium 23 Ethera 67 Noraker 120 Amoéba 24 Eurofins Optimed 68 Novadiscovery 121 ANaBior Eveon 69 122 Antagene 25 Novocib 26 EyeTechCare 71 Novotec 123 Antialis 27 Flamel Technologies 73 Orega Biotech 124 AXO Science Ayawane 28 Fluoptics 75 Bactup 29 Fondation Mérieux 76 Becton dickinson 30 GCS-Etoile 77 Bio Elpida 31 Geneuro 78 Genostar 80 genOway 82 Genzyme Polyclonals Gifrer Barbezat Glycode 86 HLA-G Technologies 87 iDD biotech 89 Roche Diagnostics 138 139 Phatophy 125 Powder Systems LimiteD (PSL) 127 Poxel 129 Prediction BioSciences 130 Presbeasy 132 84 Promise Advanced Proteomics 133 85 PX’Therapeutics 134 RCTs 136 ReproXX 137 Bioclinica 33 Bioclinome 34 Biomatech Namsa 35 BioMérieux 36 Biomnis 37 Biom’up 38 Biotem 39 Calixar 40 ILL 91 Sanofi Pasteur Centre d’Immunologie Pierre Fabre Imaxio 92 Shimadzu 141 41 ImmunID 93 Singulex 142 Cirma 42 Indicia 95 SmartINST 143 Clean Air Technologies 43 InfYnity Biomarkers 97 Sofradim 144 Clininfo 44 Innate Pharma 98 Spygen 145 Compétence Biotech 46 Institut Merieux 99 Stragen Services 146 Conidia 47 IntuiSKin 100 SynapCell 147 CoSMo 48 jlm lab 101 Synthelis 148 Kendle 102 Top Industrie 149 150 CreaCell 49 CTI-Lyon 50 Khorionyx 104 Transgene Cylergie-Cofely 52 K-PLAN 106 Vaxeal 152 Cynbiose 53 Visoon 154 107 Vivalis 155 Voxcan 156 Cytoo 54 La cosmétique alpine avancée DAMSI 55 Latoxan 108 Dendritics 56 LC2 109 l i f e s c i e n c e s d i r e c t o r y 2 0 1 1 Activities Diagnostics / Analysis method. Application fields: Animal health, Human health, Infectious diseases, Allergology, Orphan diseases, Genetic / Rare diseases, Nutrition / Food. Activities Company activities Engineering of PCR kits from the creation to the marketing R&D specialized in rapid diagnosis kits for Food Sanitary Quality, Animal Health, Human Health Genotyping applied to products traceability. Company key features General company information Multi-targets analysis kits «open system» strategy (kits can be used on every PCR platforms). Practicability and cost of kits. Company name: ADNucleis Address: 30, chemin des Mouilles Zip code: F-69290 City: Grezieu la Varenne Website: www.adnucleis.com Founded in: 03/04/2007 Number of employees: 7 Turnover: 350 000 Ke (in 2010) Main activity: Manufacturer of rapid diagnosis kits through Recent news Subsidiary of a group: No Prize winner for innovative start-up: No Innovative company (FCPI): Yes Other status: Yes Skills and know-how Funding Products / Services / Technologies RT PCR Genotyping Looking for funding: Yes Nature of funding searches: Pathogens project amount 1,000 M euros AFNOR certification for 4 kits dedicated to the detection of pathogens in Food Safety. Public funding obtained: Feder 140,000 euros Stock exchange listing: No 3 AFNOR certified kits (Salmonella spp, E.coli O157H7, Cronobacter sakazakii) 1 kit in the final stage of AFNOR certification (Listeria monocytogenes): certification planned in March 2011 Equality of certified kits with main competitor 25 kits validated internally for Food Safety 32 kits validated internally for Animal Health. H1N1 external validation is in process 4 kits for environmental analyses: legionella 30 kits validated in Human Health. Conception of kits. Extraction of nucleic acids. Amplification of genes. Genotyping Sequencing. Pipeline product 1 Preclinical: AFNOR kits. Pipeline product 2 Preclinical: Other kits in Food Safety. Pipeline product 3 Preclinical: Animal Health kits. Company contact Company services CEO contact detail First name: Michel Last name: Franck Position: CEO Email: [email protected] Phone: +33 (0)6 60 96 01 41 Conception of kits Extraction of nucleic acids Amplification of genes Genotyping Sequencing. Company technologies Quantitative PCR sequencers. Partnership opportunities / Licensing Company segmentation Business model Product developer - Biopharmaceuticals, Product developer Pharmaceuticals, Product developer - Other health, Laboratory equipment supplier. Value chain Research, Manufacturing, Marketing / Distribution. Collaboration framework Reinforcement of capital (491K today, for increase 2000K euros) Innovative project («Pathogens») in process with Oséo-Feder (financed at the end of 2008) Financing request for «Bedside» project in process. Partnership opportunities PRTechnology Analyses. laboratories. Agro-industries. Manufacturers of materials for laboratories. Academies for some R&D sectors. Out-licencing opportunity Yes if export. Possible contracts pending (Eastern Europe, North America, North Africa). l i f e s c i e n c e s d i r e c t o r y 2 0 1 1 13 Company segmentation Business model Product developer - Biopharmaceuticals, Other. Value chain Research, Preclinical, Clinical. Activities Drug delivery, Other. Application fields Human health, Metabolic diseases. Activities Company activities General company information Company name: ADOCIA Address: 115, avenue Lacassagne Zip code: 69003 City: Lyon Website: www.adocia.com Founded in: 22/12/2005 Number of employees: 49 Main activity: Adocia is a French biotech, specialized in regenerative medicine and treatment of chronic diseases. Incubator: No Subsidiary of a group: No Prize winner for innovative start-up: No Innovative company (FCPI): Yes Other status: Yes (European PME) Adocia is specialised in tissue regeneration and treatment of chronic diseases. The company develops its proprietary innovative technology BioChaperoneTM for the formulation of growth factors for regenerative medicine and also for therapeutic proteins such as human insulin and monoclonal antibodies. Company key features BioChaperoneTM is a new family of polymers, “bioinspired” by heparin, which have the property to protect and increase the efficacy of therapeutic proteins, with which they form specific molecular complexes. Various BioChaperoneTM have been tailored made for each protein studied, and have resulted in more than 20 patents being filed, covering products and applications of this system. Recent news Funding Looking for funding: No Private funding obtained: 1.8 million euros raised at the company’s inception. 12 million euros raised in November 2007. 14 million euros raised in January 2010. Public funding obtained: Loan from Oseo of 2.250.000 € granted in Sept 2006 (Osteoporosis project). Loan from Oseo of 420,000 € and grant from Feder of 420.000 € (Insulin project) granted in Sept 2009. Adocia has closed its second financial round of 14 M€ on 5 January 2010. These additional funds will permit Adocia to finance its clinical program on wound healing and bone repair. Skills and know-how Adocia can rely on a team composed of 17 PhD and a skilled management. Adocia’s core activity covers the chemistry of polymers up to preclinical studies of therapeutic protein formulations.Adocia benefits from a strong pluridisciplinary expertise in R&D, in chemistry, analysis, formulations, biologics. Company contacts CEO contact detail First name: Gérard Last name: Soula Position: CEO & President Email: [email protected] Phone: +33 (0)4 72 61 06 10 Other contact First name: Olivier Last name: Soula Position: R&D Director Email: [email protected] Phone: +33 (0)4 72 61 06 10 Fax: +33 (0)4 72 36 39 67 14 l i f e s c i e n c e s d i r e c t o r y 2 0 1 1 Products / Services / Technologies Pipeline product 1 Therapeutic area: Chronic wounds Therapeutic indication: Diabetic Foot Ulcer Preclinical: Phase 1: BC PDGF-BB Phase 2: BC PDGF-BB. Pipeline product 2 Therapeutic area: Bone repair Therapeutic indication: Spinal fusion Preclinical: BC BMP-2. Pipeline product 3 Therapeutic area: Diabet Therapeutic indication: Treatment of postprandial glycemy Preclinical: BC human Insulin. Company services Adocia do not propose any service. Company technologies BioChaperoneTM is a new family of polymers, “bioinspired” by heparin, which have the property to protect and increase the efficacy of therapeutic proteins, with which they form specific molecular complexes. Various BioChaperoneTM have been tailored made for each protein studied, and have lead to more than 20 patents being filed, covering products and applications of this system. Adocia applies its technology BioChaperone™ to regenerative medicine field by focusing on growth factors already approved and commercialized: PDGF-BB for chround wounds and Bone Morphogenic Proteins (BMPs) for spinal fusion and bone repair (non-union fractures, cartilage regeneration, osteoporosis). BioChaperone is also applied for subcut therapeutic monoclonal antibodies formulations. Partnership opportunities / Licensing Collaboration framework Adocia has 5 collaborations on going (confidentialundisclosed). Adocia aims to licence its various projects to medtech/biopharma companies. Partnership opportunities Adocia’s technology BioChaperone offers therapeutic indications for the following medical needs: – Diabetic foot ulcers – Venous ulcers – Osteoporosis – Degenerative disc disease – Non-union fractures – Human Insulin – Monoclonal Antibodies Out-licencing opportunity Adocia’s business model consists of rapidly generating convincing “Proofs of Concept” for its products (Phase IIa or animal models when relevant) and to license its products to leading companies in the field. In-licencing opportunity Non applicable. l i f e s c i e n c e s d i r e c t o r y 2 0 1 1 15 Company contacts CEO contact detail First name: Stefano Last name: Buono Position: President & CEO Email: [email protected] Phone: +33 (0)4 50 99 30 70 Other contact First name: Heinz Last name: Maeusli Position: CFO Email: [email protected] Phone: +33 (0)4 50 99 30 70 Company segmentation Business model Product developer - Pharmaceuticals. Value chain Research, Manufacturing. Activities General company information Company name: Advanced Accelerator Applications Address: 20, rue Diesel Zip code: 01630 City: Saint Genis Pouilly Website: www.adacap.com Founded in: 29/03/2002 Number of employees: 130 Turnover: 27 M Euros (in 2010) Main activity: Advanced Accelerator Applications (AAA), is a European Pharmaceutical Group founded in 2002 by Italian academics as a spin-off of the “European Organization for Nuclear Research” (CERN), Geneva, Switzerland), to develop innovative diagnostic and therapeutic applications and products. AAA main focus is on products addressing Molecular Imaging and Therapy for the personalized treatment of serious diseases (the so-called Personalized Medicine). AAA first commercial product is Gluscan® (FDG or FluoroDeoxyGlucose), a diagnostic short-lived (i.e. with a 10-hour shelf life) radiotracer used for Positron Emission Tomography (PET). PET is a state-of-the-art diagnostic technique that is today mainly used in clinical oncology, cardiology and neurology. With 10 production facilities and R&D laboratories and more than 130 employees in 5 countries (France, Italy, Switzerland, Spain and United States), AAA is a truly “private public company” with over 75 private and institutional shareholders. Subsidiary of a group: No Prize winner for innovative start-up: No Innovative company (FCPI): No Other status: Yes Funding Looking for funding: No R&D PROJECT funded accredited BY LYONBIOPOLE Theranean: Therapy through Neutron-Activated Nanopar- ticles Funding: FUI (AAP7 2009) Role in the project: Leader 16 l i f e s c i e n c e s d i r e c t o r y 2 0 1 1 Diagnostics / Analysis method, Drug discovery, Other. Application fields Human health. Activities Company activities AAA developed a unique platform for the research, development, production and distribution of radiopharmaceuticals and molecules designed for molecular diagnostics and therapy. Thanks to its comprehensive approach, AAA is able to produce and deliver both commercial drugs and research products for clinical or pre-clinical studies. Moreover, it can provide partner organizations with support for clinical studies, technology for setting up industrial production of PET radiopharmaceuticals, consultancy and people training. AAA laboratories have a Good Manufacturing Practice (GMP) qualification to the manufacturing of Investigational Medical Products (IMP). Recent news AAA has received GMP approval for the manufacture of Lutate, a radioactively labelled peptide that can be used to treat metastatic Gastro Entero Pancreatic Neuro Endocrine Tumors (GEP-NETs). The approval by the Italian Pharmaceutical Regulatory Authority will enable AAA to manufacture Lutate at its facility in Colleretto Giacosa, near Turin, Italy, making it the first industrial facility in the world approved to produce radio-labelled peptides for molecular nuclear therapy. Skills and know-how AAA has developed a unique know-how in building radiopharmaceutical laboratories to be used, at the same time, for industrial scale production and state-of-the-art R&D activities. Our laboratory concept has been tested in every-day production for more than 6 years now and proven to be entirely reliable and effective. AAA laboratories are modular and scalable, fully expandable and easy to upgrade to the latest technology and know-how to meet future market developments and customer expectations. This know-how can be transferred to AAA partners, interested in setting up their own industrial production of PET radiopharmaceuticals. AAA has already completed such technology transfers in the past and is willing to do so in the future. On-site consulting by AAA personnel, sharing of all relevant documentation, and extensive training of partners’ employees in our facilities are key to assure the successful know-how transfer. General company information Company name: ADVICENNE Address: Espace Innovation 3, 442, rue Georges Besse Zip code: 30035 Cedex 1 City: Nîmes Website: www.advicenne.com Founded in: 23/04/2007 Number of employees: 5 Main activity: Advicenne Pharma is a pharmaceutical company devoted to paediatric produts. The company focus is on development and marketing of paediatric products adressed to neurological diseases and nephrological disorders. Advicenne Pharma aim is to build and market products from a paediatric portfolio adressed to unmet medical needs. Advicenne Pharma development strategy is based on a short term (2 years) business model. The aim is to market paediatric drugs generating sales as soon as 2012. This model is based on: • Importation of drugs able to benefit from the status of compassionate access «Autorisation Temporaire d’Utilisation» (ATU) for paediatric use in France, • Market in Europe in house products first under compassionate access then under Puma status or Orphan drug status, • Paediatric formulation in short time frame and at minimal cost. Subsidiary of a group: No Prize winner for innovative start-up: No Innovative company (FCPI): Yes Other status: Yes Funding Looking for funding: Yes CEO contact detail First name: Luc André Last name: Granier Position: CEO and Medical Director Email: [email protected] Phone: +33 (0)6 19 20 29 50 Other contact First name: Marie Laure Last name: Pellotier Position: CFO Email: [email protected] Phone: +33 (0)6 31 92 15 51 Fax: +33 (0)4 66 21 23 35 s c i e n c e s d i r e c t o r y Business model Product developer - Pharmaceuticals. Value chain Research, Manufacturing, Preclinical, Clinical. Activities Other. Application fields Pediatrics, Human health, Orphan diseases, Genetic / Rare diseases, CNS related diseases. Activities Company activities Neurology ADV 6208 Is an innovative liquid formulation of a molecule. ADV 6208 is perfectly adapted to oral administration in case of child epilepsy emergency as Status Epilepticus. ADV 6209 Is a similar formulation: oral administation adressed to anaesthesia and conscious sedation. Nephrology ADV 7103 Is a paediatric formulation (micro-tabs) adressed to a nephrological genetical disease. ADV 7103 is a tasteless drug, able to cover a 8-12 hours period. ADV 7103 will benefit from an orphan status. Products / Serv ices / Technologies Company contacts l i f e Company segmentation 2 0 1 1 Pipeline product 1 Preclinical: realized Phase 1: to be launched Phase 2: to be launched Phase 3: not necessary. Pipeline product 2 Preclinical: realized Phase 1: to be launched Phase 2: to be launched Phase 3: not necessary. Pipeline product 3 Preclinical: realized Phase 1: to be launched Phase 2: to be launched Phase 3: not necessary. 17 Company segmentation Business model Product developer - Pharmaceuticals. Value chain Research, Manufacturing, Marketing / Distribution. Activities Drug discovery, Medical device, Other. Application fields Animal health, Human health, Infectious diseases, Nutrition / Food, Other. Activities General company information Company name: Aguettant Address: 1 rue alexander fleming Zip code: 69007 City: Lyon Website: www.aguettant.com Founded in: 01/01/1903 Number of employees: 500 Turnover: 80 M Euros (in 2010) Main activity: AGUETTANT designs and improves solutions and injectable drugs for patients and health care professionals, from hospital to the home. Subsidiary of a group: Yes (Groupe Aguettant) Company activities AGUETTANT is an independent family owned pharmaceutical company with more than 100 years of experience. The company is a pioneer in the injectable drugs market with 350 references. A key player in the sectors of: – Anaesthetics, – Injectable morphine, – Cardiology, – Infectious diseases, – Parenteral micro-nutrition (trace elements), – Parkinsonian acute treatment, – Small volume infusion, – Irrigation and rinsing. Recent news Aguettant develops a range of emergency drugs in plastic prefilled syringes. R&D PROJECT funded Accredited BY LYONBIOPOLE POLYBIO: Innovative plastics for a better packaging of pharmaceutical products Funding: FUI (AAP9 2010) Role in the project: Leader Company contacts CEO contact detail First name: Michel Last name: Fasne Position: President Email: [email protected] Phone: +33 (0)4 78 61 51 41 Other contact First name: Eric Last name: Debuyser Position: Director Development Email: [email protected] Phone: +33 (0)4 78 61 51 41 Fax: +33 (0)4 78 61 09 35 18 l i f e s c i e n c e s d i r e c t o r y 2 0 1 1 Skills and know-how Experienced product development and regulatory affairs teams. Products / Services / Technologies Company technologies: The filling of glass or plastic containers as, ampoules, vials, bottles or syringes, in aseptic or no aseptic conditions. Partnership opportunities / Licensing Out-licencing opportunity – Disposable auto-injector pens, – Plastic prefilled syringes, – Innovative infusion bags with integrated rinsing, – Reconstitution medical devices, – Injectable generic + pharmaceutical dossiers. In-licencing opportunity Objective: extend Aguettant products’ portfolio by acquiring: – Niche products for hospital use (pharmaceuticals or disposable small medical devices), – Co-development partners, – Generics + files for hospital. Activities Company activities General company information Company name: Alaxia Address: 3-11, rue de la Perlerie Zip code: 69120 City: Vaulx en Velin Website: www.alaxia-pharma.eu Founded in: 07/04/2008 Number of employees: 8 Main activity: Alaxia, a young innovative company (JEI and FCPI qualified) develops airway medicinal products for orphan diseases. Subsidiary of a group: No Prize winner for innovative start-up: No Innovative company (FCPI): Yes Other status: Yes (JEI, SME) Funding Looking for funding: No Alaxia, a young innovative company (JEI and FCPI qualified) developping airway solutions for respiratory diseases. Recently, its Meveol product, 1st product exiting the pipeline, has been recognised Orphan medicinal product for cystic fibrosis, CF, condition by EMEA. Meveol is both an antimicrobial and anti inflammatory product , targeting to kills bacteria, including superbugs and to compensate innate lung defense system. www.alaxia-pharma.eu Cystic Fibrosis (Mucoviscidose) an orphan disease affecting 100,000 patients in US and EU. Company key features - Products and process are protected by several patents and ODD - ALAXIA staff important knowledge on antimicrobial API - A new therapeutic approach answering clinicians and patients request taking into account antibiotic microbial resistances, biofilm protection mode… - Efficacy on MRSA, BCC - Top level European scientific/medical committee. Recent news Meveol Orphan medicinal status granted in EU, July 2009 SME status in September 2009 Meveol, Orphan drug status granted in US, Nov 2009 www.alaxia-pharma.eu. Skills and know-how AMP (antimicrobials proteins) aerosols and aerosoltherapy with our partners Based on our peroxidase plate form, we are able to produce various kind of antimicrobials active compounds (eg OSCN, OI…) &/or antiinflammatory products. Company contacts CEO contact detail First name: Philippe Last name: Bordeau Position: CEO Email: [email protected] Phone: +33 (0)4 72 81 09 26 Other contact First name: Maria Last name: Ahmed Chavarino Position: Head of regulatory affairs Email: [email protected] Phone: +33 (0)4 72 81 09 26 Fax: +33 (0)4 78 41 17 79 Company segmentation Products / Services / Technologies Pipeline product 1 Therapeutic area: Respiratory Therapeutic indication: Infectious Preclinical: Meveol. Pipeline product 2 Therapeutic area: Medical device Preclinical: Eol. Pipeline product 3 Therapeutic area: Respiratory Therapeutic indication: COPD Company technologies: Our technologies are based on our peroxidase plateform. Business model Product developer - Biopharmaceuticals, Product developer Pharmaceuticals, Product developer - Other health. Value chain Collaboration framework Research, Other. Treatment of respiratory diseases (URTI or LRTI), COPD. Activities Partnership opportunities Drug discovery, Other. Research program on , URTI, LRTI, COPD. Application fields Pediatrics, Human health, Infectious diseases, Orphan diseases, Genetic / Rare diseases. l i f e s c i e n c e s Partnership opportunities / Licensing d i r e c t o r y 2 0 1 1 Out-licencing opportunity No orphan diseases, eg Pneumonia, COPD, Nausocomial diseases. 19 Company segmentation Business model Product developer - Biopharmaceuticals, Product developer Pharmaceuticals. Value chain Research, Preclinical, Clinical. General company information Company name: Alizé Pharma Address: 15, chemin du Saquin, Bat. G Zip code: 69130 City: Écully Founded in: 2007 Main activity: The Alizé Pharma Group is specialized in the development of innovative biopharmaceuticals for the treatment of metabolic diseases and cancer. Subsidiary of a group: No Prize winner for innovative start-up: No Innovative company (FCPI): Yes Other status: Yes (JEI) R&D PROJECT FUNDED ACCREDITED BY LYONBIOPOLE ASPAREC: Development of a new RECombinant L-ASPAraginase with long acting properties Funding: FUI (AAP7 2009) Role in the project: Leader Company contacts CEO contact detail First name: Thierry Last name: Abribat Position: President Email: [email protected] Phone: +33 (0)4 72 18 94 28 Other contact First name: Valérie Last name: Wesley Position: Direction Assistant Email: [email protected] Phone: +33 (0)4 72 18 94 28 Fax: +33 (0)4 78 33 36 29 Activities Clinical trials, Preclinical trials, Drug discovery, Other. Application fields Human health, Infectious diseases, Orphan diseases, Genetic / Rare diseases, Metabolic diseases, Cancer. Activities Company activities The Alizé Pharma Group is composed of privately-held biopharmaceutical companies specialized in the development of innovative therapeutics for the treatment of metabolic diseases and cancer. The group acquires R&D programs from public or private laboratories, selecting them according to strict criteria, with particular reference to medical need and innovation. It then handles preclinical and clinical development and establishes partnerships with the pharmaceutical industry via co-development or out-licensing agreements. The first of the two entities of the Group, Alizé Pharma SAS, is dedicated to AZP-01, a program based on unacylated ghrelin agonists, a new therapeutic class for the treatment of Type II diabetes. Unacylated ghrelin and its analogs have the potential not only to control the disease but also to have a positive impact on other cardiovascular risk factors such as obesity, dyslipidemia and impaired vascular remodeling. The parent molecule and its analogs are protected by four patent families worldwide. The second entity is Alizé Pharma II SAS. It is focused on the development of Asparec® (AZP-02), a new, long-acting recombinant L-asparaginase with reduced immunogenicity for the treatment of acute lymphoblastic leukemia, and currently at the preclinical stage. Founded in April 2007, the Alizé Pharma group is based in Ecully, near Lyon, France. Its management is made up of a team of drug development experts and a board of directors offering wide international experience. Since its inception, Alizé Pharma has raised Eur 4.8 M from private and institutional investors. Recent news 2007: acquisition of the Unacylated Ghrelin (AZP-01) program from Erasmus MC (Rotterdam) and University of Turin. 2008: acquisition of the Asparec program (AZP-02) from EUSA Pharma Inc. 2009: Fund raising of Eur 3,0 M (for a total of Eur 4,8 M raised since inception). 2010: Research collaboration and license option agreement with Eli Lilly & Co. (US). 20 l i f e s c i e n c e s d i r e c t o r y 2 0 1 1 Company segmentation Business model Service provider - Scientific. Value chain Research, Preclinical, Clinical. Activities Diagnostics / Analysis method, Bioinformatics / Modeling, Other. General company information Company name: AltraBio Address: 24, rue Baldassini, porte B Zip code: 69007 City: Lyon Website: www.altrabio.com Founded in: 02/08/2006 Number of employees: 7 Turnover: 730 000 Euros (in 2009) Main activity: Biotechnology. Incubator: Yes (CREALYS) Subsidiary of a group: No Prize winner for innovative start-up: No Innovative company (FCPI): No Other status: Yes (JEI) Funding Looking for funding: Yes Nature of funding searches: Please contact us for more details. Company contacts CEO contact detail First name: Laurent Last name: Buffat Position: CEO Email: [email protected] Phone: +33 (0)4 26 84 69 63 Other contact First name: Christel Last name: Paris-Bicking Position: Partnerships and Strategic Development Manager Email: [email protected] Phone: +33 (0)4 26 84 69 63 Fax: +33 (0)4 72 70 92 42 l i f e s c i e n c e s d i r e c t o r y 2 0 1 1 Application fields Animal health, Human health, Immunology, Inflammatory diseases, Infectious diseases, Autoimmune diseases, Orphan diseases, Genetic / Rare diseases, Metabolic diseases, CNS related diseases, Cancer, Dermocosmetics, Other. Activities Company activities AltraBio delivers comprehensive solutions in exploration, mining and integrative analysis of life science data. By exploiting the full potential of experimental results, AltraBio helps optimize the preclinical and clinical development of candidate compounds. AltraBio interprets the results in the context of current biomedical knowledge and formulates hypotheses for the mechanisms of action underlying the observations. AltraBio provides data analysis services ranging from basic research applications such as gene expression profiling through clinical trial data analysis and audit. Company key features The analysis and interpretation team is made of highly skilled professionals with transversal, double expertise in medecine and bio-informatics/mathematics, who are not only able to provide quick and efficient statistical analysis, but also to understand the end customers’ own questioning and sometimes help redesign the research studies. The staff is also multicultural, with members fluent in many foreign languages, which is an advantage in international research programs. Recent news AltraBio agreed to participate in the Bio-Informatics platform of the «IRT Infectiologie» (Regional Excellence Research Program, with focus on infectious diseases). Skills and know-how AltraBio works in close cooperation with Europe’s best micro-array and next generation sequencing platforms. It focuses on developing further «tailor made»expertise in data analysis & management, at the highest possible level of interpretation, and as close as possible to the researcher’s own questioning. In this aim, the team also developed its own tools for detecting potential errors in the transmitted biological data, and in designing «easiest to read», customer friendly, analysis reports. 21 General company information Business model Company name: Alvedia Address: 60, avenue Rockefeller Zip code: 69008 City: Lyon - France Website: www.alvediavet.com Founded in: 10/01/2006 Main activity: Alvedia is specialized in the immuno- Service provider - Scientific, Product developer Pharmaceuticals, Product developer - Other health, Laboratory equipment supplier. Subsidiary of a group: No Prize winner for innovative start-up: Yes Innovative company (FCPI): No Other status: Yes Diagnostics / Analysis method, Other. Funding Activities hematology veterinary field. Looking for funding: No d i r e c t o r y Activities Application fields Animal health, Immunology, Infectious diseases. Skills and know-how Veterinary immuno-hematology. Other contact First name: Elisabeth Last name: Louis Position: Product Manager Email: [email protected] Phone: +33 (0)4 78 38 02 39 Fax: +33 (0)4 78 93 95 63 s c i e n c e s Research, Manufacturing, Marketing / Distribution. Research and developpement of innovative products for blood typing, blood transfusion, crossmatching, infectious desease. Transfusion scientific supports for the veterinary profession. Alvedia provides worldwide blood typing Quick Test for cats and dogs. CEO contact detail First name: Alice Last name: Rigal Position: General Manager Email: [email protected] Phone: +33 (0)6 33 41 17 02 l i f e Value chain Company activities Company contacts 22 Company segmentation 2 0 1 1 General company information Company name: Amoéba Address: 60, avenue Rockefeller Zip code: 69008 City: Lyon Website: www.amoeba-biocide.com Founded in: 21/07/2010 Number of employees: 7 Main activity: Amoéba is an innovative company which develops, manufactures and markets biological products and services of disruptive treatment for legionella and for amoebae in water. Our solutions open a new way of biological treatment of the legionella and amoebae risk for the industrials companies. Our biological offer is a measured and sure answer to a biological problem allowing a cost cutting with an environmental approach anticipating the future law. Incubator: Yes (CREALYS) Subsidiary of a group: No Prize winner for innovative start-up: Yes (Emerging 2010) Innovative company (FCPI): Yes Other status: Yes (JEI and CIR) Funding Looking for funding: No Public funding obtained: CREALYS € 30 K, Rhône Alpes region € 30 K, French ministry € 40 K Company segmentation Business model Other. Value chain Other. Activities Other. Application fields Other. Activities Company activities We market a solution in the form of products associated with a service to protect the cooling tower of industrials companies from the world against the bacteriological risks. Our solution is a biological agent which eliminates Legionella and Biofilm present in water from the wet cooling tower. The product will be presented in concentrated liquid form which will be injected directly into the water network. The service consists in injecting the amoebae in the water network of the cooling tower and guarantee throughout the year the threshold of the desire concentration of our Ameba to eliminate 100% Legionella and to avoid the Biofouling. In addition of our product and service, our knowledge allows us to be an European leader for the analysis and the numeration of the amoebae in industrial water. Company contacts CEO contact detail First name: Fabrice Last name: Plasson Position: President & CEO Email: [email protected] Phone: +33 (0)4 26 69 16 00 Other contact First name: Jacques Last name: Bodennec Email: [email protected] Phone: +33 (0)4 72 43 11 71 Fax: +33 (0)4 72 43 11 72 l i f e s c i e n c e s d i r e c t o r y 2 0 1 1 23 Company segmentation Business model General company information Company name: ANaBior Address: 58, route du Rivet Zip code: 38330 City: Saint-Ismier - France Founded in: 21/05/2010 Number of employees: 6 Main activity: ANaBior is dedicated to the development of an innovative technology platform that features specific bioresorbable nanoparticles as vector systems for veterinary and human pharmaceutical applications . Incubator: No Subsidiary of a group: No Prize winner for innovative start-up: No Innovative company (FCPI): No Other status: No Funding Looking for funding: Yes R&D PROJECTS FUNDED ACCREDITED BY LYONBIOPOLE PARSYNVAC: Design of a synthetic and biodegradable nanoparticulate vaccine vehicle Funding: ANR (2005 RIB) Role in the project: Partner ANABIO: Biodegradable nanoparticles of poly lactic Acid as adjuvant for subunit vaccines Funding: ANR (2008 Biotecs) Role in the project: Partner Company contacts s c i e n c e s d i r e c t o r y Research, Manufacturing, Preclinical. Activities Vaccine, Nanotechnology, Drug delivery, Other. Application fields Animal health, Human health. Activities Company activities ANaBior develops its proprietary integrated manufacturing process, from the specific bioresorbable PLA (Poly-lactic acid) polymer production to the synthesis of reproducible batches of very homogeneous nanoparticles with strong colloïdal stability . For research purposes, ANaBior is able to provide PLA nanoparticles upon request. In collaboration with scientific experts, ANaBior is also focused on the development of an innovative antigen formulation process into the nanoparticles in order to design a new synthetic vaccination vector and stabilizing agent. Company key features – Full R&D and production existing infrastructure. – Validated manufacturing process. – Established proof of concept. – Preclinical and long term data in several animal models. – Close collaboration with worldwild recognised research partners. Skills and know-how – Strong know-how on manufacturing of PLA polymers and nanoparticles and on final formulation of the active product. – Successful technology transfer experience. – Multidisciplinary and highly experienced scientific, management and production team. Company technologies – Specific polymerisation and purification process for bioresorbable polymers synthesis. – One-step, surfactant free PLA nanoparticles elaboration. – Solvent free protein formulation. Other contact First name: Jacqueline Last name: Huet Email: [email protected] Phone: +33 (0)4 76 52 51 60 Fax: +33 (0)4 76 52 49 62 l i f e Value chain Products / Services / Technologies CEO contact detail First name: Yves Last name: De Backer Position: CEO Email: [email protected] Phone: +33 (0)6 07 74 60 74 24 Product developer - Pharmaceuticals. Partnership opportunities / Licensing Partnership opportunities ANaBior is looking for strategic partners in order to co-develop innovative nanocarrier-based systems. 2 0 1 1 General company information Company segmentation Business model Company name: Antagene Address: 2 allée des Séquoias Zip code: 69578 City: Limonest Website: www.antagene.com Founded in: 10/04/2002 Number of employees: 17 Turnover: 8 K Euros (in 2010) Main activity: Biotech company in animal health and genetics. Incubator: Yes (CREALYS) Subsidiary of a group: No Prize winner for innovative start-up: Yes (2001 Service provider - Scientific, Product developer - Other health. Innovative company (FCPI): No Other status: Yes (JEI, CIR) Activities (Creation-Development)) Value chain Research, Manufacturing, Marketing / Distribution. Activities Diagnostics / Analysis method, Other. Application fields Animal health, Orphan diseases, Genetic / Rare diseases, Cancer. Company activities Development and commercialization of DNA tests for animals (dog, cat). Funding Looking for funding: Yes Nature of funding searches: We are looking for funding our reseach programs in animal genomics, genetic disorders in dog and cat as model for human diseases. Private funding obtained: € 1,4 M venture-capital between 2003 and 2009 Public funding obtained: € 540 K between 2007 and 2011 Biomarks (EuroTransbio 2007-2009) LUPA (FP7 2008-2011) Company key features Research programs in genetic disorders in dog and cat, homologous to human diseases. Skills and know-how Animal genomics Molecular genetics Dog/cat spontaneous models. Products / Services / Technologies Company contacts Company services DNA tests for genetic diseases in dog and cat Research services in comparative genomics (human-animal). CEO contact detail First name: Guillaume Last name: Queney Position: President Email: [email protected] Phone: +33 (0)4 37 49 90 03 Company technologies Whole-genome scan - DNA chip - Sequencing - Microsatellites/ SNP genotyping. Other contact First name: Anne Last name: Thomas Position: Director of R&D Email: [email protected] Phone: +33 (0)4 37 49 87 04 l i f e s c i e n c e s d i r e c t o r y 2 0 1 1 25 General company information Activities Company activities Company name: Antialis Address: 18, rue du souvenir Zip code: 69009 City: Lyon Founded in: 01/01/2001 Number of employees: 5 Main activity: Pharmaceutical. Incubator: No Subsidiary of a group: No Prize winner for innovative start-up: No Innovative company (FCPI): No Other status: No Development of new medical indications of old molecules in allergy and cancer. Funding Products / Services / Technologies Looking for funding: Yes Private funding obtained: € 0.5 M Preclinical: ANTIALIS 1. Company key features Research. Recent news POC in cancer. Skills and know-how Clinical, research and business in Pharmaceutical field. Pipeline product 1 Pipeline product 2 Preclinical: ANTIALIS 2. Company contact CEO contact detail First name: Gaetan Last name: Terrasse Position: CEO Email: [email protected] Phone: +33 (0)6 64 90 06 54 Partnership opportunities / Licensing Collaboration framework CNRS Neker IGR Paris. Partnership opportunities Cancer and allergy. Out-licencing opportunity Allergy and cancer. Company segmentation Business model Product developer - Biopharmaceuticals, Product developer Pharmaceuticals. Value chain Research, Preclinical, Clinical. Activities Drug discovery. Application fields Human health, Immunology, Allergology, Cancer. 26 l i f e s c i e n c e s d i r e c t o r y 2 0 1 1 In-licencing opportunity Cancer. General company information Company name: AXO Science Address: Parc d’activité GVIO, 2, place de l’Europe, Bât. A, Zip code: 38070 City: Saint Quentin Fallavier Website: www.axoscience.com Founded in: 20/07/2010 Number of employees: 2 Main activity: AXO Science, headed by a group of founders from marketing/commercial and scientific background, is specialized in the development of high-throughput and multiparametric analysis tools dedicated to the characterisation of biological samples. The company offers complete solutions for diagnostic tools development, both for research projects and products industrialisation. As the gold Standard in high-throughput microarray technologies, spotting facilities are mandatory for all your future diagnostic projects. Here, Axo Science is a valuable partner, bringing all its know-how and technological services to your R&D projects. Subsidiary of a group: No Prize winner for innovative start-up: No Innovative company (FCPI): No Other status: No Company contacts Company segmentation Business model Service provider - Scientific, Product developer - Other health. Value chain Research, Clinical. Activities Diagnostics / Analysis method, Instrumentation, Clinical trials, Medical device. Application fields Animal health, Human health, Immunology, Infectious diseases, Autoimmune diseases, Allergology, Genetic / Rare diseases. Activities Company activities – Microarray spotting services (high quality control, surface chemistry) – R&D activity in the field of multiparameter high-throughput assays for blood group genotyping and human serology – Consulting services: • High throughput assays development • Test efficiency improvements • Diagnostic solutions. CEO contact detail First name: Cédric Last name: Louis Position: President Email: [email protected] Phone: +33 (0)4 72 43 13 69 Other contact First name: Christophe Last name: Marquette Email: [email protected] l i f e s c i e n c e s d i r e c t o r y 2 0 1 1 27 Activities Company activities Development of veterinary care products. Research & development of biomaterials for tissue and osteoarticular repair. Company key features General company information Company name: Ayawane Address: 60, Avenue Rockefeller Zip code: 69008 City: Lyon Website: www.ayawane.com Founded in: 17/03/2010 Number of employees: 3 Main activity: Development of innovative veterinary care products. Incubator: Yes (CREALYS) Subsidiary of a group: No Prize winner for innovative start-up: No Innovative company (FCPI): No Other status: Yes Funding Looking for funding: Yes Twenty years experience in biomaterials. Multidiscipilanry team : Pharmacy, chemistry, biochemistry, and veterinary medecine. Two equine care products on the market and six to be launched in 2011. Recent news Financial support and certification: CREALYS, Novacite, Réseau entreprendre, Innotech and Oseo. Skills and know-how Research and development of new chemical entities. Non clinical and clinical assessment. Tissue and osteoarticular repair. Products / Services / Technologies Pipeline product 1 Therapeutic area: Equine Care Therapeutic indication: External care Preclinical: 2009 MA: july 2010. Pipeline product 2 Therapeutic area: Animal Health Therapeutic indication: Wound care Preclinical: ongoing. Company contact CEO contact detail First name: Latifa Last name: Dahri Correia Position: CEO Email: [email protected] Phone: +33 (0)4 78 09 34 06 Pipeline product 3 Therapeutic area: Animal heath Therapeutic indication: Viscosupplementation Preclinical: ongoing Company services Company segmentation Business model Product developer - Pharmaceuticals, Product developer Other health. Value chain Research, Manufacturing, Marketing / Distribution. Activities Other. Ayawane is an innovative company that develops and markets equine veterinary care products. Ekine Care is the first line marketed by Ayawane. Company technologies The technology of Ayawane is based on the design of biomaterials obtained by functionalization of polymers that endowed them with biospecific activities. Partnership opportunities / Licensing Collaboration framework Biotechnologies and pharmaceutical laboratories. Application fields Animal health. Partnership opportunities Dermatology, ophthalmology, surgery, orthopedy and esthetic. Out-licencing opportunity Out-licencing of the biomaterials for human use. 28 l i f e s c i e n c e s d i r e c t o r y 2 0 1 1 General company information Company name: Bactup Address: 27, chemin des Peupliers - BP 74 Zip code: 69573 City: Dardilly cedex Website: www.bactup.com Founded in: 03/07/2007 Number of employees: 5 Turnover: 425 K Euros (in 2010) Main activity: Bactup offers services on demand in microbiology. It is located in a pharmaceutical industrial plant near Lyon (France). Our activites are focused on : – Secured and confidential storage and management of collections of micro-organisms of our customers. – Microbial identification and characterization of microorganisms, based on ISO17025:2005 and BPF/GMP guidelines. – Production of master cells banks and working cells banks of micro-organisms, with calibration, according to BPF/GMP guidelines. – R&D on demand in microbiology. – Consulting and training on demand in microbiology. – EasyBactup software dedicated to the management of collections of micro-organisms. Incubator: Yes (CREALYS) Subsidiary of a group: No Prize winner for innovative start-up: No Innovative company (FCPI): No Other status: Yes (JEI) Funding Looking for funding: No Company contacts CEO contact detail First name: Raphaël Last name: Lavenir Position: CEO Email: [email protected] Phone: +33 (0)9 62 23 09 72 Company segmentation Business model Service provider - CRO, Service provider - Non Scientific, Service provider - CMO, Service provider - Scientific, Other. Value chain Research, Other. Activities Diagnostics / Analysis method, Biobank. Application fields Animal health, Human health, Infectious diseases, Nutrition / Food, Other. Activities Company activities Bactup offers services on demand in microbiology. It is located in a pharmaceutical industrial plant near Lyon (France). Our activites are focused on: – Secured and confidential storage and management of collections of micro-organisms of our customers. We use freeze-drying and freezing (-20°C to -150°C) processes. – Microbial identification and characterization of micro-organisms, based on ISO17025:2005 and BPF/GMP guidelines. We have biochemical (Vitek 2 and API) and molecular (PCR-sequencing) tools. – Production of master cells banks and working cells banks of micro-organisms, with calibration, according to BPF/GMP guidelines. We can perform freeze-drying process in vials or ampoules, or Freezing process in cryovials. – R&D on demand in microbiology. Here, we develop new processes to perform scientific essays according to our customer’s requests. – Consulting and training on demand in microbiology. We can operate in our customer’s plant to perform more efficient training and consulting. – EasyBactup software dedicated to the management of collections of micro-organisms. Other contact First name: Ludovic Last name: Champier Email: [email protected] Phone: +33 (0)9 62 23 09 72 Fax: +33 (0)4 78 64 92 39 l i f e s c i e n c e s d i r e c t o r y 2 0 1 1 29 General company information Company contact CEO contact detail First name: Christian Last name: Seux Position: CEO Email: [email protected] Phone: +33 (0)4 76 68 36 36 Company name: BD Address: 11, rue Aristide Bergès - BP4 Zip code: 38801 City: Le Pont de Claix Cedex Website: www.bd.com/fr Founded in: 01/01/1958 Number of employees: 1736 Turnover: 813 582 466 e (in 2010) Main activity: BD, a leading global medical technology company that makes and sells medical devices, instrumented systems and regents, is dedicated to improving people’s health throughout the world. The company serves healthcare institutions, life science researchers, clinical laboratories, industry and the general public. Subsidiary of a group: Yes (BD Corporate US) Company segmentation Business model Product developer - Pharmaceuticals, Laboratory equipment supplier, Other. Value chain Funding Research, Manufacturing, Preclinical, Marketing / Distribution, Clinical, Other. Looking for funding: No Activities R&D PROJECTS FUNDED ACCREDITED BY LYONBIOPOLE MICROVAX: Skin immunology and vaccination Funding: FUI (AAP1 2006) Role in the project: Leader TBDERMATEST: Development of a novel skin test using the HBHA antigen for the diagnosis of latent M. tuberculosis infection Funding: FUI (AAP6 2008) Role in the project: Partner EXPANDID: Extending the scope of application of intradermal vaccination Funding: FUI (AAP8 2009) Role in the project: Leader 30 l i f e s c i e n c e s d i r e c t o r y 2 0 1 1 Diagnostics / Analysis method, Instrumentation, Biomanufacturing, Clinical trials, Preclinical trials, Drug discovery, Medical device, Other. Application fields Human health, Other. Activities Company activities BD is focused on improving drug therapy, enhancing the quality and speed of diagnosing infectious disease, and advancing research and discovery of new drugs and vaccines. Company segmentation Business model Service provider - CMO, Product developer Biopharmaceuticals, Service provider - Scientific, Product developer - Pharmaceuticals. Value chain Research, Manufacturing, Preclinical, Clinical. Activities Vaccine, Cell therapy, Biomanufacturing, Clinical trials, Biobank, Other. Application fields General company information Company name: Bio Elpida Address: 27, chemin des Peupliers Zip code: 69572 City: Dardilly Website: www.bio-elpida.com Founded in: 18/03/2009 Number of employees: 6 Turnover: 0.5 M e (in 2009) Main activity: Bio Elpida is a Biotechnology Contract Manufacturing Company located in Lyon - France - with strong experience on innovative cell therapy products (Advanced Therapy Medicinal Product as define by the EMEA) based on cell culture and immunology approaches. Our team of experts can conduct your project all the way from early proof of concept studies to pre-clinical and clinical phases. This includes: – R&D feasibility, – Pharmaceutical development, – Manufacturing of clinical and small scale marketing batches, – Immuno-testing, – Additional support such as bulk purification, fill and finish, formulation, training, regulatory files, analytical development… For any project, you will be assigned a project manager who will work with you as a partner giving you regular updates and making sure that our top priority is the achievement of your goals, following current regulation (ICH, cGMP, CFR 21). Subsidiary of a group: No (Immodulon) Prize winner for innovative start-up: No Innovative company (FCPI): No Other status: No Funding Looking for funding: No Company contacts CEO contact detail First name: Benoît Last name: Pinteur Position: CEO Email: [email protected] Phone: +33 (0)4 78 47 94 58 Other contact First name: Gilles Last name: Devillers Position: Head of Business Development Email: [email protected] Phone: +33 (0)6 42 98 40 16 l i f e s c i e n c e s d i r e c t o r y 2 0 1 1 Human health, Immunology, Inflammatory diseases, Infectious diseases, Autoimmune diseases, Allergology, Orphan diseases, Cancer. Activities Company activities Bio Elpida is a Biotechnology Contract Manufacturing Company located in Lyon - France - with strong experience on innovative cell therapy products (Advanced Therapy Medicinal Product as define by the EMEA) based on cell culture and immunology approaches. Our team of experts can conduct your project all the way from early proof of concept studies to pre-clinical and clinical phases. This includes: – R&D feasibility, – Pharmaceutical development – Manufacturing of clinical and small scale marketing batches, – Immuno-testing – Additional support such as bulk purification, fill and finish, formulation, training, regulatory files, analytical development… For any project, you will be assigned a project manager who will work with you as a partner giving you regular updates and making sure that our top priority is the achievement of your goals, following current regulation (ICH, cGMP, CFR 21). Company key features Working with Bio Elpida means more than services. Reaching your goals, timelines and budget is the minimum to expect from a service company. At Bio Elpida, the project managers and the expert teams ensure that you benefit from our extensive knowledge and experience. We operate as an extension of your company and take your problems as ours. Hence, from a simple piece of contract service to the most complex issue in cell culture, Bio Elpida endeavours to provide you with the highest quality work possible within the following range of cell culture and cell therapy services: – R&D and feasibility – Pharmaceutical development – Manufacturing of clinical and small scale marketing batches with single use technology – Immuno-testing – Additional support such as bulk purification, fill and finish, formulation, analytical development and regulatory services Bio Elpida partners with our clients to develop client-specific, custom protocols to meet each unique need in cell therapy, cell culture and immunotherapy projects. Recent news Bio Elpida has recently released its web site. You are invited to visit it and learn more about how we can contribute to you cell therapy development success at www.bio-elpida.com. Skills and know-how Bio Elpida is a biotechnology service company focused on the development and manufacturing of cell culture and innovative cell therapy. The company’s expertise covers the pharmaceutical Research & Development, from proof of concept to late stage clinical trial, including the process development and feasibility, analytical method validation, product testing, GMP manufacturing and release. 31 Optimisation Once the technology transfer would have been performed according to plan, our scientists lead by the project manager will strive to optimise the existing process in order to increase yield, decrease time and cost of production. Scale-Up Our core competencies apply in: – Cell banking: Master Cell Bank and Working Cell Bank – Cell culture: eukaryotic cell culture as well as prokaryotic cell culture – Cell isolation from human samples – Innovative cell therapy: autologous anticancer cell therapy, regenerative stem cells approach… – Immunotherapy: immunomodulator and other bioproducts – Immunoassays: flow Cytometry, characterisation, etc. With an optimised cell culture process, the manufacturing staff will scale the process up to the desired clinical batch size. Products / Services / Technologies Analytical Method Company services R&D and feasibility During this preliminary phase, under a CDA, you will present and define your project to Bio Elpida including: your objective, the deliverables, the description of the technology… Bio Elpida will provide you with a specific proposal including a complete presentation of the company and our capability. Proof of Concept Evaluation Following the presentation, Bio Elpida will evaluate with your collaboration, the preliminary results you had obtained. Bio Elpida will propose you technical solutions to adapt your project according to your expectations, taking into account the industrialisation requirements and complying with regulatory. Bio Elpida will provide you with a «master services agreement» covering services to be delivered to manage your project including a schedule for the specific R&D and feasibility steps. Research & Development This phase is dedicated to test the different solutions imagined during the evaluation and proposed in the development program. After this R&D step, the best solution will be proposed according to the parameters defined in the development program. Feasibility Study The aim of this step is to confirm the solution selected during the R&D step according to a defined protocol. The results of this study are registered in a formal report that anticipates the pharmaceutical development procedures. During this preliminary phase, under a CDA, you will present and define your project to Bio Elpida including: your objective, the deliverables, the description of the technology… Bio Elpida will provide you with a specific proposal including a complete presentation of the company and our capability. Pharmaceutical Development Thanks to Bio Elpida’s expertise ranging from tissue acquisition to process scale-up and design, media optimisation, immuno-assay development and validation, our staff is prepared to collaborate, guide you and work with you all the way to your success. Technology transfer Prior to any development work, the dedicated project manager and staff will work as closely as possible with our partners to transfer information and verify existing methodologies, creating a defined baseline against which process improvements are measured. l i f e s c i e n c e s d i r e c t o r y At Bio Elpida, we recommend to our partners taking the Single-Use approach. Not only it represents the preferred option to Regulatory Bodies, but it is also less complex to scale up. Hence, Bio Elpida proposes to use SUB (Single Use Bioreactor) or Biowave type of bioreactor and we propose different production means such as perfusion by ultra filtration, continuous centrifugation or simply by batch. Together with the process development, the analytical methods attached to our partner’s process will be transferred, created or modified as required and agreed. Manufacturing Following the development stage of your pharmaceutical products, Bio Elpida follows strict procedures to ensure clinical batch production: Validation: • GMP • Stability • Clinical batch Testing Bio Elpida focuses on Human bio-analysis and immunotesting of cell based therapies and proposes immuno-testing as well as other analytical tests. Immuno-Testing Program Development 32 Single-Use Approach 2 0 1 1 Bio Elpida provides existing and novel immuno-assay designs and methods for immuno testing: – Flow cytometry for known antibodies and antibodies development, – Immuno-histology, – ELISA for cytokines: IL-1, IL-4, IL-10, IL-12p40, EPO IL-2, IL-5, TNF alpha, IL-12p70, EGFR, IL-3, IL-6, VEGF, IL-8, etc. Support Further to its core services, Bio Elpida also provides additional services to support your cell based product: – Aseptic Fill & Finish for vials and pre-filled syringes – Formulation of wet and dry formats such as sterile liquid, lyophilisation, spray drying… – Regulation IMPD – Training – Drug Analytical Development – Bulk Purification. When required by scale or specificity, we can expand our existing support capabilities by working with very close network of organisations. In all cases, we retain full control and responsibilities of any piece of work given to Bio Elpida. Partnership opportunities / Licensing Collaboration framework Bio Elpida would be delighted to participate and contribute to a collaborative framework you would lead in the cell therapy, cell culture, or immunology fields. Partnership opportunities Should you have a partnership in mind, we would be happy to know more about it and initiate corresponding discussions. General company information Company name: Bioclinica SAS Address: Bioparc - 60, avenue Rockefeller Zip code: 69008 City: Lyon Founded in: 08/10/2001 Number of employees: 18 Turnover: 1 622 Ke (in 2009) Main activity: BioClinica is a global clinical trials service organization, providing medical image management and eClinical services. This includes electronic data capture and clinical data management solutions to pharmaceutical, biotechnology and medical device companies and other organizations, such as contract research organizations (CROs) engaged in clinical trials. Subsidiary of a group: Yes (BIOCLINICA Inc.) Prize winner for innovative start-up: No Innovative company (FCPI): No Other status: Yes Funding Looking for funding: No Company segmentation Business model Service provider - CRO. Value chain Research. Activities Other. Application fields Human health, Geriatrics, CNS related diseases, Cancer. Activities Company activities BioClinica is a global clinical trials service organization, providing medical image management and eClinical services. This includes electronic data capture and clinical data management solutions to pharmaceutical, biotechnology and medical device companies and other organizations, such as contract research organizations (CROs) engaged in clinical trials. Company contact CEO contact detail First name: Chahin Last name: Pachai Position: Executive Director Email: [email protected] Phone: +33 (0)4 26 23 05 05 l i f e s c i e n c e s d i r e c t o r y 2 0 1 1 33 BIOCLINOME Company segmentation Business model Service provider - Scientific, Product developer - Other health. Value chain Research, Preclinical, Clinical. Activities General company information Company name: Bioclinome Address: 563, chemin Champ Jaillet Zip code: 38190 City: Bernin Website: www.bioclinome.com Founded in: 30/07/2010 Number of employees: 2 Main activity: Information technology for personalized Diagnostics / Analysis method, Bioinformatics / Modeling, Drug discovery. Application fields Human health, Geriatrics, Immunology, Autoimmune diseases, Allergology, Metabolic diseases, Cancer, Nutrition / Food, Dermocosmetics. Activities Company activities health care. Incubator: Yes (Grain) Bioclinome proposes bioprofile technology software for medical practitioners to help personalized medical diagnosis, by means of an extremely rigourous analyse system of patient data: clinical, lab’s analysis, genomic,proteomic,epigenomic, actimetric or daily habits. Funding For the hospital physiciens or medical research centers the biologic profile will allow to distinguish clearly two resembling categories of the same disease. This approch will allow to diagnose different types of cancer, cardiovascular diseases, diabets or other degeneratives diseases such that a personalized therapy could be proposed to the patient. Subsidiary of a group: No Prize winner for innovative start-up: Yes Innovative company (FCPI): Yes Other status: Yes Looking for funding: Yes Nature of funding searches: Bank loans. Company contact CEO contact detail First name: Adriana Last name: Climescu Position: CEO Email: [email protected] Phone: +33 (0)4 76 08 02 81 The physicien may follow the evolution of the bioprofile on time and the status of his patient health stady. Our approch enables to consider in the centre of the clinical process the patient instead of the disease, according to the personalized medicine principle. Bioclinome proposes also services for pharmaceutical compagnies in relationship with the developement of new target molecules. Bioclinome realises «in silico» analysis to improve the predictability of fail or succes for a molecule. Company key features Innovative technology based on new mathematical concepts derived intrinsecaly from the nature of patient biological data. Recent news Hiring researchers and engineers. Skills and know-how - Biomarkers discovery - Proposition to the hospitals of personalized treatment approaches for cancer patients - Design and validation of clinical and pharmaceutical trails - Omics data mining Multiple databases inferences. 34 l i f e s c i e n c e s d i r e c t o r y 2 0 1 1 General company information Company name: Biomatech Namsa Address: Zi de L’Islon Zip code: 38670 City: Chasse sur Rhône Website: www.biomatech.fr Founded in: 01/10/1985 Number of employees: 100 Turnover: 11 M e (in 2009) Main activity: Medical devices and biotechnology products evaluation. Biocompatibility studies. Microbiology. RD outsourcing. Clinical research. Incubator: No Subsidiary of a group: Yes (Namsa) Prize winner for innovative start-up: No Innovative company (FCPI): No Other status: Yes Funding Service provider - CRO, Product developer Biopharmaceuticals, Service provider - Scientific, Product developer - Other health. Value chain Research, Preclinical, Clinical. Activities Cell therapy, Models (animal - cellular…), Clinical trials, Preclinical trials, Nanotechnology, Medical device, Drug delivery, Other. Application fields Human health, Other. Activities Medical devices and biotechnology products evaluation. Biocompatibility studies. Microbiology. RD outsourcing. Clinical research. Company key features Company contacts Customized services and fast turnover rates. CEO contact detail First name: Jean-Pierre Last name: Boutrand Position: Managing Director Email: [email protected] Phone: +33 (0)4 78 07 92 34 Products / Services / Technologies Company services Medical devices and biotechnology products evaluation. Biocompatibility studies. Microbiology. RD outsourcing. Clinical research. Other contact First name: Hugues Last name: Danjou Position: Project Manager Email: [email protected] Phone: +33 (0)6 85 11 18 31 Fax: +33 (0)4 72 24 08 12 s c i e n c e s Business model Company activities Looking for funding: No l i f e Company segmentation d i r e c t o r y 2 0 1 1 35 Company segmentation Business model Product developer - Other health, Laboratory equipment supplier. General company information Company name: bioMérieux Address: 376, chemin de l’Orme Zip code: 69280 City: Marcy l’Étoile - France Founded in: 01/07/1963 Number of employees: 6 300 Turnover: 1 357 M Euros (in 2010) Main activity: In vitro diagnostics. Subsidiary of a group: No Prize winner for innovative start-up: No Innovative company (FCPI): No Other status: No Funding Looking for funding: No Stock exchange listing: bioMérieux is listed on the NYSE Euronext Paris market since July 6, 2004. R&D PROJECTS FUNDED ACCREDITED BY LYONBIOPOLE GAP Healthcare shield solutions against avian flu and flu pandemics Funding: FUI (2005) Role in the project: Partner DEMINAP: Use of toll-like receptors (TLRs) in order to detect inapparent microorganisms and their ligands for diagnostic and therapeutic applications Funding: FUI (AAP2 2006) Role in the project: Partner COVADIS: innovative nanoporous sensors to detect volatile organic compounds (VOC) for applications responding to two major needs in human health Funding: FUI (AAP9 2010) Role in the project: Partner ADNA: Advanced diagnostics for new therapeutic approaches Funding: OSEO (ISI 2007) Role in the project: Leader Value chain Research, Manufacturing, Marketing / Distribution. Activities Diagnostics / Analysis method, Other. Application fields Human health, Immunology, Infectious diseases, Allergology, Cancer, Nutrition / Food. Activities Company activities A world leader in the field of in vitro diagnostics for over 45 years, bioMérieux is present in more than 150 countries through 39 subsidiaries and a large network of distributors. In 2010, revenues reached €1,357 million with 87% of sales outside of France. bioMérieux provides diagnostic solutions (reagents, instruments, software) which determine the source of disease and contamination to improve patient health and ensure consumer safety. Its products are used for diagnosing infectious diseases and providing high medical value results for cancer screening and monitoring and cardiovascular emergencies. They are also used for detecting microorganisms in agri-food and biopharmaceutical products. bioMérieux is listed on the NYSE Euronext Paris market (Symbol: BIM - ISIN: FR0010096479). Other information can be found at www.biomerieux.com. Company key features – Over 45 years experience in IVD, drawing on a century of expertise in infectious diseases – Leader in microbiology analysis worldwide – The pioneer and number 1 in industrial microbiology for the food, cosmetics and biopharmaceutical industries – R&D investment above industry average (number 1 among top ten IVD companies), representing 12% of sales each year, and a substantial commitment over the long term – Only company in the industry with extensive skills in microbiology, molecular biology and immunoassays – Installed base of approx. 60,000 instruments worldwide Recent news bioMérieux’slatestnewson:www.biomerieux.com/servlet/srt/bio/ portail/dynPage?lang=en&node=press_releases_2 Company contacts CEO contact detail First name: Stephane Last name: Bancel Position: Chief Executive Officer Phone: +33 (0)4 78 87 20 00 Other contact First name: Gianluigi Last name: Moroni Position: Business Development Manager for the European Region Phone: +33 (0)4 78 87 20 00 36 l i f e s c i e n c e s d i r e c t o r y 2 0 1 1 Products / Services / Technologies Company technologies bioMérieux is one of the few companies mastering the complete range of technologies essential for in vitro diagnostics: – Microbiology – Immunoassays – Molecular biology We have a long and successful tradition of integrating the 3 detection technologies into fully automated systems, comprised of instruments, software and reagents. Systems are constantly evolving and must integrate an increasing number of parameters. Activities Company activities General company information Company name: Biomnis Address: 17/19, avenue Tony Garnier Zip code: 69007 City: Lyon Website: www.biomnis.com Founded in: 01/01/1998 Number of employees: 900 Main activity: Reference laboratory for specialised medical diagnostic. Subsidiary of a group: No Prize winner for innovative start-up: No Innovative company (FCPI): No Other status: No Company contact CEO contact detail First name: Pierre-Yves Last name: Guiavarch Position: CEO Email: [email protected] Phone: +33 (0)4 72 80 10 51 Company segmentation Business model Service provider - Scientific. Specialised Medical Pathology. Most of Biomnis’ activities focus on specialised testing based on advanced technologies in all the fields. Screening and titers are performed with the help of the most up to date and sophisticated techniques. Biomnis has his own division for clinical trials. Substantial experience has been acquired in running clinical studies for the pharmaceutical industry, an activity that is based on the expertise of 45 pathologists with access to stateof-the-art equipment. Biomnis also has an independent laboratory for genetic fingerprinting. Genetic fingerprinting is used in forensic medicine to identify or exculpate suspects, and also in paternity cases. Biomnis has a specialised fingerprinting laboratory with all the equipment and accreditations necessary to perform such tests. Legal experts from the fingerprinting laboratory are consulted in a variety of different fields, including evidence samples analyses (exhibits), profiles for the Criminal Registry, mitochondrial DNA sequencing and paternity tests. Company key features Two specialised multidisciplinary centres (in Paris and Lyon) covering all the disciplines of medical testing 45 pathologists – over 1,000 employees in France 20,000 patient records registered every day 40,000 tests per day. Over 2,500 parameters available. An affiliated transport company to ensure the collection and temperature-controlled transportation of samples: TSE Express Medical (25 logistic agencies spread throughout France, 450 employees, 380 vehicles) 2 international premises: Claymon in Dublin, leader in private medical pathology in Ireland; and a laboratory in Dubai based in Dubai Healthcare City The trust of the most established Contract Research Organisations for clinical trial tests, and of the major companies specialising in in vitro diagnosis for the development and validation of new reagents and instruments Governmental accreditations for regulated procedures Cofrac accreditation of both sites as per the EN ISO/IEC 17025 standard (No. 1-1100 and No. 1-1973, Tests, Scope available on www.cofrac.fr ). Value chain Research, Manufacturing, Clinical. Products / Services / Technologies Activities Partnership opportunities Diagnostics / Analysis method, Clinical trials, Biobank, Other. Application fields Human health, Immunology, infectious diseases, Autoimmune diseases, Allergology, Orphan diseases, Genetic / Rare diseases, Metabolicdiseases,CNSrelateddiseases,Cancer,Nutrition/Food. l i f e s c i e n c e s d i r e c t o r y 2 0 1 1 As part of his development of new diagnostics tests, automatised techniques, oncomarkers, assay methods, Biomnis is looking for partnership opportunities. 37 General company information Company name: Biom’up Address: 8, allée Joliot Curie - M7 Zip code: 69800 City: Saint Priest Website: www.biomup.com Founded in: 21/02/2005 Number of employees: 24 Turnover: 500 000 Euros (in 2009) Main activity: Since 2005, Biom’Up SAS designs, develops, manufactures and markets innovative medical devices based on biopolymers like collagen. Collagen is a unique biopolymer. It is biocompatible, absorbable and it gathers incredible polymorphism and biological properties. R&D and production services are based on our site of Saint Priest, near Lyon, France. Our energy is focused on the development of innovative and performing products, to bring confort, safety for patients and to simplify the surgical procedures. Incubator: Yes Subsidiary of a group: No Company contact CEO contact detail First name: Sylvain Last name: Picot Position: CEO Email: [email protected] Phone: +33 (0)4 86 57 36 10 38 l i f e s c i e n c e s d i r e c t o r y 2 0 1 1 Company segmentation Business model Product developer - Biopharmaceuticals, Product developer Pharmaceuticals. Value chain Research, Manufacturing, Marketing / Distribution. Activities Biomanufacturing. Application fields Pediatrics, Human health, Geriatrics. Activities Company activities Expert in absorbable biopolymers like collagen for biomedical applications, Biom’Up develops and manufactures implantable medical devices to enhance human reconstruction. Company segmentation Business model Service provider - CRO, Service provider - CMO, Service provider - Scientific. Value chain Research, Manufacturing, Preclinical, Marketing / Distribution. Activities Diagnostics / Analysis method, Vaccine, Cell therapy, Biomanufacturing, Models (animal - cellular - …), Biobank, Drug discovery, Drug delivery, Other. General company information Company name: Biotem Address: 250, route de Charavines Zip code: 38140 City: Le Rivier d’Apprieu Website: www.biotem.fr Founded in: 01/09/1980 Number of employees: 20 Turnover: 1 M Euros (in 2009) Main activity Expert in immunotechnologies, BIOTEM proposes the development of monoclonal antibodies from the hybridoma generation stages up to antibody production at any scale, antisera production, antibody purification and modification, immunoassay development and customised studies. For more than 30 years, BIOTEM has developed a unique expertise and a large panel of cutting edge proprietary technologies. For most projects BIOTEM is proud to propose contracts with guaranteed results. Subsidiary of a group: No Prize winner for innovative start-up: No Innovative company (FCPI): No Other status: Yes (ISO 9001v2008, CIR) Funding Looking for funding: No Application fields Animal health, Human health, Immunology, Inflammatory diseases, Infectious diseases, Autoimmune diseases, Allergology, Orphan diseases, Genetic / Rare diseases, Metabolic diseases, CNS related diseases, Cancer, Nutrition / Food, Dermocosmetics, Other. Activities Company activities Expert in immunotechnologies, BIOTEM is a contract research organisation that complies with ISO 9001 quality standards. Since its establishment in 1980, the company has been the privileged partner of prestigious industrial and academic laboratories for their research, development, diagnostics and therapeutics projects. Our services include the development of monoclonal antibodies from the hybridoma generation stages up to in vitro or in vivo antibody production at any scale, antisera production, antibody purification and modification, immunoassay development and customised studies. Based on a high level of expertise and exclusive technologies, BIOTEM implements the most relevant strategies for each project and is pledged to achieve the results outlined in the contract. Company key features Know-how and 30 years experience - Exclusive technologies Results guaranteed (by contract) - Quality system accreditation (ISO 9001) - Success rate (since 2005): 94,7%. Company contact CEO contact detail First name: Clarence Last name: Deffaud Position: CEO / CSO Email: [email protected] Phone: +33 (0)4 76 65 10 91 Recent news Founded in 1980, BIOTEM is the first French CMO to have proposed the production of customised monoclonal antibodies. Today, BIOTEM actively continues its development and confirms its position as a leader in the field of monoclonal antibodies.. Products / Services / Technologies Company services – Human monoclonal antibodies development – Generation of murine hybridoma Genetic, substractive, in vitro immunizations, etc. R.A.D: Rapid Antibody Development – In vitro and in vivo production: bioreactors, CELLine, production on nude mice, balb/c, etc. – Antibody purification and modification – Immunoassays design – Polyclonal serum production and purification. l i f e s c i e n c e s d i r e c t o r y 2 0 1 1 39 General company information Company name: Calixar SAS Address: c/o IBCP 7, passage du Vercors Zip code: 69367 City: Lyon Website: www.calixar.com Founded in: 22/02/2011 Main activity: Production of integral and functional membrane Company segmentation Business model Product developer - Biopharmaceuticals, Service provider Scientific, Product developer - Pharmaceuticals. Value chain Research, Manufacturing, Preclinical. Activities proteins / antigens in solution without denaturation Global service : Protein design / Expression / Extraction and Purification / Structural and functional Tests / Scale-up Specific services : Crystallization tests / 3D Structure determination. Incubator: Yes (CREALYS) Subsidiary of a group: No Prize winner for innovative start-up: Yes Innovative company (FCPI): No Other status: Yes Diagnostics / Analysis method, Vaccine, Biomanufacturing, Drug discovery, Nanotechnology. Funding Activities Application fields Animal health, Human health, Immunology, Inflammatory diseases, Infectious diseases, Autoimmune diseases, Allergology, Orphan diseases, Genetic / Rare diseases, Metabolic diseases, CNS related diseases, Cancer, Dermocosmetics. Company activities Looking for funding: Yes Company contact CEO contact detail First name: Emmanuel Last name: Dejean Position: President & CEO Email: [email protected] Phone: +33 (0)6 84 04 95 34 Calixar has developped a new innovative and patented technology for extraction of membrane proteins and antigens without denaturation. The technology is based on a multi-step extraction strategy and uses a specific serie of home-made non denaturing detergents. Calixar offers its services to industries (pharma, biopharma, biotech) and academic teams which want to work on the right therapeutic or antigenic targets and which want to master the production of their target. The technology can be applied from gene or from biological samples. Company key features Non denaturing extraction technology All expression systems compatible No refolding step Structural and functional control of the target / antigen Global service from gene to protein up to the structure Full-lenght/integral membrane protein production in solution. Recent news Novacité Label in 2011 Lyon Science Transfer Prize 2010. Skills and know-how Biochemistry of proteins in particular membrane proteins Molecular Biology Cellular Biology Crystallization of proteins Organic chemistry. 40 l i f e s c i e n c e s d i r e c t o r y 2 0 1 1 General company information Company name: Centre d’Immunologie Pierre Fabre Address: 5, avenue Napoléon III Zip code: 74160 City: Saint-Julien en Genevois Website: www.cipf.com Founded in: 01/01/1990 Number of employees: 120 Main activity: Research in cancer biotherapy. Subsidiary of a group: Yes (Pierre Fabre Laboratories) R&D PROJECTS FUNDED ACCREDITED BY LYONBIOPOLE OPTIMABS: Optimization of monoclonal antibodies drugability by emergent analytical and structural methods: from lead to clinical candidate. Funding: FUI (AAP10 2010) Role in the project: Leader Company contacts CEO contact detail First name: Nathalie Last name: Corvaia Position: Managing Director Email: [email protected] Phone: +33 (0)4 50 35 35 55 l i f e s c i e n c e s d i r e c t o r y 2 0 1 1 Company segmentation Business model Product developer - Biopharmaceuticals. Value chain Research. Activities Biomanufacturing, Drug discovery. Application fields Human health, Immunology, Cancer. Activities Company activities A Centre of excellence in biotechnology, the Centre of Immunology Pierre Fabre (CIPF) develops research programs for cancer immunotherapy, in particular the identification of therapeutic monoclonal antibodies. Since its inauguration in 1990, the CIPF has acquired its renown through the production of recombinant proteins and bacterial biomasses. Research teams that were originally working on vaccines have focused since 2003 on discovery and characterisation of monoclonal antibodies in oncology. The Research and Industrial Biotechnology departments combine their specific know-how and expertise to identify antibodies, specify their therapeutic properties and produce them at industrial scale. Cancer immunotherapy has a key role in antitumor therapy. The CIPF is at the cutting edge within the industry and has now entered the ranks of the world’s top R&D centres dedicated to antibody biotherapies. 41 Company segmentation Business model Service provider - Scientific, Product developer - Other health. Value chain Research, Preclinical. Activities Diagnostics / Analysis method, Instrumentation. General company information Company name: cirma Address: 1, avenue Bourgelat Zip code: 69280 City: Marcy l’Etoile Website: www.irm-animaux.fr Founded in: 13/03/2008 Number of employees: 3 Turnover: 50171 Euros (in 2009) Main activity: Design of new methods and instruments for animal’s MRI Background: The development of MRI in France is in two main directions: – clinical imaging at 1.5T and 3T, – and pre-clinical studies on animals at very high field at 7 T to 9.4 T. All these MRI systems are very expensive both in acquisition and running costs. We propose new innovative methods and instruments to take advantage of low field permanent magnet MRI dedicated to medium size animal studies. This low field system allows to drastically reducing the costs without compromising image quality thanks to our specific designs. cirma is: – available to veterinary practitioners to support their diagnoses of animal from mice to anesthetized horses, – able to perform preclinical longitudinal studies for health industry, – used to train veterinary students and others to practice MRI. Incubator: Yes (CREALYS) Subsidiary of a group: No Prize winner for innovative start-up: No Innovative company (FCPI): No Other status: Yes Funding Looking for funding: Yes Public funding obtained: Rhone Alpes region 60 000 euros in 2008 Faisabilty study OSEO 50 000 euros in 2008-2009 Cifre ANRT 2009. Company contacts s c i e n c e s d i r e c t o r y Activities Company activities Although it is often thought that «bigger is better» low field MRI have many advantages for veterinary medicine compared to midfield or high-field MRI units. Advantages of low-field MRI units include their larger gantry size and so the possibility to image animals of various sizes like mice, rats, cats, dogs, ewes, goats, pigs… So, “big” animal model like pigs can be used for pre clinical studies (for example cardiovascular studies) with lower purchasing and operating costs compared to a high field MRI unit. A reduced image quality is often associated with low field MRI: cirma expertise, with dedicated imaging protocols, innovative radiofrequency coils design and new contrast agents, considerably reduces the gap in image quality. Company key features cirma is a start-up issued from Creatis (I. Magnin) a well recognized research laboratory, among the leaders in medical imaging. cirma has a strong scientific expertise: all the permanent staff is PhD. cirma is located at the heart of the VetAgro-Sup campus and has strong links with animal specialists. cirma is a small company and Customer Service is the small business advantage. Products / Services / Technologies Company services cirma believes in “one medicine”, and develops efficient solutions for animal’s MRI: – for diagnostic purposes on pets to help veterinary practitioner – for longitudinal studies on important cohorts of animals in preclinical studies. Company technologies Partnership opportunities / Licensing Other contact First name: Hervé Last name: Saint-Jalmes Position: Research and development director Email: [email protected] l i f e Animal health, Metabolic diseases. Engineering of MRI kits comprising optimized radiofrequency coils and dedicated imaging protocols. Keywords: Open MRI, animal imaging, preclinical studies, radiofrequency coils, imaging protocols. CEO contact detail First name: Marie José Last name: Seurin Position: CEO Email: [email protected] Phone: +33 (0)4 78 87 56 53 42 Application fields 2 0 1 1 Partnership opportunities cirma is looking for partners to apply its breakthrough technology and methods. The know-how of cirma could be transferred to veterinary practitioners wanting to develop animal’s MRI. cirma methodology is also available to realize preclinical studies at low cost, related to all medical specialties. General company information Company name: Clean Air Technologies Address: 1, route du Dôme Zip code: 69630 City: Chaponost Website: www.catsas.com Founded in: 01/02/2011 Main activity Established in 1998, Clean Air Technologies LTD is at the forefront of Bio-containment and contamination control. With a company ethos of Teamwork, Quality and Integrity we seek to uphold our market position as a company synonymous with professional, pragmatic, cost-effective, engineered solutions to airborne contamination control issues. Offering full support to Bio-containment & Cleanroom operators on all levels, from conception of design through to upgrading of existing facilities, Clean Air Technologies have a full comprehension of the regulatory constraints and standards. In the 12 years of operation we have developed a loyal client base throughout the pharmaceutical, Bio-containment and Biotechnology industries. Clean Air Technologies SAS was created to bring this depth of experience and knowledge tied in with the business model designed to reflect the needs of a regulated market to France. Incubator: No Subsidiary of a group: Yes (Sterigene / Clean Air Technologies) Prize winner for innovative start-up: No Innovative company (FCPI): No Other status: No Funding Looking for funding: No d i r e c t o r y Service provider - CRO, Service provider - CMO, Service provider - Scientific. Value chain Research, Manufacturing, Preclinical, Clinical. Activities Other. Application fields Animal health, Pediatrics, Human health, Geriatrics, Immunology, Inflammatory diseases, Infectious diseases, Autoimmune diseases, Allergology, Orphan diseases, Genetic / Rare diseases, Metabolic diseases, CNS related diseases, Cancer, Nutrition / Food, Dermocosmetics. Activities Company activities Established in 1998, Clean Air Technologies LTD is at the forefront of Bio-containment and contamination control. With a company ethos of Teamwork, Quality and Integrity we seek to uphold our market position as a company synonymous with professional, pragmatic, cost-effective, engineered solutions to airborne contamination control issues. Offering full support to Bio-containment & Cleanroom operators on all levels, from conception of design through to upgrading of existing facilities, Clean Air Technologies have a full comprehension of the regulatory constraints and standards. In the 12 years of operation we have developed a loyal client base throughout the pharmaceutical, Bio-containment and Biotechnology industries. Recent news CEO contact detail First name: John Last name: Mumford Position: Commercial Manager Email: [email protected] Phone: +33 (0)6 01 59 12 17 s c i e n c e s Business model Clean Air Technologies SAS was created to bring this depth of experience and knowledge tied in with the business model designed to reflect the needs of a regulated market to France. Company contact l i f e Company segmentation 2 0 1 1 A Joint Venture has recently been signed which has led to the creation of Clean Air Technologies SAS. 43 clininfo General company information Company name: Clininfo SA Address: Entrée n°7 - 99, rue de Gerland Zip code: 69007 City: Lyon Website: www.clininfo.fr Founded in: 01/06/1998 Number of employees: 15 Turnover: 750 K Euros (in 2009) Main activity We apply a rigorous approach and proven methodologies developed from our university clinical origins and through our partnership with the C.R.O (Clinical Research Organization). This rigour has ensured reliable data management for the past 20 years for some of the largest controlled studies ever done. We put our adaptable expertise at your service to address your particular needs. Our scalable system can be adapted to your study, small or large, and put into place quickly to manage data from several dozen to tens of thousands of patients. This adaptability and flexibility are reflected in our products as well as in the proven skills of our team. Our systems are designed for interactivity with you—our client. Incubator: Yes (EZUS) Subsidiary of a group: No Prize winner for innovative start-up: No Innovative company (FCPI): No Other status: No Business model Service provider - CRO, Other. Value chain Research, Clinical, Other. Activities Diagnostics / Analysis method, Clinical trials, Preclinical trials, Other. Application fields Animal health, Pediatrics, Human health, Geriatrics, Immunology, Inflammatory diseases, Infectious diseases, Autoimmune diseases, Allergology, Orphan diseases, Genetic / Rare diseases, Metabolic diseases, CNS related diseases, Cancer, Nutrition / Food, Dermocosmetics, Other. Activities Company activities Our multilingual electronic case report form (eCRF) is built on more than two decades of experience with databases dedicated to clinical trials. The robustness of the concepts and the data structures we use were validated by several dozen studies, following phase IV tests in oncology (both hospital and specialist). The integrated procedures in production, development, test and maintenance were thoroughly audited and fully documented in compliance with CFR 21, Part 11. Company key features Looking for funding: No Adaptability, flexibility, and security of our products are our strengths. Our Data Management (DM) software, at your disposal, is in conformance with the requirements of FDA 21, CFR Part 11. It’s robust, reliable, and adaptable to your requirements. Company contacts Recent news Funding Our products were developed with the Clinical Pharmacology Service at the University of Lyon, and so we have managed many diverse projects: – for more than 20 years – at 20 client sites – through 460 studies – including 731,000 patients – with 240 million variables – through more than 14 on site audits CEO contact detail First name: Patrick Last name: Chevarier Position: C.E.O. Email: [email protected] Phone: +33 (0)4 78 61 44 26 Other contact First name: Myriam Last name: Gherbia Position: Personal Assistant Email: [email protected] Phone: +33 (0)4 78 61 44 20 Fax: +33 (0)4 78 58 31 67 44 Company segmentation l i f e s c i e n c e s d i r e c t o r y Skills and know-how All of our experts are available to provide the training of your choice for all of our services, at your site, in French or English. You have the opportunity to benefit from their technical skills and solid practical experience in their respective fields. 2 0 1 1 clininfo Products / Services / Technologies Company services Several quality levels are available at your request: – simple data entry – double entry, with or without adjudication – double entry with double entry / difference checking Initially integrated within a traditional CRO, our data entry group has more than 15 years of experience. We have more than 100 clinical trials, epidemiological records and studies in diversified fields: oncology, cardiology, epidemiology, psychiatry, diabetes, rheumatology, pediatrics, and economics of health care. Company technologies We are also ready to work with you to develop any other application in the medical field. We dedicate part of our activity to developing new systems in response to Requests for Proposals or for custom systems. In this way, we have developed recording systems for data collection on PCs, decentralized and autonomous randomisation, clean monitoring, management of correspondents, management of fees, and management of bibliographies. We are available to study any situation where specific data processing solutions are needed. With our Data Management solutions, you need no longer worry about technical difficulties. Trust your data to us remotely. We offer two types of contracts for information management: – Proportional fee, for individual study (for example, by the number of characters entered, by the number of controlled variables, by the number of edits and corrections, by the number of randomised patients, etc.) – Base cost fee, with the same types of invoicing as above, a monthly minimum use, and some customisation for individual studies. Simplicity of use and high functionality are two strengths of our data management solutions. The different platforms (vocal server, modem, Internet, telephone, fax) can be used interchangeably, because they access the same database used for questionnaire management and visit monitoring. The following randomisation schemas are available: – screening period – factorial design – cross-over, witness case studies, static randomisation (stratification, permuted block), dynamic randomisation (minimization) – management of provisioning on all levels (tests, country, regions, coordinators, centres). Our standard service, available 24/7, is especially designed for two applications: – centralized randomisation – self-evaluation (quality of life, evaluation of pain indicated by the patient). l i f e s c i e n c e s d i r e c t o r y 2 0 1 1 45 General company information Business model Company name: Compétence Biotech Address: Lyonbiopole Business Center Other. Zip code: 69007 City: Lyon Founded in: 02/03/2009 Number of employees: 2 Main activity: Competence biotech pools the competencies Other. 321, avenue Jean Jaurès defined by the biotech sector. Depending on the needs expressed, the employees are recruited in partnership with the biotech companies concerned. Factually, Quality Assurance and Regulatory skills are most in demand. Incubator: No Subsidiary of a group: No Prize winner for innovative start-up: No Innovative company (FCPI): No Other status: No CEO contact detail First name: Sylvie Last name: Tournand Position: Director Email: [email protected] Phone: +33 (0)6 17 17 26 33 Other contact First name: Thomas Last name: Chuzel Email: [email protected] l i f e s c i e n c e s d i r e c t o r y Value chain Activities Other. Application fields Other. Activities Company activities Competence Biotech pools the competencies defined by the biotech sector. Depending on the needs expressed, the employees are recruited in partnership with the biotech companies concerned. Factually, Quality Assurance and Regulatory skills are most in demand. Company key features Company contacts 46 Company segmentation 2 0 1 1 Proven skills: employees are senior. They provide a solid experience, operational skills and strategic decision support. Safety: a charter anticipates potential conflicts of interest, in the interests of companies and employees. Sustainability: the Competence Biotech employee is integrated in the company’s team with no limited time. General company information Company name: Conidia Address: 10, rue Raphaël Dubois Zip code: 69622 City: Villeurbanne Website: www.conidia.fr Founded in: 17/04/2005 Number of employees: 6 Turnover: 340 K Euros (in 2010) Main activity: R&D in microbiology (in particular on mould type micro-organisms). Incubator: Yes (CREALYS) Subsidiary of a group: No Company segmentation Business model Service provider - Scientific. Value chain Research. Activities Diagnostics / Analysis method, Bioinformatics / Modeling, Other. Application fields Other. Prize winner for innovative start-up: Yes (Novad’or 2009) Innovative company (FCPI): No Other status: Yes (JEI, CIR) Activities Company activities Looking for funding: No CONIDIA is working on moulds in different activity fields (pharmaceutical, phytosanitary, agro-alimentary, microbiological air quality…). We propose services of indentification by microscopy and molecular biology and we have a research team to treat specific moulds problematics. Company contacts Recent news Funding CEO contact detail First name: Sébastien Last name: Vacher Position: CEO Email: [email protected] Phone: +33 (0)4 72 43 10 43 Rewarded in 2009 by the Novad’or prize from the CCI of Lyon. Other contact First name: Catalina Last name: Hernandez Fernandez Email: [email protected] Phone: +33 (0)4 72 43 10 43 l i f e s c i e n c e s d i r e c t o r y 2 0 1 1 47 General company information Company name: CoSMo Address: 102, rue Montgolfier Zip code: 69006 City: Lyon Website: www.thecosmocompany.com Founded in: 21/06/2010 Number of employees: 6 Turnover: 750000 (in 2011) Incubator: Yes (CREALYS) Subsidiary of a group: No Prize winner for innovative start-up: No Innovative company (FCPI): Yes Other status: Yes Funding Looking for funding: Yes Company contacts CEO contact detail First name: Eric Last name: Boix Position: CEO Email: [email protected] Phone: +33 (0)6 47 88 61 55 Other contact First name: Hugues Last name: de Bantel Email: [email protected] Phone: +33 (0)6 22 42 95 67 48 l i f e s c i e n c e s d i r e c t o r y 2 0 1 1 Company segmentation Business model Service provider - Scientific. Value chain Research. Activities Diagnostics / Analysis method, Biomanufacturing, Clinical trials, Preclinical trials, Bioinformatics / Modeling, Drug discovery, Nanotechnology, Medical device, Drug delivery, Other. Application fields Animal health, Human health, Immunology, Infectiology, Aautoimmune diseases, Allergology, Orphan diseases, Genetic / Rare diseases, CNS related diseases, Cancer, Nutrition / Food, Dermocosmetics, Other. General company information Company name: CreaCell Address: biopolis 5 avenue Grand Sablon Zip code: 38700 City: La Tronche Website: www.creacell.com Founded in: 27/11/2003 Main activity: CreaCell’s activity includes two domains: development of «cardiac» Ion Channel Cell Lines for safety pharmacology and Cell Culture Services for drug discovery. Incubator: Yes (Grain) Subsidiary of a group: No Prize winner for innovative start-up: Yes (Emergence 2002) Innovative company (FCPI): No Other status: No Funding Company segmentation Business model Service provider - CRO, Product developer - Other health. Value chain Research, Manufacturing, Preclinical. Activities Models (animal - cellular - …), Drug discovery. Application fields Animal health, Human health, Immunology, Inflammatory diseases, Infectious diseases, Autoimmune diseases, Allergology, Orphan diseases, Genetic / Rare diseases, Metabolic diseases, CNS related diseases, Cancer, Nutrition / Food. Activities Looking for funding: No Company activities Development and marketing of «cardiac» Ion Channel Cell Lines for safety pharmacology is our first activity. The second is Mammalian Cell Culture Services for drug discovery, performed in our P2 laboratory. For eight years, our products and services for mammalian cell-based research have been distributing worldwide (North America - Europe - Asia) to support R&D efforts of our customers. Company contacts CEO contact detail First name: Pierre-Yves Last name: Perche Position: CEO Email: [email protected] Phone: +33 (0)4 76 63 75 89 Other contact First name: Guillaume Last name: Perche Position: Marketing manager Email: [email protected] Phone: +33 (0)4 76 63 75 89 l i f e s c i e n c e s d i r e c t o r y 2 0 1 1 49 General company information Company name: CTI-Lyon / Cell Therapy Research Institute Address: Parc technologique de Lyon St Priest 97, Allée Alexandre Borodine Cèdre 1 Zip code: 69800 City: St Priest Website: www.cticell.org Founded in: 01/12/2008 Number of employees: 12 Turnover: 330 K Euros (in 2010) Main activity: CTI-LYON studies adult and neonatal stem cell populations to investigate biological systems regulating cell proliferation and differentiation into endodermal, mesodermal and ectodermal lineages. CTI-LYON developed and validated a range of technologies enabling 2D and 3-dimensional tissue engineering using bioreactors, biomaterials and clinical-grade growth factors. CTI-LYON’s research applications include bioassay development, drug screening platforms, biomedical device, cGMP bioprocessing and clinical applications. CTI-LYON runs pre-clinical and clinical programmes to enable cell therapy applications for diabetes, stroke, cerebral palsy, hemato- immunological diseases, cranio-facial malformations, orthopaedic lesions, cancer. CTI-LYON develops 3D bioassays for molecular screening and toxicology platforms from human stem cells. Incubator: No Subsidiary of a group: No Prize winner for innovative start-up: No Innovative company (FCPI): No Other status: Yes (CIR/JEI) Funding Looking for funding: Yes Company contacts CEO contact detail First name: Colin Last name: McGuckin Position: President Email: [email protected] Phone: +33 (0)4 26 03 01 30 Other contact First name: Nico Last name: Forraz Position: Vice-President Email: [email protected] Phone: +33 (0)6 78 90 38 50 50 l i f e s c i e n c e s d i r e c t o r y 2 0 1 1 Company segmentation Business model Service provider - CRO, Service provider - CMO, Product developer - Biopharmaceuticals, Service provider - Scientific. Value chain Research, Manufacturing, Preclinical. Activities Diagnostics / Analysis method, Cell therapy, Biomanufacturing, Models (animal - cellular - …), Biobank, Preclinical trials, Drug discovery. Application fields Pediatrics, Human health, Immunology, Autoimmune diseases, Genetic / Rare diseases, CNS related diseases, Cancer. Activities Company activities CTI-Lyon developed and validated a range of technologies enabling 2D and 3-dimensional tissue engineering using bioreactors, biomaterials and clinical-grade growth factors. CTI-Lyon’s research applications include bioassay development, drug screening platforms, biomedical device, cGMP bioprocessing and clinical applications. CTI-Lyon runs pre-clinical and clinical programmes to enable cell therapy applications for diabetes, stroke, cerebral palsy, hematoimmunological diseases, cranio-facial malformations, orthopaedic lesions, cancer. CTI-Lyon expertise grew from haematology and oncology research and patient based therapy including bone marrow disorders where stem cells fail to grow. Using Cord Blood and Bone Marrow, we use normal and abnormal stem cell populations to understand control mechanisms including cytokine and transcriptional pathways. This led us to investigate human “adult” and cord blood stem cells for haematology-oncology transplantation. The noninvasive nature of collection umbilical cord and cord blood offer a distinct advantage over any other sources of adult and embryonic stem cells. Umbilical cord and cord blood cells can be characterized and cryopreserved bio-banks worldwide. With over 130 million children born each year, neonatal is an abundant stem cell source from all genetic and ethnic background. Our research has shown that cells from all three germ layers can be produced from umbilical cord, cord blood and bone marrow stem cells. We have developed routine protocols for isolation of defined cell populations from extremely immature stem cell compartments, through to more mature progenitor cells, which have allowed defined tissue engineering and regenerative procedures to be advanced. The most significant development of our work has been the development of a protocol for the production of karyotypically normal Cord Blood-derived Embryonic – like stem cells (CBE’s), which have the ability to form embryoid body – like structures and to express the majority of Embryonic Stem Cell markers. It is also possible to subculture these cells for ex vivo expansion for over 12 weeks, whilst maintaining their immaturity. This research, published in 2005, is the first production of a clone of embryonic – like cells from a non-embryonic tissue. We further demonstrated the pluripotent nature of umbilical cord and cord blood stem cells that can be differentiated into endodermal, mesodermal and ectodermal tissues including neural, endothelial, hepatic, and pancreatic tissues. Conventional cell culture methods employ 2D dimensional culture systems to propagate cells in vitro. Although this approach is useful to understand key biological features like the cell cycle, growth factor stimulation, proliferation rates and signal transduction, the large scale clinical grade ex-vivo tissue and organ expansion generation calls for 3-dimensional Tissue Bio-engineering. Our preliminary work with bioreactors has demonstrated that they allow continuous rotation, expansion and endogenous extracellular matrix production in a shear stress-free environment favouring development into functional 3-D tissues. A key finding in this was our ability to expand, maintain and differentiate CBE’s into hepatic and neural progenitors in 3-dimensions with and without supporting bioscaffolds. Company key features CTI-Lyon host a team of 15 international researchers with extensive expertise in stem cell biology and cord blood bio-processing as well as stem cell cultures and tissue engineering. Skills and know-how Our group technical expertise includes 3-dimensional tissue engineering and bioreactor systems, flow cytometry, molecular biology, microarray, proteomics, laser-scanning confocal microscopy, bioprocessing using adult (bone marrow, adipose tissues, cornea) and neonatal stem cells (umbilical cord, cord blood, placenta) as universal vectors for tissue engineering, drug screening, cell therapy and regenerative medicine research. l i f e s c i e n c e s d i r e c t o r y 2 0 1 1 51 General company information Business model Company name: Cylergie-Cofely’s Research & Development Other. Address: L’orée d’Ecully, chemin de la Forestière Zip code: 69130 City: Écully Website: www.cofely-gdfsuez.com Founded in: 1988 Number of employees: 15 Main activity: Research and development for the Cofely Value chain Center activities: management and maintenance of energy production installations. Subsidiary of a group: No (GDFSuez) Prize winner for innovative start-up: Yes Innovative company (FCPI): Yes Other status: Yes Funding Looking for funding: No R&D PROJECT FUNDED ACCREDITED BY LYONBIOPOLE COLLECTAIR: Development of an air sampling device dedicated to bioaerosol analysis for healthcare center Funding: FUI (AAP4 2007) Role in the project: Partner Company contacts CEO contact detail First name: Jean Last name: Roland Position: Administrator Email: [email protected] Phone: +33 (0)1 41 20 10 00 Other contact First name: Patrick Last name: Haenel Position: Manager Email: [email protected] Phone: +33 (0)4 72 86 09 80 Fax: +33 (0)4 78 43 30 59 52 Company segmentation l i f e s c i e n c e s d i r e c t o r y 2 0 1 1 Other. Activities Other. Application fields Human health, Other. Activities Company activities Research and technical support (marketing,assistance expertise, lobbying, training) on following subjects: – District Heating (& Cooling ) Networks – Energy Management – Metrology, Automation, Remote Systems, Indicators – Renewable Energies, New Energy Technologies – Environnement, Health, Comfort. Activities Company activities Cynbiose is a new company meeting the needs of public and private companies involved in drug development and biomedical research. Where as larger CROs already propose standard regulatory studies, Cynbiose is one of the rare European private companies with expertise in primatology, which carries out exploratory studies with the aim to reduce time of drug development. Cynbiose allows private and academic researchers to access NHP models with support to face high level of constraints due to the use of this sensitive animal model (regulatory, sanitary, technical, ethical and economical aspects). General company information Company name: Cynbiose Address: 1, avenue Bourgelat Zip code: 69280 City: Marcy l’Etoile Founded in: 25/10/2008 Number of employees: 5 Turnover: 500 K Euros (in 2010) Main activity: Cynbiose is a preclinical assesment platform dedicated to the use of Non Human Primates (NHP) models for biomedical research. Incubator: No Subsidiary of a group: No Prize winner for innovative start-up: No Innovative company (FCPI): No Other status: Yes Funding Looking for funding: No Company contact CEO contact detail First name: Hugues Last name: Contamin Position: CEO Email: [email protected] Phone: +33 (0)6 62 74 35 66 Company segmentation Business model Service provider - CRO, Service provider - Scientific. Activities Vaccine, Models (animal - cellular - …), Preclinical trials, Drug discovery, Drug delivery, Other. Application fields Pediatrics, Human health, Geriatrics, Immunology, Inflammatory diseases, Infectious diseases, Autoimmune diseases, Orphan diseases, Metabolic diseases, CNS related diseases, Cancer. s c i e n c e s d i r e c t o r y Cynbiose is also supported by different scientific experts for the development of innovative protocols on NHP. Cynbiose is also member of the world-class competitiveness cluster “Lyonbiopole”, to set-up scientific collaborations with national and international companies. Company key features – Animal facility with a high capacity (100 animals of different reliable NHP species) - biosafety level 1 and 2 – Expertise – Flexibility and Reactivity – Strategic Partners – Innovative Models developed in partnership – Science, Quality and Animal Welfare. Recent news Research and development programs in progress since 2009: “Bioavailibility of new pharmacological approaches to study neurodegenerative diseases”: partnership with CNRS (Institut des Maladies Neurodégénératives de Bordeaux) and Motac SA. “Development of non-human primate models for preclinical assessment of innovative osteoarthritis treatments”: partnership with Voxcan SARL and Bone Therapeutics SA; Grant Eurostars. Perspectives: GLP and AAALAC authorized in 2011. Skills and know-how Value chain Research, Preclinical. l i f e Cynbiose collaborates with strategic partners dedicated to the use of NHP in research: – the testing facilities are located at the Institut Claude Bourgelat at the National Veterinary School of Lyon (VetAgeo Sup, Marcy l’étoile), – Bioprim (Bazièges, France) is the only one private company in France dedicated to the import and quarantine of NHP for research with high sanitary controls, – breeding colonies supply the NHP with high quality standards. 2 0 1 1 – Expertise in NHP models from import, quarantine, housing, ethical, sanitary, technical and veterinary aspects to the development of protocols and data analyses. – Development of innovative models in immunology, neuroscience, infectious and metabolic diseases implying the use of innovative technologies for non invasive approaches (imaging, telemetry, video-monitoring). – Focused on ethics with the development of an Animal Welfare program (AAALAC accreditation expected in 2011). 53 Company segmentation Business model Product developer - Other health. Value chain Manufacturing. Activities Other. Application fields Human health, Inflammatory diseases, Infectious diseases, Autoimmune diseases, Orphan diseases, Metabolic diseases, CNS related diseases, Cancer, Dermocosmetics. Activities Company activities Cytoo focuses on innovative products for the life science research market with an emphasis in cell based assays, high content analysis and cell screening. General company information Company name: Cytoo SA Address: 7, parvis Louis Néel Zip code: 38040 City: Grenoble Website: www.cytoo.com Founded in: 01/06/2008 Number of employees: 20 Main activity: We develop, manufacture, and distribute products that make cellular analysis robust and reliable by drastically decreasing cell variability. Our new micropattern-based products are designed to meet the needs of all clients whatever their research goals in cell biology research, cell based assays and cell screening for drug discovery. Incubator: Yes (Grain) Subsidiary of a group: No Prize winner for innovative start-up: Yes (Creation Development 2008) Innovative company (FCPI): No Other status: Yes (JEI, CIR) Funding Looking for funding: Yes Private funding obtained: June 2008: €1M July 2009: € 3.2 M Company key features Cytoo was incorporated in France in June 2008 and established its premises at the heart of Grenoble’s micro and nanotechnology innovation center MINATEC after closing a seed round of 1 M€ with CEA Investissement, Rhone Alpes Creation and private investors. That same year, Cytoo was rewarded at both the Startup competition of the French Ministry for Research and the «Tremplin Entreprises» of the French Senate. Recent news In July 2009, Cytoo raised € 3.2 M (US$ 4.8 M) in a VC round with AURIGA Partners and previous private investors and in September opened a US subsidiary in Massachusetts. In January 2010, Cytoo’s headcount scores 15 including 8 PhDs. Skills and know-how Cytoo’s technology is a revolutionary discovery of the Institut Curie in Paris, based on the exquisite control of the cell’s microenvironment and offering an entirely new way of looking at cellular behavior. Specific designs of adhesive micropatterns not only control the shape and location of individual cells, but also control internal cell organization down to the position of the organelles. Cytoo’s manufacture is based on microelectronic processes such as photolithography. Products / Services / Technologies Company technologies Company contact Cytoochip: micropatterned glass chips for cell analysis in the research market Cytooplate: micropatterned microplates for High Content Analysis in cell screening. CEO contact detail First name: François Last name: Chatelain Position: President and CEO Email: [email protected] Phone: +33 (0)4 38 88 47 05 Partnership opportunities / Licensing Collaboration framework Looking for partners in projects for FP7, EUREKA, ANR, IMI. Partnership opportunities OEM with Life Science Tools companies, cell based assay kit providers, etc. 54 l i f e s c i e n c e s d i r e c t o r y 2 0 1 1 General company information Company segmentation Business model Company name: DAMsi Address: World Trade Center Cité Internationale Other. Zip code: 69006 City: Lyon Website: www.damsi.fr Founded in: 16/08/2010 Main activity: Automated & integrated solutions to secure Marketing / Distribution, Other. 15, quai Charles de Gaulle and monitor the medicines distribution circuit. Incubator: No Subsidiary of a group: No Prize winner for innovative start-up: No Innovative company (FCPI): No Other status: No Value chain Activities Drug delivery, Other. Application fields Human health, Geriatrics, Other. Activities Company activities Consulting, Research & Development, Software editor, Integration. French distributor of Japanase Tosho Inc., world leader in medicines dispensing machines. French distributor of English Stripfoil systems, automatic deblistering systems. Company contacts CEO contact detail First name: Claire Last name: Tredez Position: Chief Executive Officer Email: [email protected] Phone: +33 (0)4 26 68 38 00 Other contact First name: Stéphane Last name: Mellet Position: Director / Partner Email: [email protected] Phone: +33 (0)4 26 68 38 00 Fax: +33 (0)4 72 40 57 08 l i f e s c i e n c e s d i r e c t o r y 2 0 1 1 55 General company information Company name: Dendritics Address: 60, avenue Rockefeller Zip code: 69008 City: Lyon Website: www.dendritics.net Founded in: 03/11/2005 Number of employees: 5 Main activity: Dendritics develops and markets monoclonal antibodies targeting the dendritic cells and their microenvironment, thus providing tools for research and diagnostic. Dendritics also proposes on-demand generation of monoclonal antibodies. Dendritics develops innovative tools and processes intended for the scientific community. Subsidiary of a group: No Prize winner for innovative start-up: No Innovative company (FCPI): No Other status: Yes Funding Company contacts CEO contact detail First name: Jean-Jacques Last name: Pin Position: Head and Founder Email: [email protected] Phone: +33 (0)6 89 01 11 81 Other contact First name: Diane Last name: Razanajaona-Doll Email: [email protected] Phone: +33 (0)4 72 71 74 03 Fax: +33 (0)4 78 00 14 36 l i f e s c i e n c e s d i r e c t o r y Business model Service provider - Scientific, Product developer - Other health, Other. Value chain Research, Manufacturing, Preclinical, Marketing / Distribution, Clinical, Other. Activities Diagnostics / Analysis method, Models (animal - cellular - …), Drug discovery, Other. Application fields Animal health, Human health, Immunology, Inflammatory diseases, Infectious diseases, Autoimmune diseases, Allergology, Orphan diseases, Cancer, Other. Activities Company activities Generation and marketing of murine monoclonal antibodies Generation of murine monoclonal antibodies on-demand Development of innovative processes intented for the scientific community. Looking for funding: Yes 56 Company segmentation 2 0 1 1 DExtérité Surgical General company information Company name: Dextérité Surgical Address: 1, rue des Glières Zip code: 74000 City: Annecy Founded in: 05/11/2008 Number of employees: 4 Main activity: Develop, manufacture and sale innovative Company segmentation Business model Product developer - Other health. Value chain Research, Manufacturing, Marketing / Distribution. Activities Medical device. instruments for laparoscopic surgery. Incubator: Yes (Grain) Subsidiary of a group: No Application fields (Création-développement - 2008) Innovative company (FCPI): Yes Other status: Yes (JEI) Activities Human health. Prize winner for innovative start-up: Yes Company activities Funding Looking for funding: Yes Nature of funding searches: 2nd round of financing planned for Q4 2011. Private funding obtained: First round of € 950K closed in october 2010 Public funding obtained: Prize-winner of the national competition for innovative start-up: € 300 K Patients, medical community and health care payers are all asking for an even faster development of Laparoscopic Surgery. More than 6 millions patients did benefit from this surgery last year. Unfortunately, this minimal invasive surgery is much more difficult to perfrom and requires a long training and high dexterity. The only existing tool to ease this technique is a very expensive and cumbersome heavy Robot. Dextérité Surgical is helping surgeons to perform laparoscopic surgery by providing them with easy to use and cost effective instruments. The first of which is an «Hand Held Robot» for laparoscopic surgery that costs 10 times less than the existing heavy Robot. Company key features Company contact CEO contact detail First name: Pascal Last name: Barrier Position: CEO Email: [email protected] Phone: +33 (0)9 70 44 07 82 Over 70 years of added experience in the Medical Device industry (EU and US) for 3 of the founders. Agile, and cost effective to maximize ROI. Innovative products in a fast growing market. Recent news The first clinical use of the «Hand Held Robot» for laparoscopic surgery is planned for the first half of 2011. Products / Services / Technologies Pipeline product 1 Therapeutic area: Laparoscopic surgery Partnership opportunities / Licensing Partnership opportunities We would be delighted to discuss partnership with companies developing 3D / enhance vision for laparoscopic surgery. l i f e s c i e n c e s d i r e c t o r y 2 0 1 1 57 General company information Company segmentation Business model Company name: Drive Address: 14, place Jules Ferry Zip code: 69006 City: Lyon Website: www.driveimplants.com Founded in: 28/10/2008 Number of employees: 4 Turnover: 800 000 Euros (in 2010) Main activity: Conception, manufacturing and marketing Product developer - Other health. Prize winner for innovative start-up: No Innovative company (FCPI): No Other status: No Activities Funding Company key features Looking for funding: Yes Nature of funding searches: Oseo fundings innovation: € 100 K€, I-declik fundings: € 80 K, Bank findings: € 150 K, Private fundings: €150 K. Private funding obtained: Individuals findings Public funding obtained: See above Recent news of innovative dental implants range. Incubator: Yes (CREALYS) Subsidiary of a group: No Value chain Research, Manufacturing, Marketing / Distribution, Clinical. Activities Medical device, Other. Application fields Human health. Company activities Dental implants conception, manufacturing and sales. Innovation, Research and development, High-tech marketing, International: North Africa and Eatern Europe. Launching of a very innovating dental implant range with prosthetical and ancillary. Skills and know-how Company contacts CEO contact detail First name: Guillaume Last name: Fromental Position: CEO Email: [email protected] Phone: +33 (0)9 62 30 67 27 Other contact First name: Ivan Last name: Blondet Position: Secrétaire Général Email: [email protected] Phone: +33 (0)9 62 30 67 27 30 years experience and expertise in dental implantology, dental implantology cluster, dental implantology academy, dental implantology pilot center, dental implantology supply chain, dental implants manufacturing. Products / Services / Technologies Company services All services concerning dental implantology specially dental implants and training units for implantologists. Company technologies Patented innovative dental implants. Partnership opportunities / Licensing Collaboration framework Exploitation licence of patented implantary systems. Partnership opportunities Creation of innovative dental implantology companies cluster, pole of excellency. 58 l i f e s c i e n c e s d i r e c t o r y 2 0 1 1 Activities Company activities General company information Company name: Écrins Therapeutics Address: BIOPOLIS, 5 avenue du Grand Sablon Zip code: 38700 City: La Tronche Website: www.ecrins-therapeutics.com Founded in: 21/07/2010 Number of employees: 5 Main activity: Écrins Therapeutics is a biotechnology company which focuses on the discovery and development of novel small molecule drugs that are intended as cancer therapies. The company aims to develop these potential new drugs from the preclinical phase to phase 2 clinical proof of concept. Incubator: Yes (grain) Subsidiary of a group: No Prize winner for innovative start-up: Yes (2009 -“Emergence”; 2010 - “Création-Développement”) Innovative company (FCPI): No Other status: Yes (CIR, JEI) Funding Looking for funding: Yes Nature of funding searches: Founded in 2010 with a vision to fight cancer, Ecrins Therapeutics is also committed to delivering value to its shareholders. We are interested in the investment and/or development partners, who could speed up the progress of our technology to the market place. Public funding obtained: Canceropôle CLARA, 2009, € 478 K MESR/OSEO, «Emergence», 2009, € 26 K MESR/OSEO, “Création-Développement” , 2010, € 220 K Drawing on a range of core competencies including phenotypical and “traditional” high-throughput screening, microscopy, chemistry R&D, medicinal chemistry, molecular modeling and animal cancer models, Ecrins Therapeutics discovers and develops bioactive small molecules. Company key features Original technology; Strong intellectual property; Our lead clinical candidate shows a strong in vivo activity against human cancers and is well tolerated by animals. Recent news Our lead candidate ET-D5 is an anti-mitotic and anti-vascular compound. The latter exist in two different classes: – anti-angiogenic; – vascular-disrupting agents (VDA). The difference between them is that while the anti-angiogenic drugs prevent neovessels formation in the growing tumor, the VDA, for example ET-D5, physically disrupt already established tumor vessels. The destruction of blood vessels by ET-D5 effectively shuts down the supply of O2 and nutrients to cancer cells and provokes a massive intratumoral necrosis. Another mechanism by which ET-D5 targets cancer cells, is by arresting them in division (mitotic arrest), followed by cell death. Most importantly, ET-D5 presents interesting pharmacological properties, good toxicology profile and is active when administered per os. Skills and know-how Discovery and characterization of bioactive small molecules; Preclinical developement of anticancer drug candidates. Products / Services / Technologies Pipeline product 1 Therapeutic area: oncology Therapeutic indication: solid cancers Preclinical: proof of concept Company contact CEO contact detail First name: Andrei Last name: Popov Position: Researcher Inserm Email: [email protected] Phone: +33 (0)6 50 63 34 04 Company segmentation Company technologies Drawing on a range of core competencies including phenotypical and “traditional” high-throughput screening, microscopy, chemistry R&D, medicinal chemistry, molecular modeling and animal cancer models, Ecrins Therapeutics discovers and develops bioactive small molecules. Partnership opportunities / Licensing Business model Collaboration framework Product developer - Pharmaceuticals. We are open to collaboration proposals. Value chain Partnership opportunities Activities Diagnostics / Analysis method, Clinical trials, Preclinical trials, Bioinformatics / Modeling, Drug discovery, Other. Ecrins Therapeutics seeks outstanding partners in the pharmaceutical industry to implement challenging technology programs, essential to its growth. We would be interested in discussing joint venture proposals with regards to the following products: ET-D5. Application fields Out-licencing opportunity Research, Preclinical, Clinical. Animal health, Human health, Immunology, Infectious diseases, Autoimmune diseases, Orphan diseases, Cancer. l i f e s c i e n c e s d i r e c t o r y 2 0 1 1 We are ready to discuss sub-licencing opportunities for our lead candidate ET-D5. 59 Company segmentation Business model Product developer - Other health. Value chain Manufacturing, Marketing / Distribution. Activities Medical device, Drug delivery. Application fields Human health, Cancer. Activities Company activities General company information Company name: EDAP TMS France Address: 4, rue du Dauphiné Zip code: 69120 City: Vaulx-en-Velin Website: www.edap-tms.com Founded in: 06/05/1994 Number of employees: 90 Turnover: 18 M Euros (in 2009) Main activity: Development and marketing of high-technology, EDAP TMS France develops and markets Ablatherm, the most advanced and clinically proven choice for high-intensity focused ultrasound (HIFU) treatment of localized prostate cancer. HIFU treatment is shown to be a minimally invasive and effective treatment option with a low occurrence of side effects. Ablatherm-HIFU is generally recommended for patients with localized prostate cancer (stages T1-T2) who are not candidates for surgery or who prefer an alternative option, or for patients who failed radiotherapy treatment. Approved in Europe as a treatment for prostate cancer, Ablatherm-HIFU (High Intensity Focused Ultrasound) is currently undergoing evaluation in a multicenter U.S. Phase II/III clinical trial under an Investigational Device Exemption granted by the FDA, the ENLIGHT U.S. clinical study. The Company also is developing this technology for the potential treatment of certain other types of tumors. EDAP TMS SA also produces and commercializes medical equipment for treatment of urinary tract stones using extra-corporeal shockwave lithotripsy (ESWL). For more information on the Company, please visit www.edap-tms.com, www.hifu-planet.com. minimally invasive medical devices using therapeutic ultrasound for the treatment of localized prostate cancer and urinary stones. Incubator: No Subsidiary of a group: Yes (EDAP TMS SA (Holding)) Prize winner for innovative start-up: No Innovative company (FCPI): No Other status: No Company key features Funding as Japanese approval. Ablatherm-HIFU addressing prostate cancer under IDE clinical trials in the US. European Launch of Sonolith i-move compact lithotriptor (CE marking obtained). Looking for funding: No Public funding obtained: OSEO: € 300 K / 3 years /2008 ANR: € 212 K / 3 years / 2010 OSEO: € 65 K / 3 years /2008 Expert and leader in the development of innovative therapies using ultrasound (HIFU and shockwaves). trong cooperation with INSERM and partnerships with local and international University Hospitals. International distribution network (Subsidiaries in Germany, Italy, USA, Japan, Malaysia, Korea). Recent news € 510 K FDA (US) approval of Sonolith I-sys lithotriptor as well Skills and know-how NASDAQ market in New York since 1997. Strong knowledge and know-how in the development of focused therapteutic ultrasound for medical applications (Strong IP) Expertise in navigating approval processes for medical devices (FDA, CE marking, Japanese approvals…) Strong ability to manage clinical trials to validate technologies. Company contacts Products / Services / Technologies Stock exchange listing: EDAP TMS SA (Holding) is listed on CEO contact detail First name: Marc Last name: Oczachowski Position: President Email: [email protected] Phone: +33 (0)4 72 15 31 50 Other contact First name: Emmanuel Last name: Blanc Position: VP Research & Development Email: [email protected] Phone: +33 (0)4 72 15 31 50 Fax: +33 (0)4 72 15 31 51 Pipeline product 1 Therapeutic area: Urology: extracorporeal lithotripsy Therapeutic indication: Urinary stones MA: Sonolith i-sys & Sonolith i-move lithotriptors Pipeline product 2 Therapeutic area: Urology Therapeutic indication: Localized Prostate cancer using HIFU MA: Ablatherm-HIFU Pipeline product 3 Therapeutic area: Gastro-enterology Therapeutic indication: liver metastasis using HIFU Company technologies High Intensity Focused ultrasound, Shockwaves, Hardware, Software. 60 l i f e s c i e n c e s d i r e c t o r y 2 0 1 1 Company segmentation Business model Service provider - CRO, Service provider - Scientific. Value chain Research. Activities Drug discovery, Other. Application fields Animal health, Human health, Immunology, Infectious diseases, Autoimmune diseases, Orphan diseases, Genetic / Rare diseases, Metabolic diseases, CNS related diseases, Cancer, Dermocosmetics. General company information Company name: Edelris Address: 115, avenue Lacassagne Zip code: 69003 City: Lyon Website: www.edelris.com Founded in: 14/02/2005 Number of employees: 25 Main activity: Founded in early 2005 by a group of senior managers with extensive drug discovery expertise from Life-Science organizations, Edelris is a privately-owned research and services company offering original natural product-like collections of screening compounds, innovative fragments for FBDD and efficient hit/lead optimisation capabilities. Incubator: Yes (CREALYS) Subsidiary of a group: No Prize winner for innovative start-up: Yes (French Ministery of Research 2004 & 2005) Innovative company (FCPI): Yes Other status: Yes Funding Looking for funding: No R&D PROJECT FUNDED ACCREDITED BY LYONBIOPOLE NATHEB: New therapeutic approaches in the treatment of chronic hepatitis B Funding: FUI (AAP8 2009) Role in the project: Leader Activities Company activities Edelris’ Keymical CollectionsTM Designed to interact highly favourably with biological systems, these non-exclusive libraries of natural product-like compounds dramatically increase the potential to find viable hits with an enhanced probability to lock/unlock biological targets. At present, Edelris offers more than 15 original collections comprising 500-1,000 molecules per family and representing a total of over 9,000 potential hits with an average purity of 95%. Major Pharmas and Biotech companies have already recognized the potential of these innovative compounds. Edelris’ Smart Fragments: Fragment-based Drug Discovery represents an emerging and valuable tool to enhance the reliability of the Discovery process, and several companies have already identified clinical candidates based on this strategy. Based on its Medchem expertise and using structural information obtained from crystallographic studies, Edelris is proposing innovative and soluble 3D fragments highly enriched in biorelevant motives. Experienced medchem for optimisation As well as its Keymical Collections and Smart Fragments, Edelris provides a lead optimisation and fine tuning services based on the company’s extensive knowledge in drug discovery. Edelris is well equipped for fine tuning early - or late-stage drug candidates, and works in close collaboration with customers ranging from biotech start-ups to major pharmas. The company operates state-of-the-art laboratory facilities in Lyon, France. Recent news Future goals Edelris has set itself ambitious objectives for the near future, including the development and commercialisation of new Keymical series for 2010-2012 and others services. Edelris has already attracted several partners from Europe, Japan and the USA, for both hit-finding activities using the Keymical Collections and for hit/lead optimisation research. Skills and know-how Company contacts CEO contact detail First name: Jean-Yves Last name: Ortholand Position: CEO Email: [email protected] Phone: +33 (0)4 37 56 19 01 Chemical library synthesis; Medicinal chemistry; Total synthesis of natural products. Products / Services / Technologies Company services Medicinal chemistry; Chemical library synthesis. Company technologies Other contact First name: Didier Last name: Roche Position: Director Strategy & Innovation Email: [email protected] Phone: +33 (0)4 37 56 16 60 l i f e s c i e n c e s d i r e c t o r y 2 0 1 1 Capabilities at Edelris include 700 m2 laboratory facilities equipped with state of the art chemistry, analytical and robotic equipment. Bruker ARX 300 NMR; MS coupled analytical and preparative HPLCs (Waters Micromass ZMD and ZQ sources); Kuka robot and Gilsons liquid handlers for high speed chemistry and reliable sample processing; Biotage Flash 40/75 purification systems and Genevac HT4 and HT4X evaporators; H-cube microreactor; Electronic laboratory notebooks for secure information and data handling. 61 General company information Company name: Elicityl Address: 746, avenue Ambroise Croizat Zip code: 38920 City: Crolles Website: www.elicityl.com Founded in: 01/05/2002 Number of employees: 10 Main activity: Elicityl’s mission is to supply oligosaccharides and polysaccharides for biomedical, cosmetic, nutraceutical and plant health applications. Elicityl develops its competences for complex sugar production and valorization. Subsidiary of a group: No Prize winner for innovative start-up: Yes (2000 Emergence - 2001 Développement) Innovative company (FCPI): Yes Other status: Yes R&D PROJECT FUNDED ACCREDITED BY LYONBIOPOLE CARBINFEC: The development of an oligosaccharide library toward new antiviral therapies Funding: FUI (AAP3 2007) Role in the project: Leader Company contacts Other contact First name: Benoît Last name: Darblade Position: Healthcare program manager Email: [email protected] Phone: +33 (0)4 76 40 71 61 Fax: +33 (0)4 76 45 59 50 l i f e s c i e n c e s d i r e c t o r y Business model Service provider - CMO, Service provider - Scientific, Product developer - Other health. Value chain Research, Manufacturing. Activities Biomanufacturing, Other. Application fields Animal health, Human health, Nutrition / Food, Dermocosmetics, Other. Activities Company activities Elicityl is a biotech company focused in complex sugar engineering and production. Elicityl supplies oligosaccharides and polysaccharides for biomedical, cosmetic, nutraceutical and plant health applications. Elicityl proposes two commercial offers: - OligoTech®: offer of oligosaccharides and polysaccharides extracted from biomass, produced by bacterial fermentation and potentially modified thru chemical functionalization. The OligoTech® offer encompasses Catalogue of Complex sugars and Customized delivery. - Complex sugars for plant health: Elicityl commercialises PEL101GV®, an oligosaccharide extracted from apple which enhances natural resistance of vineyard to spring frost. PEL101GV® is approved as a phytopharmaceutical product. Skills and know-how CEO contact detail First name: Joël Last name: Monnier Position: President Email: [email protected] Phone: +33 (0)4 76 40 71 61 62 Company segmentation 2 0 1 1 These offers are based on Elicityl know-how in production, extraction, purification and fine characterization of complex sugars obtained thru proprietary industrial production means. Exclusively, our original technology allows highly purified oligosaccharides production from the mg to the kg scale. The OligoTech® offer gives business opportunities using the untapped variety of complex sugars in compliance with all aspects of regulation. General company information Company contacts CEO contact detail First name: Pierre-Olivier Last name: Goineau Position: CEO Email: [email protected] Phone: +33 (0)4 78 74 44 38 Company name: ERYtech Pharma Address: Bâtiment Adénine, 60, avenue Rockefeller Zip code: 69008 City: Lyon Website: www.erytech.com Founded in: 15/11/2004 Number of employees: 41 Main activity: ERYtech Pharma is a specialty pharma company developing new generation medicinal products through encapsulation of drugs into red blood cells. It is developing a pipeline of innovative personalized medicine therapeutics addressing current specific unmet clinical needs. It creates high value products, mainly in oncology, hematology and immunology fields. Products based on ERYtech Pharma’s technology are safe and offer innovative therapies for hospital market. Thanks to its unique technology, ERYtech Pharma is able to load red blood cells with therapeutic molecules while keeping red blood cells natural properties. It has a first clinical success with its lead compound Graspa®, which demonstrated positive results and excellent safety profile in Phase II trials. ERYtech Pharma’s business and revenue model is both: – an integrated business and revenue model for proprietary product to maximize value creation – a business development revenue model based on its R&D platform and partnership. Incubator: Yes (CREALYS) Subsidiary of a group: No Prize winner for innovative start-up: No Innovative company (FCPI): Yes Other status: Yes (JEI and CIR) Other contact First name: Yann Last name: Godfrin Position: EVP and CSO Email: [email protected] Phone: +33 (0)4 78 74 44 38 Fax: +33 (0)4 78 75 56 29 Company segmentation Business model Product developer - Biopharmaceuticals, Product developer Pharmaceuticals. Value chain Research, Manufacturing, Preclinical, Clinical. Activities Cell therapy, Biomanufacturing, Clinical trials, Preclinical trials, Drug delivery. Application fields Funding Looking for funding: Yes Private funding obtained: June 2006: 12 Millions Euros Human health, Immunology, Inflammatory diseases, Autoimmune diseases, Orphan diseases, Genetic / Rare diseases, Metabolic diseases, Cancer. Public funding obtained: Since 2008 2008: € 600 248 / subsidy; 2009: € 766 951 / subsidy, € 215 k / repayable advance; 2010: € 77 505 / subsidy Activities June 2010: 5,2 Millions Euros R&D PROJECTS FUNDED ACCREDITED BY LYONBIOPOLE GR-CAV1: A novel immunotherapy approach for cancer with Vaccin’ERY System® Funding: FUI (AAP7 2009) Role in the project: Leader POLYBIO: Innovative plastics for a better packaging of pharmaceutical products Funding: FUI (AAP9 2010) Role in the project: Partner l i f e s c i e n c e s d i r e c t o r y 2 0 1 1 Company activities ERYtech Pharma has a first clinical success with its lead product Graspa® (new medicinal product consisting in L-asparaginase entrapped into human homologous red blood cells) which was an opportunity to validate its industrial process. Three clinical trials are currently ongoing for this product: – Phase III in relapsed and allergic Acute Lymphoblastic Leukemia (ALL) patients – Phase II as first line in patients with ALL aged 55 and older – Phase I in pancreatic adenocarcinoma. 63 ERYtech Pharma has also several projects in preclinical / proof of concept status. It is developing its technological platform with partners or alone by looking for new product candidates to load into red blood cells. Thanks to the specific technology developed by ERYtech Pharma, a powerful platform has been validated: – to develop new products with long circulating action with no release of the compounds: – bio-reaction into the red cells – oxygen-hemoglobin affinity reduction – to rapidly target specific cells involved in the erythrophagocytosis (Kupffer cells, dendritic cells, macrophages): immune modulation platform: – immuno-inflammation – immune tolerance induction – immuno stimulation The ambition of the company is to become a world leader in the pharmaceutical industry using red blood cells. Company technologies Company key features Collaboration framework – Thanks to its unique ant patented technology, ERYtech Pharma is the only company in the world able to load red blood cells with therapeutic molecules at industrial scale – Its first clinical success was an opportunity to validate its industrial process, its very good reproducibility and the logistic aspects involved in treating patients – Its technological platform offers large possibilities to create new products and strong intellectual property Recent news – ERYtech Pharma and Genzyme Corporation sign collaborative research agreement in rare diseases – ERYtech Pharma signs an agreement with M. D. Anderson Cancer Center to develop a companion test for Graspa® in solid tumors – FDA grants Orphan Drug Designation to Graspa® for treatment of Acute Lymphoblastic Leukaemia Skills and know-how ERYtech Pharma has built a strong pipeline with very ambitious programs based on its proprietary technology and expertise in the physiological properties of erythrocytes. The ambition of the company is to become a world leader in the pharmaceutical industry using red blood cells. Products / Services / Technologies Pipeline product 1 Therapeutic area: hemato/oncology Therapeutic indication: relapsed Acute Lymphoblastic Leukemia in children and adults Phase 3: Graspa Pipeline product 2 Therapeutic area: hemato/oncology Therapeutic indication: relapsed Acute Lymphoblastic Leukemia in older Phase 2: Graspa Pipeline product 3 Therapeutic area: oncology Therapeutic indication: pancreatic adenocarcinoma Phase 1: Graspa 64 l i f e s c i e n c e s d i r e c t o r y 2 0 1 1 Thanks to its unique ant patented technology, ERYtech Pharma is the only company in the world able to load red blood cells with therapeutic molecules at industrial scale. Main competitive advantages of its process are: – an industrial process including automated steps – product manufacturing requires only 2-3 hours – its reproducibility: the loading of drugs into the red blood cells is made with constant quality, whatever their initial characteristics and origin (autologous or homologous) – its specificity: the product is personalized and it will be considered as a single batch – its safety: the therapeutic index of encapsulated drugs is improved compared to conventional therapies. Partnership opportunities / Licensing ERYtech Pharma is opened to discuss partnership opportunities with pharma/biotech companies dealing with: – its own proprietary products – its technological platform. Partnership opportunities ERYtech Pharma welcomes partnership discussions on entrapment of therapeutic molecules to develop new high value products mainly in these therapeutic areas: – immune tolerance induction (entrapment of therapeutic proteins eliciting inhibitors or neutralizing antibodies or proteins/antigens/peptides eliciting autoimmune diseases) – active immunotherapy (entrapment of antigens/adjuvants) – inflammatory diseases, infectious diseases, autoimmune diseases (entrapment of compounds with anti-inflammatory properties). Company segmentation Business model Service provider - CRO, Service provider - Scientific. Value chain Research, Manufacturing. Activities Diagnostics / Analysis method, Instrumentation, Biomanufacturing, Drug discovery, Nanotechnology, Drug delivery, Other. Application fields Animal health, Human health, Cancer, Nutrition / Food, Other. General company information Company name: ESRF (European Synchrotron Radiation Facility) Address: 6, rue Jules Horowitz Zip code: 38043 City: Grenoble Website: www.esrf.eu Founded in: 16/12/1988 Number of employees: 600 Main activity: The European Synchrotron Radiation Facility (ESRF) is the world’s most successful third-generation synchrotron X-ray research centre. Owned and financed by 18 European countries and Israel, it offers academic and industrial researchers a world-class array of powerful X-ray beams to explore the microstructure of matter and materials, like protein and drug structures at high resolution, and high speed and throughput. The ESRF facilities and expert scientists are available for industrial R&D through purchasing services, contract research and joint research programmes. Incubator: No Subsidiary of a group: No Prize winner for innovative start-up: No Innovative company (FCPI): No Other status: Yes (CIR) The key techniques used by pharma and biotech to accelerate R&D programmes and achieve breakthroughs in innovation are (a) protein crystallography to speed up lead optimisation, fragment-based screening and tackle challenging protein crystallographic projects with structural biology data (b) high resolution powder diffraction for drug characterisation and polymorphism studies (c) high resolution (sub-micron) X-ray tomography with phase contrast for visualising 3D images of (e.g.) drug delivery systems. All ESRF clients can count on the full cooperation of the facility’s 400 expert scientists, engineers and technicians who, every year, work closely with 4,000 researchers from all horizons. Its academic and industrial user community is made up of over 10,000 international scientists working in both pure and applied research. The ESRF’s collaborative research culture is an integral part of its service offer, ensuring that its industrial clients obtain the best results from the facility. Company services Looking for funding: No Company contact CEO contact detail First name: Edward Last name: Mitchell Position: Business Development Manager Email: [email protected] Phone: +33 (0)4 76 88 26 64 s c i e n c e s Company activities Products / Services / Technologies Funding l i f e Activities d i r e c t o r y 2 0 1 1 - Structural Biology: Our team of expert scientists with 15 years experience working with pharma and biotech get the best out of your samples with the full-service MXpress™, or bring the power of the synchrotron to the comfort of your lab with secured remote control from anywhere in the world. We also offer comprehensive crystallisation-to-structure services for when you need to fully outsource a project. - X-ray powder diffraction and 3D tomography: Our 35 other leading beamlines offer mail-in high-resolution powder diffraction (formulation and polymorphs) and sub-micron 3D tomography (API distribution) amongst other powerful techniques. 65 General company information Company name: Estenity Address: Villa Créatis - 2, rue des Mûriers Zip code: 69009 City: Lyon Website: www.estenity-europe.com Founded in: 30/05/2008 Main activity: Estenity is dedicated to the development of natural high purity excipients for the cosmetic and dermocosmetic industries. Incubator: Yes (Pepiniere Laennec) Subsidiary of a group: Yes (Kokyu Alcohol Kogyo Co) Prize winner for innovative start-up: No Innovative company (FCPI): No Other status: No Looking for funding: No Research. Activities Other. Application fields Dermocosmetics. Activities Company activities Recent news Development of new ingredients issued from sugarcane and new sustainable vegetal sources. Other contact First name: Christel Last name: Lorenzi Position: R&D laboratory Manager d i r e c t o r y Value chain – a close partnership with our R&D la in Japan – a huge know-how and a great expertise in the cosmetic field – natural, vegetal-oriented research. CEO contact detail First name: Kiyotaka Last name: Kawai Position: CEO Email: [email protected] Phone: +33 (0)4 26 23 41 30 s c i e n c e s Product developer - Other health. Company key features Company contacts l i f e Business model Estenity is dedicated to the development of natural high purity excipients for the cosmetic and dermo-cosmetic industries. Its application laboratory also develops application formulas to illustrate our ingredients and prove their effects in cosmetics. Funding 66 Company segmentation 2 0 1 1 General company information Company name: Ethera Address: 7, parvis Louis Néel Zip code: 38040 City: Grenoble Cedex 9 Website: www.ethera-labs.com Founded in: 02/03/2010 Number of employees: 8 Main activity: Ethera develops and markets measuring kits for indoor chemical pollution. Incubator: Yes (Grain) Subsidiary of a group: No Company segmentation Business model Laboratory equipment supplier, other. Value chain Manufacturing. Activities Diagnostics / Analysis method, Instrumentation, Nanotechnology. Application fields Human health. Prize winner for innovative start-up: Yes Innovative company (FCPI): No Other status: Yes Activities Ethera develops and markets measuring kits for indoor chemical pollution. Funding Looking for funding: Yes R&D PROJECT FUNDED ACCREDITED BY LYONBIOPOLE COVADIS: innovative nanoporous sensors to detect volatile organic compounds (VOC) for applications responding to two major needs in human health. Funding: FUI (AAP9 2010) Role in the project: Leader Company contacts CEO contact detail First name: Yves Last name: Bigay Position: CEO Email: [email protected] Phone: +33 (0)6 85 94 92 70 Other contact First name: Sylvain Last name: Colomb Position: Marketing and Business Development Email: [email protected] Phone: +33 (0)6 83 29 27 11 l i f e s c i e n c e s d i r e c t o r y 2 0 1 1 67 General company information Company name: Eurofins Optimed Lyon Address: 1, rue des Essarts Zip code: 38610 City: Gières Website: www.optimed.fr Founded in: 01/09/1990 Main activity: Eurofins Optimed Lyon is a CRO certified ISO 9001: 2008, providing its experience and services in clinical research: from early clinical development (Phase I and IIa) to Phases IIb to IV clinical trials and surveys. Incubator: No Subsidiary of a group: Yes (Eurofins) Prize winner for innovative start-up: No Innovative company (FCPI): No Other status: Yes (CIR) Company segmentation Business model Service provider - CRO. Value chain Clinical. Activities Clinical trials. Application fields Pediatrics, Human health, Geriatrics, Immunology, Inflammatory diseases, Infectious diseases, Autoimmune diseases, Allergology, Orphan diseases, Genetic / Rare diseases, Metabolic diseases, CNS related diseases, Cancer, Nutrition / Food, Dermocosmetics. Activities Funding Company activities Looking for funding: No Company contacts CEO contact detail First name: Yves Last name: Donazzolo Position: President Email: [email protected] Phone: +33 (0)4 38 37 27 40 Other contact First name: Marie Last name: Gilbert-Collet Position: Customer Relations Manager Email: [email protected] Phone: +33 (0)4 38 37 27 46 Fax: +33 (0)4 38 37 27 41 CRO offering a large panel of services for the set-up and realisation of clinical studies from Phase I to IV and surveys: – study initiation (methodological advice, study document writing, management of regulatory submissions, etc.) – study conduct (recruitment of healthy volunteers or patients, study conduct in our two Clinical Pharmacology Units of 100 beds, etc.) – collaboration with the Lyon Sud Hospital - monitoring - study data exploitation (data management, statistics, final report writing, etc.). Company key features – 20 years of experience in clinical research – stable team of clinical research professionals – medium-sized company integrated into an international group (Eurofins) – access to a network of Experts in various fields. Recent news Implementation of the Remote Data Capture (RDC) system, the online user interface for the ORACLE Clinical database. Skills and know-how – Approximately 800 studies conducted (First Into Human, interactions, QT/QTc, bioequivalences, etc.) in various fields (CNS, cardiovascular, respiratory, etc.) – Two Clinical Pharmacology Units comprising 100 beds, including 32 beds within the Lyon Sud Hospital – Technical platform and network of Experts. 68 l i f e s c i e n c e s d i r e c t o r y 2 0 1 1 Company segmentation Business model Service provider - Non Scientific, Product developer - Other health. Value chain Research, Manufacturing. Activities Nanotechnology, Drug delivery, Other. Application fields General company information Company name: Eveon Address: 345, rue Lavoisier Zip code: 38330 City: Montbonnot Saint-Martin Website: www.eveon.eu/en/index.html Founded in: 18/12/2008 Number of employees: 13 Main activity: Eveon is a French company created in December, 2008. Eveon dedicates itself to the design, development and manufacture of injection medical device, fully automated and secure, piston-free, perfectly adapted for subcutaneous, intradermal, intramuscular and intravenous injections. Eveon provides customized developments and manufacturing of injection medical devices from the specifications of our clients, the pharmaceutical and biotech laboratories. All our solutions are designed from configurable technological bricks which we can assemble according to precise criteria, and, in particular viscosity of the solution, injection time, volume to be injected, temperature, kind of injection and depth. We propose partnership agreements which include: – Elaboration of the specifications – Development of prototypes and pre-series – CE mark and FDA approval of the device – Manufacture from thousands to millions Incubator: Yes (Grain) Subsidiary of a group: No Prize winner for innovative start-up: No Innovative company (FCPI): No Other status: Yes Funding Looking for funding: No Company contacts CEO contact detail First name: Vincent Last name: Tempelaere Position: CEO Email: [email protected] Phone: +33 (0)4 76 44 84 17 Other contact First name: Valérie Last name: Roux-Jallet Position: VP Marketing Email: [email protected] Phone: +33 (0)4 76 41 43 82 l i f e s c i e n c e s d i r e c t o r y Human health, Immunology, Inflammatory diseases, Infectious diseases, Autoimmune diseases, Genetic / Rare diseases, CNS related diseases, Cancer. Activities Company activities Eveon is a French company created in December, 2008. Eveon dedicates itself to the design, development and manufacture of injection medical device, fully automated and secure, piston-free, perfectly adapted for subcutaneous, intradermal, intramuscular and intravenous injections. Eveon provides customized developments and manufacturing of injection medical devices from the specifications of our clients, the pharmaceutical and biotech laboratories. All our solutions are designed from configurable technological bricks which we can assemble according to precise criteria, and, in particular viscosity of the solution, injection time, volume to be injected, temperature, kind of injection and depth. We propose partnership agreements which include: – Elaboration of the specifications – Development of prototypes and pre-series – CE mark and FDA approval of the device – Manufacture from thousands to millions. Eveon is a pioneer in the design of automatic and completely secure, plunger-free injection medical devices. Eveon owns a portfolio of 6 international patents to cover all the innovative aspects of its technology. The injection device is based on 4 major innovations: – A microsystem (MEMS) injects precisely volumes ranging from µl to ml. The calibration of the MEMS insures injection time adapted to the viscosity of the solutions and avoid the degradation of sensitive molecules by shearing. Contrary to the mechanical syringes with plunger, the injection is silicone-free and rubber-free. – Integrated sensors detect and analyze human tissues (thickness, depth, consistency) to differentiate precisely a muscle from a nerve, a dermis or a vein. For example these sensors guarantee that an intramuscular injection is not made in a vein. – A retractable needle standard or customized penetrates at the right depth only when the device is in contact with the skin. After injection, the needle retracts and is auto-blocked thanks to a double security, mechanical and electronical. – A cartridge contains one or several standard vials to adapt easily and at lower cost to the standard filling lines of our clients. The cartridge is adapted for mono or multi-doses and also allows in situ rehydration of lyophilisats. Company key features The originality of the devices developped by Eveon is based on: – The safety of the injection with a needle inaccessible before, during and after injection - auto-injection subcutaneous, but also intradermal, intramuscular and tomorrow intravenous. 2 0 1 1 69 – Programmable and automatic injection thanks to a MEMS (microsystem, core technology of the device) and integrated sensors. – Dead volume reducd to few µl thanks to an innovating design. – Adaptation to the gold standards of the pharmaceutical industry, vial, cartridge. Skills and know-how Bring a real solution to the needle stick injuries due to syringes, pens and auto-injectors. Widen the auto-injection from subcutaneous to intradermal, intramuscular and the intravenous Propose a piston-free concept to solve the problems associated to the presence of silicone in the traditional syringes Integrate tissue sensors to control the needle and injection site. Products / Services / Technologies Company services Eveon provides customized developments and manufacturing of injection medical devices from the specifications of our clients, the pharmaceutical and biotech laboratories. All our solutions are designed from configurable technological bricks which we can assemble according to precise criteria, and, in particular viscosity of the solution, injection time, volume to be injected, temperature, kind of injection and depth. We propose partnership agreements which include: – Elaboration of the specifications – Development of prototypes and pre-series – CE mark and FDA approval of the device – Manufacture from thousands to millions Company technologies The injection device is based on 4 major innovations: – A microsystem (MEMS) injects precisely volumes ranging from µl to ml. The calibration of the MEMS insures injection time adapted to the viscosity of the solutions and avoid the degradation of sensitive molecules by shearing. Contrary to the mechanical syringes with plunger, the injection is silicone-free and rubber-free. – Integrated sensors detect and analyze human tissues (thickness, depth, consistency) to differentiate precisely a muscle from a nerve, a dermis or a vein. For example these sensors guarantee that an intramuscular injection is not made in a vein. – A retractable needle standard or customized penetrates at the right depth only when the device is in contact with the skin. After injection, the needle retracts and is auto-blocked thanks to a double security, mechanical and electronical. – A cartridge contains one or several standard vials to adapt easily and at lower cost to the standard filling lines of our clients. The cartridge is adapted for mono or multi-doses and also allows in situ rehydration of lyophilisats. 70 l i f e s c i e n c e s d i r e c t o r y 2 0 1 1 Partnership opportunities / Licensing Partnership opportunities Eveon proposes partnership agreements for the design, develop and manufacture of customized injection medical devices from the specifications of our clients, the pharmaceutical and biotech laboratories. All our solutions are designed from configurable technological bricks which we can assemble according to precise criteria, and, in particular viscosity of the solution, injection time, volume to be injected, temperature, kind of injection and depth. We propose modular solutions from: – Elaboration of the specifications – Development of prototypes and pre-series – CE mark and FDA approval of the device – Manufacture from thousands to millions. Company segmentation Business model Product developer - Other health. Value chain General company information Company name: EyeTechCare Address: 2871, avenue de l’Europe Zip code: 69140 City: Rillieux la Pape Website: www.eyetechcare.com Founded in: 08/07/2008 Number of employees: 11 Main activity: EyeTechCare is developing non-invasive therapeutic medical devices for the ophthalmology market based on high-intensity focused ultrasound (HIFU). HIFU technology allows ambulatory and rapid treatment to be performed, thereby limiting the cost and the risk for the patient. EyeOP1, the first device developed by the company, is for the treatment of glaucoma. EyeOP1 has been undergoing clinical trials in Lyon since March this year and is due to be launched onto the market in 2011. The device utilizes the UC3 (ultrasound circular cyclo-coagulation) procedure, which makes it possible to reduce intraocular pressure by partially and accurately destroying the ciliary bodies that produce aqueous humor. Incubator: Yes (CREALYS) Subsidiary of a group: No Prize winner for innovative start-up: No Innovative company (FCPI): Yes Other status: Yes Funding Research. Activities Medical device, Drug delivery, Other. Application fields Human health. Activities Company activities – Conception and Development of an innovative medical device for non invasive glaucoma treatment – Research and Development for new non-invasive medical devices for the treatment of ocular pathologies. Company key features – Complementarity and experiences of the founders of the company in the Medical Devices – Need and interest opthtalmologistes / patients for a new treatment for glaucoma – Glaucoma is a market of $ 7 billion/year of which approximately $500 million of medical devices (90% of the overall treatment is represented by glaucoma medical treatment) – Very good results on preclinical results. Clinical trials still in progress – 5 patents granted in conjunction with the INSERM (French National Institute of Health and Medical Research-Unit 556 Lyon) – JEI status, and support of OSEO. Recent news Looking for funding: No Total of funds raised to date: € 8.7 million (USD 10.6M) in two rounds: € 1.2M in July 2008 and € 7.5M in June 2010) Public funding obtained: € 500,000 in aid and subsidies from OSEO (the French national innovation promotion agency) and € 250,000 from France’s ministry of research. Clinical study started in March 2010: Single-center pilot study aimed to determine the tolerability and efficacy of new therapeutic method UC3 (CycloCoagulation Circular Ultrasonic) (Product EYEOP1) 1st prize TMI AGBM in May 2010 2nd fundraising of 7.5 million in June 2010 Certification of the company ISO 9001 and ISO 13485 in July 2010. Skills and know-how Developpement of new therapies for ocular diseases Use of Ultrasons for therapeutic application. Company contacts CEO contact detail First name: Fabrice Last name: Romano Position: CEO Email: [email protected] Phone: +33 (0)4 78 88 09 00 Other contact First name: Aurélie Last name: Begle Position: Project Manager Email: [email protected] Phone: +33 (0)4 72 01 79 95 Fax: +33 (0)4 78 97 45 11 l i f e s c i e n c e s d i r e c t o r y 2 0 1 1 Products / Services / Technologies Pipeline product 1 Therapeutic area: Medical Device in ophthalmology Therapeutic indication: glaucoma Preclinical: completed Company technologies EyeOP1, the company’s first device, was developed for the treatment of glaucoma. EyeOP1 has been in clinical trials in Lyon since March 2010 and should be on the market in 2011. The device utilizes the UC3 (ultrasound circular cyclo-coagulation) procedure, which makes it possible to reduce intraocular pressure by partially and accurately destroying the ciliary bodies that produce aqueous humor. 71 EyeOP1 offers numerous advantages compared to other available therapies. It is a quick procedure that takes less than a minute. It is less costly than eye drops or surgery, and is well tolerated. In effect, it causes necrosis of the tissue, not its destruction. It is a technique that requires no manual intervention and does not depend on the operator. Partnership opportunities / Licensing Collaboration framework We develop a new research project to study the impact of ultrasound on the delivery of active molecules in the eye (Drug Delivery). We are in the stage of feasibility study. Partnership opportunities We could work with pharmaceutical industry (small and medium size) to develop and find adequate formulation of active molecules. 72 l i f e s c i e n c e s d i r e c t o r y 2 0 1 1 Company segmentation Business model Product developer - Biopharmaceuticals, Service provider Scientific, Product developer - Pharmaceuticals. Value chain Research, Manufacturing, Preclinical, Clinical. Activities Clinical trials, Preclinical trials, Nanotechnology, Other. Application fields General company information Company name: Flamel Technologies Address: Parc Club moulin à Vent, 33, av. du Dr Georges Lévy Zip code: 69693 City: Vénissieux Founded in: 1990 Number of employees: 290 Turnover: 30 Millions e (in 2010) Main activity: FLAMEL Technologies (Nasdaq: FLML) is a leading drug delivery company. Flamel has developed two innovative proprietary drug formulation platforms: – Medusa® for the formulation and the delivery of biologics (peptides, proteins) – Micropump® for the formulation and the delivery of small molecule drugs. Flamel is a partnership-oriented company and has major collaborations with major pharmaceutical companies (Merck-Serono, Pfizer/Wyeth, GSK, Baxter…). Incubator: No Subsidiary of a group: No Prize winner for innovative start-up: No Innovative company (FCPI): Yes Other status: No Activities Company activities Flamel, in collaboration with major pharmaceutical and biotech companies, develops better and safer drugs using its proprietary advanced formulation technology platforms. Company key features – Unique formulation and delivery capabilities – Breakthrough know-how in the delivery of proteins and peptides – Technologies validated by an impressive track-record of succesful partnerships. Recent news Completion of key steps in the Company’s development program with Merck Serono on an extended release formulation of Interferon-beta 1-a, which led to EUR 4 million milestone announcement regarding clinical development. Signing of two further projects: one for Medusa and the other for a Micropump formulation. Skills and know-how Funding – Drug delivery – Drug formulation – Drug development. Looking for funding: No R&D PROJECT FUNDED ACCREDITED BY LYONBIOPOLE ALPHA VAC: New therapeutic approach for the treatment of hepatitis C virus infection based on the combination of a therapeutic vaccine and a nanoparticle-based formulation of IFN Funding: FUI (AAP3 2007) Role in the project: Partner Company contacts CEO contact detail First name: Stephen Last name: Willard Position: Chief Executive Officer Email: [email protected] Phone: +33 (0)4 72 78 34 34 Other contact First name: Grégoire Last name: Franoux Position: Director Licensing & Business Development Email: [email protected] Phone: +33 (0)4 72 78 34 34 Fax: +33 (0)4 72 78 34 35 l i f e Animal health, Pediatrics, Human health, Geriatrics, Immunology, Infectious diseases, Autoimmune diseases, Metabolic diseases, CNS related diseases, Cancer. s c i e n c e s d i r e c t o r y 2 0 1 1 Products / Services / Technologies Pipeline product 1 Therapeutic area: Infectious Diseases Therapeutic indication: Hepatitis C Preclinical: Completed Phase 1: Completed Phase 2: Ongoing Pipeline product 2 Therapeutic area: Metabolic dieases Therapeutic indication: Diabetes Preclinical: Completed Phase 1: Completed Company services Flamel is a world leader in innovative formulation and delivery technologies for small molecule, peptide and protein drugs. The company, alone or in partnership with leading pharmaceutical and biotech companies, is developing better and safer drugs using its proprietary technology platforms. Company technologies Medusa Medusa is a nanogel depot for the formulation of any biological drug (peptide, antibodies, fragments, vaccines, large protein drugs etc.). Medusa allows the controlled delivery of fully bioactive drugs. Flamel has Medusa partnerships with 8 of the TOP-25 pharmaceutical companies (Baxter, Merck-Serono, Pfizer etc.). 73 Micropump Micropump is a microparticle oral controlled release technology. Micropump is designed to extend the bioabsorbtion time of small molecule drugs in the small intestine. It is used by GSK in its COREG CR (Carvedilol Controlled Release), marketed in the US since 2007. Partnership opportunities / Licensing Collaboration framework Flamel is looking for new pharmaceutical & biotech partners to apply its breakthrough technologies to develop more efficient and safer drugs. Partnership opportunities Flamel is looking for new pharmaceutical & biotech partners to apply its breakthrough technologies to develop more efficient and safer drugs. Out-licencing opportunity – Medusa technology platform – Micropump technology platform – IFN alpha XL – FT-105 Basal insulin. 74 l i f e s c i e n c e s d i r e c t o r y 2 0 1 1 Company segmentation Business model Product developer - Biopharmaceuticals, Product developer Other health, Laboratory equipment supplier. Value chain Research, Manufacturing, Marketing / Distribution, Clinical. Activities Diagnostics / Analysis method, Nanotechnology, Medical device. Application fields Animal health, Human health, Cancer. Activities Company activities General company information Company name: Fluoptics Address: BHT - Bât. 52 - 7, parvis Louis Néel - BP 50 Zip code: 38040 City: Grenoble Cedex 9 Website: www.fluoptics.com Founded in: 09/02/2009 Number of employees: 7 Turnover: 500 k Euros (in 2010) Main activity: Fluoptics designs, develops and commercializes an innovative device to assist surgeons in cancerous tumors resection. This solution consists in “highlighting” tumors cells to help the surgeon during the operation to locate and remove them in real time. This technology combines the use of a fluorescent probe which specifically targets tumors cells and a near infrared imaging system. Therefore closely guided to cancerous tissues, the surgeon can make a complete resection while preserving healthy tissues as much as possible. In terms of public health, this technology brings a new hope of recovery for thousands of patients insofar as the surgery is still the main line of defense and one of the most efficient therapy against cancer. Every year, 5 million people suffering from cancer undergo surgery all over the world. Subsidiary of a group: No Prize winner for innovative start-up: Yes (Creation 2008) Innovative company (FCPI): Yes Other status: Yes (CIR & JEI) Funding Looking for funding: Yes Fluoptics developed an innovative device to assist surgeons in cancerous tumors resection. This solution consists in “highlighting” tumors cells to help the surgeon during the operation to visualize it in real time in order to ease the exerese. Fluoptics expects to be one of the first to launch this technology and looks to be a European leader in this field. This technology combines the use of a fluorescent probe which specifically targets tumors cells and a near infrared imaging system. The action of the fluorescent probe that concentrates in the tumor offers to the surgeon an acute intraoperative screen visualization of the borders of the primary tumor, the close metastasis including those invisible to the unaided eye. This way closely guided to cancerous tissues, the surgeon can make a complete resection while preserving healthy tissues as much as possible. In terms of public health, this technology is the sign of a new hope of recovery for thousands of patients insofar as the surgery is still the main line of defense and one of the most efficient therapy against cancer. Every year, 5 million people suffering from cancer undergo surgery all over the world. In France, 250.000 people are concerned that is one person every 45 seconds. This innovative solution showed very encouraging preclinical in vivo results. It is already commercialized on the preclinical research market under the name Fluobeam® and Angiostamp®. The first customers are: on one side research labs from pharmaceutical industry for the development of new drugs and on the other side surgeons for their clinical research. Company key features Multi skills integration: Physics- Biology-Chemistry Simultaneous development of both an imaging system and a fluorescent probe Scientific excellence of its technological research partners such as CEA-LETI and Université Joseph Fourier. The expertise of its partners for proofs of clinical concept through the collaboration of the main French cancer treatment and research centers. Recent news Differents french newspaper speak about Fluoptics. Please find it on Fluoptics website www.fluoptics.com. Company contact CEO contact detail First name: Odile Last name: Allard Position: CEO Email: [email protected] Phone: +33 (0)6 80 00 01 78 Skills and know-how Development of optical imaging – fluorescent probes. Products / Services / Technologies Pipeline product 1 Preclinical: FLUOBEAM Pipeline product 2 Preclinical: AngioStamp Pipeline product 3 Preclinical: SentiDye l i f e s c i e n c e s d i r e c t o r y 2 0 1 1 75 General company information Company name: Fondation Mérieux Address: 17 rue Bourgelat Zip code: 69002 City: Lyon Website: www.fondation-merieux.org Founded in: 1967 Number of employees: 50 Main activity: Fondation Mérieux is an independent family foundation, ‘reconnue d’utilité publique’. Its mission is to strengthen local capacities in developing countries to reduce the impact of infectious diseases on vulnerable population. It has four main areas of action: applied research, traning and sharing of knowledge, strengthening of health infrastructures and mother and child health. With the support of Fondation Christophe et Rodolphe Mérieux, it develops a network of biology laboratories dedicated to research and training in the field, at the heart of infected areas. Current field sites are located in Mali, Cambodia, Laos, Haiti, Madagascar, China, Lebanon and very soon in Tajikistan. Subsidiary of a group: No Prize winner for innovative start-up: No Innovative company (FCPI): No Funding Looking for funding: Yes Company contacts CEO contact detail First name: Benoit Last name: Miribel Position: Director General Email: [email protected] Phone: +33 (0)4 72 40 79 79 Other contact First name: Amal Last name: Darghouth Position: Communication Email: [email protected] Phone: +33 (0)4 50 64 80 80 Fax: +33 (0)5 40 60 07 21 76 l i f e s c i e n c e s d i r e c t o r y 2 0 1 1 Company segmentation Business model Other. Value chain Research, Other. Activities Other. Application fields Human health, Other. Activities Company activities Fondation Mérieux is an independent family foundation, ‘reconnue d’utilité publique’. Its mission is to strengthen local capacities in developing countries to reduce the impact of infectious diseases on vulnerable population. It has four main areas of action: applied research, traning and sharing of knowledge, strengthening of health infrastructures and mother and child health. With the support of Fondation Christophe et Rodolphe Mérieux, it develops a network of biology laboratories dedicated to research and training in the field, at the heart of infected areas. Current field sites are located in Mali, Cambodia, Laos, Haiti, Madagascar, China, Lebanon and very soon in Tajikistan. General company information Company name: GCS-Etoile Address: 60, avenue Rockefeller Zip code: 69008 City: Lyon Website: www.centre-etoile.org Founded in: 09/05/2007 Number of employees: 6 Turnover: 1 M Euros (in 2011) Main activity: The sanitary Cooperation Group Etoile aims at developing the National Center for Hadrontherapy for the treatment of radioresistant cancers and for applied research in hadrontherapy. The Etoile Center will open its doors in 2016 and will treat over 2,000 patients per year and will host permanent research teams involved in hadrontherapy particularly in the fields of radiobiology, dosimetry and instrumentation. Part of the research center will provide a platform open to international research teams and industry. It will provide a research room dedicated to research with a permanent access to the ion beam and scientific and technical environment for the preparation and support to experimenters. The main partners of the Etoile Center are University of Lyon, local authorities, the Ministry of Health, CNRS, IRSN, CNES the CLARA and Lyonbiopole. Incubator: No Subsidiary of a group: No Prize winner for innovative start-up: No Innovative company (FCPI): No Other status: Yes Company segmentation Business model Other. Value chain Other. Activities Diagnostics / Analysis method, Instrumentation, Models (animal - cellular - …), Clinical trials, Preclinical trials, Medical device, Other. Application fields Human health, Cancer. Activities Company activities The GCS-Etoile conducts tenders for the construction of the Center, coordinates the preliminary studies and clinical trials related to its future activity in hadrontherapy. He is looking for the necessary funding for the operation. The Etoile Center will be designed to accommodate research laboratories dedicated to applied research in hadrontherapy and enhancement of research in the fields of radiobiology, dosimetry and medical instrumentation around the patient. The GCS will become at the signature of the contract, a Public Health Establishment of national or regional scale. Funding Looking for funding: Yes Nature of funding searches: During 2011 the GCS-Etoile will look for bank loan for the financial support of the project. Company contacts CEO contact detail First name: Jacques Last name: Balosso Position: Director Email: [email protected] Phone: +33 (0)4 72 78 89 20 Other contact First name: Guillaume Last name: Wasmer Position: General officer Email: [email protected] Phone: +33 (0)4 72 78 89 25 Fax: +33 (0)4 78 76 06 43 l i f e s c i e n c e s d i r e c t o r y 2 0 1 1 77 Company segmentation Business model Product developer - Biopharmaceuticals. General company information Company name: Geneuro Address: 60, avenue de Rockefeller Zip code: 69008 City: Lyon Website: www.geneuro.com Founded in: 18/02/2009 Number of employees: 6 Main activity: Geneuro is a product development company, developing a pioneering approach for the therapy of diseases associated with human endogeneous retrovirus expression, with a primary focus on nervous system diseases. Geneuro anticipates the first clinical trial of its monoclonal antibody early 2011 in multiple sclerosis and also carries out extensive preclinical research in other diseases such as schizophrenia. Geneuro breakthrough innovation targets the envelope protein of human endegeneous retrovirus. Its lead product, a monoclonal antibody, acts upstream of the pro-inflammatory cascade, thus increasing efficacy and safety over existing drugs which mainly delay neurological damages and disability caused by Multiple sclerosis. Geneuro is driven by entrepreneurial spirit and supported by a well established network of worldwide leading industrial and academic partners. Incubator: Yes (Eclosion) Subsidiary of a group: Yes (Eclosion et Institut Mérieux) Prize winner for innovative start-up: No Innovative company (FCPI): No Other status: No Funding Public funding obtained: No Company contacts CEO contact detail First name: François Last name: Curtin Position: CEO Email: [email protected] Phone: +41 22 794 50 85 Other contact First name: Christophe Last name: Guichard Email: [email protected] Phone: +41 22 794 50 85 Fax: +41 22 794 50 86 78 l i f e s c i e n c e s d i r e c t o r y 2 0 1 1 Value chain Research, Preclinical, Clinical. Activities Models (animal - cellular - …), Clinical trials, Preclinical trials, Drug discovery. Application fields Human health, Inflammatory diseases, Autoimmune diseases, CNS related diseases. Activities Company activities GeNeuro’s novel approach primarily focuses on the development of therapeutic monoclonal antibodies, which will target and neutralize the pathogenic MSRV/HERV-W proteins and thereby prevent the initiation of the inflammatory and autoimmune cascades induced by these proteins in Multiple Sclerosis. A similar approach is applied for Schizophrenia. These antibodies have been tested in new experimental models developed by GeNeuro and have shown effective inhibitory properties, both in vitro and in vivo with no evidence of adverse effect in animal models. Unlike other drugs currently used to treat MS, which are aimed at slowing down the neurological damage and disability caused by the disease, GeNeuro’s approach is directed upstream of the inflammatory demyelinating cascade, at the origin of brain lesions. Targeting pathogenic effects of human endogenous retroviruses. The sequencing of the human genome revealed that nearly one-half of the genome is composed of repeated or retrotransposable elements. Among them, human endogenous retroviruses (HERVs) represent more than 8% of the human genome and result from integration of exogenous retroviruses that have infected the germline of their host during the primate evolution. HERVs appear to have a critical significance in physiology and in diseases, at the crossroads of genetics, virology and physiopathology. A human endogenous retrovirus, the MS associated retrovirus (MSRV), a member of the HERV-W family, had been initially isolated in cell cultures from patients affected with MS. MSRV is normally latent in the genome of individuals, but when activated by certain co-factors, it can be reactivated and express an envelope protein (HERV-W/ENV). This appears to be a major triggering and aggravating factor in the development and progression of MS. Depending on environmental co-factors, HERV-W MSRV could be involved in both Multiple Sclerosis and Schizophrenia. Company key features Geneuro is the leading company developing new therapies targeting Human Endegeneous Retroviruses, focusing on nervous system diseases. GeNeuro core technology is protected by a patent portfolio of more than 20 original patents covering sequences, products and particular applications for diagnostic and therapeutic development. The portfolio includes licenses on therapeutic monoclonal antibodies neutralizing endogenous retroviruses. Products / Services / Technologies Pipeline product 1 Therapeutic area: autoimmune diseases Therapeutic indication: Multiple sclerosis Pipeline product 2 Therapeutic area: CNS Therapeutic indication: Schizophrenia Partnership opportunities / Licensing Collaboration framework GeNeuro is aiming at excellence, both in internal activities and in collaboration with our partners. The company has a well established network of industrial partners, academic alliances, and is constantly seeking to further develop its collaborative approach. l i f e s c i e n c e s d i r e c t o r y 2 0 1 1 79 General company information Company name: Genostar Address: 60, rue Lavoisier Zip code: 38330 City: Montbonnot Website: www.genostar.com Founded in: 05/08/2004 Number of employees: 10 Main activity: Genostar provides bioinformatics solutions for microbial research from genome to metabolome. We offer data analysis and management services as well as a powerful and user-friendly software and database platform. Our solutions are well adapted to analysis of high throughput “NGS” sequence data as well as expression data. Our solutions enable scientists to characterize their microbial organisms quickly and efficiently, from sequence assembly and annotation through enzymatic characterization, metabolic pathway studies and expression data analysis. We also provide solutions for metagenomics analyses. We understand that data compatibility, centralization and accessibility are important to research organizations: our platform enables organizations to save, centralize and manage their results, building on their internal knowledge base. Incubator: No Subsidiary of a group: No Prize winner for innovative start-up: No Innovative company (FCPI): No Other status: Yes (JEI, CIR) Funding Looking for funding: No Company contacts CEO contact detail First name: Patrice Last name: Garnier Position:CEO Email: [email protected] Phone: +33 (0)6 62 28 67 66 Other contact First name: Adrienne Last name: Kennard Position: COO Email: [email protected] Phone: +33 (0)6 47 88 23 43 Fax: +33 (0)4 76 97 18 81 80 l i f e s c i e n c e s d i r e c t o r y 2 0 1 1 Company segmentation Business model Service provider - Scientific, Other. Value chain Research. Activities Diagnostics / Analysis method, Vaccine, Biomanufacturing, Bioinformatics / Modeling, Drug discovery, Other. Application fields Animal health, Human health, Infectious diseases, Metabolic diseases, Nutrition / Food, Dermocosmetics. Activities Company activities Genostar provides complete data analysis services, software and databases for microbial research. Our solutions enable life scientists to interpret their sequence and expression data both easily and visually. We have an experienced, in-house team of bioinformaticians, bioanalysts, biologists, & software engineers. This allows us to meet the challenges of new and evolving needs in bioinformatics data analysis, both in terms of software and database development and in the wide range of services that we provide to our customers. The range of our service offer is quite wide, and includes fast, largely automatic, annotation as well as comprehensive annotation, enzymatic characterization and metabolism studies, calculation of core and pan genomes, virulence studies, and metagenomics analyses. Our solutions are currently used in many fields including vaccine discovery, antibiotics and antivirulence research, probiotics (nutrition and agro-foods), diagnostics, biotechnology, green energies and more. Genostar’s flagship product is the Metabolic Pathway Builder software and database platform. The platform enables scientists to perform fast, in-depth functional and comparative annotation (genomic and proteic), comprehensive metabolic analyses, and to both save and manage their results. The platform is very well suited to high throughput, comparative analyses. The platform also enables metagenomics studies. The MicroB database is part of the Metabolic Pathway Builder platform. This database contains a constantly increasing number of complete reference genomes. For each organism, MicroB contains the complete genome, proteome and metabolome. The genomic and proteic annotations are connected the biochemical and metabolic data. This network of connections between genomes, proteomes and pathways enables scientists to quickly discover relationships, reconstruct metabolic systems and improve understanding of cellular processes. MicroB serves as both a reference database for comparative analysis and as a knowledge base: customers can easily integrate, manage, explore and visualize their annotated genomes. Data is easy to access and export as needed. Company key features Genostar creates value by providing scientists with services and tools to conduct both in-depth annotation and complex analyses linking genome to metabolome. We place an extremely high value on customer service, both in software support and training and in the quality and punctuality of our services. Key platform features include streamlined integration of a wide range of methods and heterogeneous data, a very user-friendly interface and the facility to rapidly store, manage, export and share results. In addition to the many pre-programmed queries, customers also have user-friendly query-building tools that provide even greater flexibility. The result is powerful products that are easy for researchers to use. Genostar’s products are both customizable and extendable. Customers can integrate new analytical methods, including proprietary ones written by their scientists into the software, just as they can integrate their proprietary genomes into their database. Recent news Release of Metabolic Pathway Builder 3.8: This release contains new methods for both data analysis and for centralization, management and sharing of results. Please See www.genostar.com/en/news.html?actu_id_97=31&actu_ page_97=1 Genostar now offers comprehensive bioinformatics solutions for metagenomics analyses. Genostar continues development of a bioinformatics suite for the analysis of viral genomes and proteomes. The objective of the project is to offer virologists tools specifically designed to help them better analyze and understand the structure, function and evolution of viral genomes, in particular for vaccine discovery and optimization. This project is co-funded by Oséo and FEDER. Skills and know-how Genostar’s core expertise is three-fold: we have significant experience and expertise in both software and database design as well as in microbial, and in particular, bacterial, sequence analysis. Products / Services / Technologies Company services Genostar provides a full range of services for genome annotation and reannotation, comparative analysis, expression data analysis and metagenomics analyses. - Genome annotation • Sequence assessment and assembly • Gene prediction • Functional characterization of genes/proteins - Annotations and classification terms - Proteic domains • Exploration of regulatory signals and co-regulation. - Comparative analysis s c i e n c e s d i r e c t o r y • Identification of genes and regions that are specific to an organism or to a set of organisms • Comparative metabolic analyses - Identification of specific and shared metabolic reactions and pathways - Identification of specific and shared compounds • Computation of core- and pan- genomes - Expression Data Analysis • Analyze gene expression in terms of genomic localization, functional annotation and metabolism • Visualize expression on genomic and metabolic maps - Metagenomics Analysis • Sequence assembly • Identification of genes and organisms in a sample • Identification of enzymatic activities and the metabolic reactions and pathways of a metagenome. Company technologies: Genostar’s software is integrated. This means that the user can focus on the analysis process itself, rather than having to deal with the management of data between the many different methods for analysis, the visualizers and the data repositories. The software efficiently and automatically handles data compliance, conversion and transfer. All the data are explicitly represented in an object-oriented model. Organisms, chromosomes, sequences, and sequence features such as CDS, signals, classification nodes, reactions, pathways, and so on are represented as objects. These objects are connected by relationships to form a large data web. Since the software recognizes methods as objects with typed input and output arguments, all necessary information is available for very thorough data checking and conversion. The software performs these tasks automatically. The dataweb can be explored and queried. The user can either follow the links between the objects and thus discover their relationships, or express a query to retrieve all the objects that satisfy some constraints; for instance, all the metabolic reactions that are catalyzed by products of genes that have been identified to be specific to an organism. The most frequent queries are built in and can be easily run. The user can easily construct other queries, from simple to complex, with a graphical tool. These queries can then be saved for regular use. Objects and relationships are mapped onto the tables that make up the structure of MicroB, so that their contents can be stored and integrated in this relational database, and retrieved as necessary. Partnership opportunities / Licensing Partnership opportunities Opportunities for partnerships with companies having complementary technologies. Out-licencing opportunity Licenses for Genostar’s software and databases are available on an annual and a perpetual basis. • Sequence comparison • Computation of SNPs and DIPs • Multiple sequence alignment l i f e - Phylogenetic analysis 2 0 1 1 81 Company segmentation General company information Company name: genOway City: Lyon Website: www.genoway.com Founded in: 01/03/1999 Number of employees: 60 Turnover: 8,4 M Euros (in 2009) Main activity: genOway is dedicated to the development of tailor-made genetically modified rat and mouse models of the highest reliability. Based on proprietary technologies (humanization, RNAi, inducible system) and strategic alliances, genOway proposes time saving and cost effective strategies for in vivo target validation and drug development programs. Moreover, genOway offers ready-to-use transgenic rat and mouse models as tools to increase the predictability of in vivo preclinical studies in immunology, neurology, metabolic disorders and ADMET. Subsidiary of a group: No Prize winner for innovative start-up: Yes (1999) Innovative company (FCPI): Yes Other status: No Funding Looking for funding: No R&D PROJECTS FUNDED ACCREDITED BY LYONBIOPOLE ACTIVRAT: Real time control of signaling events during the period of egg activation for the generation of clones by nuclear transfer in the rat species Funding: ANR (2005 RIB) Role in the project: Leader HU’S-MAP: Human and species monoclonal antibody production Funding: Local authorities (2007) Role in the project: Partner Business model Service provider - Scientific. Value chain Research, Preclinical. Activities Other. Application fields Pediatrics, Human health, Immunology, Inflammatory diseases, Infectious diseases, Allergology, Orphan diseases, Genetic / Rare diseases, Metabolic diseases, CNS related diseases, Cancer, Nutrition / Food. Activities Company activities genOway is fully dedicated to the development of tailor made transgenic mouse and rat models. genOway has developed a complete range of innovative technological solutions to create a new generation of improved models. genOway’s expertise combines technologies classically used in transgenesis and several cutting-edge proprietary technologies aiming at enhancing the efficiency, security and relevance of the animal model ultimately developed. Our license policy allows our partners to have a free use of the model developed. In order to maximize the use of in vivo models, genOway has developed the concept of “3-in-1” models, providing time- and cost-saving solutions. Target validation (Knock-out), in vivo evaluation of compounds towards the human target (humanized mouse) and compound specificity studies can all be addressed within a single animal model. Moreover, genOway develops animal models as ready-to-use tools aiming at increasing the predictability of in vivo pre-clinical analysis in many areas as ADME-tox, Immunology, Neurology, Metabolic disorders. Indeed, the use of these ready-to-use models enables more relevant analysis of physiopathological studies compare to human physiology and increases the relevance of candidate molecules selection. These rat and mouse lines are available with a total freedom to operate as research licenses are provided. Company key features Company contacts CEO contact detail First name: Alexandre Last name: Fraichard Position: CEO Email: [email protected] Phone: +33 (0)4 37 65 41 00 82 l i f e s c i e n c e s d i r e c t o r y 2 0 1 1 genOway is already involved in large scale projects with pharmaceutical companies (Pfizer, Bayer Corp, Boehringer Ingelheim, Eisai), with academic centres (University College, London; Kings College, London, Max Planck Institute, BIDMCHarvard, University of Pennsylvania…) and networks (German National Genome Research Network, EUGeneHeart). Our industrialized production facility guarantees the parallel development of all projects. A partnership is in place in Europe and North America with Charles River (MA, USA), the world leader in animal breeding and related services, to co-promote our core business. This collaboration provides partners of each company with the highest quality service. Operating in 22 countries in Europe, North America and Asia, genOway has developed rat and mouse lines for more than 60 companies and 200 research institutions. Recent news - Nov-Dec 2009: genOway signed four important framework agreements with prestigious academic research centres and university in US: • University of Pennsylvania • Tufts University • University of Pittsburg • BIDMC, Harvard Medical School - Oct 2009: genOway acquires exclusive license for Flex technology developed by Professor Pierre Chambon and Dr. Norbert Ghyselinck at the IGBM. Products / Services / Technologies Company technologies genOway offers an extensive portfolio of transgenic technologies including innovative approaches to secure and speed up the availability of developed animal model with: – Consultancy to define the most adapted solution before project begins – ES Cell based technology (Knock-out, Knock-in, point mutation, humanization) – Ready-to-use genetic tools and ES Cells from various genetic backgrounds – In vivo RNAi and inducible systems genOway proposes also ready-to–use transgenic mouse and rat models: – Research models aiming at increasing the predictability of analysis in ADMET, Immunology, Neurology, Metabolic disorders. – Research tools aiming at securing gene overexpression or knock-out in a time- or tissue-specific manner (recombinase expressing lines). l i f e s c i e n c e s d i r e c t o r y 2 0 1 1 83 General company information Company segmentation Business model Company name: Genzyme Polyclonals Address: 23, bd Chambaud de la Bruyère Zip code: 69007 City: Lyon Number of employees: 291 Main activity: Biotechnology. Subsidiary of a group: Yes (Genzyme) Prize winner for innovative start-up: No Innovative company (FCPI): No Other status: No Product developer - Biopharmaceuticals. Funding Activities Looking for funding: No Value chain Manufacturing. Activities Biomanufacturing, Other. Application fields Human health, Immunology, Autoimmune diseases. Company activities Biotech company. R&D PROJECT FUNDED ACCREDITED BY LYONBIOPOLE Products / Services / Technologies THYMO 2010: From thymoglobulin technical advances MA: Thymoglobuline to manufacturing process improvements and new pharmaceutical applications Funding: Local authorities Role in the project: Leader Company contacts CEO contact detail First name: Pascal Last name: Reber Position: VP - General manager Email: [email protected] Phone: +33 (0)4 37 28 16 43 Other contact First name: Didier Last name: Santucci Position: Technical Services director Email: [email protected] 84 l i f e s c i e n c e s d i r e c t o r y 2 0 1 1 Pipeline product 1 Pipeline product 2 MA: Celsior General company information Company name: Laboratoires Gifrer Barbezat Address: 8/10, rue Paul-Bert Zip code: 69153 City: Décines Cedex Website: www.Gifrer.fr Founded in: 1912 Number of employees: 240. Turnover: 40 014 M€ (in 2010) Main activity: Pharmaceutical laboratory. Manufacturing - Supply/Storage/Logistics - Development - City/Hospital Marketing - France/Export Main customers: Pharmacies, Wholesalers/Distributors, Hospitals/Private hospitals, Pharmaceutical industry. Sectors: France - Overseas departments - Export. Subsidiary of a group: Yes (Qualiphar) Prize winner for innovative start-up: No Innovative company (FCPI): No Other status: No Funding Looking for funding: No Company segmentation Business model Product developer - Pharmaceuticals, Product developer Other health. Value chain Manufacturing, Marketing / Distribution. Activities Other. Application fields Pediatrics, Human health, Infectious diseases. Activities Company activities - Manufacturing and subcontracting of three main categories of products: sterile unit-doses, plant extracts, flammable products. - Marketing: City: direct selling network in pharmacies - Hospital: market unit. - Pharmaceutical field: mainly non-refundable products/OTC. - Markets: Antisepsis, Dermatology, Ophthalmology, Pediatrics, Gastroenterology, ENT/Pneumology, Hygiene, Analgesis. Company key features Strong presence in pharmacies: about 16,000 active accounts out of 22,800 pharmacies in France and 1,300 hospitals/private hospitals out of 3,200 in France. Fame - Customer service. Company contacts CEO contact detail First name: Karl Last name: Verlinden Position: President Email: [email protected] Phone: +33 (0)4 72 93 34 34 Recent news Launch of many products: Megatone Junior, chexable tablets (multivitamin for kids) - 20 and 30 volumes Hydrogen Peroxide (dermatology) - Cold Cream (Cérat de Galien) 125 ml and 250 g (dermatology/pediatrics) - Ostrin, tablets (tonic) - Babyfen (pediatrics) - Lamiderm 80 ml (dermatology) - Proseptine (hygiene/dermatology) - Megatone Intellect, tablets (memory) Natural Touch (young nursery). Other contact First name: Tom Last name: Verlinden Position: Pharmaceutic Manager Email: [email protected] Phone: +33 (0)4 72 93 34 34 Fax: +33 (0)4 72 93 34 37 Skills and know-how - Industrial: sterile unit-doses, plant extracts, flammable line. - Commercial: market penetration, acknowledgement and leaderchip in city and hospital pharmacies. - Logistics: order processing, preparation, delivery. Products / Services / Technologies Pipeline product 3 Therapeutic area: antisepsis l i f e s c i e n c e s d i r e c t o r y 2 0 1 1 85 Value chain Research, Manufacturing. Activities Biomanufacturing, Biobank, Drug discovery, Other. Application fields Animal health, Human health, Immunology, Infectious diseases, Genetic / Rare diseases, Cancer, Other. Activities Company activities General company information Company name: Glycode Main Address: 6, rue Porte Baffat 19140 Uzerche Second address: Lyonbiopole Business Center 321, avenue Jean Jaurès 69007 Lyon Website: www.glycode.fr Founded in: 28/07/2004 Number of employees: 14 Main activity: Design of cost-effective yeast-based innovative expression systems dedicated to therapeutic glycoproteins. GlycoEngineering yeast strains to humanize glycosylation pathway in order to produce glycoproteins with homogeneous and humanized glycosylation. Incubator: No Subsidiary of a group: No Prize winner for innovative start-up: Yes Innovative company (FCPI): Yes Other status: Yes Looking for funding: No Private funding obtained: Seed Financing round (2004) € 150 K (Sofimac Partners) Series A, 2009, € 3 M (Sofimac Partners, Octalfa, SHAM, Limousin Participations) Company contacts CEO contact detail First name: Christophe Last name: Javaud Position: President and Chief Executive Officer Email: [email protected] Phone: +33 (0)5 55 73 77 19 Other contact First name: Lucie Last name: Guinoiseau Position: Management Assistant Email: [email protected] Phone: +33 (0)5 55 73 77 19 Fax: +33 (0)5 55 73 48 09 Company segmentation Business model Service provider - CRO, Service provider - CMO, Product developer - Pharmaceuticals, Other. l i f e s c i e n c e s Company key features IP secured Worldwide freedom to operate Strong knowledge of glycosylation issues Business Developement Office based in Lyon Skills in yeast genetic engineering. Skills and know-how Yeast molecular and cellular biology Glycosciences Development of «BioBetter» molecules Protein production and purification. Products / Services / Technologies Funding 86 Glycode is a biotechnology company which aims to become a leader in the field of protein glycosylation. Founded in 2004, the company has developed a proprietary innovative and powerful technology, GlycodExpress™, which consists of a bank of yeast strains genetically optimized for the production of recombinant therapeutic glycoproteins (antibodies, EPOs, growth factors…). These strains have been genetically glycoengineered to synthesize fully humanized N-glycans. Recently, Glycode has finalized the YACExpress™ technology, a 1-step method to recreate any given metabolic pathway (Glycosylation or other) by adding a stable chromosome containing all the required genetical information. Located in Uzerche (Headquarter) and Lyon (Business Developement Office), Glycode has 14 employees. d i r e c t o r y 2 0 1 1 Company services A new and innovative production platform, matching with quality and cost issues, will be the answer. In this context, the goal of Glycode is to provide to its customers a unique and powerful service in the field of protein glycosylation. The patented GlycodExpress™ technology relies on a collection of glycoengineered yeast strains optimized for production of recombinant proteins, and which glycosylation process has been genetically humanized. Then it becomes possible to produce in yeast every kind of glycoproteins, carrying glycan structures, since basic Man8-9, up to most complex (with peripheral galactose or sialic acid residues). GlycodExpress™, a Glycan-on-Demand™ technology, offers to customers the choice of protein glycosylation, and the opportunity to optimize native structure, half-life time and therapeutic power. Glycode expertise can provide to biotech and pharma companies numerous tailor-made solutions, from gene to purified protein, or outsourcing (license sales). – Engineering strains to produce glycoprotein(s) (antibodies, IL, growth factors, enzymes…), – Lab scale production and purification, – Out-licensing proprietary strains. Partnership opportunities / Licensing Collaboration framework Business Model: Out-licensing in 2 steps: 1- evaluation phase (10-12 months) 2- Granting to customer a non-exclusive license in the case of a successful evaluation phase. Out-licencing opportunity Glycoengineered Strains GlycodExpress™ and YAC-Express™ technologies. Company contacts CEO contact detail First name: Jacques-François Last name: Martin Position: President Email: [email protected] Phone: +33 (0)4 72 40 26 77 General company information Company name: HLA-G Technologies Address: 41, quai Fulchiron Zip code: 69005 City: Lyon Website: www.parteurop.com Founded in: 06/05/1998 Number of employees: 2 Main activity: HLA-G Technologies is developing new immunomodulatory compounds based on HLA-G molecule properties in tranplantation, cancer and auto immune diseases. The company focused the development of their products in two first indications: the treatment of graft rejection and the treatment of liquid cancers. The company conducted studies in 2 different graft animal models (skin graft and heart graft models), the studies showed that the injection of HLA-G peptides increase graft survival in these 2 models. The company also showed the same efficacy of our HLA-G molecule than current gold standard treatments in transplantation but with less toxicity. Another in vitro study has been conducted with hematologic cancer cell lines, the study showed that injection of a different peptidic form of the HLA-G molecule decrease tumoral cell lines proliferation. HLA-G Technologies is now moving toward full preclinical studies in transplantation. Incubator: No Subsidiary of a group: Yes (Parteurop Développement) Prize winner for innovative start-up: No Innovative company (FCPI): No Other status: No Funding Looking for funding: Yes Nature of funding searches: HLA-G Technologies is looking for 3 M euros to finalise the proof of concept studies in oncology indications and to conduct toxicology, kinetics studies and also to produce our lead product under GMP conditions in transplantation. Private funding obtained: 2.5 M Euros have been raised since 1998 Public funding obtained: ANVAR in 2001, 460 000 euros in warrants Stock exchange listing: no l i f e s c i e n c e s d i r e c t o r y 2 0 1 1 Other contact First name: Laurence Last name: Rulleau Position: Director Email: [email protected] Phone: +33 (0)4 72 40 26 77 Fax: +33 (0)4 78 42 34 24 Company segmentation Business model Product developer - Biopharmaceuticals. Value chain Research, Preclinical, Clinical. Activities Other. Application fields Human health, Immunology, Inflammatory diseases, Autoimmune diseases, Cancer. Activities Company activities HLA-G Technologies is a company involved in research and development activities in the field of immunotolerance. The company’s goal is to develop a new treatment for transplant patients with a better efficacy and moreover less toxicity as immunosuppressive treatments currently used in transplantation whose present severe side effects. The company conducted studies in 2 different graft animal models (skin graft and heart graft models), the studies showed that the injection of HLA-G peptides increase graft survival in these 2 models. The company also showed the same efficacy of our HLA-G molecule than current gold standard treatments in transplantation but with less toxicity. In oncology, the company showed that another form of HLA-G molecule, with new mechanism of action, should improve the efficacy of current cancer treatments when administered together (with less resistance of the patients to these treatments). In liquid cancers such as Non Hodgkin’s lymphoma (NHL), Rituxan is considered as the gold standard treatment but several patients developed resistance to this treatment. There is a need for a new drug treatment in this indication and other hematological cancers. 87 Company key features HLA-G Technologies has been studying HLA-G molecules for over a decade and has the best knowledge of their mechanism of action, structure and expression. The company has been involved in prospective clinical trials and has been the first to show that HLA-G expression is correlated with higher graft survival. The company owns different families of patents covering the molecule, the gene, the antibodies and the different indications. Products / Services / Technologies Pipeline product 1 Therapeutic area: Transplantation Preclinical: research Pipeline product 2 Therapeutic area: Oncology Therapeutic indication: Liquid cancers Preclinical: research Company technologies The company developed: 1. Peptidic forms of HLA-G 2. Recombinant proteins and fusion proteins 3. Antibodies These different products have been tested and used in different applications. Partnership opportunities / Licensing Collaboration framework The company is looking for a collaboration with a laboratory using oncological animal models. The company is also looking for a collaboration with a laboratory able to evaluate allogenic responses mainly doing evaluation of NK , CTL and MLR responses. Out-licencing opportunity HLA-G Technologies will look for a pharmaceutical partner to out-license its molecule in transplantation after the first human efficacy clinical trial. 88 l i f e s c i e n c e s d i r e c t o r y 2 0 1 1 General company information Company contacts CEO contact detail First name: Hélène Last name: Rouquette Position: CEO Email: [email protected] Phone: +33 (0)1 45 89 60 00 Company name: iDD biotech Address: 27, chemin des peupliers Zip code: 69570 City: Dardilly Founded in: 14/05/2008 Number of employees: 12 Main activity: iDD-Biotech is a leading biopharmaceutical R&D company operating in the emerging field of monoclonal antibody therapies for the treatment of cancer, autoimmune diseases or neurological disorders. With its proprietary hybridoma library following MAb engineering, iDD biotech develops the next generation of therapeutic antibodies. iDD-Biotech has IP on «best in class» compounds which are in preclinical developments. Incubator: No Subsidiary of a group: No Prize winner for innovative start-up: No Innovative company (FCPI): Yes Other status: Yes (JEI CIR) Other contact First name: Claudine Last name: Vermot-Desroches Position: R&D Manager Email: [email protected] Phone: +33 (0)4 72 52 30 88 Fax: +33 (0)4 72 523075 Company segmentation Business model Funding Looking for funding: Yes Nature of funding searches: We are looking for the first financial round from Capital development. Private funding obtained: In progress Public funding obtained: Financial FUI support: Project PRAVIC (€ 537 K), Project GLIADYS (€ 1 474 K) CLARA financial support: Project IPROMAH (€ 250 K) R&D PROJECTS FUNDED ACCREDITED BY LYONBIOPOLE PRAVIC: Innovative recombinant proteins with immune modulatory and anti-tumour activities Funding: FUI (2005) Role in the project: Leader GLIADYS: Malignant glioma and brain dysorders new targeted therapies Funding: FUI (AAP7 2009) Role in the project: Leader Product developer - Biopharmaceuticals. Value chain Research, Manufacturing, Preclinical. Activities Biomanufacturing, Drug discovery, Nanotechnology, Other. Application fields Animal health, Human health, Immunology, Inflammatory diseases, Infectious diseases, Autoimmune diseases, Allergology, Orphan diseases, CNS related diseases, Cancer. Activities Company activities iDD biotech’s aim is the development of new therapeutic candidates from its proprietary MAb portfolio with in parallel the industrial bio production support. In accordance with key challenges related to science, medical need and business, iDD biotech leads several R&D projects accredited by Lyonbiopole or CLARA… Company key features A wide range of murine MAb (1000 hybridoma, 75 specificities). Three complementary technical platforms (R&D and Bioprocess development). A project porfolio (2 preclinal programs and 5 R&D programs). Three patents. l i f e s c i e n c e s d i r e c t o r y 2 0 1 1 89 Recent news Since September 2009, iDD biotech has been working on strategies facilitating the industrial development of its candidate biomedicines. One of the key areas identified is the need for a cGMP-grade bioproduction unit operating on a 200-l scale and capable of producing MoAb batches for Phase I clinical trials by January 2012. Skills and know-how Know how in MAb engeeniering: naked chimeric / humanized MAbs, Antibody drug conjugate Target identification Establishment of in vitro proof of concept Managment of R&D collaborative projects. Products / Services / Technologies Pipeline product 1 Therapeutic area: Onco hematology Therapeutic indication: Autoimmunity Preclinical: R005 Pipeline product 2 Therapeutic area: Onco hematology Preclinical: R007 Pipeline product 3 Therapeutic area: Glioma Preclinical: R&D R008-R011 Company technologies Therapeutic MAb engeenering Therapeutic MAb expression Functional MAb characterization. Partnership opportunities / Licensing Out-licencing opportunity iDD biotech strategic orientation - medical need related and market driven - prosecutes in three operating segments: – by developing immunotherapeutic molecules in major indications and partnering with pharmaceutical companies for later stage development, – by independently developing and commercializing therapeutic MAbs for certain special markets, – by licensing antibodies to companies for short and medium term revenues. 90 l i f e s c i e n c e s d i r e c t o r y 2 0 1 1 General company information Company name: ILL (Institut Laue Langevin) Address: 6, rue Jules Horowitz Zip code: 38042 City: Grenoble Website: www.ill.fr Founded in: 01/01/1967 Number of employees: 500 Main activity: The Institut Laue-Langevin (ILL) is an international central facility located in Grenoble, France on a science campus that also contains the European Synchrotron Radiation Facility (ESRF), the European Molecular Biology Laboratory (EMBL), the CNRS/CEA Institute of Structural Biology (IBS) and the Institute of Cellular and Molecular Virology. Collectively the partners on the site contribute to the Partnership for Structural Biology (PSB) which provides a powerful interdisciplinary framework for the study of biological systems over a wide range of resolutions and using a wide variety of techniques. ILL facilities and expert scientists are available for industrial R&D through purchasing services, contract research and joint research programmes. Incubator: No Subsidiary of a group: No Prize winner for innovative start-up: No Innovative company (FCPI): No Other status: No Funding Value chain Research. Activities Diagnostics / Analysis method, Instrumentation. Application fields Human health, Nutrition / Food, Other. Activities Company activities The Institut Laue-Langevin (ILL) is an international central facility located in Grenoble, France on a science campus that also contains the European Synchrotron Radiation Facility (ESRF), the European Molecular Biology Laboratory (EMBL), the CNRS/CEA Institute of Structural Biology (IBS) and the Institute of Cellular and Molecular Virology (UVHCI). Collectively the partners on the site contribute to the Partnership for Structural Biology (PSB) which provides a powerful interdisciplinary framework for the study of biological systems over a wide range of resolutions and using a wide variety of techniques. ILL facilities and expert scientists are available for industrial R&D through purchasing services, contract research and joint research programmes. Products / Services / Technologies CEO contact detail First name: Trevor Last name: Forsyth Position: Professor of Biophysics Email: [email protected] Phone: +33 (0)4 76 20 71 58 d i r e c t o r y Service provider - Scientific. Molecular biology and biophysics X-ray and neutron scattering studies of biological and soft matter systems. Company contact s c i e n c e s Business model Skills and know-how Looking for funding: Yes l i f e Company segmentation 2 0 1 1 Company services & technologies Molecular biology and biophysics X-ray and neutron scattering studies of biological and soft matter systems. 91 Company segmentation Business model Product developer - Biopharmaceuticals, Service provider Scientific. Value chain Research, Preclinical, Marketing / Distribution. Activities Diagnostics / Analysis method, Vaccine, Preclinical trials, Bioinformatics / Modeling, Other. General company information Company name: Imaxio Address: 181, avenue Jean Jaurès Zip code: 69007 City: Lyon Website: www.imaxio.com Founded in: 08/09/2000 Number of employees: 18 Turnover: 4 M Euros (in 2010) Main activity: Development and marketing of vaccines: Human Leptospirosis vaccine marketed in France and development of new vaccines using a genetic adjuvant IMX313. Development of genomic diagnostic tests. Genomic services in DNA & CGH biochips, RT-PCR, highthroughput genotyping and sequencing. Incubator: Yes (BUSI) Subsidiary of a group: No Prize winner for innovative start-up: Yes Innovative company (FCPI): Yes Other status: Yes (CIR accreditation) Funding Application fields Animal health, Human health, Immunology, Infectious diseases, Cancer. Activities Company activities Imaxio markets the only human leptospirosis vaccine available in Europe and develops new vaccines with both academic and industrial partners. Imaxio also develops genomic tests, particularly in partnership with Pierre Fabre Laboratories. Company key features Human leptopirosis vaccine on the market. Proprietary genetic adjuvant for new recombinant vaccines and state-of-the-art technology platforms in genomics. Skills and know-how Protein engineering Genomic Technologies Pharmaceutical affairs. Products / Services / Technologies Looking for funding: No Company services R&D PROJECT FUNDED ACCREDITED BY LYONBIOPOLE GR-CAV1: A novel immunotherapy approach for cancer with Vaccin’ERY System® Imaxio proposes services in genomics: DNA Biochips & CGH arrays - Agilent Technologies RT / Q-PCR - Applied Biosystems Genotyping and High Throughput Sequencing - Illumina. Company technologies Imaxio has patented a protein domain IMX313, which improves the T- and B-cell responses to antigens. This technology is used in projects with industrial and academic partners to create new vaccines. Funding: FUI (AAP7 2009) Role in the project: Partner Company contact CEO contact detail First name: Fergal Last name: Hill Position: Deputy Managing Director Email: [email protected] Phone: +33 (0)4 37 65 55 04 Partnership opportunities / Licensing Collaboration framework Genetic adjuvant technology for new vaccine development available for out-licensing. Out-licencing opportunity Genetic adjuvant technology IMX313. In-licencing opportunity Niche vaccines, either marketed or in development. 92 l i f e s c i e n c e s d i r e c t o r y 2 0 1 1 General company information Company contacts CEO contact detail First name: Nicolas Last name: Pasqual Position: President & CEO Email: [email protected] Phone: +33 (0)4 38 78 57 70 Company name: ImmunID Technologies Address: 17, rue des Martyrs, CEA/IRTSV Zip code: 38054 City: Grenoble Website: www.immunid.com Founded in: 25/03/2005 Number of employees: 20 Main activity: ImmunID, offers immunomonitoring solutions to measure the impact of immunotherapy on the immune repertoire. ImmunID answers Biotech & Pharma needs enhancing success rate and decreasing cost of clinical trials. ImmunTraCkeR and Immun’Ig tests contribute to measure efficiency and safety of immunomodulators and to select patients who will benefit from the treatment. In addition, these tests are biomarkers of early diagnostic of certain pathologies (ie: leukemia, GvHD…) and of monitoring of efficacy / infectious risk ratio of a treatment to help clinician to make right decision for their patients. ImmunID proposed first the test for detection of Divpenia® and the clinical score NDL®. This biomarker, currently in clinical validation, will allow stratification of patients with infectious or toxicity risk related to pathology or to immunosuppressive effect of a treatment. The measure of Divpenia allows monitoring of immune reconstitution and measure efficiency of immune stimulating treatment. Incubator: Yes (Grain) Subsidiary of a group: No Prize winner for innovative start-up: Yes (Création 2006 et emmergence 2005) Innovative company (FCPI): No Other status: Yes (JEI, CIR) Funding Looking for funding: Yes Private funding obtained: 2,6 Millions Euros Public funding obtained: 1,8 Million Euros R&D PROJECT FUNDED ACCREDITED BY LYONBIOPOLE PLATINE: European immunomonitoring platform Funding: FUI (AAP5 2008) Role in the project: Partner l i f e s c i e n c e s d i r e c t o r y 2 0 1 1 Other contact First name: Nadia Last name: Plantier Position: Dir External Collaborations & Business Development Email: [email protected] Phone: +33 (0)4 38 78 57 70 Company segmentation Business model Service provider - CRO, Product developer - Other health. Value chain Research, Preclinical, Clinical. Activities Diagnostics / Analysis method, Clinical trials, Preclinical trials, Bioinformatics / Modeling, Other. Application fields Animal health, Human health, Immunology, Infectious diseases, Cancer, Nutrition / Food. Activities Company activities ImmunID’s business model is dual: In a context where personalized medicine cannot be ignored anymore by physicians and patients, and where each treatment has its companion diagnostic tool to determine its efficacy, ImmunID, a diagnostic company, develops tests and biomarkers to measure Immune diversity for medical and industrial applications. 93 The company sells Immunomonitoring services to pharmaceutical and Biotech Companies as well as research labs. These services are possible thanks to sustained R&D activity in immunogenetic and Bio-information system. In parallel, the clinical validation of ImmunID’s kits for diagnostic of Divpenia combined with Constel’ID® software and NDL® clinical score is currently in progress in order to validate the medical relevance of this new biomarker. The company has launched a large program of clinical research on more than 700 patients in collaboration with Centre Leon Berard and Hospices Civils de Lyon. ImmunID Technologies offers innovative immunomonitoring solutions to measure the impact of immunotherapy on the immune repertoire (i.e. measurement of treatment safety and efficacy). ImmunTraCkeR® and Immun’Ig® are available for research, preclinical and clinical validation steps. Applications include: – Clonal expansion identification and characterization – Measurement of immunodeficiency infectious risk – Measurement of combinatorial diversity kinetics – Cohorte stratification – Selection of patients to be included in clinical trials (depending on their immune profile or immune forecast) – Targeted immunotherapy monitoring – Identification of responding and non responding patients – Follow-up of clinical studies – Vaccine, adjuvants, MAb candidates screening – Humanized mice: characterization of immune response and immunoreconstitution – Databanking and datamining In addition, ImmunID Technologies solutions contribute to the identification of appropriate biomarkers that could give information about early disease detection, progression and response to treatment. More importantly, ImmunID Technologies solutions can: – Lower drug development costs and increase success rate – Accelerate time to market – Increase drug safety. Recent news ImmunID published first the divpenia definition on www.divpenia.com Ripal clinical trial (128 patients) in collaboration with HCL. Susa clinical trial (n=100) sponsored by ImmunID Roche Diagnostics France and ImmunID signed a technical collaboration Charles River and ImmunID have associated their expertise in co-marketing agreement. l i f e s c i e n c e s d i r e c t o r y The technical development of Divpenie detection is based on competences in Immunology, Cellular Biology, Molecular Biology (qPCR), software and secure web solutions development, and relies on clinical validation of diagnostic Biomarker and CE mark regulation. ImmunID technologies is certified ISO 9001-2008 and ISO 13485-2004 and complies with GLP procedures. Products / Services / Technologies Pipeline product 1 Company key features 94 Skills and know-how 2 0 1 1 Phase 1: ImmunTraCkeR Diagnostic Biomarker CE Marked Phase 2: ImmunTraCkeR Diagnostic Biomarker CE Marked Pipeline product 2 Phase 1: Immun’Ig Diagnostic Biomarker Phase 2: Immun’Ig Diagnostic Biomarker Company services “Because we believe in personalized medicine we dedicate our solutions and know-how to human health” Founded to address pharmaceutical, diagnostic and theranostic needs, ImmunID is a leader in Immune Diversity analysis. Based on its original concept of immune forecast, ImmunID contributes to the future of healthcare and ultimately to a personalized medicine. Company technologies Based on patented biomolecular and bioinformatic methods, ImmunID toolbox allows exhaustive and integrated view of the whole T and B cell repertoires by screening gene rearrangements. This approach contributes to stratify patients with infectious and early death risks following a pathology or a treatment. This biomarker helps to select and better characterize patients to be included in a clinical trial and contribute to enhance success rate of clinical trials of immuno modulator treatments. Partnership opportunities / Licensing Collaboration framework Validation of biomarker of Divpenia® and NDL® score on large cohorts (300 patients) in following domains: anti-infective treatments; immune stimulating treatments; anti-cancer treatments, pathologies: HIV, HCV, Breast cancers and metastatic cancers, leukemia and lymphoma. In-licencing opportunity Immunomonitoring Technologies: Cellular, Molecular Biology, Sequencing. General company information Company contacts CEO contact detail First name: Stéphane Last name: Legastelois Position: President & CEO Email: [email protected] Phone: +33 (0)4 72 39 14 92 Company name: Indicia Biotechnology Address: 33, avenue de la Californie Zip code: 69600 City: Oullins Website: www.indicia.fr Founded in: 01/01/1998 Number of employees: 49 Main activity: Indicia Biotechnology is a global provider of outsourced development and bioanalytical services to the pharmaceutical, biotechnology and medical device industries. As an immunotechnology specialist, Indicia Biotechnology supports bio-industries in their R&D projects, and provides services relating to immunoassays. The company is currently focusing its strategy on protein biomarkers of clinical interest and their applications for in-vitro diagnostic. By combining three competencies into a single offer: – sample bio-analysis, – assay development and – in vitro diagnostic test production Indicia Biotechnology is intended on contributing to the boost in clinical programmes and in providing new theranostic solutions. In the same time, Indicia Biotechnology intends to develop proprietary products and analyses thanks to collaborative and internal research projects.. Incubator: No Subsidiary of a group: No Prize winner for innovative start-up: No Innovative company (FCPI): No Other status: No Funding Looking for funding: Yes Nature of funding searches: In process. R&D PROJECTS FUNDED ACCREDITED BY LYONBIOPOLE THYMO 2010: From thymoglobulin technical advances tomanufacturingprocessimprovementsandnewpharmaceutical applications Funding: Local authorities (2007) Role in the project: Partner GLIADYS: Malignant glioma and brain dysorders new targeted therapies Funding: FUI (AAP7 2009) Role in the project: Partner of Crohn disease relapses and for therapeutic monitoring. Clinical validation. Funding: FUI (AAP10 2010) Role in the project: Leader s c i e n c e s d i r e c t o r y Company segmentation Business model Service provider - CRO, Service provider - CMO, Product developer - Biopharmaceuticals, Service provider - Scientific, Product developer - Pharmaceuticals, Product developer Other health. Value chain Research, Manufacturing, Preclinical, Clinical. Activities Diagnostics / Analysis method, Vaccine, Biomanufacturing, Clinical trials, Preclinical trials, Drug discovery, Medical device, Other. Application fields Animal health, Pediatrics, Human health, Geriatrics, Immunology, Inflammatory diseases, Infectious diseases, Autoimmune diseases, Allergology, Orphan diseases, Genetic / Rare diseases, Metabolic diseases, CNS related diseases, Cancer, Nutrition / Food, Dermocosmetics, Other. Activities Company activities Indicia Biotechnology is positioning as a specialist in immunotechnology and biochemistry. We offer R&D and bioanalysis services to biopharmaceutical, CRO & diagnostic companies. We support research and development of bioanalytical methods. Company key features FEMTOKINE: High sensitive immunoassays for the prediction l i f e Other contact First name: Elodie Last name: Panier Position: General manager Email: [email protected] Phone: +33 (0)4 72 39 14 92 Fax: +33 (0)4 72 39 16 01 2 0 1 1 Indicia Biotechnology is an ISO 9001/ISO 13485 certified company, meet GMP guidelines and is duly approved within the framework of the French Research Tax Credit. 95 Recent news – June 2011: co-exposition with LyonBiopole at the BIO event in Washington – September 2010: Femtokine FUI project (Crohn’s disease) – May 2010: collaboration with Singulex (USA) to provide ultrasensitive and early biomarker detection through Erenna® Immunoassay System – September 2009: Gliadys project (based on therapeutic antibodies against different glioma forms) – June 2009: Septick shock project (development of an assay to adjust treatments for people with septic shock). Skills and know-how Our expertise allows us to offer tailor-made solutions to measure biological targets (companion diag tests, methods to evaluate immunogenicity, assays for biomarkers, QC methods…). Products / Services / Technologies Company services Custom immunoassay based on conventional and emergent technologies: Erenna Singulex, ELISA, Luminex, Lateral flow… – Custom monoclonal and polyclonal antibodies and associated services – Custom coated microparticles and separation methods... – OEM Sterile liquid reagents: chemical and biological API, solvents and preservative solutions for injectable forms, chromatographic media for protein purification… – OEM media for cell culture, microbiology, in process control Different packaging: tubes, bottles,bags. Company technologies Indicia Biotechnology’s offer includes bioanalysis and developpment on the following technological plateforms: – Immunoassays: Luminex®, Erenna® Singulex, ELISA, EIA, – Rapid tests: lateral flow tests, slide agglutination tests, – Raw material: polyclonal and monoclonal antibodies, coated microparticles. 96 l i f e s c i e n c e s d i r e c t o r y 2 0 1 1 Activities Company activities General company information Company name: InfYnity Biomarkers Address: 40, avenue Guy de Collongue Zip code: 69130 City: Ecully Website: www.infynity-biomarkers.com Founded in: 09/11/2009 Number of employees: 3 Main activity: Identification and validation of biomarkers of clinical interest in infectious and inflammatory diseases. Incubator: Yes (CREALYS) Subsidiary of a group: No Prize winner for innovative start-up: No Innovative company (FCPI): Yes Other status: Yes (JEI, CIR) Identification of biomarkers of clinical interest, biological validation Identification and optimization of antigenic structures (epitopes) on protein; design of antigenic and immunogenic peptides Development of immunoassays for the determination of biomarkers Design and production of the peptide, recombinant proteins and monoclonal antibodies for use in diagnostic and therapeutic products Design and validation of immunoassays for monitoring clinical trials of therapeutic molecules (companion diagnostics). Company key features Strong experience in the identification of epitopes on proteins of human pathogens. Design of protein antigens for the development of immunodiagnostic tests Design and Optimization of immunoassay methods on different platforms (solid-phase, beads, membrane, etc.). Recent news Funding Developing a test for detecting antibodies associated with inflammatory processes leading to heart disease (cardiomyopathy). Looking for funding: No Skills and know-how Company contacts CEO contact detail First name: Maan Last name: Zrein Position: President & CSO Email: [email protected] Phone: +33 (0)6 30 56 57 34 Expertise in the development of multiparameter testing, immunoassay methods, design of peptides with antigenic or immunogenic properties. Expertise in regulatory processes concerning biosimilars including monoclonal antibodies. Products / Services / Technologies Pipeline product 1 Therapeutic area: Cardiovascular Company segmentation Business model Service provider - CRO, Product developer Biopharmaceuticals, Service provider - Scientific, Product developer - Other health. Value chain Partnership opportunities / Licensing Collaboration framework Partnership covering the biopharmaceutical company with HIKMA (www.hikma.com). Partnership for the adaptation of a novel biomarker in an automated immunoassay. Research, Manufacturing, Preclinical. Partnership opportunities Activities Out-licencing opportunity Diagnostics / Analysis method, Biomanufacturing, Clinical trials, Biobank, Preclinical trials, Bioinformatics / Modeling. Application fields Human health, Inflammatory diseases, Infectious diseases, Autoimmune diseases. l i f e s c i e n c e s d i r e c t o r y 2 0 1 1 Automation of immunoassays. Patent for an inflammatory biomarker involved in cardiac complications. In-licencing opportunity Interest for in-licensing of any new biomarker infection and monitored clinical trials. 97 Company contacts CEO contact detail First name: Hervé Last name: Brailly Position: Director Email: [email protected] Phone: +33 (0)4 30 30 30 30 General company information Company name: Innate Pharma Main address: 117, avenue de Luminy Zip code: 13009 City: Marseille Second address: Bâtiment Domylion - 321 avenue JeanJaurès Zip code: 69007 City: Lyon Website: www.innate-pharma.com Founded in: 23/09/1999 Number of employees: 85 Main activity: Innate Pharma SA is a biopharmarceutical company developing first in class immunotherapy durgs for cancer and inflammatory diseases. The company specializes in development of new monoclonal antibodies targeting receptors and pathways controlling the activation of innate immunity cells. Incubator: Yes Subsidiary of a group: No Prize winner for innovative start-up: Yes Other status: Yes Looking for funding: No Stock exchange listing: Euronext 2006 ISIN Code FR 0010331421 Ticket code IPH R&D PROJECTS FUNDED ACCREDITED BY LYONBIOPOLE DEMINAP: Use of toll-like receptors (TLRs) in order to detect inapparent microorganisms and their ligands for diagnostic and therapeutic applications Funding: FUI (AAP2 2006) Role in the project: Leader PLATINE: European immunomonitoring platform Funding: FUI (AAP5 2008) Role in the project: Leader GR-CAV1: A novel immunotherapy approach for cancer with Vaccin’ERY System® Funding: FUI (AAP7 2009) Role in the project: Partner l i f e s c i e n c e s Company segmentation Business model Product developer - Biopharmaceuticals. Value chain Research, Preclinical, Clinical. Activities Models (animal - cellular - …), Clinical trials, Preclinical trials, Drug discovery. Application fields Human health, Immunology, Inflammatory diseases, Cancer. Activities Funding 98 Other contact First name: Yannis Last name: Morel Email: [email protected] Phone: +33 (0)4 30 30 30 30 d i r e c t o r y 2 0 1 1 Company activities Innate Pharma SA is a biopharmarceutical company developing first in class immunotherapy durgs for cancer and inflammatory diseases. The company specializes in development of new monoclonal antibodies targeting receptors and pathways controlling the activation of innate immunity cells.It has 2 priorietary clinical stage drug candidates: IPH 1101, a small molecule agonist of gamma delta T cells, has achieved proof of concept in 2 phases IIA trials in type C viral hepatitis and follicular lymphoma. IPH 2101, an anti-KIR monoclonal antibody potentiating NK cells activation, is currently in Phase II clinical trials in hematologic cancers. Innate Pharma is also developing a preclinical portfolio of immunomodulatory or cytotoxic monoclonal antibodies. Two of its preclinical programs in chronic inflammation have been out-licensed to Novo Nordisk A/S. Innate Pharma ’s key expertise is in immunopharmacology and antibody technology. The Company has implemented in-house a large panel of molecular and cellular assays and in vivo models for assessing the pharmacodynamics and pharmacotoxicology of drug candidates. In addition, Innate Pharma has access to a very large set of unique research tools in cellular immunology through its worldwide network of scientific collaborations. Incorporated in 1999 and listed on NYSE-Euronext in Paris in 2006, Innate Pharma is based in Marseilles, France, and had 85 employees as at December 31, 2010. Learn more about Innate Pharma at www.innate-pharma.com General company information Company name: Institut Mérieux Address: 17, rue Bourgelat Zip code: 69002 City: Lyon Website: www.institut-merieux.com Founded in: 10/11/1988 Number of employees: 1 000 Turnover: 1 400 000 000 Euros (en 2010) Main activity: Holding with major stakes in the bioindustrial companies bioMérieux (diagnostics), Transgene (immunotherapy) and Mérieux NuriSciences (food safety and quality controls, nutrition) and also in the R&D company ABL, in the invesment company Mérieux Développement and in IMAccess, a not for profit company dedicated to diagnostics in developing countries. Incubator: No Subsidiary of a group: No CEO contact detail First name: Michel Last name: Baguenault de Puchesse Position: Chief operating officer Email: [email protected] Phone: +33 (0)4 78 87 70 70 Other contact First name: Dominique Last name: Takizawa Position: Chief financial officer Email: [email protected] Phone: +33 (0)4 78 87 70 70 s c i e n c e s d i r e c t o r y Business model Service provider - CRO, Product developer Biopharmaceuticals, Service provider - Scientific, Laboratory equipment supplier. Value chain Research, Manufacturing / Production, Preclinical, Marketing / Distribution, Clinical. Activities Diagnostics / Analysis method, Vaccine, Biomanufacturing, Clinical trials, Preclinical trials, Drug discovery, Other. Application fields Human health, Immunology, Infectious diseases, Cancer, Nutrition / Food. Activities Company activities In vitro diagnostics with bioMérieux and IMAccess Company contacts l i f e Company segmentation 2 0 1 1 Immunotherapy with Transgene Food safety and quality controls, R&D in the field of nutrition with Mérieux NutriSciences R&D in virology with ABL. Company key features Expertise in infectious diseases and cancers Bioindustrial capacities International network R&D capacities. Recent news Structuring of a nutrition and health division : Mérieux NutriSciences creation of IMAccess dedicated to diagnostics in developing countries. Skills and know-how Diagnostics and immunotherapy of Infectious diseases and cancers Biomanufacturing clinical surveys microbiological and chemical analysis in agrifood industry. 99 General company information Business model Company name: IntuiSKin Address: Parc Activillage des Fontaines ZI Bernin Zip code: 38926 City: Crolles Website: www.intuiskin.com Founded in: 24/11/2004 Number of employees: 15 Turnover: 2 M Euro (in 2009) Main activity: Research, Development and Commercialization Product developer - Other health, Laboratory equipment supplier. Subsidiary of a group: Yes (MEMSCAP) Prize winner for innovative start-up: No Innovative company (FCPI): No Other status: No Application fields Funding Company activities of innovative skindiagnostic and skin care solutions. Looking for funding: Yes R&D PROJECT FUNDED ACCREDITED BY LYONBIOPOLE MELASCAN: Innovative solution for screening and monitoring in vivo of skin cancer, standardized for general practitioners and specialists Funding: ANR (2010 Tecsan) Role in the project: Leader Company contact CEO contact detail First name: Pascal Last name: Ränsch Position: Managing Director Email: [email protected] Phone: +33 (0)4 76 92 85 15 100 Company segmentation l i f e s c i e n c e s d i r e c t o r y 2 0 1 1 Value chain Research, Manufacturing, Clinical. Activities Diagnostics / Analysis method, Instrumentation, Medical device, Other. Human health, Cancer, Dermocosmetics. Activities Development of micro and macroscopic imaging devices / physico-chemical MEMS based measurements. Development of dermocosmetic and cosmetic products. Brands: IOMA Esthetics, IOMA Derm, IOMA Beuty Proline Innovative skin care solutions. General company information Company contact CEO contact detail First name: Jung Last name: Jean François Position: Director Email: [email protected] Phone: +33 (0)6 87 27 37 02 Company name: jlm lab Address: 18, rue du Bourgamon Zip code: 38400 City: Saint Martin d’Hères Founded in: 21/12/2008 Number of employees: 3 Main activity: JLM Lab designs and makes level 2 and 3 biosafe laboratories, innovative in many aspects. These products are offered ready to use and turn-key. Their reliability,mobility (every transport mode is possible: maritime, road and air transports) and standalone (water, electricity, and special fluids) qualities authorize their fast setting up and implementation in any area of the world.These modular laboratories provide as well, by their design (clean rooms expertise, high technology materials…) outstanding security and containment guaranties, and respect the standards and legislation (ISO 16 644-4 and ISO 14 644-1, legislation concerning the biological risks prevention and the containment use of GMO).This offer, which is today a quasi unique concept in the market, comes from a constructive approach trough 5 innovation strong guiding axis : – Search of an optimal hygene by using welded partition walls with half-round fillet (no silicone). – Search of a maximum security with an engineering concerned by containment, ergony and flood management. – Provide a true energetic autonomy, based on technologies allowing a prompt mobility, an easy transport and reduced costs. – Supply products designed with high technology materials, guarantying outstanding containment and no porosity qualities (synthesized resin(3)). – Design to allow an easy maintenance. Incubator: Yes (Grain) Subsidiary of a group: No Prize winner for innovative start-up: No Innovative company (FCPI): Yes Other status: Yes Company segmentation Business model Laboratory equipment supplier. Value chain Research, Manufacturing. Activities Other. Application fields Immunology, Infectious diseases. Activities Company activities JLM Lab offers standalone and mobile level 2 & 3 biosafe laboratories, wich could be uded in particular by civilian, military and NGO health services, for missions such asepidemiologic watch, pandemic risks, and sanitary emergencies.Furthermore, these modular laboratories can also be an extremely pertinent answer (reduced costs, setting up responsiveness) for the provision of directly operational premises, for pharmaceutical and biotechnologies sectors, within the framework of R&D missions with definite duration. Funding Looking for funding: No l i f e s c i e n c e s d i r e c t o r y 2 0 1 1 101 General company information Company name: Kendle Address: Espace Brotteaux - 13, place Jules Ferry Zip code: 69006 City: Lyon Website: www.kendle.com Founded in: 01/01/2005 Number of employees: 21 Main activity: Kendle is a leading global clinical research organization providing the full range of early - to late - stage clinical development services. We focus on innovative solutions that reduce cycle times for our customers and accelerate delivery of life-enhancing drugs to market for patients worldwide. The Lyon Office opened in 2005. (Kendle was founded in 1981 in Cincinnati, USA and the French affiliate was created in France in Issy-Les-Moulineaux in 1999). Winner of Aderly Award 2008 – Best Company progress over 3 Years 3 352 employees Worldwide and 100 in France. Incubator: No Subsidiary of a group: Yes (Kendle International) Prize winner for innovative start-up: No Innovative company (FCPI): No Other status: No Funding Looking for funding: No Company contacts CEO contact detail First name: Eric Last name: Leray Position: General Manager Kendle France Email: [email protected] Phone: +33 (0)1 70 36 78 86 Other contact First name: Fabien Last name: Berthomeau Position: Associate Director Clinical Operations, Lyon Office Head Email: [email protected] Phone: +33 (0)4 78 65 15 21 Fax: +33 (0)4 78 65 09 44 102 l i f e s c i e n c e s d i r e c t o r y 2 0 1 1 Company segmentation Business model Service provider - CRO. Value chain Research, Clinical. Activities Vaccine, Clinical trials, Drug discovery, Medical device. Application fields Pediatrics, Human health, Geriatrics, Immunology, Inflammatory diseases, Infectious diseases, Autoimmune diseases, Allergology, Orphan diseases, Genetic / Rare diseases, Metabolic diseases, CNS related diseases, Cancer, Nutrition / Food, Dermocosmetics. Activities Company activities As one of the world’s largest global providers of Phase I-IV services, we offer experience spanning more than 100 countries, along with industry-leading patient access and retention capabilities and broad therapeutic expertise, to meet our customers’ clinical development challenges. Focused on five regions, North America, Europe, Asia/Pacific, Latin America and Africa, we ensure on-the-ground presence wherever you need it. We are one of the few CROs positioned to deliver in the next generation of strategic partnerships. We’re committed to success in every partnership, large or small, and are focused on delivering consistent quality and value for every one of our customers. We believe that strategic partnerships are the business model of the future, where earlier and fuller collaboration will provide the foundation for innovation and accelerated productivity. Our vision «To be the best-in-class provider of clinical development services to the biopharmaceutical industry through broad therapeutic and geographic expertise». Company key features – Top-tier CRO uniquely positioned to deliver Phase I-IV clinical trials – Services provided in more than 100 countries – Customers include 44 of the world’s top 50 biopharmaceutical companies – 51 clinical development locations in 31 countries spanning six continents Experience across all major therapeutic areas. We contribute to the development, approval and life cycle management of innovative therapies for a broad range of medical conditions. Our global and local therapeutic expertise includes oncology, central nervous system, cardiovascular, inflammatory and respiratory diseases, endocrinology, analgesia, women’s health, vaccines and dermatology. We focus our therapeutic offerings on market needs and already are aligned with the top areas expected to represent more than 70 percent of worldwide drug sales through 2014: cancer/oncology/hematology, antibiotics/ antivirals, cardiology, arthritis/rheumatology/inflammation, respiratory and diabetes.1 Independent research shows Kendle is your ideal partner At Kendle, our strong site relationships and ability to deliver consistent quality services make us an excellent partner for biopharmaceutical companies. In fact, independent quantitative research has demonstrated our ability to maintain excellent site relationships and deliver consistent quality services. Recent news – Kendle is the only CRO to have been ranked consistently among the top two providers in the 2009, 2008 and 2007 CenterWatch Surveys of U.S. and European Investigative Sites 2 – In a March 2009 survey conducted by Industry Standard Research, Kendle was: The top-rated CRO for “Efficient Site Start-up”: Found to deliver «the most consistent quality services» out of all CROs. One of only two CROs to be rated as exceeding expectation for project manager quality/experience. Kendle was named Winner “Best Technological Development in Clinical Trials – Software Solution” at the GCPj Clinical Research Excellence Awards. Skills and know-how Committed project teams: We provide highly experienced Project Leaders and multi-functional study teams who will work with you proactively and creatively to accelerate the clinical development process. Project Leaders are given clear authority and accountability for study performance and are involved in projects from the onset. Because they have primary responsibility for customer relationships and repeat business, they carefully plan study strategy, drive the development of project-specific operating procedures and control team assignments and activities. l i f e s c i e n c e s d i r e c t o r y 2 0 1 1 Products / Services / Technologies Company services Preview Kendle’s capabilities: – Early Stage – Phase I - Innovative solutions based on ground-breaking science to accelerate your product’s clinical development – Late Stage – Phase II - IV Expert help for large, complex global studies or smaller, regional trials – Clinical Trial Elements: Critical key services to ensure your project’s success: – Getting started – Robust and proactive strategies to accelerate study start-up and lay the foundation for trial success – The right advice – Invaluable regulatory expertise and advice to help you navigate through the regulatory landscape – Tech tools – Ground-breaking technologies for efficient communication and high-quality clinical trial data – Managing sites – Strong site relationships integrated with innovative data technologies – Medical know-how – Experience in every major therapeutic area, along with many niche diseases – Protecting patients – Accurate adverse event reporting and risk assessment document preparation – Medical writing – Expertise ranging from protocols to regulatory submissions and study reports – Delivering data – Expertise in Electronic Data Capture and Biostatistical analysis, along with submitting ISS/ISEsupported NDAs and SDTM- and ADaM-formatted documents. Company technologies Unique study and data management tools Kendle’s proprietary suite of software products, TrialWare®, allows our customers to conduct their clinical trials faster, with greater accuracy and efficiency. The TrialWare® family of technology includes everything from TrialWatch®, our global clinical trial management system to TrialEAS™, our award-winning, Web-based solution that expedites the review of documents, scans and other medical materials by independent adjudicators. In addition, we are at the forefront of Electronic Data Capture. Our statisticians are highly trained and knowledgeable in this field, with strong international expertise. Kendle has experience utilizing the leading EDC software packages, a dedicated EDC Support Center and the expertise gained through the successful completion of hundreds of EDC trials. Partnership opportunities / Licensing Partnership opportunities We’re experts in managing successful partnerships – it’s what we do best With Kendle, each partnership is different. Whether you need a long-term strategic partner or you’re simply looking for a partner to help you with a single project, we have unique capabilities and the flexibility to act quickly and efficiently. Kendle is specifically organized to realize operational efficiencies, so we can streamline activities, accelerate productivity and reduce your costs, while still maintaining the highest quality standards. The Kendle difference Kendle is the first of a new generation of CROs. We are committed to success in every partnership. Whether it’s a large-scale strategic collaboration or a functional service provider relationship, making it happen is where we truly excel. 103 General company information Company name: Khorionyx Address: 1, rue des Greffières Zip code: 69890 City: La Tour de Salvagny - France Website: www.khorionyx.com Founded in: 27/03/2003 Number of employees: 1 Main activity: Development of the medical applications of human globin. Autologous implant as a dermal filler for injection in skin folds and wrinkles. Other formulations for bone augmentation and wound healing. Subsidiary of a group: No Prize winner for innovative start-up: No Innovative company (FCPI): No Other status: No Funding Looking for funding: Yes Nature of funding searches: Need to raise 3 millions euros in June 2011 in order to perform the pivotal clinical trial in USA necessary to get the BLA (Biologics License Application) for producing and distributing the autologous globin dermal filler in USA. This capital raise is conditioned by the results of the ongoing pilot clinical trial in USA. Private funding obtained: Feb 27, 2009: first raise of 250.000 euros including the participation of Groupe Saint Olive in Lyon Nov 15, 2010: Second raise of 250.000 euros including the participation of Groupe Saint Olive in Lyon Public funding obtained: Sep 12, 2006: loan granted by Oséo of 100.000 euros Company segmentation Business model Product developer - Biopharmaceuticals, Product developer - Other health. Value chain Research, Preclinical, Clinical. Activities Biomanufacturing, Clinical trials, Other. Application fields Human health, Dermocosmetics, Other. Activities Company activities Development of the medical applications of human globin, the colourless insoluble protein derived from hemoglobin. Autologous paste for injection and filling of dermal folds and wrinkles. Other formulations or associations for bone augmentation and wound healing. Company key features Products, technology and applications protected by 5 recent and complementary international patent families (2003 to 2010). Product prepared in 1 hour: 8 syringes of 1ml from a 10 ml blood sample of the patient (autologous globin) or about 500 syringes from an outdated individual red cell pouch (homologous globin). Competitive approach for different existing applications of animal collagens. Biological component to create new composite active biomaterials. Recent news Company contacts CEO contact detail First name: Jean-Louis Last name: Tayot Position: Manager Email: [email protected] Phone: +33 (0)6 73 89 53 00 August 24, 2010: I.N.D. (Investigational New Drug) granted by FDA, to start the first pilot clinical trial of the autologous globin implant for correction of nasolabial folds in 15 subjects. Human globin is considered as a biologically active product by FDA. November 15, 2010: Capital raise of 250.000 euros including the participation of Groupe Saint Olive in Lyon December 3, 2010: starting the pilot clinical study of the autologous globin as dermal filler. Skills and know-how Other contact First name: Jean Last name: Bernasconi Position: Property Industrial Direction Email: [email protected] Phone: +33 (0)6 71 17 92 83 104 l i f e s c i e n c e s d i r e c t o r y 2 0 1 1 20 years experience of biological research and industry in Pasteur Mérieux, now Sanofi Pasteur. 20 years experience of the manufacturing and medical applications of collagens and biomaterials since 1987, shown by the top management of Imedex and the creation or active contribution to the development of three biotech companies in Lyon area (Episkin, Symatese, Imedex Biomateriaux) and a Florida based start up (Albiorex). Products / Services / Technologies Pipeline product 1 Therapeutic area: dermal implant Therapeutic indication: skin folds filling Preclinical: done Phase 1: ongoing Phase 2: ongoing Phase 3: 2012 MA: 2013-2014 Partnership opportunities / Licensing Collaboration framework 3 millions euros for the next capital raise. Partnership opportunities Financial or corporate company to become a shareholder and/or partner of Khorionyx. Out-licencing opportunity Pipeline product 2 Therapeutic area: wound healing Therapeutic indication: chronic wounds Preclinical: in progress Dermo-cosmetology, wound healing, bone augmentation, biological complement to existing devices or composite biomaterials: chemical adhesives, biological glue, mineral fillers, meshes. Pipeline product 3 Therapeutic area: dental implant Therapeutic indication: bone augmentation Preclinical: in progress Company services No employee. Collaboration with Albiorex and other subcontracting companies in USA (manufacturing, CRO). Company technologies Human globin is the most abundant protein component in the blood: 140mg/ml. It is easily and largely available from any patient. Its colourless and insoluble character at physiological pH enables to use it in the formulation of new biomaterials. Globin may be prepared from autologous blood or from fully controlled red cells in sterile conditions. Also the resistance of globin to denaturation allows its sterilization if necessary. The process and its control guarantee the absence of any eventual virus or transmissible agent. The human origin of globin explains a better biocompatibility compared to animal collagens, in particular for repeating injections in the skin. l i f e s c i e n c e s d i r e c t o r y 2 0 1 1 105 General company information Company name: K-PLAN Address: 11, avenue Albert Einstein Zip code: 69100 City: Villeurbanne Website: www.k-plan.fr Founded in: 11/07/2007 Number of employees: 6 Turnover: 150Ke (in 2009) Main activity: Engineering in research and development of bio-medical applications. Study, development and marketing of its own range of on-site devices, development of new technologies in the field of biology and diagnosis. Incubator: No Subsidiary of a group: No Prize winner for innovative start-up: No Innovative company (FCPI): No Other status: Yes Funding Looking for funding: Yes R&D PROJECT FUNDED ACCREDITED BY LYONBIOPOLE KALLISTE: Functional and robust equipment for the evauation of pathogen agents chemosensitivity Funding: FUI (AAP6 2008) Role in the project: Leader Company contacts CEO contact detail First name: Dominique Last name: Parzy Position: Manager Email: [email protected] Phone: +33 (0)6 71 23 84 07 106 l i f e s c i e n c e s d i r e c t o r y 2 0 1 1 Company segmentation Business model Laboratory equipment supplier. Value chain Research, Manufacturing. Activities Instrumentation, Medical device, Other. Application fields Animal health, Human health, Infectious diseases, Other. Activities Company activities Engineering company located in the science and technology center Einstein in Villeurbanne-Lyon, and adhere to the world competitive cluster Lyonbiopole. Investing since its creation in research and development of bio-medical applications, the team developed in parallel to his activity of expertise, its own range of on-site-devices. Innovation: microbiological laboratory «all in one», system patented, all equiped (sampling, preparation, analysis, microbiological incubation), deployable on all fronts by 2 people, air transportable by standard commercial flight, integrated into 4 flight cases in carbon fiber. Use: Increase the capacity of biological response teams on site (epidemic, war, natural disaster…), Military teams, NGO, Humanitarian Foundations. Development Collaborative (French and Foreign laboratories) since 2007, patent, trading since June 2009. Company key features Young team consistued of engineers with complementary skills (electronics, computer, optics and mechanics). – Responsiveness – Patents – Research laboratories working in collaboration with K-Plan – Expanding Market of the biological and medical mobile laboratory on site. Company segmentation Business model Product developer - Other health, Other. General company information Company name: La cosmétique alpine avancée Address: 12, quai du commerce Zip code: 69009 City: Lyon Founded in: 12/04/2010 Number of employees: 1 Main activity: Research, development and commercialisation of high performance dermo-cosmetic solutions. The company is currently cooperating with one of Lyon’s most famous university laboratories in order to develop an innovative biochemical process aiming to improve the efficiency of active principles (mostly derived from natural ingredients from the Alps) and to better control their activity on and inside the human skin. The targeted sector of the company’s R&D programme is dermo-cosmetics but the innovative process could be potentially used in other sectors (ex. healthcare, food). Incubator: No Subsidiary of a group: No Prize winner for innovative start-up: No Innovative company (FCPI): Yes Other status: Yes Funding Looking for funding: Yes Nature of funding searches: The company was founded with the support of a small group of investors. We are now seeking institutional investors. The plan is to raise between 100K and 200K Euros in 2011 and then another similar sized round in 2012. Public funding obtained: The company recently applied for Oseo’s “Innovation Support Funding Programme”. Value chain Research, Marketing / Distribution. Activities Other. Application fields Dermocosmetics. Activities Company activities The company has two interdependent areas of activity. The first one, which has just started, is “R&D” (i.e. development of exclusive biochemical technologies in partnership with prestigious research organisations). The second one, which is planned to start at the end of 2012, is the “marketing and distribution” of high performing dermo-cosmetic products exclusively through an international selection of luxury points of sale (i.e. luxury Spas, high end Perfumery and department stores). Company key features - Developing proprietary technologies in the dermo-cosmetics sector - Marketing and distribution of cosmetic products on an international basis - Outsourcing any non-core capabilities. Recent news Beginning of the research and development programme. Its completion date is planned for the 2nd quarter of 2012. Skills and know-how R&D, Marketing and distribution on a global scale. Company contact CEO contact detail First name: Florent Last name: Gerphagnon Position: CEO & Founder Email: [email protected] Phone: +33 (0)6 73 79 39 51 Partnership opportunities / Licensing Collaboration framework Possibilities of cooperation in the areas of research and development, marketing and distribution of the company’s dermocosmetic products. Out-licencing opportunity Licensing opportunity of the company’s (future) patented technology in non-core areas. l i f e s c i e n c e s d i r e c t o r y 2 0 1 1 107 General company information Company name: Latoxan S.A.S. Address: 20, rue Léon Blum Zip code: F-26000 City: Valence Founded in: 01/02/1982 Number of employees: 8 Turnover: 1.6 M Euros (in 2010) Main activity: Production and sales of natural bioactive ingredients for Drug Discovery, Life Sciences Research, cosmetics and antivenom serae production. We supply: Venoms and Libraries of venom fractions and of animal toxins Plant extracts and purified plant molecules. Incubator: No Subsidiary of a group: No Prize winner for innovative start-up: No Innovative company (FCPI): No Other status: No Business model Other. Value chain Manufacturing, Marketing / Distribution. Activities Drug discovery, Other. Application fields Animal health, Human health, Immunology, Infectious diseases, Orphan diseases, CNS related diseases, Cancer, Nutrition / Food, Dermocosmetics. Activities Company activities Looking for funding: Yes Nature of funding searches: We are willing to invest Farming venomous species in facilities duly certified and controled by authorities and audited by several international pharmaceutical companies. Production of venoms, venom fractions and animal toxins. We sell the world most comprehensive catalogue of venoms and venom toxins. Purification of venom fractions and toxins Supply of plant extracts and plant purified molecules through an exclusive partnership with an asian organism duly certified by local environment authorities for the controlled harvest of plants. Company contacts Company key features CEO contact detail First name: Harold Last name: de Pomyers Position: President Email: [email protected] Phone: +33 (0)4 75 41 91 91 Recent news Funding in additional capacity for purification and synthesis of peptides from our unique venom catalogue. The world widest venom and toxin catalogue Capcity to fetch venomous specimens from the wild Adaptability and swiftness. Marketing of Kitoxan a Library of venom fractions from 60 diffrent venomous species. Skills and know-how Other contact First name: Bénédicte Last name: Bourgeaud Position: Assistant Email: [email protected] Phone: +33 (0)4 75 41 91 91 Fax: +33 (0)4 75 41 91 99 108 Company segmentation l i f e s c i e n c e s d i r e c t o r y Venomous animals fetching and farming Venom production Venom peptides purification Peptide hits deconvolution and synthesis. 2 0 1 1 Company segmentation Business model Service provider - CRO, Service provider - Non Scientific, Service provider - CMO, Service provider - Scientific. Value chain Manufacturing, Marketing / Distribution. Activities Clinical trials, Other. Application fields Animal health, Human health, Nutrition / Food, Dermocosmetics. Activities Company activities General company information Company name: LC2 Address: ZA de Charpenay - 10, rue de l’aqueduc Zip code: 69210 City: Lentilly Website: www.lc2.com Founded in: 02/10/1995 Number of employees: 32 Turnover: 2800 k Euros (in 2010) Main activity: Packaging, logistics and quality control for the healthcare industries. As a high-quality pharmaceutical establishment and service provider, since 1995 LC2 has used its unique expertide for the packaging and logistics of clinical trials and pilot batches. – Import/QP Release – Primary and secondary packaging – Storage and «forward & reverse» logistics – Destruction – Quality control and stability studies – Batch certification. Subsidiary of a group: No Prize winner for innovative start-up: No Innovative company (FCPI): No Other status: No Funding CEO contact detail First name: Arnaud Last name: Grivel Position: Qualified Person - CEO Email: [email protected] Phone: +33 (0)4 74 72 17 77 Other contact First name: Christiane Last name: Dally Position: Business Development Marketing Manager Email: [email protected] Phone: +33 (0)6 07 65 54 99 Fax: +33 (0)4 74 72 17 60 d i r e c t o r y Adaptability-reactivity-reliability-quality. Skills and know-how – To perform all operations, from receipt of the protocol to project closure. – To check all steps in processes and guarantee product storage under controlled and secure conditions. – To certify a high degree of quality based on an exhaustive set of pharmaceutical regulation-compliant procedures. – To place data management at the heart of our activity, guaranteeing optimum clarity and confidentiality concerning the detail of operations performed. Company services Company contacts s c i e n c e s Company key features Products / Services / Technologies Looking for funding: No l i f e – Project design, advice – Import – Purchase of comparators – Batch file – Development of placebo units – Encapsulation – Primary packaging: blisters, bottles, vials, sachets – Secondary packaging: boxes, blisters-card, wallet, foam – Randomization – Label design and multilingual printing – Printing code break envelopes/lists – Analytical method transfer and validation – Analytical control – Stability and comparative dissolution studies – Secured storage, controlled conditions: -25°C to -15°C/+2°C to +8°C/+15°C to +25°C – Shipments: France, Europe, International – Pick up on investigation site – Inventory of returns, destruction – Batch certification/QP Release. 2 0 1 1 – Project design, advice – Import – Purchase of comparators – Batch file – Development of placebo units – Encapsulation – Primary packaging: blisters, bottles, vials, sachets – Secondary packaging: boxes, blisters-card, wallet, foam – Randomization – Label design and multilingual printing – Printing code break envelopes/lists – Analytical method transfer and validation – Analytical control – Stability and comparative dissolution studies – Secured storage, controlled conditions: -25°C to -15°C/+2°C to +8°C/+15°C to +25°C – Shipments: France, Europe, International – Pick up on investigation site – Inventory of returns, destruction – Batch certification/QP Release. 109 Company segmentation Business model Service provider - Scientific, Product developer - Other health. Value chain Research, Manufacturing, Marketing / Distribution, Other. Activities Diagnostics / Analysis method, Medical device, Other. Application fields Animal health, Human health, Nutrition / Food. General company information Company name: Magnisense Address: 27, chemin des Peupliers - BP 62 Zip code: 69572 City: Dardilly Website: www.magnisense.com Founded in: 01/01/2007 Number of employees: 10 Main activity: Magnisense is a diagnostics company that develops and markets magnetic bioassays, under its own brand or in collaboration with the diagnostics industry. Incubator: No Subsidiary of a group: No Prize winner for innovative start-up: No Innovative company (FCPI): No Other status: No Funding Looking for funding: No Company contacts CEO contact detail First name: Luc Last name: Lenglet Position: President Email: [email protected] Phone: +33 (0)4 72 17 50 62 Other contact First name: Hayat Last name: El Yousfi Position: Marketing Manager Email: [email protected] 110 l i f e s c i e n c e s d i r e c t o r y 2 0 1 1 Activities Company activities Magnisense is a diagnostics company that develops and markets magnetic bioassays, under its own brand or in collaboration with the diagnostics industry. These next-generation bioassays improve rapid diagnostic performance for human and animal diagnostics, food safety and environmental protection testing. They are based on magnetic bead markers, which can be used to achieve the accuracy of laboratory testing with the ease of use of rapid test methods Exploiting a unique feature of magnetic bead markers, Magnisense’s MIAtek®: technology provides true quantification of a large volume sample. The magnetic signal is free of interference from environmental factors, permitting a more sensitive and reproducible detection than possible with other surface-restricted approaches common in lateral flow rapid testing. Magnisense is developing two test formats for different application areas: – MIAstrip®: Point of care testing with a single dose, producing objective, quantifiable and traceable results via a portable reader. MIAstrip enables the identification of a target via detection of known markers for a number of diseases including avian flu, cardiac disease, tetanus, and bacterial, viral, parasitic or mycotic infections. – MIAflo®: Disposable cartridges for detection of targets, such as bacterial contamination in food products, e.g. Listeria and Salmonella, or in water, e.g. Legionella, with a sensitivity that brings a significant reduction in testing time. Recent news – July 10, 2010: Magnisense, a developer of next generation bioassays for human and animal diagnostics, food safety and environmental protection, today announced that the US Patent and Trademark Office has issued the company’s founding patent entitled Method for Analyzing a Mixture of Biological and/or Chemical Components using Magnetic Particles and Device for the Implementation of said Method - a patent which had already been granted in Europe in 2009. – March 18, 2009: Magnisense, a developer of next generation bioassays for human and animal diagnostics, food safety and environmental protection, announced the launch of a new discovery platform for the construction and characterization of next generation nanomagnetic materials. This work, in collaboration with the Paris 13 University and the Claude Bernard Lyon 1 University, is funded by a 920,000 EUR grant from l’Agence Nationale de la Recherche (ANR). It also benefits the subsidies of the French agency for innovation, OSEO. – March 5, 2009: Wave 80 Biosciences and Magnisense announced the establishment of a new strategic partnership to explore synergies between the companies’ industry-leading technology platforms, MIAtek® magnetic detection technology and SCATM assay cartridge technology. Products / Services / Technologies Pipeline product 1 Preclinical: MIAtek® Pipeline product 2 Preclinical: MIAstrip® Pipeline product 3 Preclinical: MIAflo® Company technologies Magnisense has developed MIAtek®, a novel diagnostic technology which promises to revolutionize diagnostic assays. Magnisense uniqueness relies on the assessment of the magnetic signature of magnetic beads as labels to permit sensitive detection and precise quantification of a biological target. Not only a « signal » our readers are looking after, but a full « signature ». Subsequent robustness (no moving parts) and versatility (various geometries) allow a wider range of applications: – Single tests: from strip tests (MIAstrip®) to flow-through assays (MIAflo®), – Multiparametric assays: from chip assays (MIAchip®) to multi-bead multiparametric assays (MIAplex®), – Magnetic immunoassays or molecular biology. We believe it will finally allow tapping into the full potential of magnetic detection for life sciences: – Point of care testing: e.g., cardiac markers demanding both high senstivity and wide dynamic range, – Faster and quantified bacteria detection in, e.g., agro-food products, water. l i f e s c i e n c e s d i r e c t o r y 2 0 1 1 111 Company segmentation Business model Product developer - Pharmaceuticals, Product developer Other health. Value chain Research, Preclinical, Clinical. Activities Diagnostics / Analysis method, Models (animal - cellular - …), Clinical trials, Preclinical trials, Drug discovery. Application fields Human health, Autoimmune diseases, Metabolic diseases, Nutrition / Food. Activities General company information Company name: Mellitech SAS Address: CEA Grenoble INAC/SCIB Bat C5 Zip code: 38054 City: Grenoble Website: www.mellitech.com Founded in: 27/10/2005 Number of employees: 6 Main activity: Mellitech SAS, a biopharmaceutical and drug discovery company, engages in the discovery and development of therapies and companion diagnostics for diabetes care. Subsidiary of a group: No Prize winner for innovative start-up: Yes Innovative company (FCPI): Yes Other status: Yes Funding Looking for funding: Yes Company activities Mellitech SAS, a biopharmaceutical and drug discovery company, engages in the discovery and development of anti-diabetics, diagnostic methods, and a functional imaging technology for the pancreas. The company’s 3 lead projects are: – The development of a 1st-in-class ZnT8 agonist for type 2 diabetes through to phase I/IIa, at which point it will be licensed out. – The development of a functioning beta cell imaging technology based on Mellitech’s IP protected anti-body; – The development of ZnT8 peptides to treat type I diabetes. Company key features ZnT8 is a major new T2D target (Science, Nature, Nature Genetics, Diabetes, Diabetologia, Diabetes Care, PNAS 2007-2010) that is expected to revolutionize diabetes treatment and follow-up. Mellitech is the most advanced company in the development in ZnT8-derived applications in diabetes therapy, diagnostics and imaging. Recent news Mellitech and their academic partners within CEA, INSERM and UJF have been selected by the National Research Agency (ANR) through the call BiotecS 2010 for their 3-year R&D project «Preclinical development of molecular imaging antibodies targeting the ZnT8 protein for the diagnosis and follow-up of diabetes. Company contacts CEO contact detail First name: Richard Last name: Platford Position: CEO Email: [email protected] Phone: +33 (0)4 38 78 43 54 Skills and know-how Other contact First name: Yann Last name: De Boysson Position: Head of Business Development Email: [email protected] Phone: +33 (0)4 38 78 43 54 Fax: +33 (0)4 38 78 50 90 – ZnT8 biology – HTS screening for compounds with potential ZnT8 agonist activity; – Zinc and insulin testing in-vitro and ex-vivo (animal and human islets). Products / Services / Technologies Pipeline product 1 Therapeutic area: Type II diabetes Therapeutic indication: oral treatment Pipeline product 2 Therapeutic area: Diabetes Therapeutic indication: in vivo imaging Pipeline product 3 Therapeutic area: Type I diabetes Therapeutic indication: Prevention therapy 112 l i f e s c i e n c e s d i r e c t o r y 2 0 1 1 Company contacts CEO contact detail First name: Jean-Louis Last name: Crosia Position: Chairman Merial SAS Phone: +33 (0)4 72 72 30 00 General company information Company name: Merial Address: 29, avenue Tony Garnier Zip code: 69007 City: Lyon Website: www.merial.com Founded in: 01/08/1997 Number of employees: 5700 Turnover: 2,6 Mds dollars (in 2009) Main activity: Merial is a world-leading, innovation-driven animal health company, providing a comprehensive range of products to enhance the health, well-being and performance of a wide range of animals. Merial employs approximately 5,700 people and operates in more than 150 countries worldwide. Its 2009 sales were over $2.6 billion. Merial is the Animal Health subsidiary of sanofi-aventis. Subsidiary of a group: Yes (sanofi-aventis) Prize winner for innovative start-up: No Innovative company (FCPI): No Other contact First name: Corinne Last name: Demée Position: Merial SAS Communication Director Email: [email protected] Company segmentation Business model Product developer - Biopharmaceuticals, Product developer Pharmaceuticals, Product developer - Other health. Other status: No Value chain Funding Activities Research, Manufacturing, Marketing / Distribution, Clinical. Vaccine, Other. Looking for funding: No Application fields R&D PROJECTS FUNDED ACCREDITED BY LYONBIOPOLE GAP: Healthcare shield solutions against avian flu and flu pandemics Funding: FUI (2005) Role in the project: Leader HYPERBAR: Bringing into the vaccine production industry an alternative to chemicals for bacteria and viruses inactivation by high pressure treatment Funding: FUI (AAP3 2007) Role in the project: Leader FIV-VAX: Development of a vaccine against feline immunodeficiency virus (FIV) Funding: FUI (AAP6 2008) Role in the project: Leader PATVAX: Process Analytical Technology for Vaccines Funding: FUI (AAP8 2009) Role in the project: Partner NOVADUCK: Novel avian influenza diva recombinant vaccines for duck Funding: Europe (FP6) Role in the project: Leader l i f e s c i e n c e s d i r e c t o r y Animal health, Immunology, Infectious diseases. Activities Company activities Merial is a world-leading, innovation-driven animal health company, providing a comprehensive range of products to enhance the health, well-being and performance of a wide range of animals. Merial employs approximately 5,700 people and operates in more than 150 countries worldwide. Its 2009 sales were over $2.6 billion. Merial is the Animal Health subsidiary of sanofi-aventis. Company key features MERIAL is the only worldwide player exclusively dedicated to the animal health sector. N° 1 in the Companion Animal sector N° 1 in Foot and Mouth Disease (FMD) and Bluetongue (BTV) vaccines N° 1 in Rabies vaccines N° 2 in the Avian market. Recent news 100% sanofi-aventis from september, 2009. Skills and know-how – Vaccines – Pets infectious diseases – Developing diseases. 2 0 1 1 113 General company information Company name: Metabolys Address: Faculté de Médecine Laennec Zip code: 69372 City: Lyon Cedex 08 Website: www.metabolys.com Founded in: 20/11/2008 Number of employees: 5 Turnover: 35 k€ (in 2009) Main activity: Metabolys acts as a CRO to predict early during the preclinical development the safety and efficacy of drug candidates/chemicals/biologics using cellular metabolomics, an innovative approach. Cellular metabolomics provides a panoramic view not only of the metabolic pathways in any human or animal cell type in vitro but also of the beneficial and adverse effects of milligram amounts of test compounds with these metabolic pathways. Metabolys has also a drug discovery line in the diabetes field. Incubator: Yes (CREALYS et EML) Subsidiary of a group: No Prize winner for innovative start-up: Yes (emergence (2007); creation/development (2009)) Innovative company (FCPI): No Other status: Yes Activities Company activities Metabolys acts as a CRO to predict early during the preclinical development the safety and efficacy of drug candidates/ chemicals/biologics using cellular metabolomics, an innovative approach. Cellular metabolomics provides a panoramic view not only of the metabolic pathways in any human or animal cell type in vitro but also of the beneficial and adverse effects of milligram amounts of test compounds with these metabolic pathways. Metabolys has also a drug discovery line in the diabetes field. Company key features – Prediction of the safety and efficacy of test compounds early during their discovery/preclinical development - use of metabolically differentiated cells in vitro – Use of an innovative approach that accelerates and reduces the cost of drug development – Drug discovery (antidiabetic candidates). Recent news The activity of Metabolys started on the 1st October 2009. Metabolys has recently discovered a series of antidiabetic candidates and would like to develop one of them up to Phase IIa. Skills and know-how Funding Looking for funding: Yes Nature of funding searches: Metabolys would like to raise funds for the establishment of the preclinical and clinical proofs of concept (up to Phase IIa) for an antidiabetic candidate. Private funding obtained: equity: € 170.5 K Public funding obtained: Ministry of Universities and Research/OSEO laureate: 2007 (€ 39 K) and 2009 (€ 395 K) OSEO in July 2010: € 150 K Cellular metabolomics combines the use of any human or animal cell type in vitro with (i) the measurement of substrate utilization and product formation by both enzymatic and carbon 13 NMR techniques and (ii) mathematical modelling of cellular metabolic pathways in the absence and the presence of small amounts of test compounds. Products / Services / Technologies Pipeline product 1 Company contact CEO contact detail First name: Gabriel Last name: Baverel Position: CEO Email: [email protected] Phone: +33 (0)6 84 85 57 75 Preclinical: cellular metabolomic Phase 1: metabolomic Phase 2: metabolomic Phase 3: metabolomic Company services see above. Company technologies see above. Partnership opportunities / Licensing Company segmentation Business model Service provider - CRO, Product developer - Pharmaceuticals. Value chain: Research, Preclinical, Clinical. Activities – Study of the safety of drug candidates from any therapeutic class – Study of the efficacy of drug candidates aimed at treating metabolic diseases (diabetes), cancer and neurodegenerative diseases – Provision of primary cancer cells. Models (animal - cellular - …), Preclinical trials, Bioinformatics / Modeling, Drug discovery, Other. Partnership opportunities Application fields Out-licencing opportunity Human health, Infectious diseases, Metabolic diseases, CNS related diseases, Cancer, Nutrition / Food. 114 Collaboration framework l i f e s c i e n c e s d i r e c t o r y 2 0 1 1 Co-development of an antidiabetic candidate. One antidiabetic candidate. Company segmentation Business model Product developer - Other health, Other. Value chain Manufacturing. Activities Bioinformatics / Modeling, Other. Application fields Human health, Geriatrics, Genetic / Rare diseases, Other. Activities Company activities Design and sales of tools for joint assessment for rehabilitations purposes Design of Daily physical activity monitoring tools. Company key features Unique expertise in human motion features development IP: 250 patents/65 patent families. Recent news General company information Company name: Movea Address: 4, avenue Doyen Louis Weil Zip code: 38000 City: Grenoble Website: www.movea.com Founded in: 07/04/2007 Number of employees: 46 Turnover: 12 M dollars (in 2010) Main activity: Design of intertial measurment units for consumer electronics and particularly for sports, fitness, entertainment and wellness applications . Incubator: Yes (GRAIN) Subsidiary of a group: No Prize winner for innovative start-up: Yes (Creadev 2007) Innovative company (FCPI): Yes Other status: Yes (JEI, CIR) Funding Looking for funding: Yes Nature of funding searches: Enhance our existing tools for joint assessment for rehabilitations purposes develop Daily physical activity monitoring tools for massive adoption. Private funding obtained: € 7.3M in December 2007 and € 4M in September 2010 Public funding obtained: € 1.5M per year from CIR and funded projects Developed and manufactured our second generation intertial measurment units development for rehabilitation purposes Daily physical activity monitoring demonstrator. Skills and know-how Extensive know-how for developping human motion sensing based on low cost MEMS sensors. Products / Services / Technologies Pipeline product 1 Therapeutic area: Physical rehabilitation Therapeutic indication: joint assessment and biofeedback exercises Pipeline product 2 Therapeutic area: Daily physical activity monitoring Therapeutic indication: physical activity assessment for aging population management Company services From requirements/specification, Movea can design specific motion features for specific applications. Company technologies Chip/chipset and software solutions for: – measuring human motion – classifing human motion. Partnership opportunities / Licensing Company contact Collaboration framework Movea is looking for partners who wish to integrate motion technology and build their own product and take it to market. CEO contact detail First name: Sam Last name: Guilaumé Position: CEO Email: [email protected] Phone: +33 (0)4 38 21 19 21 Partnership opportunities Looking for system integrators that have access to a end user market and wish to integrate movea’s motion sensing technology. Out-licencing opportunity Yes this is part of Movea’s business model, toprovide licenses to system integrators and solution providers. In-licencing opportunity Yes, other Motion sensing technology companies that can add value to Movea existing IP portfolio. l i f e s c i e n c e s d i r e c t o r y 2 0 1 1 115 Company contacts General company information Company name: Nano-H SAS Address: 2, place de l’Europe - Bât. A - Parc d’activite GVIO Zip code: 38070 City: Saint Quentin Fallavier Website: www.nano-h.com Founded in: 27/12/2004 Number of employees: 6 Turnover: 0,5 M Euros (in 2009) Main activity: Nano-H develops and uses innovative technology for manufacturing new materials, nanoparticle hybrids. Innovative company, it offers service and material for high technology industries and research laboratories: phosphors, counterfeiting, plotter, medical imaging and bio-sensors, biological detection and in-vivo or in vitro. Products are high quality by their size and their chemical and physical adaptability. The materials are defined by specific nanoparticle hybrids with size and surface adaptable to graft hybrid molecules: organic (fluorpohores) or biological. The many additional properties of these nano-hybrid: optical, magnetic, radio-active, ensure a real multifunctional tool. They are also new contrast agents (medical imaging), therapeutic agents (oncology) and tracers in the fields of cell labeling and tracking and anti-counterfeit marking mass or unit. Subsidiary of a group: No Prize winner for innovative start-up: Yes (Creaction & Development, 2004) Innovative company (FCPI): Yes Other status: Yes Funding Looking for funding: No R&D PROJECTS FUNDED ACCREDITED BY LYONBIOPOLE Other contact First name: Laurence Last name: Marmuse Position: R&D Engineer Email: [email protected] Phone: +33 (0)4 74 94 53 46 Fax: +33 (0)4 74 94 53 46 Company segmentation Business model Service provider - Scientific, Product developer - Other health. Value chain Research, Manufacturing, Preclinical. Activities Cell therapy, Preclinical trials, Nanotechnology, Other. Application fields Animal health, Human health, Orphan diseases, Cancer. Activities Company activities Nano-H is an innovative company aimed at high technology industries and research laboratories, users of nanoparticles: phosphors, counterfeiting, plotter, medical imaging and bio-sensors, biological detection and in-vivo or in vitro. It offers its services to manufacturing and marketing of its products based on nanoparticles. They meet the needs of high quality by their size and their chemical and physical adaptability. THERANEAN: Therapy through Neutron-Activated Nanopar- Nano-H develops specific materials for its partners based on functional nano-objects best suited to their specific applications. Funding: FUI (AAP7 2009) Role in the project: Partner The specific products that Nano-H offers are defined by hybrid nanoparticles: size and surface functionality with adaptable by grafting hybrid molecules: organic (fluorpohores) or biological. The many additional properties of these nano-hybrid: optical, magnetic, radio-active, make a real multifunctional tool available, with significantly improved performance in many sectors of industry and nanotechnology. ticles ) NANOGADO: Rare earth oxyde nanoparticles: new agents for diagnostic and combined therapy Funding: ANR (2005 NANO) Role in the project: Leader CAPTCODE: Labelless diagnostic lab on chip, use of hybrid luminescent nanoparticles Funding: ANR (2005 NANO) Role in the project: Partner APTAPROBE: Nanohybrids grafted with aptamer targeting tumoral tissue for multimodal detection and therapy Funding: ANR (2008 Biotecs) Role in the project: Partner 116 First name: Cedric Last name: Louis Position: President Email: [email protected] Phone: +33 (0)4 74 94 53 46 l i f e s c i e n c e s d i r e c t o r y 2 0 1 1 These nano-hybrids can offer and market analysis of biological probes of high sensitivity capable of lowering the threshold of current detection. They are also new contrast agents for the imaging industry medical potential of therapeutic agents capable of penetrating the market for treatment of cancer, probes for labeling and for cell therapy, and tracers for in vivo consider targeting and active treatment for localized tumors. Several products are currently under preclinical evaluation. Finally we propose a new generation of tracers in the field of anti-counterfeit marking mass or unit. General company information Company name: NatX-ray Address: Zone Minatec BHT Bat , 7, parvis Louis Neel BP 50 Zip code: 38040 City: Grenoble Cedex 9 Website: www.natx-ray.com Founded in: 01/04/2009 Number of employees: 4 Turnover: 353000 Euros (in 2010) Main activity: development, manufacturing and sale of robotized systems for crystallography resale of consumable products for crystallography. Incubator: Yes (Grain) Subsidiary of a group: No Prize winner for innovative start-up: Yes Innovative company (FCPI): Yes Other status: Yes Funding Company segmentation Business model Laboratory equipment supplier. Value chain Research, Preclinical. Activities Instrumentation. Application fields Human health, Other. Activities Company activities Development, manufacturing and sale of automated systems for data collection in crystallography (G-Rob systems) Resale of consumable products for crystallography labs (crystallography plates, phasing kits…). Looking for funding: No Company contacts CEO contact detail First name: Nathalie Last name: Larive Position: President Email: [email protected] Phone: (0)01 858 775 0207 Other contact First name: Jean-Luc Last name: Ferrer Email: [email protected] Phone: +33 (0)6 89 45 13 57 l i f e s c i e n c e s d i r e c t o r y 2 0 1 1 117 Company segmentation Business model Product developer - Pharmaceuticals. Value chain Research, Preclinical, Clinical. Activities Drug discovery, Other. General company information Company name: NETRIS Pharma Address: Centre Léon Bérard - 28, rue Laennec Zip code: 69008 City: Lyon Website: www.netrispharma.com Founded in: 26/06/2008 Number of employees: 5 Main activity: NETRIS Pharma is a R&D company developping therapeutic molecules for targeted therapy of cancer, based on the innovative concept of dependence receptors. Incubator: Yes (CREALYS) Subsidiary of a group: No Prize winner for innovative start-up: Yes (Category Emergence in 2006 - Category Creation and Development in 2008) Innovative company (FCPI): No Other status: No Looking for funding: Yes R&D PROJECT FUNDED ACCREDITED BY LYONBIOPOLE NETRIS: A new targeted anti-tumoral therapy based on the concept of dependence receptors Funding: ANR (2008 Biotecs) Role in the project: Leader Company contacts CEO contact detail First name: Agnès Last name: Bernet Position: CEO Email: [email protected] Phone: +33 (0)4 78 78 59 71 Other contact First name: Pascale Last name: Nony Position: COO Email: [email protected] Phone: +33 (0)6 42 32 74 17 Fax: +33 (0)4 78 78 28 87 l i f e s c i e n c e s d i r e c t o r y Human health, Cancer. Activities Company activities NETRIS Pharma develops innovative medicine based on the concept of dependence receptors. The concept has been described by Patrick Mehlen, leader of the “Apoptose, Cancer and Development” laboratory (Centre Léon Bérard) and co-founder of NETRIS Pharma. In the respect of ethical rules and within a legal framework, NETRIS Pharma evaluates and optimizes, in both in vitro and in vivo models, the pharmacological profile of the drug candidates the company is developing. Pharmacokinetic and toxicological aspects are integrated from the beginning. This means that NETRIS Pharma is able to propose, under the best conditions, licensing and collaborative agreements to the pharmaceutical industry. In the future, NETRIS Pharma will be involved in co-development strategies. Funding 118 Application fields 2 0 1 1 NETRIS Pharma has one drug candidate in preclinical for which the anti tumoral activity has been validated in lung cancer animal models. Drug candidates targeting other dependence receptors are under development. Company key features: – Innovative drug candidates for cancer therapy: NETRIS Pharma is the leader on the market – The potentiality of the market (Breast cancer, lung cancer etc.) – Expertise and know how of the collaborators. Recent news Prix Universal Biotech in 2009. Skills and know-how R&D Pre-clinical studies Quality procedures Strategic Development. Partnership opportunities / Licensing Out-licencing opportunity NETRIS Pharma has an out-licencing strategy for the innovative drug candidates the company develops. The company is therefore looking for pharmaceutical industries with interest in NETRIS’ projects for the targeted therapy of cancer. General company information Company name: Nocosium Address: 15, rue Jules Romains Zip code: 69120 City: Vaulx-en-Velin Website: www.nocosium.com Founded in: 11/12/2008 Number of employees: 2 Turnover: in creation (in 2009) Main activity: Nocosium is a firm acting principally in health domains like hospital, transfusion, pharmaceutical, bioengineering, researches, industrial activities, based on the mastering of environment and biocontamination. In its field of activities, Nocosium developed the concept of an Integrated Operating Theater (“Plateau Technique Hospitalier Intégré” PTHI in French), which is proposed turnkey. This approach is innovative (copyright n°QF-2008-168016938407257-001 2008-05-30) because of its prophylactic concept. Subsidiary of a group: Yes Prize winner for innovative start-up: No Funding Nature of funding searches: 3 principal steps are planned: – Prototype realization end commercialization – Industrialization plan – Funding of innovations. Company contacts CEO contact detail First name: Gérard Last name: Santailler Position: President Email: [email protected] Phone: +33 (0)6 85 55 59 93 Other contact First name: Amalric Last name: Montalibet Position: Scientific Director Email: [email protected] Phone: +33 (0)6 67 93 05 41 Fax: +33 (0)4 78 32 87 53 l i f e s c i e n c e s d i r e c t o r y 2 0 1 1 Company segmentation Business model Other. Value chain Other. Activities Other. Application fields Animal health, Pediatrics, Human health, Geriatrics, Immunology, Inflammatory diseases, Infectious diseases, Allergology, Orphan diseases, Genetic / Rare diseases, Metabolic diseases, CNS related diseases, Cancer, Nutrition / Food, Dermocosmetics, Other. Activities Company activities Nocosium is a firm acting principally in health domains like hospital, transfusion, pharmaceutical, bioengineering, researches, industrial activities, based on the mastering of environment and biocontamination. In its field of activities, Nocosium developed the concept of an Integrated Operating Theater (“Plateau Technique Hospitalier Intégré” PTHI in french), which is proposed turnkey. Prevalence inquiries show that 6 to 10% of patients situated in an hospital a specified day have got a nosocomial infection. The most concerned medical services are by decreased order: intensive care (30% prevalence) and surgery (7 to 9% prevalence). For example in surgery services, 3% of operations are submitted to surgical site infection complications. (origin: ministère de la santé et des sports, 4 mars 2009). In 2007, the French National Institute of Sanitary Watching (INVS) counted 4188 (probably 9000) deceases entirely linked to a nosocomial infection. On the same period of time, car accidents made 4274 deceases. (origin: INVS, 12 janvier 2007, Ministère de la sécurité routière) Nosocomial infections are a major societal health problematic, generating an estimated over cost of 2,6 to 6 Billion Euros per year. The approach of construction of PTHI is innovative (copyrighted) because of its prophylactic concept. 119 General company information Company name: Noraker Address: 13, avenue Albert Einstein Zip code: 69100 City: Villeurbanne Website: www.noraker.com Founded in: 05/07/2005 Number of employees: 11 Turnover: 110 365 Euros (in 2010) Incubator: Yes (CREALYS) Subsidiary of a group: No Prize winner for innovative start-up: Yes Innovative company (FCPI): Yes Other status: Yes Company contacts CEO contact detail First name: Rachid Last name: Zenati Email: [email protected] Phone: +33 (0)4 78 93 30 92 Other contact First name: Michel Last name: Domenget Email: [email protected] 120 l i f e s c i e n c e s d i r e c t o r y 2 0 1 1 Company segmentation Business model Product developer - Other health. Value chain Research. Activities Medical device. Application fields Human health. General company information Company name: Novadiscovery Address: Bioparc Laënnec - 60, avenue Rockefeller Zip code: 69008 City: Lyon Website: www.novadiscovery.fr Founded in: 20/04/2010 Number of employees: 7 Main activity: Novadiscovery is a life sciences company specialised in translational research. We have developed a proprietary toolbox to ensure the optimal transfer of knowledge from bench to clinic geared towards applications in public health and personalised medicine. Member of the Lyonbiopole centre of excellence, the company has developed a unique expertise in numerical modelling in biology (biomathematics, computing and data management) applied to drug and biomarker R&D programs. Novadiscovery is the only platform globally to offer partners and clients an integrated environment to predict the individual and population-level impact in terms of efficacy of all results produced throughout their research. We are focused on bringing to our partners and clients best-in-class innovation capabilities to improve R&D economics through increased success rates, the ability to de-risk critical decision points and accelerate proof of concept. Subsidiary of a group: No Other status: Yes (JEI) Company contacts CEO contact detail First name: François-Henri Last name: Boissel Position: CEO Email: [email protected] Phone: +33 (0)4 63 60 05 06 l i f e s c i e n c e s d i r e c t o r y 2 0 1 1 Company segmentation Business model Service provider - Scientific, Other. Value chain Research, Other. Activities Bioinformatics / Modeling, Drug discovery, Other. Application fields Animal health, Human health. Activities Company activities Our translational research platform brings high value-creating services to our partners and clients: – Structured knowledge – a dynamic environment to organise and manage scientific knowledge, experimental and clinical data in connection with a given therapeutic area; – In silico screening of potential drug targets and identification of biomarker systems – from the very first stages of research, our technology enables the selection of targets and biomarkers on the basis of their systemic and populational effects. The reference criteria is the optimal populational benefit as measured in terms of the number of averted events or survival; – Predicting efficacy at the population level – a public health impact prediction technology over a population of interest to combine populational benefit and pharmaco-economic criteria at each decision-point of their R&D programs; – Personalising treatments – identifying and validating prognostic biomarkers of a clinical event and efficacy biomarkers for a treatment or drug candidate; – In silico experimentation – a versatile approach, comparatively faster and cheaper than existing alternatives, to explore and generate new hypotheses ahead of in vitro and in vivo experiments. 121 Company segmentation Business model Service provider - Scientific, Product developer - Other health. Value chain Research, Manufacturing. General company information Company name: NovoCIB Address: 115, avenue Lacassagne Zip code: 69003 City: Lyon Website: www.novocib.com Founded in: 17/05/2005 Number of employees: 4 Turnover: 60 ke (in 2010) Main activity: Nucleotides are universal metabolites Diagnostics / Analysis method, Drug discovery. Application fields Infectious diseases, Genetic / Rare diseases, Cancer, Other. Activities Company activities Funding Based on its expertise of the metabolism of nucleotides and its know-how in enzymology and molecular biology, NovoCIB has built a portfolio of enzymes and assays which are marketed since 2008. This range has already shown numerous opportunities for answering the needs expressed by the health industry and the agrifood market. NovoCIB valorizes its enzyme portfolio by marketing easy-to-use enzymatic kits which can be used on the field with portable luminometers, already on the marketed for several years. These apparatus are currently used for hygiene microbiological control. They use the ATP-dependent luciferase from firefly. This bioluminescence (ATP-metry) has already attracted a large number of industrials (Promega, Berthold, Kikkoman, Hygiena, Charm…). Another luciferase exists. It is bacterial, NAD(P)H-dependent, and its potential of applications is comparable to ATP-metry, but for other uses. However, the industrial production of the enzyme has always come up against technical problems regarding yield and stabilization of the heterodimeric enzyme. After 2 years of research, NovoCIB has broken down these technological barriers and is about to provide the market with a purified highly active bacterial luciferase and to develop a range of innovative bioluminescence kits for Research, Diagnosis, Food and environmental markets. Looking for funding: Yes Private funding obtained: 2009: € 270 K from Business Company key features of all earth-living organisms. Buiding blocks of DNA, RNA, they are also substrates of numerous enzymes involved in cell metabolism processes. NovoCIB has developed: – a range of unique recombinant enzymes of nucleotide metabolism – a bacterial luciferase (NAD(P)H-dependent) for the ultrasensitive detection of metabolites by bioluminescence This portfolio is the technological basis from which NovoCIB develop and market new enzymatic assays and kits to answer the needs of: – pharmaceutical market, by providing enzymatic assays for the ultrasensitive detection of the metabolites produced by therapeutic target enzymes – diagnosis in metabolic disorder – food industry, through the development of a portable system for freshness analysis of perishable foodstuffs. Incubator: Yes (Grain) Subsidiary of a group: No Prize winner for innovative start-up: Yes 2003 (Emergence), 2005 (Creation & Development) Innovative company (FCPI): No Other status: Yes (JEI, Certified ) Angels (Savoie Angels & its Investments Funds) Public funding obtained: € 450 K (2005) Company contacts CEO contact detail First name: Larissa Last name: Balakierva Position: President, CSO Email: [email protected] Phone: +33 (0)4 78 53 63 95 l i f e s c i e n c e s d i r e c t o r y A well-defined positioning centered on the study of a precise metabolism (nucleotide). NovoCIB’s expertise in this field is now recognized by its partners and customers. A unique range of enzymes and kits. A global vision of the application range that NovoCIB’s R&D results and enzyme technology can offer to other unsatisfied markets. Recent news Partnership with ChemRAR (Moscow, Russia) for the research and Development of new drugs against Hepatitis C Virus. Skills and know-how Other contact First name: Nicolas Last name: Godard Position: Partner, Development Manager Email: [email protected] Phone: +33 (0)4 78 53 63 95 Fax: +33 (0)4 78 53 63 95 122 Activities 2 0 1 1 Besides its enzyme portfolio, NovoCIB offers in vitro assays and whole-cell assays for a fast evaluation of the pharmacological potential of new nucleoside analogs (pro-drugs) whose efficacy depends upon: – their activation by nucleoside kinases – their resistance to cellular hydrolases (phosphohydrolases, pyrophosphohydrolases, deaminases) – the intracellular concentration of the natural competing nucleotide. Company segmentation Business model Service provider - CRO, Service provider - CMO, Service provider - Scientific. Value chain Research, Preclinical. Activities Biomanufacturing, Models (animal - cellular - …), Preclinical trials. Application fields Animal health, Human health, Immunology, Cancer. Activities General company information Company name: Novotec Address: 13-15, rue J. Monod Zip code: 69007 City: Lyon Website: www.novotec-labs.com Founded in: 04/11/1997 Number of employees: 5 Turnover: 0.4 M Euros (in 2010) Main activity: Development, production and distribution of a large line of polyclonal and monoclonal antibodies directed against macromolecules of the ExtraCellular Matrix: collagens, elastin, fibronectin and laminin, purified from human and various animal species. Special expertises on the immunohistochemistry of ECM components and the tissular and serological evaluation of ECM remodeling, in particular during organ fibrosis. Global array of services related to the tissular evaluation (histology, immunohistochemistry, image analysis, in situ hybridization ..) and to cell cultures (cytocompatibility, viability, RNA and protein expression…). Incubator: No Subsidiary of a group: No Prize winner for innovative start-up: No Innovative company (FCPI): No Other status: Yes (CIR) Company activities Development, production and distribution of a large line of polyclonal and monoclonal antibodies directed against macromolecules of the ExtraCellular Matrix: collagens, elastin, fibronectin and laminin, purified from human and various animal species. Special expertises on the immunohistochemistry of ECM components and the tissular and serological evaluation of ECM remodeling, in particular during organ fibrosis. Global array of services related to the tissular evaluation (histology, immunohistochemistry, image analysis, in situ hybridization…) and to cell cultures (cytocompatibility, viability, RNA and protein expression…). Company key features ECM, fibrosis evaluation, extra- and intracellular expertise (kidney, liver, lung, skin) animal models. Recent news The scientific background of Novotec is linked to the Claude Bernard University of Lyon, in the tissular evaluation of a few pathological diseases. Skills and know-how 20 years experience and know-how of its senior scientific staff in these fields. Whatever the experiment, histological and immunohistochemical analysis can be carry out to study different Moreover, Novotec has the advantage to propose experimental models to test the effect of different molecules or specific treatments . R&D PROJECT FUNDED ACCREDITED BY LYONBIOPOLE Products / Services / Technologies THYMO 2010: From thymoglobulin technical advances Company services to manufacturing process improvements and new pharmaceutical Funding: Local authorities (2007) Role in the project: Partner Novotec has developed several investigation methods at the tissular level: histological and immunohistochemical techniques In vitro cell proliferation assay Detection of gelatin in process food (food industry, interspecies gelatine contamination). Company technologies Company contacts CEO contact detail First name: Daniel Last name: Hartmann Position: Manager Email: [email protected] Phone: +33 (0)4 78 61 46 31 Other contact First name: Martine Last name: Melin Position: Scientist Email: [email protected] Phone: +33 (0)4 78 61 46 31 Fax: +33 (0)4 78 61 46 32 l i f e s c i e n c e s d i r e c t o r y 2 0 1 1 At tissular level:macroscopic, histological and immunohistochemistry observations; semi-quantitative or quantitative evaluation using histological scores, image analysis, colorimetric dosage. In biological fluids:RIA, ELISA tests. Partnership opportunities / Licensing Collaboration framework Biomnis Laboratory(Lyon), IBCP (Biochemical and chemical Proteins Intitute, Lyon), INSA (National Applied Sciences Institute, Lyon), Biomaterials laboratory (UCBL-1, Lyon), ENVL (National VeterinarySchool, Lyon). Partnership opportunities Organogenesis Inc Genzyme Polyclonals Rousselot. 123 General company information Company name: Orega Biotech Address: Espace Européen, 15, chemin du Saquin Zip code: 69130 City: Ecully Website: www.orega-biotech.com Founded in: 09/03/2010 Number of employees: 8 Main activity: Orega-Biotech is a biotech company committed to the development of innovative immunotherapeutics (monoclonal antibodies) for cancer. Backed by INSERMTransfert and Octalfa, Orega-Biotech was set up in March 2010. Gilles Alberici (PharmD, PhD), with more than 20-year experience in the pharmaceutical industry and biotech start-ups, is the President. Orega-Biotech is based on the research conducted by the other founders, Nathalie Bonnefoy-Berard (PhD) and Armand Bensussan (PhD), Research Directors at INSERM, and Jean-François Eliaou (MD, PhD), Professor of Medicine and Head of the Department of Immunology at the University Hospital of Montpellier. Initially, the company has developed antibodies for modulating regulatory T cells activity in cancer. In 2009, two new projects at different R&D stages were included in the pipeline. The business strategy is to bring several R&D programs into early clinical stages, and then to license them out to larger pharmaceutical companies. . Incubator: Yes (CREALYS) Subsidiary of a group: No Prize winner for innovative start-up: Yes Innovative company (FCPI): Yes Other status: Yes Funding Looking for funding: No Public funding obtained: Region Rhone Alpes (€ 45 k), OSEO emergence (€ 40 K), OSEO creation (€ 350 K), OSEO help to transfert (€ 270 K), ANR (€ 300 K) Company contacts CEO contact detail First name: Gilles Last name: Alberici Position: President Email: [email protected] Phone: +33 (0)4 37 49 87 70 Other contact First name: Jeremy Last name: Bastid Position: Program Director Email: [email protected] Phone: +33 (0)4 37 49 87 72 124 l i f e s c i e n c e s d i r e c t o r y 2 0 1 1 Company segmentation Business model Product developer - Pharmaceuticals. Value chain Research, Preclinical. Activities Drug discovery. Application fields Human health, Immunology, Cancer. Activities Company activities Orega-Biotech is a biotech company committed to the development of innovative immunotherapeutics (monoclonal antibodies) for cancer. Company segmentation Business model Service provider - CRO, Service provider - Scientific. Value chain Research, Manufacturing, Preclinical. Activities Diagnostics / Analysis method, Vaccine, Models (animal cellular - …), Preclinical trials, Drug delivery. Application fields General company information Company name: Phatophy Address: 17, rue Thimonnier Zip code: 69160 City: Tassin la Demi Lune Website: www.phatophy.com Founded in: 01/03/1981 Number of employees: 15 Turnover: 1 M Euros (in 2009) Main activity: Phatophy is a CRO providing 4 kinds of services: – in-vivo studies on animals to test veterinary medicinal products (with Marketing Authorization or not) and other products as shampoo, pets food, but also health products for Humans… – development and validation of analytical methods for the determination of molecules in biological matrices for application in pharmacokinetic, efficacy and residue studies, – quality controls for products (medicinal or other), with development and validation of analytical methods and stability studies, – expert valuation and writing of regulatory dossiers Incubator: No Subsidiary of a group: No Prize winner for innovative start-up: No Innovative company (FCPI): No Other status: No Funding Animal health, Human health, Cancer, Nutrition / Food, Dermocosmetics. Activities Company activities In-life phases: pre-clinical studies on animals (pharmacokinetic, pharmacodynamy, tolerance, residues…) or for preliminary steps. Development of animal models (veterinary or human medicine) ether for various studies (cancer, infection, inflammation…) or for comprehension of pathology itself. Bioanalysis: analysis (by HPLC or LC-MS/MS methods) of molecules in biological specimens (blood, plasma, urine, faeces, tissues, milk, eggs…) supplied by our customer or issued from experimental studies, according to validated methods, developed by Phatophy or not. Pharmaceutical analysis (Quality of product): analysis and physico-chemical tests to characterize active substances, degradation products, preservatives or other substance in every kind of product (veterinary or human products, cosmetics, pet food, feed additives…) under every forms (powder, tablet, solution…). Storage and stability studies (long-term, accelerated, in-use, stability to light…). Validation of manufacturing process. Possible development of analytical method. Regulatoryaffairs:expertise(dataanalysis)andwritingofregulatory reports (variations, marketing authorization, MRLs…). Looking for funding: No Company key features Company contacts CEO contact detail First name: Jacques Last name: Goutalier Position: manager Email: [email protected] Phone: +33 (0)4 78 87 17 37 Other contact First name: Sandrine Last name: Combeau Email: [email protected] Phone: +33 (0)4 78 87 17 37 Fax: +33 (0)4 78 44 21 95 l i f e s c i e n c e s d i r e c t o r y 2 0 1 1 Thanks to its various activities, Phatophy can propose global services to answer to customer projects. - Established within the Veterinary School of Lyon (VetAgro Sup Lyon),Phatophyhasaccesstovariousandcomplementaryservices: surgery, medical imaging, conventional animal housing… - Full compliance with Good Laboratory Practices. - High capacities of animal housing, thanks to various partnerships - Respect of animals included in tests by protocol submission to an independant ethic committee. Recent news - May 2010: new GLP inspection, concluding to our full compliance with GLP requirements (level A) for the major part of our activities. - July 2010: association with an experimental test site for the increase of our capacities, in the housing of large animals. - Participation to a MATWIN project on a new formulation of anticancer drugs. 125 Skills and know-how Studies on every animal species, through every routes of administration and with every kinds of sampling. 30 years of experience allow the mastery of a large number of analytical methods in every kind of biological or pharmaceutical matrices, with a high level in sample preparation. Our competence extend from health products (veterinary or human) to every form of finished products like cosmetics, biomaterials, products dedicated to hygiene… Products / Services / Technologies Company services Five study directors agreed for experimental studies in a very large panel of animal species and on various test sites with a real ability in the different methods of treatment and sampling (including non-usual routes, such as ocular, intranasal, intraauricular…). Five study directors for analytical phases, with good knowledge in analytical chemistry and preparation methods to apply to biological samples or to pharmaceutical preparations, working with qualified equipments. Company technologies HPLC equipment with validated acquisition software, qualified according to Good Laboratory Practices, with UV (diode array detector), refractometry and fluorimetry detections. Six climatic cabinets for stability studies (including photostability), under alarm 24h/24. Dissolution equipment, disaggregation equipment for tablet forms, titrators (including Karl Fisher), densimeter, UV-Vis spetrophotomer, and various other laboratory materials… Data analysis and pharmacokinetic modeling thanks to Kinetica software. 126 l i f e s c i e n c e s d i r e c t o r y 2 0 1 1 Company segmentation Business model Service provider - Non Scientific, Product developer - Other health, Laboratory equipment supplier. Value chain Manufacturing. Activities Other. Application fields General company information Company name: Powder Systems Limited Address: 5, rue de Brest Zip code: 69002 City: Lyon Website: www.powdersystems.com Founded in: 01/01/1989 Number of employees: 60 Main activity: PSL is an international manufacturer of filtration, drying and high containment solutions. We have been supporting the pharmaceutical, biopharmaceutical, sterile, chemical and laboratory industries for 22 years. Our solutions enable clients to bring new generation drugs into the market place faster, using the latest technology in containment and production equipment. PSL is an original pioneer of containment and has significant experience designing and engineering advanced containment processes for highly potent and valuable products, from small scale production to full process systems. Incubator: No Subsidiary of a group: No Prize winner for innovative start-up: No Innovative company (FCPI): No Other status: No Funding Company activities PSL is an international manufacturer of filtration, drying and high containment solutions. We have been supporting the pharmaceutical, biopharmaceutical, sterile, chemical and laboratory industries for 22 years. Our solutions enable clients to bring new generation drugs into the market place faster, using the latest technology in containment and production equipment. PSL is an original pioneer of containment and has significant experience designing and engineering advanced containment processes for highly potent and valuable products, from small scale production to full process systems. Core Products Filter Dryers, from lab scale bench top units, pilot plant through to full production scale units. Tray Dryers, Innovative tray dryer designs engineered with ergonomics, efficiency and safety in minds. Containment systems, for operations such as charging, dispensing, sampling, milling and processing potent powders. GFD, Glass Lab Filter Dryer, small scale filter dryer, scale up is simplified. Simplefilter, versatile & cost effective filtration solution. Total process solutions: from front end design studies, through to equipment assembly, testing, installation and commission, all the way to preventative maintenance and after sales service. Company contacts CEO contact detail First name: Rémy Last name: Wattiaux Position: Office & Sales Manager Email: [email protected] Phone: +33 (0)9 53 40 44 48 Other contact First name: Hayat Last name: Meguellati Position: European Sales Executive Email: [email protected] Phone: +33 (0)9 53 40 44 48 s c i e n c e s Activities New Products Looking for funding: No l i f e Animal health, Pediatrics, Human health, Geriatrics, Immunology, Inflammatory diseases, Infectious diseases, Autoimmune diseases, Allergology, Orphan diseases, Genetic / Rare diseases, Metabolic diseases, CNS related diseases, Cancer, Nutrition / Food, Dermocosmetics, Other. d i r e c t o r y 2 0 1 1 Company key features 22 years of experience providing main blue-chip companies worldwide. Global presence with Sales offices and Factory in Liverpool, UK. Sales offices in Lyon, France and USA. Logistic and Supply Chain office in Czech Republic. Business Partner in Japan, and future Sales and Engineering Offices in India. Global Clientele: Bio / Pharmaceutical companies, including all of the Top 10 pharmaceutical organizations such as GSK, AstraZeneca, Pfizer, Merck, BMS, Lilly, Roche, Sanofi Aventis, etc. Recent news To celebrate 22 years of providing innovative pharmaceutical processes and containment solutions to blue chip companies across the world, PSL launch the GFD into the laboratory market. Based on the concepts of the larger PSL Filter Dryers, the laboratory scale Glass Filter Dryers (GFDs) are a real development… that you can see! Powder Systems Ltd will be exhibiting at the next Interphex NewYork show, booth 1827 on March 29th 31st, 2011 127 Skills and know-how Our experienced engineering teams work closely with our skilled chemists to accelerate process development and create the most suitable and ergonomic solutions. PSL’s established supply chain management ensures all components, sourced from across the globe, are of the highest quality and value. This enables market savings to be passed directly onto our customers. Products / Services / Technologies Company services Engineering Services: From front end design studies, through to equipment assembly, testing, installation and commission, all the way to preventative maintenance and after sales service. PSL Serve team ensures that equipement remains in peak condition with the supply of quality approved spare parts, meeting industry regulations. PSL can provide a full Operator Exposure Level (OEL) certification program. Process systems can be tested and validated to achieve guaranteed containment to nanograms level. Finally, our service engineers maintain, validate or if needed upgrade equipment, making sure that each piece of installed system meets industry regulations and that people, products and business are protected. Company technologies PSL is a centre of excellence in the design and manufacture of Filter Dryers. With a range of sizes and specifications to meet all requirements, from chemical development to bulk production, PSL Filter Dryers provide the total reliability needed in the pharmaceutical industry. PSL offers a complete product range suitable for API and high potency oncology production with a complete heal recovery solution at 1ppm cleaning. PSL has the process expertise to provide a complete solution for production ofyour HAPI with containment protection dow to nanograms level. PSL offer containment solution for all your chemical and formulation processes: Dispensing, sampling, vessel charging, tray drying, filtration, milling, micronizing and sieving. Mulitple process steps can be integrated within a single isolator. PSL quality is assured by embracing the principles and requirements of both PAT and GAMP. 128 l i f e s c i e n c e s d i r e c t o r y 2 0 1 1 Company contacts CEO contact detail First name: Thomas Last name: Kuhn Position: CEO Email: [email protected] Phone: +33 (0)4 37 37 20 10 Other contact First name: Pascale Last name: Malgouyres Position: Business Development Director Email: [email protected] Phone: +33 (0)4 37 37 20 10 Fax: +33 (0)4 37 70 88 15 Company segmentation Business model Product developer - Pharmaceuticals General company information Company name: Poxel Address: 200, avenue Jean Jaurès Zip code: 69007 City: Lyon Website: www.poxel.com Founded in: 11/03/2009 Number of employees: 9 Main activity: Poxel is a biopharmaceutical company developing innovative first-in-class drugs with a primary focus on Type 2 diabetes. The company develops drug candidates to clinical proof of concept before partnering with pharmaceutical companies. Poxel operates independently as a lean organization with strong in-house drug development expertise. Incubator: Yes (EM Lyon) Subsidiary of a group: No Prize winner for innovative start-up: No Innovative company (FCPI): Yes Other status: Yes (JEI) Funding Looking for funding: Yes Nature of funding searches: Poxel seeks for non diluting financing. Private funding obtained: July 2010: €16M from Edmond de Rothschild Investment Partners, CDC Entreprises, and Credit Agricole Private Equity. Public funding obtained: Sept. 2009: €215,000 euros as a grant from FEDER and €250,000 as a grant from the Greater Lyon for the collaborative NATHEB project. R&D PROJECT FUNDED ACCREDITED BY LYONBIOPOLE NATHEB: New therapeutic approaches in the treatment of chronic hepatitis B Funding: FUI (AAP8 2009) Role in the project: Partner Value chain Research, Preclinical, Marketing / Distribution, Clinical Activities Clinical trials, Preclinical trials, Drug discovery, Other Application fields Human health, Metabolic diseases Activities Company activities Poxel is a biopharmaceutical company developing innovative first-in-class drugs with a primary focus on Type 2 diabetes. The company develops drug candidates to clinical proof of concept before partnering with pharmaceutical companies. Poxel operates independently as a lean organization with strong in-house drug development expertise. Its pipeline consists in innovative projects with new mechanisms of action, with an activity on glucose metabolism, other cardiovascular risk factors and with an improved safety profile compared to currently available therapies. Company key features Imeglimin, 1st-in-class oral antidiabetic agent, having already achieved its clinical proof of concept. Excellent benefit/risk ratio. 5 other innovative programs in early stage development. Strong IP position. Seasoned team of executives coming from the Pharma Industry. Network of international key opinion leaders, experts and suppliers. Products / Services / Technologies Pipeline product 1 Therapeutic area: Metabolism Therapeutic indication: Type 2 diabetes Phase 1: Imeglimin Phase 2: Imeglimin Partnership opportunities / Licensing Partnership opportunities Poxel will look at any partnership opportunity, depending on the program concerned. Out-licencing opportunity Poxel will look at any opportunity, depending on the program concerned. l i f e s c i e n c e s d i r e c t o r y 2 0 1 1 129 Company segmentation Business model Product developer - Biopharmaceuticals, Product developer Other health. Value chain Research, Clinical. Activities Diagnostics / Analysis method, Bioinformatics / Modeling, Medical device. Application fields Human health, Cancer. General company information Company name: Prediction BioSciences SAS Address: 60, avenue Rockfeller Zip code: 69008 City: Lyon Website: www.predict.net Founded in: 11/01/2010 Main activity: Our company mainly focuses its R&D activities on molecular markers to develop biomarker-based diagnostic to predict more accurately risk of specific disease recurrence or treatment with indications in stroke and oncology. We use a cross-disciplinary approach between medical biology and advanced informatics to accurately classify individual patients into risk of recurrence categories. The tests under development will lead to more personalized medicine and provide patients with early, accurate, and individualized prognostic information to guide their treatment choices. The company has a currently marketed test for prediction of chemotherapy benefit in breast cancer on the market in the U.S., with EU introduction planned for 2012. Incubator: No Subsidiary of a group: No Prize winner for innovative start-up: No Innovative company (FCPI): Yes Other status: No Company contacts CEO contact detail First name: Cornelius Last name: Diamond Position: CEO Email: [email protected] Phone: +33 (0)6 43 52 10 24 Activities Company activities Some of the prognosis and diagnosis we are developing are presented below: (I) InsightDXTM Breast Cancer profile. We have develop a marker-based test using a nonlinear algorithm that combines protein with standard clinicopathologic features to predict more accurately risk of metastases in hormone receptor-positive breast cancer patients. This test establishes risk scores and risk categories obtained by incorporating immunoscores for 9 molecular markers (eight of them collected by IHC and one detected by FISH) plus three clinicopathologic factors into a non-linear algorithm developed by our company. It accurately estimates distant recurrence and disease-related death and outperforms current clinical guidelines (such as NPI, Adj!Online, 2007 St Gallen) providing valuable guidance in adjuvant treatment choices, such as cytotoxic chemotherapy. This test has been introduced on US market in 2009 and EU introduction is scheduled at the end 2011. (II) Gene RxTM Colorectal Cancer progression. Current clinical guidelines recommend cytotoxic chemotherapy for approximately 95% of stage II colorectal cancer patients, even though less than 5% of them would likely derive any direct benefit. Cytotoxic chemotherapy can lead to serious adverse events, as well as both short-term and long-term quality of life issues. We have conducted a study designed to produce a model to predict outcome in chemotherapy-treated colorectal cancer patients. Using the same methodology as for InsightDXTM Breast Cancer profile, we already have identified five protein markers with accurate prediction value to discriminate “good” and “bad” prognosis colorectal cancer. This profile is still under evaluation and validation. (III) RapidResponseTM c-Fn Diagnosis. Currently, there is no way to predict the evolution of ischemic stroke to hemorrhage following thrombolytic therapy. A bloodbased marker has been shown to be predictive of severe hemorrhagic transformation (HT) in thrombolytic-treated ischemic stroke patients. However, all proteomic quantification measurements in prior studies were done with enzyme-linked immunoabsorbant assays (ELISA), which is a slow analytical method. To bring a biomarker-based diagnostic for an emergency setting (POC test), it is necessary to develop a faster test to determine biomarker levels for patients being considered for thrombolytic treatment. This rapid test is currently under development by Prediction Biosciences. The end result of this R&D program is to product a diagnostic which will predict patients likely to have a severe hemorrhage if given a thrombolytic and prevent severe and often deadly side effect occuring in 6%-11% of patients treated with tPa. Other contact First name: Caroline Last name: Bourgin-Hierle Position: Research manager Email: [email protected] Phone: +33 (0)6 16 50 75 52 Fax: +33 (0)4 26 78 08 38 (iv) Others biomarker-based diagnostic are currently under development (training and validation phases in retrospective studies) with indications in neurovascular disease and oncology. 130 l i f e s c i e n c e s d i r e c t o r y 2 0 1 1 Products / Services / Technologies Pipeline product 1 Therapeutic area: oncologie Therapeutic indication: breast cancer MA: 2011/2012 Pipeline product 2 Therapeutic area: oncologie Therapeutic indication: Colorectal cancer Pipeline product 3 Therapeutic area: cardiovascular Therapeutic indication: ischemic stroke Preclinical: 2011 Company technologies Biomarkers-based prognosis and diagnostic to be used as medical device in stoke (RapidResponseTM c-Fn Test) and oncology (GeneRxTM Breast Cancer Profile) Pipeline GeneRxTM Colorectal Cancer Profile; GeneRxTM Lithium/Bipolar Test; GeneRxTM for Hypertension Treatment. l i f e s c i e n c e s d i r e c t o r y 2 0 1 1 131 Company segmentation Business model Service provider - CRO. Value chain General company information Company name: Presbeasy Address: 24, rue Jean Baldassini Zip code: 69007 City: Lyon Founded in: 01/03/2011 Main activity: The target of Presbeasy is the development of diffractive multifocal intracorneal lenses for the chirurgical correction of presbyopia, by a unique combination of optical conception and materials and processes. Diffractive lenses are known to have a better efficiency compared to refractive lenses which are too sensitive to the environment. The reversibility of the technique will remove a psychological barrier for the patient, as opposed to laser techniques which are not reversible. The intracorneal surgery is not invasive for the eye, which garantees innocuity, as opposed to endocular surgery (like cataract surgery). Incubator: Yes (CREALYS) Subsidiary of a group: No Prize winner for innovative start-up: Yes Funding Looking for funding: Yes Nature of funding searches: The financing needs must support the operations till the validation of the technology following clinical trials, i.e. 2 to 3 years. Research, Preclinical, Clinical. Activities Other. Application fields Human health. Activities Company activities The Presbeasy lens is a multifocal diffractive intracorneal lens, which combines the efficiency of the multifocal diffractiion which is necessary for the correction of presbyopia, to the innocuity of the corneal surgery and its full reversibility. This innovative solution brings a good response to the growing population of people suffering from presbyopia and who do not want to wear spectacles when they reach 40. Company key features The project has been initiated by an ophtalmologist practising surgery, who knows the need of such solution for the correction of presbyopia in his daily practise. This guarantees the value of the approach. He has protected the key concepts. The technology will allow a combined correction with other visual defects (myopia, hypermetropy, astigmatism). The project is supported by a complementary team : a specialist of ophtalmic surgery and a manager familiar with industrialisation of innovative products. Recent news Company contacts CEO contact detail First name: Gilbert Last name: Cohen Position: President Email: [email protected] Phone: +33 (0)6 17 45 28 99 Other contact First name: Jean-Christophe Last name: Robert Position: CEO Email: [email protected] Phone: +33 (0)6 15 65 23 15 The basic features have been validated, the first samples of the product are now being produced, in order to have final confirmation of the proof of concept. A first business study has helped to position the future company. Another study in partnership with the Wesford Business School (Grenoble) will be based on interviews of specialists in the field, in order to havecnfirmation of the value proposition by key decision makers. Skills and know-how The project has made significant progress through a triple partnership: -on materials design and optimization with the LCPP chemistry lab CNRS/CPE -on the optimisation of optical properties with the Currien lab in Saint-Etienne on biocompatibility constraints with the biomaterials research lab CNRS/Lyon I University The first samples of the lens are produced with a leader in moulding of optical components. Partnership opportunities / Licensing Collaboration framework We are looking for financial partners, first round will target € 1.5 to 2.5 M. 132 l i f e s c i e n c e s d i r e c t o r y 2 0 1 1 Company segmentation Business model Service provider - CRO, Service provider - Scientific. Value chain Research, Preclinical, Clinical. Activities Diagnostics / Analysis method. Application fields Animal health, Pediatrics, Human health, Geriatrics, Immunology, Inflammatory diseases, Infectious diseases, Autoimmune diseases, Allergology, Orphan diseases, Genetic / Rare diseases, Metabolic diseases, CNS related diseases, Cancer, Nutrition / Food, Dermocosmetics, Other. General company information Company name: Promise Advanced Proteomics Address: 7, parvis Louis Néel, BP50, Minatec BHT/52B Zip code: 38040 City: Grenoble Website: www.promise-proteomics.com Founded in: 01/08/2010 Main activity: Promise Advanced Proteomics is a subsidiary of PX’Therapeutics group which holds an exclusive license of a patented technology called PSAQ (Protein standard for Absolute Quantification). This technology allows the absolute quantification of proteins in complex biological samples using mass spectrometry. Quantification results obtained using this technology are more accurate, sensitive and specific than the ones obtained using classical immunologic approaches or other MS-based techniques. Therefore, PSAQ technology is the brand new method for the quantification of proteins such as biomarkers or therapeutic proteins. Incubator: No Subsidiary of a group: Yes (PX’Therapeutics) Prize winner for innovative start-up: No Innovative company (FCPI): No Other status: Yes R&D PROJECT FUNDED ACCREDITED BY LYONBIOPOLE OPTIMABS: Optimization of monoclonal antibodies drugability by emergent analytical and structural methods: from lead to clinical candidate. Funding: FUI (AAP10 2010) Role in the project: Partner Activities Company activities Promise Advanced Proteomics’ technology can be of interest for: – diagnostic companies, as PSAQ technology permits the quantification of several biomarkers in one single analysis, with very high levels of sensitivity and specificity (pg/mL of serum scale). PSAQ technology is compatible with any biological matrices (serum, urine, plasma…), – biopharmaceutical or biotechnology companies, for the quantification of their protein candidate during pharmacokinetics or bioavailability studies for example, – any other applications for which there is a need for very accurate or sensitive results which are not possible with classical immunological techniques: doping control or food quality control for example. Promise Advanced Proteomics proposes to its clients the production of protein standards and/or the development of the MS-based assay and the transfer of the method to the client or to a third party (CRO). Company key features Promise Advanced Proteomics holds an exclusive license of PSAQ technology and has acquired a great expertise in the development of labeled protein standards, thanks also to its mother company PX’Therapeutics. Promise’s team has a very good understanding of mass spectrometry techniques and is able to propose clever strategies to address the accurate quantification of proteins in complex matrices. Recent news Promise Advanced Proteomics is involved in a granted project (FUI) certified by Lyon BioPole and lead by the CIPF (Centre d’Immunologie Pierre fabre), called OPTIMABS. This collaborative project aims at improving the development of therapeutic monoclonal antibodies. Skills and know-how Company contacts CEO contact detail First name: Nicolas Last name: Mouz Position: President Email: [email protected] Phone: +33 (0)4 38 02 36 50 Other contact First name: Claire Last name: Untereiner Position: Director, Business Development Email: [email protected] Phone: +33 (0)4 38 02 36 50 Fax: +33 (0)4 76 96 10 38 l i f e s c i e n c e s d i r e c t o r y 2 0 1 1 - Mass spectrometry - Biological sample preparation (enrichment, depletion…) - Development of stable isotope-labeled full-length protein standards. Products / Services / Technologies Company services Production of PSAQ (Protein Standard for Absolute Quantification) Development of MS-based method. Company technologies PSAQ: Protein Standard for Absolute Quantification, based on the development of protein standard and using mass spectrometry. 133 SASTIM: Sorting of Antigen Specific T cells for Immunotherapy of Melanoma Funding: ANR (2009 Biotecs) Role in the project: Leader General company information Company name: PX’Therapeutics Address: 7, parvis Louis Néel BP50 , Minatec BHT/52B Zip code: 38040 City: Grenoble Website: www.px-therapeutics.com Founded in: 01/11/2000 Number of employees: 62 Turnover: 4 M Euros (in 2010) Main activity: PX’Therapeutics provides integrated HU’S-MAP: Human and species monoclonal antibody production Funding: Local authorities (2007) Role in the project: Leader Company contacts CEO contact detail First name: Tristan Last name: Rousselle Position: CEO Email: [email protected] Phone: +33 (0)4 38 02 36 50 biotherapeutics and recombinant vaccines development and manufacturing services. Organized around 4 integrated platforms (recombinant protein R&D, monoclonal antibody development, cGMP manufacturing, analytics), PX’Therapeutics offers custom programs which may include depending on clients specifications, murine antibody generation, humanization strategies, protein engineering, process development and/or small scale cGMP manufacturing services. In 2010 a new subsidiary named Promise Advanced Proteomics was created to offer mass spec based absolute quantification of proteins. Subsidiary of a group: No Prize winner for innovative start-up: No (Tremplin Fondation Aventis) Innovative company (FCPI): No Other status: Yes Funding Other contact First name: Claire Last name: Untereiner Position: DIrector, Business Development Email: [email protected] Phone: +33 (0)4 38 02 36 50 Company segmentation Looking for funding: Yes Business model Service provider - CRO, Service provider - CMO. R&D PROJECTS FUNDED ACCREDITED BY LYONBIOPOLE PRAVIC: Innovative recombinant proteins with immune Research, Manufacturing, Preclinical, Clinical. modulatory and anti-tumour activities Funding: FUI (2005) Role in the project: Partner Activities FIV-VAX: Development of a vaccine against feline immunodeficiency virus (FIV) Funding: FUI (AAP2 2006) Role in the project: Partner Application fields TBDERMATEST: Development of a novel skin test using the HBHA antigen for the diagnosis of latent M. tuberculosis infection Funding: FUI (AAP6 2008) Role in the project: Leader ASPAREC: Development of a new RECombinant L-ASPAraginase with long acting properties Funding: FUI (AAP7 2009) Role in the project: Partner TTMCMV: Development of GMP compliant MHC/tetramers and cell sorting procedures for adoptive immunotherapy against CMV infections Funding: ANR (2007 RIB) Role in the project: Leader 134 Value chain l i f e s c i e n c e s d i r e c t o r y 2 0 1 1 Diagnostics / Analysis method, Vaccine, Biomanufacturing, Other. Animal health, Pediatrics, Human health, Immunology, Inflammatory diseases, Infectious diseases, Autoimmune diseases, Allergology, Orphan diseases, Genetic / Rare diseases, Metabolic diseases, CNS related diseases, Cancer, Dermocosmetics, Other. Activities Company activities 1/DevelopmentandProductionofRecombinantProteins(research grade) - Gene synthesis and molecular biology (including mutagenesis) Protein engineering - Optimization of the protein sequence in order to solve specific solubility or refolding issues for instance - Definition of relevant combinations of vectors, signal peptides, strains/hostcellstoachieveimprovedexpressionorsecretionyield - Production protocol transfer from the client and protein batch production - Development and optimization of expression and purification protocols - Development of refolding protocols for insoluble proteins - Cell culture in transient conditions - Development of stable cell lines - Development of fermentation process (batch, fed-batch) and scale up of purification scheme in view of large scale industrial or GMP manufacturing - Production of protein batches (from mg to gram scale, research to crystallography grade) - Quality controls Expression Systems – bacterial (E. coli). Specific know-how for insoluble protein. – yeast (S. cerevisiae, Pichia pastoris) – baculovirus / insect cells – mammalian cell lines (CHO, HEK, COS, etc.) 2/ Development and Production of Monoclonal Antibodies We differentiate from other service companies by our vocation to propose: – original and relevant approaches to address antibody development related issues such as immunization of animals with difficult-to-express antigens or generation of antibodies directed against rare and weakly antigenic epitopes – strategies for the development humanized antibodies based on a « fee for service » model. Those strategies are essentially based on know-how and not on proprietary technologies in order to lower the level of intellectual property associated to the product and increase its value for the client. A. Development of Murine Monoclonal Antibodies - Mice immunization protocols adapted to the material available from DNA if the protein material is not accessible - from peptide and protein - from transfected cells - Substractive immunization strategy for the development of antibodies directed against rare or weakly antigenic epitopes - Fusion with myeloma cells, generation and screening of hybridomas - Development of screening methods: Western-Blot, ELISA, Immunofluoresence, FACS - Cloning and characterization of producing hydridomas - Production and purification of antibody batch (optional) - Other services upon request Company key features Our Added Value Our specific organization and the mix of R&D and manufacturing competences of our team ensure added value to customers. Our strengths rely on: – a strong scientific expertise associated to the regulatory understanding of biotherapeutic products development – the capability to accompany our clients from early stage research and engineering up to clinical batches manufacturing – the optimization of timelines for the development of therapeutic candidates due to the synergy between the research and cGMP manufacturing platforms. Recent news Opening of a new cGMP biomanufacturing facility dedicated to mammalian cells in Q3 2010. Products / Services / Technologies Company technologies PSAQ (through PX’Therapeutics subsidiary Promise Advanced Proteomics) PSAQ (Protein Standard for Absolute Quantification) is a patented technology for absolute quantification of proteins in biological samples. The technology is based on the development of protein standard which are full-length stable isotope labelled protein and mass spectrometry analysis. It allows unequalled results in terms of specificity, sensitiviy, accuracy and precision of the protein dosage. B. Development of Humanized Antibodies Molecular engineering strategy: RT-PCR cloning of variable part of the antibody, gene optimization and sub-cloning into expression vectors adapted to the production in CHO cell lines, chimerization of constant human Ig parts, humanization based upon structural biology data in order to prevent immunogenicity. 3/ Bioproduction - Cell banking (Master Cell Bank / Working Cell Bank) - Development and validation of analytical methods - Scale up of production process - Preclinical & Clinical batch manufacturing (Phase I/II, niche market) and batch release - Fill & Finish (through qualified partners) - Regulatory support all along the project. l i f e s c i e n c e s d i r e c t o r y 2 0 1 1 135 General company information Company name: RCTs Address: 38, rue du Plat Zip code: 69002 City: Lyon Founded in: 17/07/1989 Number of employees: 30 Turnover: 2,9 Me (in 2009) Main activity: Clinical trials, pharmacoepidemiologic studies. Subsidiary of a group: No Prize winner for innovative start-up: No Innovative company (FCPI): No Other status: No Funding Company segmentation Business model Service provider - CRO. Value chain Clinical. Activities Clinical trials, Other. Application fields Pediatrics, Human health, Geriatrics, Immunology, Infectious diseases, Autoimmune diseases, Allergology, Orphan diseases, Genetic / Rare diseases, Metabolic diseases, CNS related diseases, Cancer, Nutrition / Food, Dermocosmetics. Activities Looking for funding: No Company activities See our website www.rcts.fr. Company contacts CEO contact detail First name: Yves Last name: Alamercery Position: CEO Email: [email protected] Phone: +33 (0)4 37 45 17 48 136 l i f e s c i e n c e s d i r e c t o r y 2 0 1 1 General company information Company name: ReproXX SAS Address: 80, rue de la Garenne Zip code: 69005 City: Lyon Website: www.reproxx.com Founded in: 10/02/2010 Number of employees: 3 Main activity: Based on research from INSERM - (French research Institute for Human Health), Reproxx’s mission is to develop and market tools to facilitate the management of reproduction in animals. Reproxx, is preparing the launch of its product in the first half of 2011, this product will be the first rapid test for early pregnancy diagnosis in the cow. This innovative tool will allow an unprecedented optimization of the management in bovine reproduction. Incubator: Yes (CREALYS) Subsidiary of a group: No Prize winner for innovative start-up: Yes (tremplin entreprises 2010) Innovative company (FCPI): No Other status: Yes (JEI et CIR) Company segmentation Business mode Product developer - Biopharmaceuticals, Product developer Other health. Value chain Manufacturing, Marketing / Distribution. Activities Diagnostics / Analysis method, Biomanufacturing, Other. Application fields Animal health, Human health, Nutrition / Food, Other. Activities Company activities Reproxx, is preparing the launch of its product in the first half of 2011, this product will be the first rapid test for early pregnancy diagnosis in the cow. This innovative tool will allow an unprecedented optimization of the management in bovine reproduction. Company key features Looking for funding: No A team of experienced researchers and veterinarians has worked many years to develop the first rapid test diagnostic of pregnancy in the cow. The unique combination of expertise in immunology, and specialists in the rapid testing turns Reproxx in one of the most advanced company in this field. Company contacts Recent news Funding CEO contact detail First name: Pascal Last name: Vallejo Position: CEO Email: [email protected] Phone: +33 (0)06 28 04 48 72 Reproxx is now labelised by NOVACITE The Lyon Chamber of Commerce innovation incubator. Other contact First name: Jean-Christophe Last name: Vullierme Email: [email protected] Phone: +33 (0)6 07 80 71 69 l i f e s c i e n c e s d i r e c t o r y 2 0 1 1 137 General company information Company name: Roche Diagnostics Address: 2, avenue du vercors Zip code: 38240 City: Meylan Website: www.rochediagnostics.fr Founded in: 15/06/1977 Number of employees: 540 Turnover: 342 000 000e (in 2009) Main activity: Diagnostic in vitro (marketing sales, training, services and logistic for analytical systems for labs) Diabete (blood glucose mnitoring and pump therapy). Subsidiary of a group: Yes (ROCHE) Prize winner for innovative start-up: No Innovative company (FCPI): Yes Other status: No Looking for funding: Yes CEO contact detail First name: Bertrand Last name: Le bert Position: General Manager Email: [email protected] Phone: +33 (0)4 76 76 30 02 Other contact First name: Frank Last name: Leenhardt Position: Business development manager Email: [email protected] Phone: +33 (0)4 76 76 46 85 Fax: +33 (0)4 76 76 46 11 s c i e n c e s d i r e c t o r y Service provider - Non Scientific, Product developer - Other health, Laboratory equipment supplier. Value chain Marketing / Distribution. Activities Diagnostics / Analysis method, Instrumentation, Other. Application fields Human health, Immunology, Inflammatory diseases, Infectious diseases, Allergology, Orphan diseases, Genetic / Rare diseases, Metabolic diseases, CNS related diseases, Cancer. Activities and logistic for analytical systems for labs) Diabete (blood glucose mnitoring and pump therapy). Company contacts l i f e Business model Company activities Diagnostic in vitro (marketing, sales, training, services Funding 138 Company segmentation 2 0 1 1 Company contacts CEO contact detail First name: Eric Last name: Meunier Position: Sanofi Pasteur France General Manager Email: [email protected] Phone: +33 (0)4 37 37 01 00 Other contact First name: Marie-José Last name: Quentin-Millet Position: Product Conception & Development Vice-President Email: [email protected] Phone: +33 (0)4 37 37 01 00 General company information Company name: Sanofi Pasteur Address: 2, avenue Pont Pasteur Zip code: 69007 City: Lyon Website: www.sanofipasteur.com Founded in: 08/02/1989 Number of employees: 12547 Turnover: 3 483 M e (in 2009) Main activity: Sanofi Pasteur, the vaccines division of sanofi-aventis Group, is the largest company in the world entirely dedicated to human vaccines. Our vision is a world in which no one suffers or dies from a vaccine-preventable disease. Our mission is to protect and improve human health worldwide by providing superior, innovative vaccines for the prevention and treatment of disease, playing an active role in the immunization community. Incubator: No Subsidiary of a group: Yes (Sanofi-Aventis) Prize winner for innovative start-up: No Innovative company (FCPI): No Other status: Yes (CIR) Product developer - Pharmaceuticals. Value chain Research, Manufacturing, Preclinical, Marketing / Distribution, Clinical, Other. Activities Vaccine, Other. Application fields Human health. Company activities Looking for funding: Yes R&D PROJECTS FUNDED ACCREDITED BY LYONBIOPOLE GAP: Healthcare shield solutions against avian flu and flu pandemics Funding: FUI (2005) Role in the project: Partner MICROVAX: Skin immunology and vaccination Funding: FUI (AAP1 2006) Role in the project: Partner EXPANDID: Extending the scope of application of intradermal vaccination Funding: FUI (AAP8 2009) Role in the project: Partner PATVAX: Process analytical technology for vaccines Funding: FUI (AAP8 2009) Role in the project: Leader EMER-FAB: Establishment and regulatory validation of a model to develop and produce passive immunotherapy solutions against the hemontagic fevers Funding: FUI (AAP10 2010) Role in the project: Partner s c i e n c e s Business model Activities Funding l i f e Company segmentation d i r e c t o r y 2 0 1 1 Sanofi Pasteur is the vaccines division of sanofi-aventis Group, a leading global pharmaceutical company that discovers, develops and distributes therapeutic solutions to improve the lives of everyone. Sanofi Pasteur is the largest company entirely dedicated to vaccines. The company distributes more than 1.6 billion doses of vaccine per year, making it possible to immunize more than 500 million people across the globe. A world leader in the vaccine industry, sanofi pasteur offers the broadest range of vaccines, protecting against 20 infectious diseases. Sanofi Pasteur: a global company • Headquarters: Lyon, France • Revenue: 3,483 million euros in 2009, a 19.2% increase from 2008 (on a comparable basis) • Market share: approximately a quarter of the world’s vaccine market • R&D and industrial sites worldwide: – 11 production and/or R&D sites located in Marcy l’Etoile and Val de Reuil, France; in Swiftwater (Pennsylvania), Cambridge and Canton (Massachusetts), and Rockville (Maryland), USA; in Toronto, Canada; in Pilar, Argentina; in Shenzhen, China; in Hyderabad, India and in Chachoengsao, Thailand. – 3 new facilities under construction in Ocoyoacac, Mexico ; Neuville, France ; and Shenzhen, China. Company key features Our Assets: • The broadest vaccine portfolio in the industry • A global presence • A leadership position in influenza, pediatrics, meningitis and boosters 139 • R&D: more than €1 million invested per day and a promising pipeline with 18 vaccines in development • Significant on-going investments to expand production capacity • At the forefront of the immunization community (Who, UNICEF, PAHO, CDC, GAVI Alliance, AAP, etc.) Recent news • Final stage of clinical development for sanofi pasteur’s dengue vaccine, the world’s most clinically advanced dengue vaccine candidate - Nov 2010 • Acquisition of Vaxdesign, a U.S. biotechnology company Sept 2010 • Partnership with Vivalis for the discovery of human monoclonal antibodies against infectious diseases - June 2010 • Partnership with Kalobios on novel biologic for the prevention and treatment of pseudomonas aeruginosa infections - Jan 2010. Skills and know-how • More than a century of innovation since the foundation of the Institut Mérieux in Lyon in 1897 • Promising research pipe-line including: -New vaccines against endemic diseases (dengue, hospital-acquired infections, etc.) -Next-generation vaccines -New combination vaccines • A strong commitment to R&D partnerships with major universities,researchinstitutes,governmentbodies,biotechnology companies and contract research organizations Partnership opportunities / Licensing Collaboration framework When partnering with Sanofi Pasteur, you will interact with a multidisciplinary team that has years of experience in working to ensure that partnerships are executed successfully and nurtured for the mutual benefit of all parties. This approach utilizes the value-addedsanofipasteuralliancemanagementcapability,which focuses on the relationship by facilitating open communication, trust, understanding, and clear expectations across the project lifecycle. Combined with the technical competencies of the alliance,thisbalanceprovidesawell-roundedenvironmentforyour technology to flourish. Partnership opportunities SanofiPasteurisinterestedinpotentialpartneringopportunitiesin the field of active and passive human immunization, including: • New antigens, vaccines, and supporting technologies, such as: – Antigen discovery and characterization for infectious diseases – Carrier proteins and protein-polysaccharide conjugation methods or alternative technologies – Monoclonal antibodies for infectious diseases • Agents to enhance vaccine immune responses such as adjuvants and immunomodulators • New routes of vaccine administration and vaccine delivery systems • Tools for improving vaccine research, development and production In-licencing opportunity In the field of immunology, microbiology, vaccine. 140 l i f e s c i e n c e s d i r e c t o r y 2 0 1 1 General company information Company name: Shimadzu France Address: Bureau de Lyon - 213, rue de Gerland - Bât.F1 Zip code: 69007 City: Lyon Website: www.shimadzu.fr Founded in: 02/01/2002 Number of employees: 55 Turnover: 13 M e (in 2009) Main activity: Shimadzu is a world-leading developer Company segmentation Business model Service provider - Scientific, Laboratory equipment supplier. Value chain Research, Manufacturing. Activities Diagnostics / Analysis method, Instrumentation, Drug discovery, Nanotechnology. and manufacturer in innovative products for laboratories in industry, science and governmental institutions since 1875.The main activity of Shimadzu consists of analytical instrumentation, biotechnologies and medical technology. Shimadzu is a world wide company with R&D and production centers located in japan, USA, Europe, China and Australia. Listed on the Tokyo Stock Exchange, Shimadzu is strong of 10,000 employes. The french Headquarter is based near Paris. Shimadzu France has also an agency in Lyon which is the first regional office of the group. Its goal is to be within close reach of our customers, offering demonstrative room and customer training. Subsidiary of a group: Yes (Shimadzu Corporation) Prize winner for innovative start-up: No Innovative company (FCPI): No Other status: No Application fields Funding Shimadzu has a broad bandwidth of solutions for physicschemistry analysis. A long history since 1875. Success is based on R&D and instrumental development which lead M. Tanaka to be awarded with Nobel Prize in Chemistry in 2002 (SHIMADZU Japan). Looking for funding: No Company contacts d i r e c t o r y Company activities Shimadzu offers a broad bandwidth of product for analytical instrumentation. Our product lines include analytical systems for chromatography (HPLC, LCMS, GC, GCMS), spectroscopy (UV/VIS, FTIR, AAS) and environmental analysis (TOC) but also Universal Testing machines, hardness testers, particule size analyzers. SHIMADZU is one of the world’s leading manufacturers of advanced imaging systems and equipment for use in medical diagnosis and treatment based on X-Rays technology. Company key features New World fastest Tandem Quadrupole LC/MS/MS System Nexera: Next Era of U-HPLC Industrial partnership with Biomerieux for bacteria identification based on MALDI technology system. Skills and know-how SHIMADZU: the analytical instrumental solution combined with expertise close to customer. Other contact First name: Eric Last name: Sauvage Email: [email protected] Phone: +33 (0)4 72 24 63 82 s c i e n c e s Activities Recent news CEO contact detail First name: Ronan Last name: Penlae Position: Marketing manager Email: [email protected] Phone: +33 (0)1 60 95 10 10 l i f e Animal health, Human health, Nutrition / Food. 2 0 1 1 141 General company information Company name: Singulex R&D Europe Address: 321, avenue Jean Jaurés, Immeuble Domilyon Zip code: 69007 City: Lyon Website: www.Singulex.com Founded in: 07/04/2010 Main activity: Singulex is a biotechnology company that develops and markets a digital technology Erenna® of direct molecular detection and assay kits and reagents. We also offer services of custom test development and samples analysis. Incubator: No Subsidiary of a group: No Prize winner for innovative start-up: No Innovative company (FCPI): No Other status: No Funding Looking for funding: Yes R&D PROJECT FUNDED ACCREDITED BY LYONBIOPOLE FEMTOKINE: Ultrasensitive immunoassay for the prediction of relapse of Crohn’s disease and monitor treatment. Clinical validation. Funding: FUI (AAP10 2010) Role in the project: Partner Company contacts CEO contact detail First name: Eric Last name: Cevoz-Goyat Position: General Manager, European Lifesciences Operations Email: [email protected] Phone: + 33 (0)4 72 70 25 78 Other contact First name: Nathalie Last name: Rousselot Position: Research Project Manager; European Application & Technical Services Email: [email protected] Phone: +33 (0)6 68 65 02 22 Fax: + 33 (0)4 72 70 25 78 142 l i f e s c i e n c e s d i r e c t o r y 2 0 1 1 Company segmentation Business model Laboratory equipment supplier. Value chain Other. Activities Diagnostics / Analysis method. Application fields Immunology, Inflammatory diseases, Infectious diseases, Autoimmune diseases, Cancer. Activities Company activities Singulex develops and markets digital technology of direct molecular detection. It also develops biomarkers diagnostic systems to detect and quantify protein markers in normal subjects and patients. It allows researchers and clinicians to understand and manage certain diseases. Singulex offers various services for the development of immunoassays, custom assays and access to commercial assay kits, samples analysis service in a GLP laboratory, technical support for assays and the technology. Singulex Europe is developing collaborations with academic institutions, LyonBiopole and pharmaceutiques partners. Singulex Europe develops new R & D projects and researchs and appropriate funding. Singulex also provided sales and technical services to customers. General company information Company name: smartINST Address: 46, allée d’Italie Zip code: 69009 City: Lyon Website: www.smartinst.fr Founded in: 01/10/2009 Number of employees: 3 Incubator: Yes (CREALYS) Subsidiary of a group: No Prize winner for innovative start-up: No Innovative company (FCPI): No Other status: Yes Company segmentation Business model Service provider - CMO, Service provider - Scientific, Laboratory equipment supplier. Value chain Manufacturing. Activities Instrumentation. Application fields Other. R&D PROJECT FUNDED ACCREDITED BY LYONBIOPOLE PATVAX: Process Analytical Technology for Vaccines Funding: FUI (AAP8 2009) Role in the project: Partner Company contacts CEO contact detail First name: Christophe Last name: Graffin Email: [email protected] Phone: +33 (0)4 72 72 89 00 Other contact First name: Yoann Last name: Gasteuil Email: [email protected] Phone: +33 (0)6 64 19 06 03 Fax: +33 (0)4 72 72 88 81 l i f e s c i e n c e s d i r e c t o r y 2 0 1 1 143 General company information Company segmentation Business model Company name: Sofradim Production Address: 116, avenue du Formans Zip code: 01600 City: Trevoux Founded in: 27/10/1992 Number of employees: 199 Main activity: Manufacture of implantable surgical devices Incubator: No Subsidiary of a group: Yes (Covidien (USA)) Prize winner for innovative start-up: No Innovative company (FCPI): No Other status: No Product developer - Other health. Funding Company activities Value chain Research, Manufacturing. Activities Other. Application fields Human health. Activities Medical devices manufacturer. Looking for funding: No Company key features Soft tissue repair. R&D PROJECT FUNDED ACCREDITED BY LYONBIOPOLE TREBARO: Conception of a bioresorbable, anti-infectious and MRI visible mesh for soft tissue reinforcement in surgical treatment of genital prolapsus Funding: ANR (2008 Tecsan) Role in the project: Leader Company contacts CEO contact detail First name: Thierry Last name: Darnis Position: Plant Manager Email: [email protected] Phone: +33 (0)4 74 08 92 47 Other contact First name: Olivier Last name: Lefranc Position: R&D Scientist Email: [email protected] Phone: +33 (0)4 74 08 79 05 Fax: +33 (0)4 74 08 92 30 144 l i f e s c i e n c e s d i r e c t o r y 2 0 1 1 General company information Company name: Spygen Address: Savoie Technolac, 12, allée du Lac de Garde Zip code: 73370 City: Le Bourget du Lac Website: www.spygen.fr Founded in: 21/01/2011 Main activity: Spygen has developed an DNA-based innovative approach for studying biological diversity (animal, plant and microorganism species) in the environment (water, soil) or in complex substrates (food products, cosmetics, feces, etc.). This method can also be used to identify species from biological samples (fragments of plants, of skin, etc.). Incubator: Yes (GRAIN) Subsidiary of a group: No Prize winner for innovative start-up: No Innovative company (FCPI): No Other status: No Funding Looking for funding: No CEO contact detail First name: Tony Last name: Dejean Position: Chairman Email: [email protected] Phone: +33 (0)4 79 26 15 83 s c i e n c e s d i r e c t o r y Business model Service provider - Scientific. Value chain Other. Activities Other. Application fields Other. Activities Company activities 1. Ecological analysis The method developed by Spygen enables the detection of aquatic and semi-aquatic species from a simple water sample by analyzing the DNA released by organisms into the environment (environmental DNA - eDNA). This technique has no impact on the ecosystem and offers unequalled performance. It is particularly suited to the monitoring of rare and/or discreet species. 2. Authenticity & traceability checks With the methods developed by Spygen it is possible to determine the composition of a processed product (animal, plant and micro-organism species) by analyzing the fragments of DNA present in the sample. This innovative method can also be used on biological samples (fragments of plants, of skin, etc.) to check the authenticity of a species. Company contacts l i f e Company segmentation 3. Diet analysis The method developed by Spygen is based on the analysis of feces or stomach contents. It uses the fragments of DNA present in a sample to identify the plant and/or animal species ingested. 2 0 1 1 145 General company information Company name: Stragen Services SAS Address: 1, rue des Quatre Chapeaux Zip code: 69002 City: Lyon Website: www.stragen-services.com Founded in: 26/08/2009 Main activity: Service provider for pharmacovigilance and clinical development strategy. Scope of expertise: Innovative medicines including orphan drugs, generic products, medical devices. Incubator: No Subsidiary of a group: Yes (Stragen) Prize winner for innovative start-up: No Innovative company (FCPI): No Other status: Yes Company segmentation Business model Service provider - Scientific, Other. Value chain Research, Marketing / Distribution, Clinical. Activities Clinical trials, Other. Application fields Pediatrics, Human health, Geriatrics, Immunology, Inflammatory diseases, Infectious diseases, Autoimmune diseases, Allergology, Orphan diseases, Genetic / Rare diseases, Metabolic diseases, CNS related diseases, Cancer, Nutrition / Food, Dermocosmetics, Other. Activities Funding Company activities Looking for funding: No Pharmacovigilance or tailored solutions for companies that prefer to work in-house. Stragen Services assists pharmaceutical & biotech companies in the design and implementation of innovative Clinical Development strategies in order to bring products to registration in the most efficient and cost-effective manner. Company contacts CEO contact detail First name: Annie-Claude Last name: Benichou Position: General Manager Email: [email protected] Phone: +33 (0)4 78 42 95 26 Stragen Services helps pharmaceutical & biotech companies to understand and interpret regulatory requirements and guidelines and to manage clinical programs, from phase I to phase IV. Company key features – Solutions and Services designed around Customer Needs and key business Requirements – 24/7 Medical Monitoring services – Regulation-driven experienced team of physicians, pharmacists and scientists, specialized in bridging clinical concepts, passionate about medical affairs and familiar with the challenges that pharmaceutical companies are facing – Stragen Services is a customer-minded partner. – Top Quality Services: precision & clarity, aiming at effective solutions/recommendations. 146 l i f e s c i e n c e s d i r e c t o r y 2 0 1 1 General company information Company name: SynapCell Address: Pépinière Biopolis - 5, avenue du Grand Sablon Zip code: 38700 City: La Tronche Website: www.synapcell.com Founded in: 04/04/2005 Number of employees: 8 Turnover: 0,19 K e (in 2009) Main activity: SynapCell is an innovative contract research company providing pre-clinical services based on functional activity of neuronal networks in models mimicking human CNS pathologies. Incubator: Yes (Grain) Subsidiary of a group: No Prize winner for innovative start-up: Yes (Creation Development - National contest for innovative companies) Innovative company (FCPI): Yes Other status: Yes Funding Looking for funding: No Company segmentation Business model Service provider - Scientific. Value chain Preclinical. Activities Models (animal - cellular - …), Preclinical trials, Other. Application fields Human health, CNS related diseases. Activities Company activities SynapCell is an innovative contract research company providing pre-clinical services based on functional activity of neuronal networks in models mimicking human CNS pathologies. SynapCell evaluates potential therapeutic and/or side effects of drug candidates on translational murine models of epilepsy (GAERS and MTLE mouse). Skills and know-how Funding: FUI (AAP9 2010) Role in the project: Partner • Study of neuronal networks with electrophysiology: – in vivo (deep and cortical EEG on vigil animal) – in vitro (multi-electrode array with acute and organotypic slices) • Stereotaxic surgery (mouse and rat) • Organotypic culture of slices (hippocampus), allowing chronic studies (up to one month) • Behavioural analysis. Company contacts Products / Services / Technologies R&D PROJECT FUNDED ACCREDITED BY LYONBIOPOLE RHENEPI: Platform of neuronal modeling to discover and validate pharmacological treatments against epilepsy disease. Company services CEO contact detail First name: Corinne Last name: Roucard Position: CEO - president Email: [email protected] Phone: +33 (0)4 76 63 75 90 We assess the anti-epileptic, anti-epileptogenic and pro-epileptic effects of drug candidates with rodent models of absence (GAERS) or temporal lobe epilepsy (MTLE Mouse). We define activity profile of drug candidates on neuronal network contained in brain slices by the use of Multi-Electrode Array. Company technologies Electrophysiology with Electroencephalogram (EEG) and Multi-Electrode Array (MEA). l i f e s c i e n c e s d i r e c t o r y 2 0 1 1 147 Company segmentation Business model Service provider - CRO, Product developer Biopharmaceuticals. General company information Company name: Synthelis Address: 5, avenue du Grand Sablon Zip code: 38700 City: La Tronche Website: www.synthelis.com Founded in: 01/12/2010 Turnover: 160 000 e (in 2009) Main activity: – custom membrane protein production – vectorization of membrane protein for therapeutic or vaccine development. Incubator: Yes (Grain) Subsidiary of a group: No Prize winner for innovative start-up: Yes Innovative company (FCPI): Yes Other status: Yes Funding Looking for funding: Yes Nature of funding searches: Business Angels, ISF Funds, Holding, Seed capital, Venture capital, Capital développement, others. Public funding obtained: Oseo: €170 000 in 2010 Company contacts CEO contact detail First name: Bruno Last name: Tillier Position: CEO Email: [email protected] Phone: +33 (0)6 11 19 21 47 Value chain Research, Manufacturing, Preclinical. Activities Biomanufacturing, Drug delivery. Application fields Animal health, Human health, Immunology, Infectious diseases, Autoimmune diseases, Orphan diseases, CNS related diseases, Cancer, Dermocosmetics. Activities Company activities Synthelis specializes in the production of customized membrane proteins. With our new optimised membrane protein expression system, we can provide: – Active proteoliposomes containing one or several different membrane proteins which preserve protein functionnally – Customised soluble membrane proteins Company key features – process dedicated to membrane protein production with functionality and structure preserved – broad range of applications with the technology – business model based on service and bioproduct development – patent application in national and regional phases – dedicated know-how. Skills and know-how – membrane protein production and characterization. Products / Services / Technologies Pipeline product 1 Therapeutic area: Oncolgy Therapeutic indication: glioblastoma Preclinical: x Pipeline product 2 Therapeutic area: Infectious diseases Therapeutic indication: vaccine Preclinical: x Company services Custom membrane protein production membrane protein characterization. Company technologies Proprietary cell-free system membrane protein vectorization for therapeutic or vaccine application. 148 l i f e s c i e n c e s d i r e c t o r y 2 0 1 1 General company information Company name: Top Industrie Address: 80, rue Marinoni Zip code: F77013 City: Vaux le Penil Cedex France Website: www.top-industrie.com Founded in: 01/01/1983 Number of employees: 30 Turnover: 5.5 M e (in 2011) Main activity: High Pressure Cells, High Pressure Autoclaves, very high Pressure «Pascalisation», Chemical Autoclaves, Pressure test benches. Incubator: No Subsidiary of a group: No Prize winner for innovative start-up: No Other status: No Company segmentation Business model Laboratory equipment supplier. Value chain Manufacturing. Activities Vaccine, Biomanufacturing. Application fields Animal health, Human health. Activities Company activities Funding High Pressure Cells, High Pressure Autoclaves, very high Pressure «Pascalisation», Chemical Autoclaves, Pressure test benches. Looking for funding: No Company key features Reactivity, large experience in High Pressure. Skills and know-how R&D PROJECT FUNDED ACCREDITED BY LYONBIOPOLE Know how in high Pressure engineering and high Temperature. HYPERBAR: Bringing into the vaccine production industry an alternative to chemicals for bacteria and viruses inactivation by high pressure treatment Funding: FUI (AAP3 2007) Role in the project: Partner Company contacts CEO contact detail First name: Gildas Last name: Merian Position: President Email: [email protected] Phone: +33 (0)1 64 10 45 50 l i f e s c i e n c e s d i r e c t o r y 2 0 1 1 149 General company information Company name: Transgene SA Address: Boulevard Gonthier d’Andernach, Parc d’Innovation Zip code: 67405 City: Illkirch-Graffenstaden Website: www.transgene.fr Founded in: 30/12/1979 Number of employees: 280 Turnover: 10 M E (in 2009) Main activity: Transgene is a biopharmaceutical company that discovers and develops immunotherapy products for the treatment of cancers and chronic infectious diseases. Its expertise covers all product development stages, including researach, manufacturing of clinical batches and conducting clinical trials. Five products are currently under clinical development, four in phase II and one in phase I. Transgene has signed business agreements with Roche (2007), Novartis (2010) and Jennerex (2010) Transgene is a partner in a major, externally funded, research project (ADNA program) that aims to achieve individualized medicine for cancers, infectious diseases and genetic diseases. The program focuses on the identification and development of biological markers, and its findings are making a substantial contribution to the future development of its products. Transgene is committed to scientific excellence and medical innovation, with the company’s top level scientists focusing on applying their research findings to developing new therapies in order to treat unmet medical needs. A strong pre-clinical pipeline bears witness to this commitment. For over 25 years Transgene has built on its recognized scientific expertise. Today, it is a major player in the field of immunotherapy. Incubator: No Subsidiary of a group: Yes (Institut Mérieux) Prize winner for innovative start-up: No Innovative company (FCPI): Yes Other status: No Funding Looking for funding: Yes Nature of funding searches: Transgene is searching for partners to co-finance/co-develop its pre clinical and clinical product development pipeline. Stock exchange listing: NYSE Euronext Paris- Eurolist (compartment B) Listed 26 March 1998 Nouveau Marchée and Nasdaq (de-listed Nasdaq 2005) 150 l i f e s c i e n c e s d i r e c t o r y 2 0 1 1 R&D PROJECTS FUNDED ACCREDITED BY LYONBIOPOLE BIOTHERAPIC: Therapeutic solutions against hepatitis C virus Funding: FUI (2005) Role in the project: Leader DEMINAP: Use of toll-like receptors (TLRs) in order to detect inapparent microorganisms and their ligands for diagnostic and therapeutic applications Funding: FUI (AAP2 2006) Role in the project: Partner ALPHA VAC: New therapeutic approach for the treatment of hepatitis C virus infection based on the combination of a therapeutic vaccine and a nanoparticle-based formulation of IFN Funding: FUI (AAP3 2007) Role in the project: Leader PLATINE: European immunomonitoring platform Funding: FUI (AAP5 2008) Role in the project: Partner NATHEB: New therapeutic approaches in the treatment of chronic hepatitis B Funding: FUI (AAP8 2009) Role in the project: Partner ADNA: Advanced diagnostics for new therapeutic approaches Funding: OSEO (ISI) Role in the project: Partner Company contacts CEO contact detail First name: Philippe Last name: Archinard Position: Chairman & CEO Email: [email protected] Phone: + 33 (0)3 88 27 91 22 Other contact First name: Stéphane Last name: Boissel Position: Executive Vice President & CFO Email: [email protected] Phone: +33 (0)3 88 27 81 21 Products / Services / Technologies Pipeline product 1 Company segmentation Business model Product developer - Biopharmaceuticals, Product developer Pharmaceuticals. Value chain Research, Manufacturing, Preclinical, Marketing / Distribution, Clinical. Activities Vaccine, Biomanufacturing, Models (animal - cellular - …), Clinical trials, Preclinical trials, Other. Application fields Human health, Immunology, Infectious diseases, Cancer. Activities Company activities Transgene’s know-how is based on gene transfer technology that works from inside the patient’s immune system to treat major unmet medical needs in cancer and infectious diseases. Since 1992, the company has specialised in developing gene transfer therapy with the aim of helping patients fight life threatening diseases through restoring the immune’s system capacity to eliminate abnormal or infected cells. Company key features Transgene’s R&D teams are currently conducting investigational programs on innovative immunotherapy strategies to offer new solutions to treat cancers and infectious diseases. The company has a three pillars strategy based on its historic MVA platform, oncolytic viruses and monoclonal antibodies. To support this research, Transgene is pursuing a large biomarker R&D program (prognostic and predictive biomarkers) intended to increase the efficacy of its products. Recent news - October 18, 2010 - Third Quarter 2010 Financial Report - September 29, 2010 - Transgene Signs an Agreement with Venatana Medical Systems Inc. - September 8, 2010 - Jennerex and Transgene enter into an ExclusivePartnershipfortheDevelopmentandCommercialization of JX-594 -September1,2010-TransgeneReceivesPositiveScientificAdvice from the EMA for the Phase IIb/III trial of TG4010. Skills and know-how At the heart of Transgene’s expertise is the capacity to develop safe, reliable and modular gene transfer methods and we currently use three types of vectors: Modified Vaccinia Ankara (MVA), vaccinia virus and adenovirus. The effectiveness of a vector is determined by its ability to carry the desired gene, to transfer sufficient quantities into the correct target cells, and to allow either the gene to be expressed, and thus produce the target protein over a sufficient long period to ensure the effectiveness of the treatment, or to induce a broad immune response. l i f e s c i e n c e s d i r e c t o r y 2 0 1 1 Therapeutic area: Cancer Therapeutic indication: Non Small Cell Lung Cancer (NSCLC) Phase 2: TG4010 (MVA-Muc1-IL) Phase IIb/III - indication NSCLC start mid 2011 Pipeline product 2 Therapeutic area: Infectious Diseases Therapeutic indication: Precancerous cervical lesions caused by the HPV virus Phase 2: TG4001/R3484; indication precancerous lesions of the cervix (HPV16) Phase IIb interim data end 2011 Pipeline product 3 Therapeutic area: Cancer Therapeutic indication: Hepatocarcinoma & other solid tumors Phase 2: JX-594/Oncolytic- Phase IIb (HCC) + Phase Ib (CRC) start mid-2011 Partnership opportunities / Licensing Collaboration framework Collaborative innovation - whether through collaborative programs or corporate partnerships - is a key business driver at Transgene and our capacity to generate a number of important agreements in this domain testifies to the solidity of our scientific expertise and business model. We have a strong track record of fruitful collaboration with pharmaceutical companies, and other third party organizations, for the research and development of novel product candidates in the area of oncology and infectious diseases. Partnership opportunities Our principal strategy is to seek out co-development partnership opportunities for advanced clinical product candidates that aim to treat large unmet medical needs, and which require the support of major pharmaceutical partners for phase III trials and beyond. The strategic agreement with Novartis is an example of this strategy applied to one of our lead product candidates TG4010. Out-licencing opportunity Based on our strategy and business needs, Transgene can make its technologies and products available to the industry under research or commercial licenses, or through collaboration agreements. Transgene is seeking, more and more, out-licensing opportunities structured around codevelopment partnerships so as to fully maximise the value of its product pipeline. In-licencing opportunity Transgene is particularly interested in technologies and product candidates for immunotherapy applications. These include: – Poxvirus related technologies (manufacturing process enhancement, novel formulation, etc.) – Novel active immunotherapy products – Novel tumor associated antigens – Clinically tested adjuvants (to viral vectors and proteins) – Novel targets in infectious diseases (small molecules) – Therapeutic monoclonal antibodies – Oncolytics viruses. 151 Company segmentation Business model Product developer - Biopharmaceuticals. Value chain Research, Preclinical. Activities Vaccine, Models (animal - cellular - …), Preclinical trials. Application fields Immunology, Infectious diseases, Cancer. General company information Company name: Vaxeal City: Lyon Website: www.vaxeal-group.com Founded in: 15/12/2010 Main activity: Vaxeal and its strategic partner, the CEA (FR), are strongly focused on developing new long synthetic peptide (LSP)-based therapeutic vaccines with tremendous medical need, for the treatment of cancer and infectious diseases. In the field of oncology, Long Synthetic Peptides (LSP) containing T cell epitopes of Survivin and Midkine, proteins over-expressed in large number of carcinomas and melanomas - but not in normal cells - and associated with a poor prognosis, have been identified. These targets, in monotherapy or in combination, represent highly promising candidates for the treatment of several cancers. In the field of infectious diseases, we developed 2 novel therapeutic vaccines against HCV genotype 1a (main sub-genotype in USA), and Plasmodium falciparum (Malaria). This Malaria vaccine will be partnered with the UNIL. Moreover, the company is also acquiring a novel generation of adjuvants capable of inducing strong and sustainable systemic and mucosal responses. . Incubator: No Subsidiary of a group: Yes (Vaxeal Holding SA) Prize winner for innovative start-up: No Innovative company (FCPI): No Other status: No Funding Looking for funding: Yes Nature of funding searches: Vaxeal is actually preparing a seed round table of 2 million euros. The seed will allow us to complete the pre-clinical trials on our 2 first therapeutic vaccines: Surivvin and hepatits C genotype 1 (CMC packages, IND). CEO contact detail First name: Ahmed Last name: Bouzidi Position: CEO Email: [email protected] Phone: + (0)41 79 917 1434 Other contact First name: Bernard Last name: Maillère Position: CSO Email: [email protected] Phone: +33 (0)1 69 08 94 47 l i f e s c i e n c e s d i r e c t o r y Company activities Vaxeal and its partners, the CEA, INSERM, and the University of Lausanne, have developed several technology platforms in order to develop their vaccine candidates. These platforms allow us to identify new targets, the peptide synthesis, the formulation, as well as pre-clinical and clinical validations of our therapeutic vaccines Cellular evaluation of immunogenicity These assays allow us to investigate the capacity of peptides or proteins to prime CD4+ and CD8+ T cells harvested from a panel of naïve donors representative of the HLA class II diversity in human. This assay allows: – To evaluate the intensity of the T cell response raised against tested peptides or proteins in each donor; – To evaluate the frequency of responders of the tested peptides or proteins (immunoprevalence); – To rank tested peptides or proteins based on their immunogenicity; – To identify CD4+ and CD8+ T cell stimulating peptides with a wide frequency of responders; – To evaluate cross reactivity of natural variants; – To evaluate the lytic ability of peptide specific T cells: Fully automated peptide binding assays specific for HLA class II molecules Due to the polymorphism of HLA class II molecules, immunogenic peptides vary from one individual to another. These binding assays allow: – To evaluate the binding affinity of each peptide for HLA class II molecules; – To identify peptides with a broad specificity for HLA class II molecules; – To evaluate the influence of natural sequence variations on the binding properties; – To optimize the sequence for the binding to HLA class II molecules. Synthesis of Long Synthetic Peptide (LSP)-Based Therapeutic Vaccines Company contacts 152 Activities 2 0 1 1 Our peptide based strategy employs cocktails of Multi-epitopic Long Synthetic Peptides (average of 25 amino acids) that can be modified with a lipid tail. The laboratory has developed appropriate synthesis strategy: – To synthesize long fragments of various size; – To ligate chemo-selectively a lipid tail to obtain lipopeptides. Adjuvant Platform (AFP) The proprietary FAP has been developed in partnership with the University of Cambridge (UK). The FAP is based on Proteoliposome (PL). AFPL1 and AFCo1 induce in mice and human a Th1 immune response. They are capable of inducing IFN-α responses, and chemokine secretions, like MIP-1α and MIP-1α, but no IgE, nor IL4/IL5 responses. AFPL1 and AFCo1 work in neonatal mice and prime for memory immune response. AFPL1 has already been injected in humans. Pre-clinical Platform (INSERM) This platform has standardized various assays to monitor immune response in both systemic and mucosal sites in mice. – Techniques developed include: Tetramer, Elispot, luminex, CFSE labelled cells, cytotoxicity assay). – In addition, various animal models are available: – HLA class I and II transgenic mice – Spontaneous tumor models associated cancers. – Human cell lines derived from various human cancers to be grafted in immunodeficient mice. Immunomonitoring platform This platform is labelled by Canceropole d’Ile de France. This platform is dedicated to the detection and characterization of T cell response after vaccine and immunotherapy protocols. This platform has standardized methods (Elispot, Tetramers, Intracellular cytokine detection by cytometry…) to detect T cells and has participated to quality control and standardization programs. Company key features Vaxeal’s key feature is first the know-how of its team. Our cumulated experience exceeds 140 years in the fields of vaccine research, immune-therapy, peptide synthesis, company management, as well as regulatory and medical affairs. The IP position is also an asset. Vaxeal has already signed an exclusive license agreement with the CEA protecting its products, and is finalizing an agreement regarding the adjuvants. Recent news Vaxeal is actually incorporating its operational affiliate in Lyon. Lately, Vaxeal signed an exclusive license agreement with the CEA, protecting key products of the company. The company has also been awarded with a MIT special prize, and was finalist of the Intel/Berkeley entrepreneurship challenge. Vaxeal will also be soon member of Europabio. Skills and know-how Vaxeal was incorporated with one of the best team in the field of immune-therapy in oncology and infectious diseases. The know-how of the team covers identification of vaccinal epitopes, adjuvant setting, synthesis of long fragments, development of relevant animal and in vitro models, as well as clinical investigation according to the regulatory requirements. Products / Services / Technologies Pipeline product 1 Therapeutic area: Survivin Therapeutic indication: Urologic cancers Preclinical: Yes Pipeline product 2 Therapeutic area: Midkine Therapeutic indication: NSCLC, colorectal cancer Preclinical: Yes Company technologies – Cellular evaluation of immunogenicity Investigation of the capacity of peptides or proteins to prime CD4+ and CD8+ T cells harvested from a panel of naïve donors representative of the HLA class II diversity in human. – Fully automated peptide binding assays specific for HLA class II molecules A bank of HLA class II molecules has been constituted (most preponderant HLA class II molecules). – Synthesis of Long Synthetic Peptide (LSP) Our peptide based strategy employs cocktails of Multi-epitopic Long Synthetic Peptides that can be modified with a lipid tail. – Adjuvant Platform AFPL1 and AFCo1 adjuvants induce in mice and human a Th1 immune response. – Pre-clinical Platform This platform has standardized various assays to monitor immune response in both systemic and mucosal sites in mice. – Immunomonitoring platform This platform is dedicated to the detection and characterization of T cell response after vaccine and immunotherapy protocols. Partnership opportunities / Licensing Collaboration framework Vaxeal has defined a strategic partnership with the CEA. The company has also established ties with other leading European institutes: INSERM, and University of Lausanne. Partnership opportunities Vaxeal is very open to co-development. The company is seeking academic partnerships in order to consolidate its intellectual propertyanditsoperationalcapability(diagnosis,clinicalresearch). The company is also seeking industrial partnerships (CROs, manufacturing, end users).. Out-licencing opportunity The business model of Vaxeal is to perform the proof of concept of its products prior to out-license them to the pharmaceutical industry. We intend to out-license, after the phase IIa clinical trials, to our industrial partners, immune-therapy products that they can integrate into their end user products. Our partners will be carefully selected for their ability to continue the development of our immune-therapy products, sales and marketing capability to maximize the commercial potential of our products. Nevertheless, the company will remain open to co-develop a product at an earlier stage of development if the pharma can bring a clear leverage effect. In-licencing opportunity Vaxeal is open to any invention allowing the company to consolidate its IP assets (novel epitopes, delivery systems…). Pipeline product 3 Therapeutic area: Hepatitis C Therapeutic indication: Hepatitis C genotype 1 Preclinical: Yes l i f e s c i e n c e s d i r e c t o r y 2 0 1 1 153 General company information Company name: Visoon Address: 60, avenue Rockefeller Zip code: 69008 City: Lyon Website: www.visoon.com Founded in: 10/04/2006 Number of employees: 4 Turnover: 85 K Euros (in 2009) Main activity: Visoon is dedicated to developing computerized decision support systems based on automated image analysis in Life Sciences. Visoon software programs are intended for everyone needing to make decisions using images from living organs, tissues or cells. Visoon has been conducting a clinical evaluation of its automated analysis system of pigmented skin lesions. Incubator: Yes (CREALYS, Novacite) Subsidiary of a group: No Prize winner for innovative start-up: Yes (Creation/development 2005) Innovative company (FCPI): No Other status: Yes (JEI, CIR) Funding Looking for funding: Yes Nature of funding searches: Visoon is looking for fundings in order to industrialize and commercialize its Automated Analysis System of dermoscopic images for melanoma detection. Company segmentation Business model Product developer - Other health. Value chain Research, Manufacturing. Activities Medical device, Other. Application fields Human health, Cancer. Activities Company activities Visoon is a French High Tech company dedicated to developing computerized decision support systems based on automated image analysis in Life Sciences. Visoon offers innovative solutions which rely on classification and search of images only using image content. Visoon software programs are intended for everyone needing to make decisions using images from living organs, tissues or cells (medical research laboratories, pharmaceutical and biotech companies, physicians…). So, Visoon software programs allow image analysis automation, and then make safe and speed-up decision taking. Three examples of applications are listed below: – Automated Classification of chromosomes – Automated screening of TMA (Tissue array) slides in Research Life Sciences Laboratories – Automated classification of leukocytes. Skills and know-how Company contacts CEO contact detail First name: André Last name: Fond Position: CEO Email: [email protected] Phone: +33 (0)6 61 34 86 08 154 l i f e s c i e n c e s d i r e c t o r y 2 0 1 1 Visoon engineers are specialized in developing systems and software for Life Sciences image acquisition, processing and management along with computerized decision support systems. VISOON offers innovative solutions which rely on classification and search of images only using image content. General company information Company name: Vivalis Address: 41, quai Fulchiron Zip code: 69005 City: Lyon Website: www.vivalis.com Founded in: 01/02/1999 Number of employees: 120 Turnover: 4.8 M E (in 2010) Main activity: Vivalis is a biopharmaceutical company that provides innovative solutions for the manufacture of vaccines and proteins and develops new therapeutic molecules.. Incubator: No Subsidiary of a group: Yes (Grimaud) Prize winner for innovative start-up: No Innovative company (FCPI): No Other status: No Funding Activities Company activities Vivalis has developed an embryonnic avian cell lines dedicated to the pharmaceutical industry for the manufacture of vaccines and proteins. Vivalis also generates therapeutic fully human monoclonal antibodies for the treatment of inflammatory, auto-immune and infectious diseases. Finally, Vivalis identifies and develops small molecules against viral targets. Company key features Vivalis is a world leader in ES cells. Vivalis uses one of the last reamining technology for the discovery of fully human therapeutic monoclonal antibodies not owned by a Big Pharma. Recent news In June 2010, Vivalis signed with Sanofi Pasteur a commercial license and collaboration agreement for the discovery and development of fully human monoclonal antibodies against several infectious targets. Skills and know-how Looking for funding: No Strong industrial and scientific experience in ES cells, immunology and B lymphocyte biology. Company contacts CEO contact detail First name: Philippe Last name: Guillot-Chêne Position: Head of Lyon site Email: [email protected] Phone: +33 (0)4 72 40 27 31 Other contact First name: Nicola Last name: Beltraminelli Position: Laboratory manager Email: [email protected] Phone: +33 (0)4 78 74 80 03 Company segmentation Business model Product developer - Biopharmaceuticals. Value chain Research, Manufacturing, Preclinical. Products / Services / Technologies Company technologies: - EB66® Technology Based on the properties of duck embryonic stem cells, Vivalis has developed the EB66® cell line which overcomes the limitations associated with egg - based vaccine s and allow the production of monoclonal antibodies (ADCC enhanced). - Humalex® Platform Based on an optimized EBV technology, the Humalex platform allows the isolation of human monoclonal antibodies of interest produced by immortalized Human B-lymphocytes harvested from individuals previously exposed to a targeted pathology. The Humalex platform, by immortalizing a high number of human B-lymphocytes, makes the EBV methodology suitable for industry level discovery research. - 3D Screen® Platform Based on the assumption that the tri-dimensional structure of a protein dictates its biological activity, Vivalis has developed an innovative drug screening platform, to identify anti-viral molecules. Activities Biomanufacturing, Drug discovery, Other. Partnership opportunities / Licensing Application fields Partnership opportunities Animal health, Human health, Immunology, Inflammatory diseases, Infectious diseases, Autoimmune diseases, Cancer. l i f e s c i e n c e s d i r e c t o r y 2 0 1 1 Vivalis proposes research and commercial licenses of its EB66 cell lines for vaccines and proteins manufacturing. Vivalis receives upfront fees, milestone payments and royalties on its licensees net sales. Vivalis proposes solutions for the discovery, development and production of therapeutic human monoclonal antibodies. Vivalis receives upfronts, milestones payments and royalties on its licensees net sales. 155 General company information Company name: Voxcan Address: 1, avenue Bourgelat Zip code: 69280 City: Marcy l’Etoile Website: www.voxcan.fr Founded in: 13/04/2007 Number of employees: 6 Turnover: 500 K € (in 2009) Main activity: Voxcan is a CRO specialized in 3D medical imaging services adapted to preclinical studies in a wide range of therapeutic areas: bone and cartilage, implants, vascular and pulmonary diseases, oncology and metabolic deseases. Our services are designed to increase biological measurement accuracy and to allow customers to save animal models, time and money. Subsidiary of a group: No Prize winner for innovative start-up: No Innovative company (FCPI): Yes Other status: Yes Funding Looking for funding: No Company contacts CEO contact detail First name: Emmanuel Last name: Chereul Position: General Manager Email: [email protected] Phone: +33 (0)4 78 19 52 38 l i f e s c i e n c e s d i r e c t o r y Business model Service provider - CRO, Service provider - Scientific. Value chain Research, Preclinical. Activities Diagnostics / Analysis method, Models (animal - cellular - …), Preclinical trials. Application fields Animal health, Human health, Inflammatory diseases, Infectious diseases, Metabolic diseases, Cancer, Nutrition / Food. Activities Company activities Voxcan is specialized in 3D Medical Imaging Services (Anatomical and Functional) on animal models from mouse to pig. Our services provide our customers with in-vivo quantitative results to test new drugs, in a non-invasive way, in areas such as bone-cartilage, oncology, cardiovascular, body composition, bio distribution and pharmacokinetics… under controlled sanitary conditions. Our activity covers standard or made-to-order protocols for your R&D and Preclinical projects. Services are performed under GLP requirements on an analysis imaging platform (X-ray Computed Tomography and Optical Molecular imaging).Their specificities allow to conciliate both ethical concerns and financial profits as well as to obtain a twice shorter study time with respect to histology analyses. Recent news Other contact First name: Thomas Last name: Chuzel Position: Regulatory Affairs Manager Email: [email protected] Phone: +33 (0)4 78 19 52 39 Fax: +33 (0)4 78 19 52 40 156 Company segmentation 2 0 1 1 • 01-07-2010: PRIM-OA project is funding by Europe within the framework of an approved Eurostars project • 01-12-2009: Signature of a Partnership Convention between Voxcan, Floralis anf Joseph Fourier University. • 20-10-2009: Voxcan is supported by Rhône-Alpes Region for its new range of innovative services. • 15-07-2009: Voxcan is supported by the Rhône Department Innovation Fund. Companies Start-up projects Investors start-up projects Rhône-Alpes’Gateway to Innovative Business in Life Sciences Start-up projects index 158 l i f e s c i e n c e s d i r e c t o r y 2 0 1 1 A-Tech 159 Cavi-T 160 EBV Biotech 161 Kallistem 162 Smartox 164 Vet Biobank 165 Virologics 166 ViroScan3D 167 A-TECH General INFORMATION ON PROJECT Name of the project: A-Tech (project: UroClip) Incubator: Crealys Main activity planned: Prostate cancer is the most common form of male cancer, and is increasing due to aging population and new means of detection. Surgery is the leading treatment, and over 24,000 operations are performed every year in France (>250,000/year worldwide). During the surgery, particularly difficult suturing operations are required. A-Tech has developed a product that will dramatically simplify those suturing operations. A-Tech offers high value added for Patients (health benefits), Surgeons (surgical efficiency and precision), Hospitals (financial benefits and improved image) and insurance companies. The UroClip protocol and device are both patent pending and have been designed as a result of extensive interviews with urologists, A-Tech’s Advisory Board and field studies. Having successfully entered the manual segment of prostate removal surgery, A-Tech will develop its technology to robot-assisted surgery, and more generally to other surgical fields requiring particular suturing. Prize winner for innovative start-up: No Looking for funding: Yes Nature of funding searches: A-Tech management team will seek private investments for the tests on living animals, end 2011. Investors having connections with domains liked to the project will clearly be preferred. PROJECT segmentation Business model Product developer - Other health. Value chain Research, Other. Activities Medical device. Application fields Human health. START-UP PROJECT Project presentation Currently, A-Tech is working on the UroClip’s proof of concept. The project is incubated at Crealys and has recently signed a partnership with VetAgro Sup (vet lab in Lyon), knowledged in Life Sciences, tissues, biomaterials and animal surgeries. The current objective is to perform the proof of concept (pre-clinical trials). Tests on living animals will start end 2011. PROJECT contactS Project leader First name: Arnold Last name: Ferlin Position: Project leader Email: [email protected] Phone: +33 (0)6 78 06 58 61 Other contact First name: Renaud Last name: Marin l i f e s c i e n c e s d i r e c t o r y 2 0 1 1 159 CAVI-T General INFORMATION ON PROJECT Name of the project: CAVI-T Incubator: CREALYS Main activity planned: R&D, manufacturing and sales of innovative devices based on the ultrasound cavitation technology for the research market (cells transfection) and the therapy market (release and/or maximization of therapeutic products , i.e. chemotherapy) . Prize winner for innovative start-up: Yes Looking for funding: Yes PROJECT segmentation Business model Service provider - Scientific, Product developer - Other health, Laboratory equipment supplier. Value chain Research, Manufacturing, Preclinical, Marketing / Distribution. Activities Instrumentation, Cell therapy, Preclinical trials, Nanotechnology, Medical device, Drug delivery. Application fields Animal health, Human health, Orphan diseases, Genetic / Rare diseases, Cancer. PROJECT contact Project leader First name: Jérôme Last name: Lavaure Position: Project leader Email: [email protected] Phone: +33 (0)6 87 66 17 35 START-UP PROJECT Project presentation CAVI-T project is based on a technology breakthrough that has been recently patented by a worldwide renowned public research laboratory (Lyon). New innovative tools able to induce a precise, stable and reproducible mechanical stimulation will be developed and proposed to researchers and clinicians. The control of therapeutic ultrasound in general and the stabilization of cavitation in particular are bringing new horizons in cell biology, in oncology and more generally in new generations of therapeutics. Opportunities For our business of cell transfection we would like to develop collaboration with worldwide renowned research laboratories. For the maximization of therapeutic products we would like to develop partnership with pharmaceutical industries from the chemotherapy field. 160 l i f e s c i e n c e s d i r e c t o r y 2 0 1 1 General INFORMATION ON PROJECT Name of the project: EBV Biotech Incubator: CREALYS Main activity planned: EBV Biotech (project accompanied by CREALYS) develop actually a kit of predictive diagnostic of Epstein-Barr virus(EBV)-associated tumor: carcinomas and lymphomas. Our project open a new innovative theranostic never realized till now for EBV-associated cancers (an immunotherapy combined with a diagnostic test). Prize winner for innovative start-up: No Looking for funding: Yes PROJECT segmentation Business model Product developer - Biopharmaceuticals. Value chain Marketing / Distribution. Activities Diagnostics / Analysis method, Biomanufacturing, Drug discovery. Application fields Human health. START-UP PROJECT PROJECT contact Project presentation Project leader First name: Tadamasa Last name: Ooka Position: Project leader Email: [email protected] Phone: +33 (0)4 78 77 10 78 Our project consists of establishing a specific, feasable and predictive diagnostic test for Epstein-Barr virus-associated cancers -an immunotherapy to treat EBV-associated cancers. The commercialization of diagnostic test and humanized antibody are planned for our future EBV Biotech incubated by CREALYS incubator. Project key features A diagnostic test capable of detecting the patients developing EBV-related cancers. Immunotherapy permitting to suppress EBV-associated tumor by �inhibition of EB- encoded protein action. Recent news Our project is incubated by Crealys. Two European patents were deposited in August 2008, then tranformed in PCT in August 2009. Skills and know-how Diagnostic, Immunotherapy and animal experience. Opportunities We are looking for industrials as subcontractors capable of providing the poly- and monoclonal antibodies and of commercializing Elisa diagnostic test . We are looking for also the companies capable of humanizing mouse monoclonal antibodies. l i f e s c i e n c e s d i r e c t o r y 2 0 1 1 161 PROJECT segmentation Business model Service provider - CRO, Service provider - Scientific, Product developer - Other health. Value chain Research, Preclinical. Activities Diagnostics / Analysis method, Models (animal - cellular - …), Drug discovery. Application fields General INFORMATION ON PROJECT Name of the project: Kallistem Incubator: CREALYS Main activity planned: Kallistem offers to industry (chemical, pharmaceutical, food, cosmetics) its expertise and in vitro cell models for studies of «physio-toxicology» of spermatogenesis and the development of new treatments of male infertility and testicular cancers. The benefits bring by Kallistem are: – Reduction of cost, time, number of animals used, – Accuracy / relevance of results – Knowledge of the mode of action of the molecules tested (mechanistic toxicology / explanatory). Products and services offered: – Studies to «way» –R&D Website: www.kallistem.com. Prize winner for innovative start-up: No Looking for funding: Yes Nature of funding searches: we are looking for investors, business angels, partners. PROJECT contactS Project leader First name: Philippe Last name: Durand Position: Research Director / President Email: [email protected] Phone: + 33 (0)4 72 72 89 65 Mobile: +33 (0)6 80 17 58 12 Other contact First name: Christophe Last name: Grenet Position: Director Email: [email protected] Phone: +33 (0)4 99 61 02 73 Mobile: +33 (0)6 63 87 59 66 162 l i f e s c i e n c e s d i r e c t o r y 2 0 1 1 Animal health, Pediatrics, Human health, Cancer, Dermocosmetics, Other. START-UP PROJECT Project presentation We have developed innovative systems for co-culture of germ cells and Sertoli cells (somatic cells that support and nourish germ cells) in «bicameral» culture chambers that allow maintaining or reforming the blood-testis barrier (structure that isolates the most mature germ cells from the bloodstream), which allow the different stages of male rat gamete formation to occur in culture over a period of 2 to 4 weeks. Thanks to the methods of analysis: cytological, biochemical and genomic we have developed, our systems can also be used to investigate the toxic and / or carcinogenic effects of organic or minerals, compounds, or nanoparticles, on male reproductive function. Our goal now is to create a company offering services in predictive or regulatory toxicology in the field of male reproduction to meet the needs of pharmaceutical, cosmetic and chemical industries, but also to enhance the fundamental knowledge on molecules having a deleterious impact on public health, and identify new therapeutic candidates in the context of male fertility( traetment of infertility or male contraception) and testicular cancers. Project key features Increasingly, toxicology uses toxicogenomic studies on cell lines in culture to highlight the genes whose expression is altered by toxic substances. However, this approach is not feasible in toxicology of spermatogenesis, because there are no lines of germ cells differentiating in vitro that can respond to this request. Therefore the practice is in vivo studies (that is to say in living animals). However, toxicology in vivo tests used for regulation are mostly irrelevant and not very informative. The systems that we developed allow us to study precisely the effects and mechanisms of action of toxic molecules, substantially reduce the cost and duration of reproductive toxicology studies on spermatogenetic function, while dividing by 10 or 20 the number of animals required for these evaluations. From our cultures, it is possible to study a large number of parameters exploring the mechanisms of toxic effects such as: 1) the alterations of the blood-testis barrier; 2) the survival and/or cell death, proliferation of Sertoli cells and spermatogonia (stem cells of spermatogenesis); 3) the conduct of the meiotic divisions (key stage of spermatogenesis during which genetic recombination takes place); 4) the cytogenetic abnormalities of germ cells; 5) the expression of specific genes in germ cells or Sertoli cells. We can then correlate the somatic and germ disturbances, observed in culture, to the changes in the transcriptome and proteome of these cells (toxicogenomics) to define a panel of genes and proteins most relevant to assess in reproductive toxicity studies (alteration of spermatogenesis and / or cancer genes). Using the same cell population exposed (treated group) or not (control group) can dispense with much of the variability between animals that are encountered in testing in vivo, thereby maximizing the power of tests. It should be stressed that knowledge of the mode of action of molecules studied can also establish whether the observations made in animals are transferable to humans, which remains a major problem in this type of study. By contrast, in vivo methods are less informative unlike our system, for studying the cellular and molecular effects (or lack of effect) of a product or product cocktails. Opportunities We are looking for partners and clients to create a start-up The intended customers are from chemical, pharma, cosmeto industries government laboratories, associations for health and environmental protection. Among some, partners may be partners for R & D investors, «promoters» of our systems (CRO), users. Recent news Analysis of spermatogenesis ex vivo: application to the analysis of testicular toxicity Médecine / Sciences 26: 305-10. The new challenges of testicular toxicology (editorial) Andrologie 20: 117119 The academic work supporting Kallistem will be one of the Award Winners of the Innovative Techniques for Environment ADEME-Pollutec 2010. Skills and know-how – Cell Models: • co-culture of germ cells of rat with Sertoli cells in «bicameral» chambers of culture • culture of testicular somatic cells • purification of different types of germ cells. – Analyses: • light and electron microscopy • immunocytochemistry • cytogenetics • flow cytometry, cell sorting • BrdU incorporation • survival test • proliferation test • test of differentiation • study the different phases of meiosis • cytotoxicity test. – Test of apoptosis: • obtaining cell extracts • protein assay and enzyme activities • measuring the expression of certain proteins considered cellular biomarkers • metabolism • gene expression, RT-PCR, DNA chips • mass spectrometry to monitor protein and peptide products. l i f e s c i e n c e s d i r e c t o r y 2 0 1 1 163 General INFORMATION ON PROJECT Name of the project: Smartox Incubator: Grain Main activity planned: Smartox biotech is specialized in chemical synthesis of animal peptide toxins. Peptide toxins are bioactive molecules that target mainly ion channels and G protein coupled receptors. These two membrane receptor families are implicated in several pathologies (cancer, pain, diabetes, auto-immune diseases, etc.).Toxins are usually used as research tools, and have also led to the discovery of new therapeutic molecules (Byetta®, Prialt®, Captotril, etc.) In this context, Smartox proposes a catalogue of toxins for research activities on membrane proteins, and offers also additional services (bespoke syntheses of peptide toxins, toxin characterization). Smartox has the ambition to develop its own drug discovery program based on screening and characterization of venom compounds. Prize winner for innovative start-up: Yes PROJECT contactS Project leader First name: Michel Last name: DeWaard Position: Project leader Email: [email protected] Phone: +33 (0)4 56 52 05 63 Other contact First name: Aurélien Last name: Claeyssen Position: Business developer Email: [email protected] Phone: +33 (0)4 76 54 95 29 164 l i f e s c i e n c e s d i r e c t o r y 2 0 1 1 PROJECT segmentation Business model Service provider - CMO, Product developer - Other health. Value chain Research, Manufacturing. Activities Biomanufacturing. Application fields Animal health, Human health, Inflammatory diseases, Autoimmune diseases, CNS related diseases, Cancer. START-UP PROJECT Project presentation Smartox is currently a business unit of Floralis (technology transfer office of the university of Joseph Fourier). This project directed by Michel De Waard was born in 2008. Two R&D and production engineers are now being employed. Smartox is proud to count among his clients some of the most prestigious pharmaceutical and biopharmaceutical industries. The start-up creation is scheduled for 2011. General INFORMATION ON PROJECT PROJECT segmentation Business model Name of the project: Vet Biobank Incubator: CREALYS Main activity planned: Cell and tissue banking activities Product developer - Biopharmaceuticals, Product developer Other health. Prize winner for innovative start-up: Yes Looking for funding: Yes Nature of funding searches: Proof of concept stage is Manufacturing, Preclinical, Marketing / Distribution, Clinical. for veterinarians. achieved Marketing of the first service (stem cell banking) is due to start before the end of the first trimester 2011. Financing resource is seaken to allow initial investment (equipment; material, consummables stock) and to finance the growth of working capital based on the planned ramp up of activity. Value chain Activities Diagnostics / Analysis method, Cell therapy, Biomanufacturing, Clinical trials, Biobank, Preclinical trials. Application fields Animal health, Immunology, Inflammatory diseases, Autoimmune diseases, Cancer, Other. START-UP PROJECT Project presentation PROJECT contact Project leader First name: Stéphane Last name: Maddens Position: Project leader Email: [email protected] Phone: +33 (0)6 05 21 27 20 In first instance, Vet Biobank propose to racehorse owners to bank their foal’s own mesenchymal stem cells contained in the umbilical cord collected at birht. Those cells represent a high value biological resource in order to optimize the treatment of the future injuries they may experience in their racing carreer. This service relies on the tissue regenerating potentiel of those stem cells. Project key features This service answers to an unmet medical need, since both medical and surgical veterinary healtcare do not answer or partially. Still today, an injury represents the cause of horse discharge from racetracks. Partnership with the Lyon Vet School (Vetagro Sup). Business model which optimize the market to be captured Stong knowledge of market through in-depth investment in market study Growing customers portfolio. Recent news Market study finalized (with a strong investment on the field) Businss model optimized. Skills and know-how Value chain management and know-how by the project leader Precise knowledge of the market adressed. Opportunities Vet Biobank is seeking partnerships in the following fields: – long term cell banking infrastructure – Good manufacturing practices compliant clean rooms to host growing activities (ISO8 à ISO5) – financial support. l i f e s c i e n c e s d i r e c t o r y 2 0 1 1 165 VIROLOGICS PROJECT segmentation Business model Product developer - Pharmaceuticals. Value chain General INFORMATION ON PROJECT Name of the project: Virologics Incubator: CREALYS Main activity planned: Virologics will develop antivirals against targets of RNA viruses such as hepatitis, influenza… identified through the Interactome technology .Which allows to identify cellular functional modules that are essential for viral replication at the time of infection. These cellular functions are targeted by small molecules to either inhibit viral replication or stimulate the production of virus by the cell. Prize winner for innovative start-up: No Looking for funding: Yes PROJECT contactS Project leader First name: Sonia Last name: Escaich Position: Director Email: [email protected] Phone: +33 (0)6 18 63 38 90 Research, Preclinical. Activities Vaccine, Drug discovery. Application fields Human health, Infectious diseases. START-UP PROJECT Project presentation To create a biopharmaceutical company specialized in the research and development of new antiviral molecules with an original mechanism of action. This project is based on results and technologies from the research laboratory Inserm U851 including results of the broad mapping of interactions between the viral proteins and cell proteins. The company aims to discover and develop innovative therapeutic molecules till proof of concept in man and to license them to the pharmaceutical industry. Project key features The interest of host proteins inhibition to develop new antivirals is that the molecules won’t select resistance associated with mutations in the virus targets. Inhibition of cellular targets shared by several viruses such as the one common to the different influenza virus, or by the hepatitis B and C viruses will allow finding molecules that have broad-spectrum activities. The hits are active molecules which have known pharmacological properties. This will allow shortening and reducing the risks associated with clinical development. Other contact First name: Vincent Last name: Lotteau Email: [email protected] Recent news Virologics will start with a solid portfolio of therapeutic interest targets validated by inhibitors. Active molecules have already been identified by cell screening for the hepatitis viruses with a molecule in clinical evaluation and several molecules are inhibitory of influenza viruses. For influenza viruses provirales molecules have also been identified. Skills and know-how Identification of targets for different viruses including human and avian influenza, hepatitis C virus, hepatitis B virus, the dengue virus, West Nile virus, yellow fever virus, virus Chikungunya etc. Data mining to identify molecules hits Virological assays for in vitro screening and validation of molecules. Opportunities – Search for partners for seed funding of the startup company. – Molecules acting on the cellular target have either antiviral either proviral activity. These can be applied to stimulation of virus production for production of vaccine. We are looking for partners for this application to vaccine production. 166 l i f e s c i e n c e s d i r e c t o r y 2 0 1 1 General INFORMATION ON PROJECT Name of the project: ViroScan3D Incubator: CREALYS Main activity planned: broad-spectrum pathogen identification & pathogen discovery Discovery of new targets for diagnostic, vaccine and therapeutics. Prize winner for innovative start-up: No Looking for funding: Yes PROJECT segmentation Business model Service provider - CRO, Service provider - Scientific. Value chain Research. Activities Diagnostics / Analysis method. Application fields Animal health, Human health, Immunology, Infectious diseases. PROJECT contactS Project leader First name: Catherine Last name: Legras-Lachuer Position: President Email: [email protected] Phone: +33 (0)4 37 28 76 15 Mobile: +33 (0)6 63 43 24 04 Other contact First name: Angela Last name: Rea-Boutrois Position: Director Email: [email protected] Phone: +33 (0)4 37 28 76 15 Mobile: +33 (0)6 12 59 81 60 START-UP PROJECT Project presentation ViroScan3D will offer new custom services targeted towards: the detection of a broad-spectrum of pathogens, pathogen discovery and the identification of novel diagnostic targets. Innovative tools and technologies of ViroScan3D include: (i) multiplex PCR (ii) resequencing DNA chips (iii) panvirus arrays, for the detection of all known human and animal viruses (iv) next-generation sequencing, for the identification of all pathogens (v) microarrays for the discovery of new molecular signatures. Project key features – The innovative tools and technologies shared by the University of Lyon 1 and the Mérieux Foundation: syndromic, genomic, broad-spectrum detection tools and the next-generation sequencing technologies. – The team, including: (i) the experienced scientific team, anchored in the industrial and academic environment, and who brings an unique expertise in the fields of infectious diagnosis and genomic (ii) the experienced strategic team anchored in the economic and business environment. Skills and know-how Infectious diagnosis High throughput genomics. l i f e s c i e n c e s d i r e c t o r y 2 0 1 1 167 Companies Start-up projects Investors Investors Rhône-Alpes’Gateway to Innovative Business in Life Sciences Investors Index Agcom Biotech 171 Angels Santé 172 Banque Rhône Alpes 173 Bryan Garnier & Co 174 Carvest 175 CDC Entreprises 176 CEA Investissement 177 CIC Vizille Capital Innovation 178 Crédit Agricole Private Equity 179 Eclosion 180 Edmond De Rothschild - Entreprises Patrimoniales 181 170 Edmond de Rothschild Investment Partners 182 Grenoble Angels 183 Inserm Transfert Initiative 184 Lyon Angels 185 Merck Serono Ventures 186 Mérieux Développement 187 Nyse Euronext 188 Octalfa 189 Oddo Asset Management 190 OTC Asset Management 191 Rhône-Alpes Création 192 Savoie Angels 193 Seventure Partners 194 Sham 195 SiPAREX 196 Sofimac Partners 197 Sofinnova Partners 198 Ventech 199 Viveris Management 200 ACTIVITIES Business General INFORMATION ON INVESTOR Investor name: Agcom Biotech Address: 11, rue HectorBerlioz City: Lyon Zip code: 69009 Creation date: 02/01/2007 AgCom biotech is an independant advisory firm in International Business Development, founded in 2007 by several partners with expertise in biosciences, R&D, Industry, legal affairs, finance, business develpment and international trade. We are strategic strategic advisors and partners of the inovative companies, SMEs, start-ups and major investors looking to expand their worldwide presence. Our services are intended primarily for Environment, Healthcare and Life Sciences Industries, Stakeholders, Private Investors, Business Angels,Banks and Private Equity Funds. Focus Areas We provides assistance and personnalized solutions in Environment, Healthcare and Life Science Industries. – Pharmaceutical & Biotech: Drugs, vaccines, diagnostics – Agrofood & Wellness: Functional Food, Nutrition, Cosmetic, Biosafety – Healthcare Technologies & Services: NTIC, Medical Devices, Imaging, Biomaterials – Environment & Cleantech: Waste Management, Bioremediation, Biomass, Production, Industrial effluents treatments. INVESTOR contact General Manager First name: Edwige Last name: Morand Position: CEO Email: [email protected] Phone: +33 (0)4 78 47 89 14 Description of your activity Our mission is to help all companies to transfer their technology, and give them some operational support to market new concept, from research to industrialization. Agcom Biotech has positioned itself around 3 interrelated services: • Strategy & Corporate Finance: - Diagnosis & Potential for Innovation, Due Diligence – Funds Raising (from Seed Stage to Large Cap) – M&A, Acquisitions and Divestitures Support, Special/ Distressed Situations. • Business Development & Licensing: – Business Development Operations – Negotiation & Agreements – Marketing & Sales – Personnal skills, cultural issues & behaviour • Technologies & Innovation – Support to establish industry & academic partnerships – R&D Alliance & Consortium: KOL search and selection – Supply Agreements & Outsourcing Our services are intended primarily for: – Environment, Healthcare & Life Science Industry & start ups – Stakeholders, Major & Private Investors – Banks & Private Equity Funds. Recent news We would like to meet companies looking for fund raising, strategic growth and business development support at national and international levels.References: Danone Group, Osyris SA, Sloning GmbH (Morphosys buy-out), Medical Device Company (Sweden), ABA Incubator, Seventure Partners, Private Holding (Biofarming, GMO), Olive Oil Company. More Informations: www.agcombiotech.com. l i f e s c i e n c e s d i r e c t o r y 2 0 1 1 171 General INFORMATION ON INVESTOR Investor name: Angels Santé Address: 8, terrasse Bellini, La Défense 11 City: Puteaux Zip code: 92800 Number of employees: 60 Creation date: 15/04/2008 ACTIVITIES Business Angels Santé is the first network of Business Angels in Healthcare in France. Approved by the Ministry of Economy of Finances and Employment in 2008, the network brings together private investors wishing to invest in innovative companies or with high potential of growth in the healthcare field. Focus Areas Our investments are done in 4 fields: – Drugs and Biotech – Medical devices – Healthcare services – New technologies for health. INVESTOR contact General Manager First name: Pierre Emmanuel Last name: Aubert Position: General Manager Email: [email protected] Phone: +33 (0)6 07 57 99 16 Description of your activity Members of our network share a few key values: Taste for Entrepreneurship - Willingness to support entrepreneurial adventures - Participation in seed or early stage - Position in regional branches throughout France - Close links with institutions of the Health sector - Sponsorship Committee composed of Inserm transfer, LEEM, France Biotech, Medicen pole. Investments - Allied Health - Santelog - DNA Therapeutics - Laboratoire Davioud - Ekkyo - Primadiag - Neorphys - Nutrivercell - Graftys - Alize Pharma - Kreactive. Recent news Angels Santé had been awarded as « Network of the year – Category « Espoir » at the occasion of the Congress France Angels on October 14th, 2009 – award supported by the French Ministry of Industry and Employment. 172 l i f e s c i e n c e s d i r e c t o r y 2 0 1 1 General INFORMATION ON INVESTOR Investor name: Banque Rhône Alpes Address: 235, cours Lafayette City: Lyon Zip code: 69006 Creation date: 01/01/1988 ACTIVITIES Business Financing markets of individuals, professionals and businesses – Market operations – Venture capital. Focus Areas All sectors. Recent news INVESTOR contactS General Manager First name: Bruno Last name: Deschamp Position: President Email: bruno.deschamp@banque-rhône-alpes.fr Phone: +33 (0)4 72 75 86 86 The international branch in Lyon, located rue du Bât d’Argent, will welcome new comers in Lyon… and the others ! For any queries you may have, please feel free contact Catherine Schatz at +33 4 72 75 88 52 [email protected] Other contact First name: Patrick Last name: Pelletier Position: Financial Affairs Director Email: [email protected] Phone: +33 (0)4 72 75 86 90 l i f e s c i e n c e s d i r e c t o r y 2 0 1 1 173 General INFORMATION ON INVESTOR Investor name: Bryan Garnier & Co Address: 26, avenue des Champs Elysées City: PARIS Zip code: 75008 Number of employees: 80 Creation date: 29/06/1996 INVESTOR contactS ACTIVITIES Business Equity Research & Brokerage, Asset Management, Corporate Finance. Focus Areas Technology, Media, Telecom Healthcare Renewables Consumer brands & Specialty retail Business services. Description of your activity General Manager First name: Olivier Last name: Garnier Position: President Email: [email protected] Phone: +33 (0)1 56 68 75 29 Other contact First name: Christian Last name: Finan Position: Director ECM Email: [email protected] Phone: +33 (0) 1 56 68 75 30 Fax: +33 (0) 1 56 63 75 21 Bryan Garnier & Co is an independent investment banking firm focused on fast-growing companies and growth-oriented investors. From offices in London, Paris, Geneva and New York, Bryan Garnier & Co offers the full range of investment banking capabilities and institutional brokerage resources, with unique investment ideas and personalized attention to our clients. With a research-driven approach, Bryan Garnier & Co provides Corporate Finance advisory, Sales & Trading and Asset Management to a diverse range of corporate clients, private equity firms and institutional investors. Bryan Garnier & co has deployed its expertise for more than 10 years. It is authorized and regulated by the Financial Services Authority (FSA) in the United Kingdom, and is member of London Stock Exchange and Euronext, Alternext Listing Sponsor, and is active on all European Capital Markets. Recent news The news concern the operations realized by Bryan Garnier & Co http://www.bryangarnier.com 174 l i f e s c i e n c e s d i r e c t o r y 2 0 1 1 General INFORMATION ON INVESTOR Investor name: Carvest - Crédit Agricole Création Address: 1, rue Pierre de Truchis de Lays City: Champagne au Mont d’Or Zip code: 69410 Number of employees: 12 Creation date: 01/06/1998 ACTIVITIES Business Venture capital, development, transmission. Focus Areas Industrial or service companies, start-ups, young innovative companies or with potential for growth. Recent news Several investments in 2009 in innovative start-ups (high-tech, life Sciences). INVESTOR contact General Manager First name: Olivier Last name: Solinas Position: Project Manager Email: [email protected] Phone: +33 (0)4 72 20 07 07 l i f e s c i e n c e s d i r e c t o r y 2 0 1 1 175 ACTIVITIES Business CDC Entreprises, an asset management company approved by the AMF (Autorité des Marchés Financiers, the French securities regulator) and a wholly-owned subsidiary of Caisse des Dépôts, manages the group’s public interest activities, including the FSI (the French Sovereign Fund), in the field of private equity for SMEs. CDC Entreprises invests in private, national and regional investment funds, and directly in SMEs. General INFORMATION ON INVESTOR Investor name: CDC Entreprises Address: 137, rue de l’Université City: 75007 Zip code: Paris Number of employees: 90 Creation date: 01/01/1994 Focus Areas CDC Entreprises covers SMEs’ entire financing chain, involving itself directly and/or indirectly in SMEs, from seed money for technological start-ups to small mergers and acquisitions. It takes more risk than the traditional players, positioning itself much more strongly in activities such as the provision of seed money and venture capital, and targeted areas such as biotechnology. It takes stakes in SMEs’ capital up to a maximum of €15 million for any one company. Description of your activity INVESTOR contact General Manager First name: Olivier Last name: Martinez Position: Investment Director Email: [email protected] Phone: +33 (0)1 58 50 85 51 CDC Entreprises operates under market conditions, and seeks levels of efficiency and profitability that will enable it to encourage private investment. It mainly manages funds of funds and takes minority stakes in national and regional private equity funds. It also manages funds which invest directly in SMEs. CDC Entreprises and its subsidiaries carry out transactions of the following types: – general risk capital and private equity transactions, and small business mergers and acquisitions in all business sectors, – sectoral transactions in businesses: cultural and creative; providing innovative technological products and services in the field of healthcare; the timber industry, – mezzanine finance in convertible bonds for businesses not wishing to open up their capital in the short term, – transactions aimed at bolstering equity for businesses weakened by the crisis but having real development potential. Investments Close to 4,600 SMEs financed in 15 years of business. More than 2,700 currently in the portfolios of the 189 investment funds that are affiliated to it, including 100 directly financed businesses. CDC Entreprises finances a new SME almost every day. Recent news As part of its plans for future investment, the French government has entrusted to CDC Entreprises the management of the future FNA (Fonds National d’Amorçage or National Seed Money Fund) in an amount of €400 million. The FNA’s objective is to invest in funds which will themselves invest in innovative, particularly technological, businesses. The FNA’s mission is to make a significant contribution to the success of innovative businesses bringing competitive advantages and growth potential to the French economy. 176 l i f e s c i e n c e s d i r e c t o r y 2 0 1 1 ACTIVITIES General INFORMATION ON INVESTOR Investor name: CEA Investissement Address: 3, parvis Louis Néel City: Grenoble Zip code: 38054 Number of employees: 6 Creation date: 01/06/1999 INVESTOR contactS General Manager First name: Celia Last name: Hart Position: Manager Investment, Life Sciences Email: [email protected] Phone: +33 (0)4 38 78 29 48 Other contact First name: François Last name: Breniaux Email: [email protected] Phone: +33 (0)1 69 08 41 94 l i f e s c i e n c e s d i r e c t o r y Business CEA Investment invests in the development of highly innovative startups that work on technologies related to the fields of activities of the CEA. Focus Areas CEA Investment invests in the development of highly innovative startups that work on technologies related to the fields of activities of the CEA. Among these fields there are: information technologies, micro-electronic, healthcare, energy and environment. Description of your activity CEA Investment, Ltd. with capital of 27 million is the investment branch of the CEA, a major institution for technological research, development and innovation. Investments More than 20 companies – in life Sciences: Alchimedics (MedTech) EyeTechCare (MedTech) Fluoptics (MedTech) Cytoo, ImmunId (Diagnostic) Neorphys, Neurokin, Vaxeal, Fermentalg. Recent news – July 2010: EyeTechCare SA, which is developing non-invasive therapeutic medical devices using ultrasound technology, announces the completion of a EUR 7.5-million funding round. The funds were provided by Lyon-based insurance company SHAM, a first time investor, Crédit Agricole Private Equity (CAPE), CEA Investment. – May 2010: CEA Investment participated in the first financing round at 750,000 euros of Fluoptics, specialised in fluorescence imaging for cancer surgery. With this funding, Fluoptics aims to finalise the preclinical phases of its fluorescent tracer and develop its sales at the international level and reinforce its managing team. Fluoptics comes from CEA/LETI. – July 2009: CYTOO Announces the completion of a second fund raising of 3.2 million and the entry of AURIGA PARTNERS in its capital. The company will use the funding to continue the industrialization of its products and expand internationally. – May 2009: ImmunID raised 2.4 million funds from VCI, CEA Investment SOFIMAC. This brings to more than 5 Million euros for its clinical development for personalized medicine kits ImmunTraCkeR Immun’Ig . – March 2009: Neorphys closes its second financing round. A second financing round of 1.2 Million euros had been achieved in 2009 with Soridec, CEA Valorisation, Fa Diese 2, Seillans and a number of independent business angels. It will be used to complete the regulatory preclinical development of NEO1509. – February 2009: the Emertec 4 fund, CEA Valorisation Aquitaine Creation Innovation and Picoty Development participed in the first financing round of Fermentalg company. 2 0 1 1 177 General INFORMATION ON INVESTOR Investor name: CIC Vizille Capital Innovation Address: 2, rue Président Carnot City: Lyon Zip code: 69002 Number of employees: 6 Creation date: 18/02/2003 General Manager First name: Karine Last name: Lignel Position: Investment Director Email: [email protected] Phone: +33 (0)4 78 38 64 90 l i f e s c i e n c e s d i r e c t o r y Business Venture Capital. Focus Areas Technological companies: IT, Hardware, Life Sciences, Greentech. Description of your activity We invest in and follow technological companies, on high growth market sectors, and with a huge development capability. INVESTOR contact 178 ACTIVITIES 2 0 1 1 Recent news Last investments (2010): > Nanobiotix (Life Science) > iCosmeceuticals (Cosmetic) > Kalistick (IT). General INFORMATION ON INVESTOR Investor name: Crédit Agricole Private Equity Address: 100, bd du Montparnasse City: Paris Zip code: 75682 Number of employees: 95 Creation date: 16/11/2004 ACTIVITIES Business Crédit Agricole Private Equity is the Crédit Agricole group’s private equity arm. As an AMF-accredited asset management company, Crédit Agricole Private Equity manages 3.3 Billion Euros. As the leading equity investor in French SMEs, Crédit Agricole Private Equity works on a daily basis to support 160 businesses and infrastructure projects. Focus Areas INVESTOR contact General Manager First name: Alexia Last name: Perouse Position: Partner Email: [email protected] Phone: +33 (0)1 43 23 95 94 Its team of 95 professionals supports companies at all stages of their growth and expansion, from start-up right through to sale, in a long-term relationship of mutual trust and proximity. Description of your activity Comprising 11 investment professionals, Crédit Agricole Private Equity’s venture capital team manages more than 470M€ as of today and acquires minority stakes in young companies with high growth potential. Its main areas of interest are financing innovative business ventures in the information technology and life sciences sectors. Investments Therapeutic: ArGEN-X, Cythéris, Poxel, Xention, Complix… Medtech: SuperSonic Imagine, CircuLite, EOS imaging, EyeTechCare, Spineguard, Stentys, SpineGuard… Recent news January 2011, sale of Biovex to Amgen for a potential amount of 1Md$. The company develops therapeutic vaccines for the treatment of cancer. October 2010, success of Stentys’IPO on Euronext. This medtech company proposes a new generation of stents for the treatment of acute myocardial infarction End of 2009, sale of the start-up Fovea pharmaceuticals which is specialized in the treatment of the eye diseases to Sanofi Aventis for a potential amount of € 370 M. l i f e s c i e n c e s d i r e c t o r y 2 0 1 1 179 General INFORMATION ON INVESTOR Investor name: Eclosion Address: 14, chemin des Aulx City: Plan-les-Ouates Zip code: 1228 Number of employees: 6 Creation date: 04/12/2004 ACTIVITIES Business Eclosion bridges the gap between academic projects and the time when a start-up can reasonably attract venture capital. Eclosion offers the management support, financial investment and infrastructure solutions that allow the most promising projects to become successful start-ups. Focus Areas Life Sciences. Description of your activity INVESTOR contactS General Manager First name: Jesus Last name: Martin-Garcia Position: Partner Email: [email protected] Phone: +41 22 880 10 10 Other contact First name: Benoit Last name: Dubuis Position: Partner Email: [email protected] Phone: +41 22 880 10 10 180 l i f e s c i e n c e s d i r e c t o r y 2 0 1 1 Support of Proof of Concept studies emerging from academic labs: management - financial and infrastructure solutions. Seed investments to development capital, from discovery to early clinical phases. Investments Geneuro, GenKyoTex, Arisgen, Melcure. General INFORMATION ON INVESTOR Investor name: Edmond De Rothschild Entreprises Patrimoniales Address: 55, avenue Foch City: Lyon Zip code: 69006 Number of employees: 15 Creation date: 04/11/1999 Description of your activity Edmond de Rothschild Entreprises Patrimoniales is a French advisory firm specializing on small and mid-size companies. Our mission is to help entrepreneurs throughout the process of raising capital, merger-acquisitions, LBO/MBO/MBI/OBO and IPO. Edmond de Rothschild Enterprises Patrimoniales is a subsidiary of La Compagnie Financière Edmond de Rothschild. Investments NA Advisory firm. Other contact First name: Henriette Last name: Le Bihan Email: [email protected] Phone: +33 (0)4 26 72 95 00 d i r e c t o r y Funds raising, Mergers & Acquisitions, LBO/MBO/MBI/OBO, IPO. Medical Devices, Drug development, Biotechnology, Pharmacy, Imaging, IT for the healthcare sector, home medical services… General Manager First name: David Last name: Laurent Position: President Email: [email protected] Phone: +33 (0)4 26 72 95 00 s c i e n c e s Business Focus Areas INVESTOR contactS l i f e ACTIVITIES Recent news Consistent track record in the healthcare sector. Recent deals: Audacia, Provepharm, Trod Medical, ABM, Hopital&Domicile, Medtech… 2 0 1 1 181 General INFORMATION ON INVESTOR Investor name: Edmond de Rothschild Investment Partners Address: 47, rue du Faubourg Saint-Honoré City: Paris Zip code: 75008 Number of employees: 20 Creation date: 01/12/2004 ACTIVITIES Business Investment in venture capital and development capital. Focus Areas Pharmacy, Biotechnologies, medical devices, molecular diagnostics. Description of your activity Investment and company development. Recent news INVESTOR contactS General Manager First name: Pierre-Michel Last name: Passy Position: Managing Partner Email: [email protected] Phone: +33 (0)1 40 17 23 49 Other contact First name: Gilles Last name: Nobecourt Position: Partner Email: [email protected] Phone: +33 (0)1 40 17 25 41 182 l i f e s c i e n c e s d i r e c t o r y 2 0 1 1 Partial sales of Pangenetics to Abbott (Nov 2009) - Fundraising of BioDiscovery € 3 to 155M (May 2009). General INFORMATION ON INVESTOR Investor name: Grenoble Angels Address: 1, place André Malraux - BP 297 City: Grenoble Zip code: 38016 Number of employees: 160 Creation date: 12/05/2005 ACTIVITIES Business Business Angel, Early stage investment. Focus Areas NICT/Internet/E-commerce, Software/Multimedia, Electronic/ Hardware, Telecommunications/Mobile,Health Sciences, Energy/Cleantechs, Consumer Goods/Distribution, Services, Industry, Biotechnology. Description of your activity INVESTOR contactS General Manager First name: Jean-Louis Last name: Brunet Position: CEO Email: [email protected] Phone: +33 (0)4 76 28 25 32 Other contact First name: Cheikhou Last name: Dièye Position: General delegate Email: [email protected] Phone: +33 (0)4 76 28 25 32 Fax: +33 (0)4 76 28 27 54 A Business Angel is an individual who invests part of its money in an innovative company with potential and, in addition to money, makes available to the entrepreneur, his skills, experience, personal networks and some of his time. Investments Acerde Altimet Sas Fcg Rugby Koffeware La Generale de Piscine (Ex Sas O-Viva) Made In Design Starzik Visio Technic Vitamib Widip (Ex Infomut) Synapcell Sweetbeam Fluoptics Accessurg Picual Ecosoftec Abk Company. Recent news Grenoble Angels was named «Best Business Angels network 2009». l i f e s c i e n c e s d i r e c t o r y 2 0 1 1 183 General INFORMATION ON INVESTOR Investor name: Inserm Transfert Initiative Address: 7, rue Watt City: Paris Zip code: 75013 Number of employees: 3 Creation date: 04/05/2005 General Manager First name: Matthieu Last name: Coutet Position: Investissement Director Email: [email protected] Phone: +33 (0)1 55 03 01 23 Other contact First name: Jean-François Last name: Rax Position: Analyst Email: [email protected] Phone: +33 (0)1 55 03 01 25 Fax: +33 (0)1 55 03 01 60 l i f e s c i e n c e s d i r e c t o r y Business Support for company creation and seed capital investment. Focus Areas Human health. Description of your activity Seed investment in start-ups whose technology come from an academic technology transfer. Investments INVESTOR contact 184 ACTIVITIES 2 0 1 1 Hemarina Neurokin Neorphys Sensorion DNA Therapeutics Pharmaxon Genoscreen TxCell TCLand Expression TCL Pharma CellVir Metagenex Vaxon Biotech. General INFORMATION ON INVESTOR Investor name: Lyon Angels Address: Place de la Bourse City: Lyon Zip code: 69002 Number of employees: 65 Creation date: 01/06/2004 ACTIVITIES Business Business Angels Association. Focus Areas All field of activity but the files with come before all others are close to Lyon. Description of your activity To select and to put entrepreneurs in touch with investors who wish to involve themselves in the enterprise. Business Angels can bring to entrepreneurs experience, skills and network. INVESTOR contactS First name: Eric Last name: Lafond Position: Chairman Email: [email protected] Phone: +33 (0)6 07 05 82 97 Investments There are Business Angels who invest and not Lyon Angels Association. Other contact First name: Jean-Pierre Last name: Coutenson Position: Vice-President Email: [email protected] Phone: +33 (0)6 07 33 47 65 l i f e s c i e n c e s d i r e c t o r y 2 0 1 1 185 General INFORMATION ON INVESTOR Company name: Merck Serono Ventures Address: 9, chemin des Mines Zip code: CH - 1211 City: Geneva 20 Founded in: 2010 INVESTOR contact General Manager First name: Nilesh Last name: Kumar Position: Associate Director Merck Serono Ventures Email: [email protected] Phone: + 41 22 414 32 68 186 l i f e s c i e n c e s d i r e c t o r y 2 0 1 1 ACTIVITIES About Merck Serono: Merck Serono is the biopharmaceutical division of Merck KGaA, Darmstadt, Germany, a global pharmaceutical and chemical company. Headquartered in Geneva, Switzerland, Merck Serono discovers, develops, manufactures and markets prescription medicines of both chemical and biological origin in specialist indications. In the United States and Canada, EMD Serono operates through separately incorporated affiliates. Merck Serono has leading brands serving patients with cancer (Erbitux®, cetuximab), multiple sclerosis (Rebif®, interferon beta-1a), infertility (Gonal-f®, follitropin alfa), endocrine and metabolic disorders (Saizen® and Serostim®, somatropin), (Kuvan®, sapropterin dihydrochloride) as well as cardiometabolic diseases (Glucophage®, metformin), (Concor®, bisoprolol), (Euthyrox®, levothyroxine). Not all products are available in all markets. With an annual R&D expenditure of over € 1bn, Merck Serono is committed to growing its business in specialist-focused therapeutic areas including neurodegenerative diseases, oncology, fertility and endocrinology, as well as new areas potentially arising out of research and development in rheumatology. For more information, please visit www.merckserono.com or www.merck.de General INFORMATION ON INVESTOR Investor name: Mérieux Développement Address: 17, rue Bourgelat City: Lyon Zip code: 69002 Number of employees: 4 Creation date: 04/08/2009 INVESTOR contactS General Manager First name: François Last name: Valencony Position: Managing Director Email: françois.valencony@merieux- developpement.com Phone: +33 (0)4 78 87 73 72 Other contact First name: Aurelie Last name: Boulleray Email: ACTIVITIES Business A healthcare investment company. Focus Areas New Products Services Theranostics Medical Devices Imaging Home care Patient monitoring Prevention Therapy (Vaccines - Probiotics & Nutrition) Public Health Priorities: Cancer Alzheimer & degenerative diseases Aging New pandemics & nosocomial infections Well- being. Description of your activity Mérieux Développement intends to be an active minority shareholder, taking an advisory role with the management team and having a seat on the board of directors of the companies it invests in. The main goal of Mérieux Développement is to pass on the new shareholders its stake in high performing companies (across business, industrial operations and R&D aspects). aurelie.boulleray@merieux-developpement. com Phone: +33 (0)4 78 87 37 00 l i f e s c i e n c e s d i r e c t o r y 2 0 1 1 187 General INFORMATION ON INVESTOR Investor name: Nyse Euronext Address: 39, rue Cambon City: PARIS Zip code: 75001 Number of employees: 250 Creation date: 01/01/2000 INVESTOR contactS General Manager First name: Stéphane Last name: Laskart Position: Business Development Email: [email protected] Phone: +33 (0)1 49 27 10 31 Other contact First name: Isabelle Last name: Dube-Cote Email: [email protected] Phone: +33 (0)1 49 27 11 22 ACTIVITIES Business NYSE Euronext (NYX) is a leading global operator of financial markets and provider of innovative trading technologies. With approximately 8,000 listed issues (excluding European Structured Products), Nyse Euronext’s equities markets – the New York Stock Exchange, Nyse Euronext, Nyse Amex, Nyse Alternext and Nyse Arca – represent one third of the world’s equities trading, the most liquidity of any global exchange group.In Europe, Nyse Euronext trade equities through its two main markets - Euronext and Alternext, our platform dedicated to SMEs from all sectors. There are 28 Biotech companies listed on our European markets, 19 on Euronext and 9 on Alternext, making it the largest biotech peer group in Continental Europe. For further information: www.euronext.com Focus Areas Nyse Euronext’s Business Development team is there to support non listed companies in their reflection process, from early on communication of information to the admission on our market. Once a company lists on our markets, it will benefit from a large and diverse international investor base, a strong visibility through analyst and media coverage as well as support in investor related efforts through the organisation and sponsorship of events. Finally, a unique benefit for biotech firms is our Next Biotech index. This European index serves as a benchmark for the sector and promotes the constituent companies. Despite extreme adverse market conditions, the index significantly outperformed the DJ Euro Stoxx 50 and FTSE 100 since its launch in 2008, showing the strong potential of the sector. Recent news In 2010 four biotech companies realized their IPO on our European markets: AB Science, Integragen, Neovacs and Novagali Pharma, raising between 7 and 32 millions euros. In addition two Medtech companies – Carmat and Stentys also listed on our markets raising 16 and 23 millions euros.In 2010, approximately 50% of IPOs on the European market of Nyse Euronext and NYSE Alternext were Life Sciences companies. 188 l i f e s c i e n c e s d i r e c t o r y 2 0 1 1 General INFORMATION ON INVESTOR Investor name: Octalfa Address: 15, chemin du Saquin, Bât G City: Ecully Zip code: 69130 Number of employees: 3 Creation date: 01/03/2006 ACTIVITIES Business Created in 2006 by Gilles Alberici, Octalfa is a family-owned, independent investment company. Octalfa operates as a holding. Focus Areas Life Sciences. Description of your activity INVESTOR contactS General Manager First name: Gilles Last name: Alberici Position: President Email: [email protected] Phone: +33 (0)4 37 49 87 20 Other contact First name: Jérémy Last name: Bastid Position: Consultant Email: [email protected] Phone: +33 (0)4 37 49 87 20 Fax: +33 (0)4 78 33 36 29 l i f e s c i e n c e s d i r e c t o r y 2 0 1 1 We focus on early-stage operations, striving to show an active presence and to provide reliable and enduring support to our partners. Octalfa also intevenes as a co-investor in later-stage companies. Our team has entrepreneurial experience, which we wish to pass on for the benefit of business entrepreneurs. In parallel and consistent with its values, Octalfa established the Dominique Alberici-Octalfa Corporate Foundation (www.fondation-dominique-alberici.org). Investments Alize Pharma I Alize Pharma Ii Ipsogen, Graftys, Glycode, Docea Power, Orega-Biotech, Antagene. Recent news Octalfa also supports an Investment Fund, specializing in health and environment technologies. This Fund, named Octalfa 360 (Health and Green Technologies) is managed by the company 360 am (www.360-am.com) and advised by Xenia Gestion Privée. 189 General INFORMATION ON INVESTOR Investor name: Oddo Asset Management Address: 12, bd de la Madeleine City: Paris Zip code: 75009 Number of employees: 900 Creation date: 1880 INVESTOR contact General Manager First name: Laurent Last name: Dumas-Crouzillac Position: Investment Director Email: [email protected] Phone: +33 (0)1 44 51 82 72 190 l i f e s c i e n c e s d i r e c t o r y 2 0 1 1 ACTIVITIES Business Capital investor in growing companies in France and abroad. Focus Areas All sectors that have a focus on Medical devices and Cleantech. Investments 35 participations in Life Sciences: MDW (Belgium), Airinspace (Holland), Visiomed (France). General INFORMATION ON INVESTOR Investor name: OTC Asset Management Address: 79, rue de la Boétie City: Paris Zip code: 75008 Number of employees: 20 Creation date: 26/01/2001 INVESTOR contactS General Manager First name: Emmanuelle Last name: Deponge Position: Manager in investment Email: [email protected] Phone: +33 (0)1 53 96 52 50 ACTIVITIES Focus Areas All fields of activities: life sciences, ICT, environment. Description of your activity Founded in 2001, OTC Asset Management is a company of independent management for Venture Capital approved by the AMF, which manages, through its investment funds, 315 million euros. His expertise is in financing companies that represent the French economic activity, in all sectors. It provides the funds necessary for their development and their sustainability. OTC Asset Management has funded over 80 companies that have generated a total turnover of 1.3 billion euros and employ 7000 employees. The company is ranked within the first French venture capital companies (regarding the number of SMEs funded and regarding amounts invested in 2008 according to the study published by Private Equity Magazine in January 2009). Other contact First name: Michel Last name: Gomart Email: [email protected] Phone: +33 (0)1 53 96 52 57 Fax: +33 (0)1 53 96 52 51 l i f e s c i e n c e s d i r e c t o r y 2 0 1 1 191 General INFORMATION ON INVESTOR Investor name: Rhône-Alpes Creation Address: 10, rue du Château d’Eau City: Champagne au Mont d’Or Zip code: 69410 Number of employees: 7 Creation date: 21/09/1989 INVESTOR contactS General Manager First name: Guy Last name: Rigaud Position: President Email: [email protected] Phone: +33 (0)4 72 52 39 39 Other contact First name: Aurélie Last name: Wirotius Position: Project Manager Email: [email protected] Phone: +33 (0)4 72 52 39 39 192 l i f e s c i e n c e s d i r e c t o r y 2 0 1 1 ACTIVITIES Business Rhône-Alpes Création is a private Venture Capital Company (RSC) wich invests in innovative start-ups based in the Rhône-Alpes area. It is specialised in seed capital and venture capital. Focus Areas Rhône-Alpes Creation mobilizes equity for young (less than 5 years) and high potentiel companies, wich are based in the Rhône-Alpes area. The investment focus is companies in the information technology, biotechnologies, and environment sectors. Description of your activity Rhône-Alpes Création is a French Private Equity company with a portfolio of 52 companies and € 17,5 M under management. Its intervention is systematically co-investment with other seed funds, proximity venture capitalists, or business-angels. It supports its affiliates to define strategic guide lines and to rise new founds by mobilizing its national and international network of investors. Investments 52 companies. General INFORMATION ON INVESTOR Investor name: Business Angel (membre de Savoie Angels) Address: 3, rue Louis Boch City: Annecy Zip code: 74000 Number of employees: 160 Creation date: 01/01/2007 INVESTOR contact General Manager First name: Yves Last name: Laruaz Position: Business Angel Email: [email protected] Phone: +33 (0)4 50 51 51 41 l i f e s c i e n c e s d i r e c t o r y 2 0 1 1 ACTIVITIES Focus Areas Biotech/ICT / Leisure/tourism/hostels/fashion/. Description of your activity Business Angel Consultant. Investments TSL: equipment, leisure; Holosfind: ICT; Sweetbeam: services in luxury hostels; Wan Design: fashion; Allobroges Participations; Injection 74 : plasturgy ; Marinettes Picual : fast food for companies; Savoie Angels Invest SCR : venture capital (council member). 193 General INFORMATION ON INVESTOR Investor name: Seventure Partners Address: 5-7, rue de Monttessuy City: Paris Zip code: 75007 Number of employees: 20 Creation date: 31/12/1997 ACTIVITIES Business An active partner of companies presenting strong growth potential, Seventure Partners has been investing in innovative sectors since 1997, focusing in particular on French and European companies operating in the ITC and life sciences industries. With some €500 million in assets under management, Seventure Partners stands out as one of Europe’s leading VC players. Focus Areas INVESTOR contact General Manager First name: Isabelle Last name: de Cremoux Position: General Partner / Dir.of Lifesciences department Email: [email protected] Phone: +33 (0)1 58 19 22 77 In life sciences, our four main investment sectors are biotechnology and pharmaceutical R&D, medical equipment, industrial chemistry and biotechnology and nutrition. However,we also invest in diagnostics, galenic improvements, environmental services, bio-energy, skin care, well-being and services. Description of your activity Seventure is a subsidiary of Natixis Private Equity, the asset management of Natixis, with over €4,2bn in private equity investments. A typical investment ranges from €500K to €10M per round, up to €20M per company, from early to later stage. Investments In Lifesciences: Nutraceutics D&S, Polaris, Implanet, Biophytis, Biancamed, Agro Biotech Accelerator, Biomatlante, Tekka, Vivostat, Santaris Pharma, Fluxome Sciences, Noxxon Pharma… En NTIC: Anevia, Conject, Kayentis, Talensoft, 24H00, Mobilire, Webinterpret, Presensia, Retailo… Recent news Nutraceutics D&S, Polaris, Implanet, Biophytis, Biancamed, Agro Biotech Accelerator, Biomatlante. 194 l i f e s c i e n c e s d i r e c t o r y 2 0 1 1 General INFORMATION ON INVESTOR Investor name: SHAM Address: 18, rue Edouard Rochet City: Lyon Zip code: 69008 Number of employees: 265 Creation date: 10/12/1924 Focus Areas Investment in public and private innovative firms evolving in the healthcare industry (biotech, medtech, med IT…) and satellite ones (security, food…). Description of your activity General Manager First name: Olivier Last name: Szymkowiak Position: Investment Manager Email: [email protected] Phone: +33 (0)4 72 75 80 61 s c i e n c e s d i r e c t o r y Business SHAM is a french mutual insurance company based in Lyon that specializes in medical malpractice civil liability. SHAM is one of the french leaders in its industry. INVESTOR contact l i f e ACTIVITIES 2 0 1 1 SHAM manages 1.4 billion euros, invested on diversified asset classes. 7% of this portfolio is allocated to public and private equity investments in innovative firms. Investments Venture capital portfolio: Voluntis / Nokad / Laboratoires Narval (sold on october 2009) / Ekkyo / Alize Pharma / Alize Pharma II / Pharmaxon / Adocia / Glycode / Eyetechcare / Orega Biotech / Biomup. 195 General INFORMATION ON INVESTOR Investor name: Siparex - Sigefi Venture Gestion Address: 139, rue Vendôme City: Lyon Zip code: 69477 Number of employees: 10 Creation date: 01/09/1996 INVESTOR contactS General Manager First name: Sébastien Last name: Touvron Position: Director Email: [email protected] Phone: +33 (0)4 72 83 23 23 Other contact First name: Gwenaël Last name: Hamon Position: Project Manager Email: [email protected] Phone: +33 (0)4 72 83 23 23 Fax: +33 (0)4 72 83 40 69 ACTIVITIES Business Siparex, founded 33 years ago, is France’s independent middle-market private equity specialist. The Group has more than €1 billion in assets under management, divided between “growth capital/LBO financing” for the middle market and “regional growth capital” and venture capital for innovative and technology companies. Siparex also consults on fund management in emerging markets. Siparex stresses geographic proximity to its investee companies. It covers all of France from its offices in Paris, Lyon, Besançon, Lille, Nantes, and Strasbourg, and it also has a presence in Madrid and Milan. The Group employs some 90 staff members, including 55 investment professionals. Focus Areas – Life Sciences (40%): drug discovery & delivery, medical devices (implantable or not) diagnostics, personal care (preventive or personalized medicine) – ICT (40%): microelectronics, software, telecoms – Cleantech (20%): green chemistry, renewable energies, environment. Description of your activity In venture capital: – Direct intervention in equity (equity / convertible bonds) from € 300 K to € 2/3 M in several financing rounds. – Minority and temporary stakes (liquidity search from 5 to 7 years). – Intervention stage: ideally, for the first round of financing. Investments Exonhit, Genoway, Bioalliance, OPi, Novagali… 196 l i f e s c i e n c e s d i r e c t o r y 2 0 1 1 General INFORMATION ON INVESTOR Investor name: Sofimac Partners Address: 24, avenue de l’Agriculture City: Clermont Ferrand Zip code: 63100 Number of employees: 20 Creation date: 01/09/1999 INVESTOR contactS General Manager First name: Pascal Last name: Voulton Position: Chairman and Chief Executive Officer Email: [email protected] Phone: +33 (0)4 73 74 57 57 Other contact First name: Philippe Last name: Vuagnat Position: Chief Executive Officer Email: [email protected] Phone: +33 (0)4 37 26 20 92 l i f e s c i e n c e s d i r e c t o r y 2 0 1 1 ACTIVITIES Business Sofimac Partners is an independant asset management company registered under the A.M.F (French Stock Market Authority). Sofimac Partners Group benefits from a 30 years expertise in equity investment non quoted SMEs. Focus Areas Sofimac Partners manages FCPR, FCPi, FIP, SCR management mandates, covering the whole range of regional investment segments: seed capital, venture capital, growth capital, leverage buy out and recovery. Description of your activity In the Healthcare field the company has a highly qualified dedicated team focused on young innovative Biotech or Medtech companies coaching. The 4 investors team in charge of the Fund Technologies and Sante is covering the South-East of France and North of Italy and invests in the following fields: Medical devices, diagnostic, medical imaging, nuclear medicine, surgery devices.The FCPR Technologies and Sante takes minority stakes with investments ranging from 500 000 to 2 000 000. The company manages today more than 180 million euros brought by regional, national and international subscribers. Recent news Participation in the companies Biom’up, Dexterite Surgical and first investment in Glomeria Therapeutics (Italy). 197 General INFORMATION ON INVESTOR Investor name: Sofinnova Partners Address: 17, rue de Surene City: Paris Zip code: 75008 Number of employees: 25 Creation date: 19/01/1972 INVESTOR contact General Manager First name: Denis Last name: Lucquin Position: Managing Partner Email: [email protected] Phone: +33 (0)1 53 05 41 00 198 l i f e s c i e n c e s d i r e c t o r y 2 0 1 1 ACTIVITIES Business Venture Capital. Focus Areas Technology, Life Sciences and Cleantech. Description of your activity Sofinnova Partners is an independent venture capital firm based in Paris, France. For over 35 years, the firm has backed nearly 500 companies at different stages of development – pure creations, spin-offs, as well as turnaround situations – and worked alongside Europe’s key entrepreneurs in the technology, life sciences and cleantech sectors. With more than €1 billion of funds under management, Sofinnova Partners’ experienced team and hands-on approach in nurturing and supporting portfolio companies through to exit have created market leaders and multiplied revenues, from landmark historical investments including Genentech and Biogen to more recent successes such as Actelion, Vistaprint and CoreValve. With a global mindset, the firm has offices in Shanghai, China and a sister organization in San Francisco, California. Please visit www.sofinnova.fr for more information on Sofinnova’s team and portfolio. General INFORMATION ON INVESTOR Investor name: Ventech Address: 5/7, rue de Monttessuy City: Paris Cedex 07 Zip code: 75340 Creation date: 2010 INVESTOR contactS General Manager First name: Laurent Last name: Assaraf Position: Director Email: [email protected] Phone: + 33 1 58 19 21 50 Other contact First name: Mounia Last name: Chaoui Position: General Partner Email: [email protected] Phone: + 33 1 58 19 21 50 ACTIVITIES Business Since 1998, Ventech has been partnering with the best entrepreneurs in Information Technology and Life Sciences sectors. With more than €360m under management, Ventech selects and finances the most ambitious European projects and backs them to gain a global leadership position. Thanks to its initiative in China, Ventech is able to back investees in their development in Asia, and to invest locally through a dedicated fund. OUR VISION Since its creation, Ventech has pursued an unchanged strategy, investing in start-ups in the innovation-driven sectors of Information Technologies and Life Sciences. Focus Areas LIFE SCIENCES In the Life Sciences field, Ventech invests primarily in European companies striving to become global leaders in their line of business. Ventech favours a broad and international approach covering different fields of human health and various maturity levels in order to build up a balanced portfolio of investments. l i f e s c i e n c e s d i r e c t o r y 2 0 1 1 BIOTHERAPEUTICS Currently, over half of the newly approved drugs have been developed by biotechnology firms with development costs more than half those of the pharmaceutical industry. Biotechnologies therefore constitute a fertile ground of new attractive treatments to feed the big pharma pipelines. This creates an environment propitious for high value strategic alliances and M&A transactions that in some instances will be timed relatively early on. DIAGNOSTICS Diagnostics have also undergone a sweeping transformation. The boom of biomarkers and personalized medicine has contributed to the emergence of many new companies. The sector is still young. Currently, the most significant valuations reward companies generating revenues of several million euros, achievable with a significant capital base. MEDICAL EQUIPMENT/NUTRITION Medical equipment for therapeutic use is one of the very few human health sectors that could reach the breakeven before the VCs’ exit. The more and more regulated nutrition sector requires clinical trials and therefore more capital than previously. Description of your activity - Focus on identifying disruptive innovations and creating incremental value Alongside the best entrepreneurs and executives, Ventech backs ambitious companies driven to grab or create a sizeable market by ushering in groundbreaking innovation (technological, business model, etc.) and gaining global leadership. Ventech’s sector expertise allows it to take an active role in furthering these projects and assist companies bring new products to the markets. The determination to take or share the lead in the investment process stems from Ventech’s philosophy as an investor, and reflects the very strong commitment of every team member, who put their operating and financial expertise at the service of the entrepreneurs. Ventech has made it a rule to obtain board representation and therefore contributes added value to the company’s development and strategy. - Provide sustained support Ventech invests in the initial phases of a project, typically in the first round of institutional financing (Series A) as part of a streamlined, totally committed shareholder structure. Ventech then accompanies and assists the managers during each successive financing round until the company’s initial public offering or M&A event. In practice, Ventech invests on average between €5 million and €10 million in any one company, typically between €2 million and €5 million in the first financing round. - Build up global leaders Ventech Capital III invests principally in Continental Europe but will consider making significant investment opportunities in other regions alongside first-rate local investors. The managers of the companies can turn to Ventech for assistance to build up local franchises and become world leaders. - Provide a global presence Ventech has been present in Mainland China since 2007 both to invest locally through a dedicated fund, Natixis Ventech China, and to assist European companies in which Ventech has invested to develop their business in Asia. Because of its presence in China and the experience accumulated over time, Ventech is able to support European and American investees in their strategic development and facilitate their access to Asian markets and partners. 199 General INFORMATION ON INVESTOR Investor name: Viveris Management Address: 6, allée Turcat Mery City: Marseille Zip code: 13008 Number of employees: 49 Creation date: 01/07/2000 ACTIVITIES Business With 28 investment professionals dedicated to one of the six private equity divisions, Viveris Management is an asset management company specialized in Private Equity for unlisted SMEs. The company supports more than 120 SMEs and manages nearly € 400 million spread over investment vehicles like FCPI-FIP-FCPR. Focus Areas INVESTOR contact General Manager First name: Marie-Stéphane Last name: de Cerou Position: Investissement Manager Email: [email protected] Phone: +33 (0)4 91 29 41 50 200 l i f e s c i e n c e s d i r e c t o r y 2 0 1 1 Targeted business sectors are: biotechnologies, medical-health, ICT, energy, materials, environment and electronics. Description of your activity We are interested in SMEs at a early stage leading projects innovation, to be followed up all along their development. Investments: Portfolio of Life Sciences companies: Adocia, Carmat, Gloster Europe, Innate Pharma, Ipsogen, Metabolic Explorer, Trophos. Companies Start-up projects Investors Index Rhône-Alpes’Gateway to Innovative Business in Life Sciences Index 202 Index by kind of activities 203 Index by application fields 206 Index by R&D projects accredited by Lyonbiopole and funded 209 Index by kind of activities l i f e s c i e n c e s d i r e c t o r y 2 0 1 1 203 Index by kind of activities 204 l i f e s c i e n c e s d i r e c t o r y 2 0 1 1 Index by kind of activities l i f e s c i e n c e s d i r e c t o r y 2 0 1 1 205 Index by application fields 206 l i f e s c i e n c e s d i r e c t o r y 2 0 1 1 Index by application fields l i f e s c i e n c e s d i r e c t o r y 2 0 1 1 207 Index by application fields 208 l i f e s c i e n c e s d i r e c t o r y 2 0 1 1 Index by R&D Projects l i f e s c i e n c e s d i r e c t o r y 2 0 1 1 209 Index by R&D Projects 210 l i f e s c i e n c e s d i r e c t o r y 2 0 1 1 notes l i f e s c i e n c e s d i r e c t o r y 2 0 1 1 211 notes 212 l i f e s c i e n c e s d i r e c t o r y 2 0 1 1 212 notes l i f e s c i e n c e s d i r e c t o r y 2 0 1 1 213 notes 214 l i f e s c i e n c e s d i r e c t o r y 2 0 1 1 214 Lyonbiopole’s team Immeuble Domilyon - 321, avenue Jean Jaurès, 69007 Lyon T : +33 (0)4 72 76 53 30 - F : +33 (0)4 72 70 48 29 E-mail : [email protected] Website: www.lyonbiopole.com Philippe Archinard, President [email protected] Yves Laurent, General Manager [email protected] SCIENTIFIC DIRECTION Bernard Mandrand, Scientific Director [email protected] Claudia Chagneau, Project Manager [email protected] Estelle Vincent, Project Management Assistant [email protected] Pauline Cottin, Sepsis Program Coodinator [email protected] For further information about R&D projects: [email protected] ECONOMICS, INTERNATIONAL AFFAIRS AND COMMUNICATION DIRECTION Isabelle Scarabin, Economic & International Affairs Director [email protected] Kevin Romani, International Project Manager [email protected] Emilie Roméo, Project Manager [email protected] Périne Michon, Communication Assistant [email protected] For further information: [email protected] ADMINISTRATIVE AND ACCOUNTING SERVICE Audrey Guilbert, Administrative and Accounting [email protected] Bérangère Maire, Administratve and Accounting Assistant in work-based learning [email protected] Corinne Peyrolles, Office Assistant [email protected] INFECTIOUS DISEASES CENTRE François Martin, Director [email protected] Ludovic Dolt, Technician of industrial maintenance [email protected] Marie-Claire Gallet, Support logistics and technical laboratory Céline Laborde, Quality Health Safety and Environment assistant in work-based learning [email protected] l i f e s c i e n c e s d i r e c t o r y 2 0 1 1 l i f e s c i e n c e s d i r e c t o r y 2 0 1 1 216 m e ta m o r p h o z 0 6 8 1 6 2 3 5 2 8 LYONBIOPOLE Bâtiment Domilyon 321 avenue Jean Jaurès, 69007 Lyon T : +33 (0)4 72 76 53 39 – F : +33 (0)4 72 70 48 29 [email protected] - www.lyonbiopole.com